ާ⣲≌೙ᓮቇ⻠ᐳި
㧔1㧕⣲≌∛ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
∛ℂቇߦ߅ߌࠆ⎇ⓥߪ㧘ㆮવሶ࡟ࡌ࡞ߩၮ␆⊛ߥ߽ߩ߆ࠄੱ૕៰಴ᬌ૕ࠍ᧚ᢱߣߔࠆ⥃ᐥ∛ℂ⊛ߥ߽ߩ߹ߢߩᐢ▸ߥ㗔ၞࠍභ߼ࠆ‫ޕ‬ᢎቶߩવ⛔⊛ߥਥⷐ࠹࡯ࡑߢ޽ࠆ㧘⣲≌ߩ⊒↢߆ࠄ੍㒐߹ߢߩ∛ℂቇ⊛⎇ⓥࠍ⛮⛯ߒߡ⎇ⓥߔࠆߣߣ߽ߦ㧘ౣ↢ක≮㧘ᐙ⚦⢩කቇߦ߽㑐ㅪߒߚᣂⷙ∛ℂቇಽ㊁ߩ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕ㆮવሶᡷᄌࡑ࠙ࠬ૞⵾ᛛⴚࠍ↪޿ߚᄢ⣺⊒߇ࠎߩಽሶᯏ᭴⸃᣿
ES ⚦⢩ߢߩ⋧ห⚵ߺ឵߃ᛛⴚࠍ೑↪ߒߚ㧘ࠦࡦ࠺࡚ࠖࠪ࠽࡞ࡁ࠶ࠢࠕ࠙࠻ࡑ࠙ࠬ㧘ㆮવሶ⊒⃻⺃ዉࡑ࠙ࠬࠍ૞⵾‫ޕ‬ᄢ⣺⊒߇ࠎߩࡔࠞ࠾࠭ࡓ⸃᣿ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧕߇ࠎ⚦⢩࡝ࡊࡠࠣ࡜ࡒࡦࠣߦࠃࠆ߇ࠎࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⇣Ᏹߩᗧ⟵⸃᣿
Oct4, Sox2, Myc, Klf4 ߣ޿߁ 4 ࿃ሶ⊒⃻ߦࠃࠅ㧘ಽൻ⚦⢩ߩೋᦼൻ߇น⢻ߣߥߞߚ㧔iPS ⚦⢩㧕‫ࠎ߇ޕ‬⚦⢩ߦߎߩᛛⴚࠍᔕ↪ߒ㧘߇ࠎ⚦⢩ߢߩࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⁁ᘒࠍᄌൻߐߖ㧘߇ࠎ⚦⢩․⇣⊛ߥᄌൻࠍห
ቯߔࠆߎߣߢ㧘߇ࠎ⚦⢩ߢߩࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⇣Ᏹߩᗧ⟵ࠍ᣿ࠄ߆ߦߔࠆ‫ޕ‬
3㧕DNA ࡔ࠴࡞ൻᯏ᭴ߣ⣲≌⊒↢ߩ⸃᣿ㆮવሶ⊒⃻⺞▵ߩⷐ㧘ࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ೙ᓮᯏ᭴ߩ 1 ߟߢ޽ࠆ DNA ࡔ࠴࡞ൻᯏ᭴ߣ⣲≌⊒↢ࠍੑߟߩⷞὐ[1]Site specific DNA hypermethylation [2]Global DNA hypomethylation ߦᵈ⋡ߒߡ⎇ⓥߒߡ޿ࠆ‫[ޕ‬1]ߪญ⣧ᚳᐔ਄⊹≸ࠍ᧚ᢱߦ≸ᛥ೙ㆮવሶߩ⊒⃻ࡊࡠࡕ࡯࠲࡯ㇱ૏ߦ߅ߌࠆ DNA ࡔ࠴࡞ൻߣ⣲≌⊒↢ߩ㑐ଥࠍ⎇ⓥߒ㧘[2]ߦߟ޿ߡߪ㧘DNA ૐࡔ࠴࡞ൻࡑ࠙ࠬ㧔⛽ᜬࡔ࠴࡞ၮォ⒖㉂⚛ߢ޽ࠆ Dnmt1 ߩૐ⊒⃻ࡑ࠙ࠬ㧕ࠍ↪޿ߡ㧘ฦ⒳⣲≌⊒↢ߦ߅ߌࠆ DNA ࡔ࠴࡞ൻߩᗧ⟵⸃᣿ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
4㧕ౣ↢ක≮㧘ᐙ⚦⢩කቇߦ㑐ㅪߔࠆ⣲≌⊒↢ߩ⸃᣿ߣߘߩ੍㒐ౣ↢කቇߩ⥃ᐥᔕ↪߇ㅴࠎߢ޿ߥ޿ℂ↱ߩ৻ߟߦ㧘in vitro ߢߩ⍮⷗߇ᔅߕߒ߽ in vivo ߢߪታ⃻ߢ߈ߡ޿ߥ޿ߎߣ㧘ߘߒߡ㧘⢦ᕈᐙ⚦⢩㧔ES ⚦⢩㧕ࠍ⚵❱ౣ↢ߦ೑↪ߒߚ႐ว㧘ߒ߫ߒ߫ᄸᒻ⣲ߣߒߡᱜᏱ
⚵❱߹ߢ⎕უߔࠆ⣲≌ᕈჇᱺࠍ߈ߚߔߎߣ߇޽ߍࠄࠇࠆ‫ޕ‬ᒰᢎቶߢߪ⣲≌∛ℂߩ⍮⼂ࠍ߽ߣߦౣ↢කቇߩ⥃ᐥᔕ↪ߩ㓙ߦ໧㗴ߣߥࠆ⣲≌⊒↢ࠍ㧘߇ࠎᐙ⚦⢩㧔cancer stem cell㧕ߣ㑐ㅪߐߖߡ⎇ⓥߒߡ޿ࠆ‫ޕ‬5㧕␹⚻ౣ↢⎇ⓥߩߚ߼ߩ␹⚻㓚ኂേ‛ࡕ࠺࡞ߩ㐿⊒␹⚻ゲ⚝ౝࠍᢿ ൻ DNA ߇࠳ࠗ࠽ࡒ࠶ࠢߦࠪ࠽ࡊࠬㇱ߹ߢ⒖േߔࠆߎߣࠍ␹⚻ߩࠕࡐ࠻࡯ࠪࠬߦ․⇣⊛⃻⽎ߣߒߡႎ๔ߒ㧘৻ㆊᕈ⣖⯯ⴊߦ઻߁ᶏ㚍 CA1 㗔ၞߩㆃ⊒ᕈ⚦⢩ᱫ߇ࠕࡐ࠻࡯ࠪࠬߢ޽ࠆߎߣࠍ⸽
᣿ߒߚ‫∔⚻␹ޕ‬ᖚࡕ࠺࡞ߣߒߡߩᛒ޿߿ߔߐ߆ࠄ㧘ࡑ࠙ࠬ✂⤑ߦᵈ⋡ߒ㧘␹⚻⚦⢩ᱫߣࠕࡐ࠻࡯ࠪࠬߩ㑐ଥࠍ᣿ࠄ߆ߦߔࠆ৻ᣇ㧘✂⤑␹⚻⚦⢩ߩㆬᛯ⊛㓚ኂࡕ࠺࡞ࠍ⏕┙ߒ㧘␹⚻ౣ↢කቇ߳ߩᔕ↪ߦขࠅ⚵ࠎߢ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ේ ᣿
ಎᢎ᝼㧦 ጊ↰ᵏᐢ

Akira Hara
Yasuhiro Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
1㧕 Mori H, Yamada Y, Kuno T, Oyama T, Hara A. Precursor lesions for stomach and colonic carcinomas inanimal models. In: Bamba H, Ota S, eds. Recent Advances in Gastrointestinal Carcinogenesis. Kerela:
Research Signpost; 2006:215-229.
2㧕 Hara A, Niwa M, Aoki H, Taguchi A, Yamada Y, Mori H. New research on neuronal networks. In:
Neuronal Network Research Horizons, ed by Weiss ML, New York: Nova Science Publish; 2007:99-118.
3㧕 Yamada Y, Oyama T, Tomita H, Taguchi A, Hara A and Mori H. Premalignant lesions of the colon inrodents. In: Tanaka T, ed. Cancer: Disease Progression and Chemoprevention. Kerala: Research
Signpost; 2007:1-13.
4㧕 Niwa K, Mori H, Tamaya T. Endometrial precancerous conditions in mouse carcinogenesis. A review.
In: Litchfield JE, ed. Precancerous condition: new research. New York Nova Science Publishers;
2007:245-252.
5㧕 Mori H, Yamada Y, Hirose Y, Hara A. Precancerous conditions of the colon; multistage carcinogenesis
in animal models. A review. In: RP Arroye, ed. Cancer Prevention Research Progress. New York Nova
Science Publishers; 2008:97-116.

㧙㧙6㧕 Hara A, Oka N, Aoki H, Taguchi A, Yamada Y, Niwa M, Mori H. OCT-3/4 Expressing Cells as Cancer
Stem Cells in Human Immature Teratoma: Cancer Differentiation Potential. In Saitama H, ed. New
Cell Differentiation Research Topics. New York Nova Science Publish; 2008:1-6.
✚⺑㧔๺ᢥ㧕
1㧕 ේ ᣿㧘᫪ ⑲᮸㧚ⴚਛㄦㅦ⸻ᢿ࡮ಓ⚿⚵❱ᮡᧄߩᱧผ㧘ᣣᧄක੐ᣂႎ 2007 ᐕ㧧4319 ภ㧦114㧙115.
✚⺑㧔᰷ᢥ㧕
1㧕 Yamada Y, Mori H. Multistep carcinogenesis in the colon of Apc Min/+ mouse. Cancer Sci.
2007;98:6-10.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ᵏᐢ㧚ߎߣ߫ߩࠞ࡞࠹ 177гOct3/4㧦ࡔ࠺ࠖࠞ࡞࠻࡝ࡆࡘ࡯ࡦ 2008 ᐕ㧧41 Ꮞ㧦46㧚
2㧕 ጊ↰ᵏᐢ㧘ේ ᣿㧘᫪ ⑲᮸㧚∔ᖚࡕ࠺࡞േ‛ࠍ↪޿ߚࠛࡇࠫࠚࡀ࠹ࠖࠢࠬ⎇ⓥгᄢ⣺ᄙᲑ㓏⊒߇ࠎߦ߅ߌ
ࠆ㧰㧺㧭ࡔ࠴࡞ൻ⇣Ᏹߩᗧ⟵㧘ᦨᣂකቇ 2008 ᐕ㧧63 Ꮞ㧦772㧙777㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
2㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist, methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
3㧕 Suzui M, Tanaka T, Mori H, Nakayama T, Aonahara M, Yoshimi N. Pulmonary hypoplasia andchondrocyte p21CIPI expression in patients with lethal short-limbed dwarfism. Ryukyu Med J.
2006;25:31-46.
4㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A,
Mori H. beta-Catenin-accumulated crypts in the colonic mucosa of juvenile Apc(Min/+) mice. Cancer
Lett. 2006;239:123-128.
5㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Kuno T, Hirose Y, Hara A, Mori H. Lack ofenhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated
crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett. 2006;238:69-75.
6㧕 Mori Y, Tatematsu K, Koide A, Sugie S, Tanaka T, Mori H. Modification by curcumin of mutagenic
activation of carcinogenic N-nitrosamine by extrahepatic cytochromes P-450 2B1 and 2E1 in rats.
Cancer Sci. 2006;97:896-904.
7㧕 Kuno T, Hirose Y, Yamada Y, Hata K, Qiang SH, Asano N, Oyama T, Zhi H, Iwasaki T, Kobayashi H,
Mori H. Chemoprevention of mouse urinary bladder carcinogenesis by the fermented brown rice andrice bran. Oncol Rep. 2006;15:533-538.
8㧕 Lian Z, Niwa K, Onogi K, Mori H, Harrigan RC, Tamaya T. Anti-tumor effects of herbal medicines on
endometrial
carcinomas
via
estrigen
receptor-alpha-related
mechanism.
Oncol
Rep.
2006;15:1133-1136.
9㧕 Kato K, Hara A, Kuno T, Mori H, Toida M, Shibata T. Aberrant promoter hypermethylation of p16 and
MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. J Cancer Res
Clin Oncol. 2006;132:735-743.
10㧕 Aoki H, Hara A, Nakagawa S, Motohashi T, Hirano M, Takahashi Y, Kunisada T. Embryonic stem cells
that differentiate into RPE cell precursors in vitro develop into RPE cell monolayers in vivo. Exp Eye
Res. 2006;82:265-274.
11㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-alpha decreases hsp 27 in humanblood mononuclear cells: Involvement of protein kinase C. Life Sci. 2006;80:181-186.
12㧕 Onogi K. Niwa K, Tang L, Yun W, Mori H, Tamaya T. Inhibitory effects of Hocyu-ekki-to on
endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta̅estradiol in mice. Oncol
Rep. 2006;16:343-1348.
13㧕 Asano N, Kuno T, Hirose Y, Yamada Y, Yoshida K, Tomita H, Nakamura Y, Mori H. Preventive Effects
of a Flavonoid Myricitrin on the Formation of Azoxymethane-induced Premalignant Lesions in Colonsof Rats. Asian Pac J Cancer Prev. 2007;8:73-76.
14㧕 Hara A, Taguchi A, Niwa H, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model ofphotoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.
15㧕 Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart
H, Mori H Development of gastric tumors in Apc Min/+ mice by the activation of the Ǫ-catenin/Tcf
signaling pathway. Cancer Res. 2007;67:4079-4087.
16㧕 Oka N, Soeda A, Inagaki A, Onodera M, Maruyama H, Hara A, Kunisada T, Mori H, Iwama T. VEGF
promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res㧙㧙

IF 2.218

IF 2.218

IF 3.398

IF 3.398

IF 3.165

IF 1.597

IF 1.597

IF 2.366

IF 2.651
IF 2.257

IF 1.597

IF 2.121

IF 7.672

Commun. 2007;360:553-559.
17㧕 Zhi H, Yamada Y, Hirose Y, Kato K, Sheng H, Zheng Q, Oyama T, Asano N, Kuno T, Hara A, Mori H.
Effect of 2-(carboxyphenyl) retinamide and genistein on the formation of early lesions in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Asian Pac J Cancer Prev. 2007;8:33-38.
18㧕 Sheng HQ, Hirose Y, Hata K, Zheng Q,T Kuno T, Asano N, Yamada Y, Hara A, Osawa T, Mori H.
Modifying effect of dietary sesaminol glucosides on the formation of azoxymethane-inducedpremalignant lesions of rat colon. Cancer Lett. 2007;246:63-68.
19㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
20㧕 Yun W, Niwa K, Onogi K, Tang L, Mori H, Tamaya T. Effects of selective estrogen receptor modulatorsand genistein on ERalpha/beta and COX-1/2 expressions in ovarectomized mice uteri. Eur J Gynaecol
Oncol. 2007;28:89-94.
21㧕 Miyazaki Y, Hara A, Kato K, Oyama T, Yamada Y, Mori H, Shibata T. The effect of hypoxic
microenvironment on matrix metalloproteinase expression in xenografts of human oral squamous cell
carcinoma. Int J Oncol. 2008;32:145-151.
22㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.
23㧕 Tomita H, Kuno T, Yamada Y, Oyama T, Asano N, Miyazaki Y, Baba S, Taguchi A, Hara A, Iwasaki T,
Kobayashi H, Mori H. Preventive effect of fermented brown rice and rice bran on
N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis in rats. Oncol Rep.
2008;19:11-15.
24㧕 Hozumi I, Suzuki JS, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C.
Metallothionein-3 (GIF) is expressed in the brain and various peripheral organs of the rat. Neurosci
Lett. 2008;438:54-58.
25㧕 Kato K, Long NK, Makita H, Toida M, Yamashita T, Hatakeyama D, Hara A, Mori H, Shibata T.
Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral
squamous cell carcinoma cells. Br J Cancer. 2008;99:647-654.
26㧕 Aoki H, Hara A, Motohashi T, Chem H, Kunisada T. Iris as a recipient tissue for pigment cells:organized in vivo differentiation of melanocytes and pigmented epithelium derived from embryonicstem cells in vitro. Dev Dynam. 2008;237:2394-2404.
27㧕 Oyama T, Yamada Y, Hata K, Tomita H, Hirata A, Sheng HQ, Hara A, Aoki H, Kunisada T, Yamashita
S, Mori H. Further upregulation of Ǫ-catenin/Tcf transcription is involved in the development ofmacroscopic tumors in the colon of Apc Min/+ mice. Carcinogenesis 2008;29:666-672.
28㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
29㧕 Aoki H, Yoshida H, Hara A, Suzuki T, Kunisada T. Transplantation of Melanocytes into Iris: Method
for Iris Re-pigmentation. Transplantation. 2008;85:492-494.
30㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like Differentiation and
Selective Ablation of Undifferentiated Embryonic Stem Cells Containing Suicide Gene with Oct-4
Promoter. Stem Cells Dev. 2008;17:619-627.
31㧕 Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T,
Meissner A, Jaenisch R. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylationand transcriptional silencing. Genes Dev. 2008;21:3110-3122.
32㧕 Long NK, Kato K, Yamashita T, Makita H, Toida M, Hatakeyama D, Hara A, Mori H, Shibata T.
Hypermethylation of the RECK gene predicts poor prognosis in oral squamous cell carcinomas. Oral
Oncol. 2008;44:1052-1058.

IF 2.749

IF 3.398

IF 2.265

IF 0.587

IF 2.295
IF 2.218

IF 1.597

IF 2.121

IF 4.635

IF 3.084

IF 5.406

IF 1.590
IF 3.641

IF 3.224

IF 14.795

IF 2.1034㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪⑲᮸㧘⎇ⓥಽᜂ⠪㧦ጊ↰ᵏᐢ㧘ᑝἑༀା㧘᧻᳗⎇๋㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦 ࠞ࠹࠾ࡦ/TCF pathway ࠍนⷞൻߒߚㆮવሶዉ౉ࡑ࠙ࠬߦࠃࠆ೨≸∛ᄌߩ⎇ⓥ㧧ᐔᚑ
17㧙19 ᐕᐲ㧧13,600 ජ౞(8,200㧦3,300㧦2,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧘⎇ⓥಽᜂ⠪㧦᫪⑲᮸㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦DNA ૐࡔ࠴࡞ൻߣ⊒≸㧧ᐔᚑ 18㧙19 ᐕᐲ㧧5,700 ජ౞(3,900㧦1,800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(A)㧦૕⚦⢩ߦ߅ߌࠆᧂಽൻᕈ⛽ᜬᯏ᭴⸃᣿ߣߘߩ⊒≸ࡔࠞ࠾࠭ࡓ⸃᣿߳ߩᔕ↪㧧ᐔᚑ 19㧙21 ᐕᐲ㧧14,000 ජ౞(6,000㧦4,300㧦3,700 ජ౞)4㧕 ⎇ⓥઍ⴫⠪㧦ේ ᣿㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࡑ࠙ࠬ✂⤑␹⚻ᄌᕈᓟߩ⥄Ვㆮવሶ㧙㧙ዉ౉⢦ᕈᐙ⚦⢩ߦࠃࠆ␹⚻ౣ↢ߣ⣲≌ൻߩᛥ೙㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,900 ජ౞(1,800㧦1,100 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦‐ፉବ๺㧚⎇ⓥಽᜂ⠪㧦ጊ↰ᵏᐢ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧧ࡅ࠻ᄙᲑ㓏⊒߇ࠎㆊ⒟ߦ߅ߌࠆࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢߥ⇣Ᏹߩ✂⟜⊛⸃᣿ߣ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧
12,000 ජ౞(4,000㧦4,000㧦4,000 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧧․ቯ㗔ၞ⎇ⓥ㧧⣺▤਄⊹ߩჇᱺ࡮ಽൻߦ߅ߌࠆࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ೙ᓮᯏ
᭴⸃᣿ߣߘߩ⊒߇ࠎ⎇ⓥ߳ߩᔕ↪㧧ᐔᚑ 20㧙21 ᐕᐲ㧧10,200 ජ౞(5,100㧦5,100 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ᵏᐢ㧧⑼ቇᛛⴚᝄ⥝ᯏ᭴(JST)ߐ߈߇ߌ⎇ⓥ㧧࡝ࡊࡠࠣ࡜ࡒࡦࠣߦࠃࠆ߇ࠎ⚦⢩ࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢ⇣Ᏹߩ⿠Ḯ⸃᣿ߣߘߩ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙23 ᐕᐲ㧧39,900 ජ౞(10,000㧦10,000㧦10,000㧦9,900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⑲᮸㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 18 ᐕᐲ㧧4,581 ජ౞㧦(ᩣ)଻ஜ⑼ቇ⎇ⓥᚲ
2㧕 ᫪⑲᮸㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 19 ᐕᐲ㧧4,548 ජ౞㧦(ᩣ)଻ஜ⑼ቇ⎇ⓥᚲ
3㧕 ᫪⑲᮸㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 19 ᐕᐲ㧧2,496 ජ౞㧦(ᩣ)᧲ᶏ⚦⢩⎇ⓥᚲ
4㧕 ේ ᣿㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 20 ᐕᐲ㧧4,497 ජ౞㧦(ᩣ)଻ஜ⑼ቇ⎇ⓥᚲ
5㧕 ේ ᣿㧦∛ℂ⸻ᢿߩࠦࡦࠨ࡞࠲ࡦ࠻㧧ᐔᚑ 20 ᐕᐲ㧧492 ජ౞㧦(ᩣ)᧲ᶏ⚦⢩⎇ⓥᚲ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬේ ᣿㧦
1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⣖␹⚻ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊ↰ᵏᐢ㧦
1㧕 ╙ 3 ࿁ᣣᧄ≸ቇળࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 3 ᦬㧘‫ޟ‬േ‛ࡕ࠺࡞ߦࠃࠆᣂᤨઍߩ߇ࠎ⎇ⓥг⊒∝ᯏ᭴߆ࠄᴦ≮߹ߢ‫ޠ‬᜗ᓙ⻠Ṷ‫ޟ‬DNA ࡔ࠴࡞ൻߩᄢ⣺⊒≸߳ߩୃ㘼‫ޠ‬Ṷ⠪)
2㧕 ╙ 65 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 9 ᦬㧘‫⇣ߥࠢ࠶ࠖ࠹ࡀࠚࠫࡇࠛޟ‬Ᏹߩ⿠Ḯߣടㅦ‫ޠ‬᜗ᓙࠪࡦࡐࠫࠬ࠻ ‫ޟ‬DNMT ߩ⇣Ᏹߦࠃࠆ⊒߇ࠎߩଦㅴߣᛥ೙‫ޠ‬Ṷ⠪)‫ޟ‬Multistep carcinogenesis of the3㧕 ╙ 38 ࿁㜞᧻ችᅥ≸⎇ⓥၮ㊄࿖㓙ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 11 ᦬㧘colon in Apc Min mouse‫ޠ‬Ṷ⠪)
4㧕 ╙ 66 ࿁ᣣᧄ≸ቇળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ࠪࡦࡐࠫ࠙ࡓᐳ㐳߅ࠃ߮ࠪࡦࡐࠫࠬ࠻‫ᧂޟ‬ಽൻᕈ⛽ᜬᯏ᭴ߩᄢ⣺⊒߇ࠎㆊ⒟⸃᣿߳ߩᔕ↪‫ޠ‬ᐳ㐳㧘Ṷ⠪)
5㧕 ╙ 58 ࿁ᣣᧄ㔚᳇ᵒേቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘
‫ޟ‬DNA ࡔ࠴࡞ൻ⇣Ᏹߩᄢ⣺⊒߇ࠎ߳ߩୃ㘼‫ޠ‬Ṷ⠪)
6㧕 Northeastern Asian Symposium oňCancer Epigenetics̍(2008.11㧘Jeju㧘Korea㧘Symposium‫ޟ‬Role of DNA methylation in multistage colon carcinogenesis‫ޠ‬Ṷ⠪)7㧕 ╙ 67 ࿁ ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬The role of DNA methylationin carcinogenesis in digestive tract‫ޠ‬Ṷ⠪)8㧕 ╙ 97 ࿁ ᣣᧄ∛ℂቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘㊄ᴛ㧘ࠪࡦࡐࠫ࠙ࡓ‫ᧂޟ‬ಽൻᕈߩ⛽ᜬߣ⊒߇ࠎ‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ጊ↰ᵏᐢ㧦╙ 23 ࿁ᣣᧄᲥᕈ∛ℂቇળળ㐳⾨(ᐔᚑ 19 ᐕᐲ)
9㧚␠ળᵴേේ ᣿㧦
1㧕 ጘ㒂⋵౏ⴐⴡ↢ᬌᩏ࠮ࡦ࠲࡯ᜰዉ⋙〈ක(ᐔᚑ 18 ᐕᐲ)
2㧕 ጘ㒂⋵ᚑੱ∛⸻ᢿ▤ℂᜰዉද⼏ળ߇ࠎ⊓㍳⹏ଔㇱળᆔຬ(ᐔᚑ 18 ᐕ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ጊ↰ᵏᐢ㧦DNA ૐࡔ࠴࡞ൻߣ⊒≸㧦ᐔᚑ 18 ᐕᐲᢥㇱ⑼ቇ⋭․ቯ㗔ၞ⎇ⓥ‫⎇ޠࠎ߇ޟ‬ⓥႎ๔㓸㍳㧦
122(2007 ᐕ)
2㧕 ጊ↰ᵏᐢ㧦DNA ૐࡔ࠴࡞ൻߣ⊒≸㧦ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭․ቯ㗔ၞ⎇ⓥ‫⎇ޠࠎ߇ޟ‬ⓥႎ๔㓸㍳㧦
122(2008 ᐕ)
3㧕 ጊ↰ᵏᐢ㧦ࡅ࠻ᄙᲑ㓏⊒߇ࠎㆊ⒟ߦ߅ߌࠆࠛࡇࠫࠚࡀ࠹ࠖ࠶ࠢߥ⇣Ᏹߩ✂⟜⊛⸃᣿ߣ⥃ᐥᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲ╙ 3 ᰴኻ߇ࠎ✚วᚢ⇛⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᛞ㍳㓸㧔‐ፉ⃰㧕㧦7㧙10(2008 ᐕ)
11㧚ႎ㆏
1㧕 ᫪ ⑲᮸㧦ߏ߹ߩ฽᦭ᚑಽ‫ߩޠ࡞࡯ࡁࡒࠨ࠮ޟ‬㧘ᄢ⣺߇ࠎᛥ೙㧦ਛᣣᣂ⡞(2006 ᐕ 5 ᦬ 13 ᣣ)
2㧕 ේ ᣿㧦ES ⚦⢩ࠍ✂⤑⚦⢩ߦ᛫߇ࠎ೷↪޿ಽൻߦᚑഞ㧙ࡑ࠙ࠬ⌒⃿ౝߢ㧦ᣣೀᎿᬺᣂ⡞(2006 ᐕ 9
᦬ 5 ᣣ)
3㧕 ේ ᣿㧦߇ࠎൻߐߖߕߦ ES ⚦⢩ࠍᵴ↪㧙⊕ⴊ∛⮎૶߁㧦ᣣᧄ⚻ᷣᣂ⡞(2006 ᐕ 9 ᦬ 25 ᣣ)
4㧕 ේ ᣿㧦⣲≌ൻߒߘ߁ߥ ES ⚦⢩ࠍㆬᛯ⊛ߦឃ㒰 ␹⚻⚦⢩ࠍౣ↢㧦ᣣೀᎿᬺᣂ⡞ឝタ(2007 ᐕ 9 ᦬
27 ᣣ)
5㧕 ේ ᣿㧦‫ࠎ߇ޟ‬ᐙ⚦⢩‫ ⺑ޠ‬⣉శᶎ߮ࠆ ᣂߚߥᴦ≮ᚢ⇛ߦ㆏ ౣ↢කቇߣⲢวㅴ߻ ਛㇱ⚻ᷣᣂ⡞(2007 ᐕ 2 ᦬ 3 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔකቇ⍮⼂㧘කቇ⎇ⓥߩ࿖㓙᳓Ḱࠍ⛽ᜬߒ߁ࠆ࡟ࡌ࡞ߩ࿖㓙㔀⹹߳ߩ⎇ⓥ⊒⴫ߪ⋡ᮡㅢࠅߢ߈ߡ޿ࠆߣ
ᕁࠊࠇࠆ‫ߒߛߚޕ‬㧘ੱ⊛૛⵨߇ߥ޿ߚ߼㧘⧯ᚻߩ⢒ᚑߥߤ⺖㗴߇ᱷࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ጘ㒂ᄢቇቇ㐳ࠍヘ಴ߒ㧘⃻⁁ߢߪ㧘ᐔᚑ 20 ᐕߦ߅ߌࠆᏱൕ⎇ⓥ⡯ 2 ฬߢ޽ࠅ㧘ੱ⊛૛⵨߇ߥ߆ߞߚ‫ޕ‬ߒ߆ࠆߴ߈⎇ⓥ⠪ߩ⢒ᚑ㧘⵬ల߇✕ᕆߩ⺖㗴ߢ޽ࠆ‫ߚ߹ޕ‬㧘ᐔᚑ 20 ᐕ 4 ᦬ 1 ᣣࠃࠅ‫ޟ‬ක≮ᴺᣉⴕ઎ߩ৻
ㇱࠍᡷᱜߔࠆ᡽઎‫߮ࠃ߅ޠ‬ෘ↢ഭ௛⋭઎ߦࠃࠅ㧘∛ℂ⸻ᢿ⑼߇කᬺߦ㑐ߒߡᐢ๔ߢ߈ࠆ⸻≮ᮡ᭙⑼ฬߣ
ߥߞߚ‫੹ޕ‬ᓟ㧘∛ℂ⸻ᢿᬺോߩක≮㧘␠ળߦᨐߚߔ⽿છ߇ߎࠇ߹ߢએ਄ߦჇߒߡࠁߊߣ⠨߃ࠄࠇࠆ‫∛ޕ‬ℂኾ㐷ක㧘⚦⢩⸻ኾ㐷කߩᵷ㆜߇⃻ታ⊛ߦᦸ߹ࠇߡ߅ࠅ㧘࿾ၞක≮߳ߩ⽸₂ߣ޿߁ὐߦ߅޿ߡ߽⧯ᚻ∛ℂකߩ⢒ᚑ߇✕ᕆ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸᢎቶߩવ⛔⊛ߥ࠹࡯ࡑߢ޽ࠆ㧘⣲≌ߩ⊒↢߆ࠄ੍㒐߹ߢߩ∛ℂቇ⊛⎇ⓥ૕೙ࠍ⛽ᜬߔࠆߣߣ߽ߦ㧘ౣ↢ක≮㧘ᐙ⚦⢩කቇߦ߽㑐ㅪߒߚᣂⷙ∛ℂቇಽ㊁ࠍ㐿ᜏߔࠆ‫ޕ‬න⁛ಽ㊁ߢߩ⁛┙ߒߚ⎇ⓥ૕೙ߦߪ㒢⇇߇޽ࠆߚ߼㧘ᄢቇౝߢߩⶄᢙಽ㊁ߣߩදജ૕೙ࠍⓍᭂ⊛ߦ࿑ࠆ‫ߚ߹ޕ‬㧘∛ℂቇߩၮ␆ߣߒߡੱ૕∛ℂ㧔⸻ᢿ∛ℂ㧕ࠍ㊀ⷞߒ㧘∛㒮∛ℂㇱߣㅪ៤ߒߚ਄ߢ࿾ၞක≮ߦ⽸₂ߢ߈ࠆ∛ℂකࠍ⢒ߡࠆ‫ޕ‬㧙㧙㧔2㧕఺∉∛ℂቇಽ㊁
1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽ߦ఺∉෻ᔕߩ઀⚵ߺࠍ⸃᣿ߔࠆߎߣࠍ⋡⊛ߦ⎇ⓥࠍⴕ߁߇, ᒁ߈⛯߈ᰴߩ 2 ὐߦὶὐࠍ
ᒰߡߡ⎇ⓥࠍㅴ߼ࠆ‫ޕ‬1㧕఺∉⚦⢩Ⴧᱺ∝୥⟲ߩ⸻ᢿ╬ߦ㑐ߔࠆ⎇ⓥ㧦ᖡᕈ࡝ࡦࡄ⣲ߩ੍ᓟߪ⚵❱੝ဳߦḰߓߡᄢ߈ߊ⇣ߥࠆߎߣ߆ࠄ, ఺∉ቇߩᦨᣂߩ⍮⷗ࠍᔕ↪ߒ, ᣂߚߥ⸻ᢿᴺߥࠄ߮ߦ੍ᓟߩ⏕ቯᴺࠍ㐿⊒ߔࠆ‫ޕ‬
2㧕᛫⣲≌఺∉෻ᔕߩ⎇ⓥ㧦ࡅ࠻⣲≌ߩ఺∉ቇ⊛ᴦ≮, ᧂߛචಽߥᆭജࠍ⊒ើߔࠆߦ⥋ߞߡ޿ߥ޿‫ߩߎޕ‬ේ࿃ࠍ⚵❱ᒻᘒቇߥࠄ߮ߦಽሶ↢‛ቇ⊛ᚻᴺࠍ㚟૶ߒߡ᣿ࠄ߆ߦߒ, ࠃࠅᒝജߥ᛫⣲≌఺∉≮ᴺߩ⏕┙ࠍ⋡ᜰߔ‫ޕ‬
2㧚ฬ★
㜞⷗ ೰
ᢎ᝼㧦
ಎᢎ᝼㧦 㥱የᓕ⋥ᓟ⮮ዏ⛗ഥᢎ㧦

Tsuyoshi Takami
Masanao Saio
Naoe Goto3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᄢᐔᐘሶ㧘᧻ጟᢅ↵㧘㜞⷗೰㧚ਛ㜞ᐕ⊓ጊ⠪ߩታᘒ⺞ᩏ̆ᅏⓄ㜞ጪ⊓ጊ⠪ࠍኻ⽎ߣߒߡ㧙㧚Japn J Mountain
Medicine 2007 ᐕ㧧27 Ꮞ㧦31㧙42㧚
2㧕 ଻㉿ᗆ৻㧘ᚑ↰ᵗ㧘㥱የᓕ⋥㧚੃⣼ glycogen-rich clear cell carcinoma ߩ৻଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ⹹ 2008
ᐕ㧧69 Ꮞ㧦25㧙29㧚
3㧕 㝩㗡ാテ㧘ᵄᄙ㊁⵨৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧘㥱የᓕ⋥㧘᧻ᧄ⌀੺㧘⊕ᯅᐘᵗ㧘ጤ↰ዏ㧘㜞⷗೰㧚Micronodular
thymoma with lymphoid stroma ߩ৻଀㧘⸻ᢿ∛ℂ 2008 ᐕ㧧25 Ꮞ㧦267㧙271㧚
4㧕 ═ේජ༹㧘ේᱞᔒ㧘㢬⷗ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘Japn J
Antibiot 2008 ᐕ㧧61 Ꮞ㧦115㧙21㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Suwa T, Saio M, Umemura N, Yamashita T, Toida M, Shibata T, Takami T. Preoperative radiotherapy
contributes to induction of proliferative activity of CD8+ tumor-infiltrating T-cells in oral squamouscell carcinoma. Oncol Rep. 2006;15:757-763.
2㧕 Ouyang GF, Saio M, Suwa T, Imai H, Nakagawa J, Nonaka K, Umemura N, Mika K, Takami T.
Interleukin-2 augmented activation of tumor associated macrophage plays the main role in MHC class
I in vivo induction in tumor cells that are MHC negative in vitro. Int J Oncol. 2006;28:1201-1208.
3㧕 Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M,
Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Fas and Fas ligand expression on
germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 2006;76:465-472.
4㧕 Amaoka N, Saio M, Nonaka K, Imai H, Tomita H, Sakashita F, Takahashi T, Sugiyama Y, Takami T,
Adachi Y. Expression of vascular endothelial growth factor receptors is closely related to thehistological grade of hepatocellular carcinoma. Oncol Rep. 2006;16:3-10.
5㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor
receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s
lymphoma. Eur J Haematol. 2006;77:217-225.
6㧕 Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H,
Soehendro N. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of㧙㧙

IF 1.597

IF 2.295

IF 2.163

IF 1.597

IF 2.163

unknown origin. Endoscopy. 2006;38:919-924.
7㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
8㧕 Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF,
Ohe N, Yano H, Yoshimura S, Iwama T, Takami T. TNF expressed by tumor-associated macrophages,
but not microglia, can eliminate glioma. Int J Oncol. 2007;30:803-811.
9㧕 Toita N, Hatano N, Ono S, Yamada M, Kobayashi R, Kobayashi I, Kawamura N, Okano M, Satoh A,
Nakagawa A, Ohshima K, Shindoh M, Takami T, Kobayashi K, Ariga T. Epstein-Barr virus-AssociatedB-cell lymphoma in a patient with DNA ligase IV (LIG4) syndrome. Am J Med Genet A.
2007;143:742-745.
10㧕 Imai H, Saio M, Nonaka K, Suwa T, Umemura N, Ouyang GF, Nakagawa J, Tomita H, Osada S,
Sugiyama Y, Adachi Y, Takami T. Depletion of CD4+CD25+ regulatory T cells enhancesinterleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma. Cancer Sci.
2007;98:416-423.
11㧕 Kimura A, Tan CF, Wakida K, Saio M, Hozumi I, Inuzuka T, Takahashi H. Venous congestive
myelopathy of the cervical spinal cord: an autopsy case showing a rapidly progressive clinical course.
Neuropathology. 2007;27:284-289.
12㧕 Kato H, Kanematsu M, Zhang X, Saio M, Kondo H, Goshima S, Fujita H. Computer-aided diagnosis ofhepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method andan artificial neural network. Am J Roentgenol. 2007;189:117-122.
13㧕 Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M,
Takami T, Moriwaki H. A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107-114.
14㧕 Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, Ouyang G F, Okada M, Balazs M, Adany R,
Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamedmonocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol. 2008;83:1136-1144.
15㧕 Okubo M, Kawasaki M, Ishihara Y, Takeyama U, Yasuda S, Kubota T, Tanaka S, Yamaki T, Ojio S,
Nishigaki K, Takemura G, Saio M, Takami T, Fujiwara H, Minatoguchi S. Tissue characterization ofcoronary plaques. Circ J. 2008;72:1631-1639.
16㧕 Okubo M, Kawasaki M, Ishihara Y, Takeyama U, Kubota T, Yamaki T, Ojio S, Nishigaki K, Takemura
G, Saio M, Takami T, Minatoguchi S, Fujiwara H. Development of integrated backscatter
intravascular ultrasound for tissue characterization of coronary plaques. Ultrasound Med Biol.
2008;34:655-663.
17㧕 Nonaka K, Saio M, Suwa T, Frey A B, Umemura N, Imai H, Ouyang G F, Osada S, Balazs M, Adany R,
Kawaguchi Y, Yoshida K, Takami T. Skewing the Th cell phenotype toward Th1 alters the maturationof tumor-infiltrating mononuclear phagocytes. J Leukoc Biol. 2008;84:679-688.
18㧕 Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role ofCD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952-961.
19㧕 Hozumi I, Suzuki J, S, Kanazawa H, Hara A, Saio M, Inuzuka T, Miyairi S, Naganuma A, Tohyama C.
Metallothionein-3 is expressed in the brain and various peripheral organs of the rat. Neurosci Lett.
2008;438:54-58.
20㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami
T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicated withduodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.
21㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa J, Shimizu M,
Oyama M, Moriwaki, H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.

IF 4.166
IF 5.487

IF 2.295

IF 2.440

IF 3.115

IF 1.326

IF 2.470

IF 2.180

IF 4.128

IF 2.373

IF 1.922

IF 4.128
IF 6.620

IF 2.085

IF 2.1804㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㥱የᓕ⋥㧘⎇ⓥಽᜂ⠪㧦㜞⷗೰㧘ᄢᳯ⋥ⴕ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦⤔⚦⢩⣲≌ౝᶐẢ᮸⁁⚦⢩ߩ⣖․⇣⊛ಽൻ࡮ᚑᾫᯏᐨߩ⸃᣿㧧ᐔᚑ 18㧙20 ᐕᐲ㧧21,080 ජ౞(12,040㧦6,240㧦2,800 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ㧙㧙5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ㜞⷗೰㧦
1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ఺∉ቇળ⹏⼏ຬ࡮ㆇ༡ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ∛ℂቇળਛㇱᡰㇱᐙ੐(㨪⃻࿷)㥱የᓕ⋥㧦1㧕 ᣣᧄ∛ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅㜞⷗೰㧦
1㧕 ╙ੑ࿁ᣣᧄ∛ℂቇળਛㇱᡰㇱᄐߩቇᩞ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㜞⷗೰㧦
1㧕 ╙ 97 ࿁ᣣᧄ∛ℂቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘㊄ᴛ㧘ኋ㗴ႎ๔Τ‫∉఺ࠎ߇࠻ࡅޟ‬೙ᓮߩಽሶ∛ℂቇ⊛ၮ⋚‫ޠ‬ᐳ㐳㧕
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ㥱የᓕ⋥㧦
1㧕 ╙ 11 ࿁≸⎇ⓥߩㅴᱠ਎⇇ળ⼏ቇળ⾨(2006.10.14)
9㧚␠ળᵴേ
㜞⷗೰㧦
1㧕 2006 ᐕᐲ㨪2008 ᐕᐲጘ㒂ᄢቇකቇㇱᅏⓄ㜞ጪᄐጊ⸻≮ᚲㆇ༡ᆔຬળᆔຬ㐳2㧕 ጘ㒂ᄢቇකቇㇱᅏⓄ㜞ጪᄐጊ⸻≮ᚲ 50 ๟ᐕ⸥ᔨ⻠Ṷળ(2008 ᐕ 11 ᦬ 30 ᣣ㧘ጘ㒂)
3㧕 ಴೨⻠⟵㧦ਛᵤ㜞ᩞ(2008 ᐕ 11 ᦬ 13 ᣣ)㧘ศၔ㜞ᩞ(2008 ᐕ 12 ᦬ 11 ᣣ)
10㧚ႎ๔ᦠ
1㧕 㥱የᓕ⋥㧘㜞⷗೰㧘ᄢᳯ⋥ⴕ㧦ή⚦⢩Ⱞ⊕⊒⃻♽ࠍ↪޿ߚࡊࡠ࠹ࠝࡒࠢࠬᤨઍߩ⤔⚦⢩⣲≌఺∉ᴦ
≮ᴺߩ㐿⊒㧦ᐔᚑ 16 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ(2006 ᐕ 3
᦬ 31 ᣣ)11㧚ႎ㆏
1㧕 㜞⷗೰㧦∛ℂቇળਛㇱᡰㇱ‫ޟ‬ᄐߩቇᩞ‫∛ޠ‬ℂቇߩ㝯ജ㧦ਛᣣᣂ⡞(2008 ᐕ 8 ᦬ 31 ᣣ)
2㧕 㜞⷗೰㧦ᅏⓄ㜞ጪᄐጊ⸻≮ᚲ 50 ๟ᐕ⸥ᔨ⻠Ṷળ㧦ጘ㒂ᣂ⡞(2008 ᐕ 12 ᦬ 1 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᖡᕈ࡝ࡦࡄ⣲ߩ⎇ⓥߪ, දห⎇ⓥ⠪ߢ޽ࠆⴊᶧ∛ᘒቇࠣ࡞࡯ࡊߣߩදജߩਅ, ᣂߚߥ੍ᓟ࿃ሶߩหቯ
ߥߤߩᚑᨐߦߟߥ߇ࠅ⺰ᢥߣߒߡᖱႎࠍ⊒ାߢ߈ߚ߇, ᄖㇱ⾗㊄ߩ₪ᓧ, ․⸵಴㗿߹ߢ⊒ዷߐߖࠆߎߣ
߇ߢ߈ߡ޿ߥ޿ߎߣ߇੹ᓟߩ⺖㗴ߣߒߡᱷߐࠇߚ‫ޕ‬᛫⣲≌఺∉෻ᔕߩ⸃᣿ߪ㥱የಎᢎ᝼߇ਛᔃߦ♖ജ⊛ߦㅴ߼ࠄࠇ, ⹏ଔߩ㜞޿㔀⹹ߦឝタߐࠇࠆߣߣ߽ߦᄖㇱ⾗㊄߽₪ᓧߢ߈, චಽߦ⹏ଔߢ߈ࠆ߽ߩߣ⠨߃ߡ޿ࠆ‫ޕ‬
೨ภߢ޽ߍߚቇળᵴേ߿␠ળᵴേߦ߽ജࠍᵈ޿ߛ‫∛ޕ‬ℂක₪ᓧࠍ⋡ᜰߒߚ‫ޟ‬ᄐߩቇᩞ‫߅ࠍޠ‬਎⹤ߔࠆߣߣ߽ߦ, ᅏⓄ㜞ጪᄐጊ⸻≮ᚲߦ㑐ߔࠆකቇㇱߩࡎ࡯ࡓࡍ࡯ࠫߦᖱႎࠍタߖ, 50 ๟ᐕ⸥ᔨ⻠Ṷળࠍ㐿௅㧙㧙ߒߡஜᐽߩ⛽ᜬߣჇᒝߦ㑐ߔࠆࡔ࠶࠮࡯ࠫࠍ⊒ାߔࠆߎߣ߇ߢ߈ߚ‫ߪߦࠄߐޕ‬, 2 ࿁ߩ಴೨⻠⟵ࠍᜂᒰߒ,㜞ᩞ↢ߩකቇ࡮ක≮ߩߺߥࠄߕࠨࠗࠛࡦࠬߦኻߔࠆ⥝๧߇Ⴧߔࠃ߁ദജߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᢎቶຬߩዋߥ޿⃻⁁ߢߪ޽ࠆ߇, ⎇ⓥߣᢎ⢒࡮␠ળᵴേࠍߘࠇߙࠇಽᜂߒߡദജߔࠆߎߣߦࠃࠅ, Ყセ⊛ߦࡃ࡜ࡦࠬߩߣࠇߚᵴേࠍߔࠆߎߣ߇ߢ߈ߚ‫ߒ߆ߒޕ‬, ᢎቶຬࠍჇ߿ߔ߹ߢߦߪ⥋ࠄߕ, ᒁ߈⛯߈∛ℂක޽ࠆ޿ߪၮ␆ቇ໧ࠍᔒߔੱ᧚ߩ⊒ជߦദജߔࠆߎߣ߇ᔅⷐߣ⠨߃ߡ޿ࠆ‫ߩߘޕ‬ᣇ╷ߣߒߡ, ‫ޟ‬ᄐߩቇᩞ‫ߦޠ‬කቇㇱቇ↢߿⎇ୃකࠍᏎ߈ㄟ߻ߎߣ, 㐳ᦼ⊛ߦߪ‫ޟ‬಴೨⻠⟵‫ࠆࠃߦߤߥޠ‬໪⫥ࠍ࿾㆏ߦ⛯ߌࠆߎߣ߇ᔅⷐߣ⠨߃ࠆ‫ޕ‬੹ᓟߩዷᦸ╙৻ߦᖡᕈ࡝ࡦࡄ⣲ߩ੍ᓟࠍⷙቯߔࠆ࿃ሶߣ఺∉෻ᔕߣߩ㑐ଥࠍ⸃᣿ߔࠆߎߣߢ, ᣂߚߥ⸻ᢿᴺߥࠄ
߮ߦᴦ≮ᴺߩ㐿⊒ࠍㅴ߼ࠆ‫ޕ‬᛫⣲≌఺∉ߢߪ⣲≌ዪᚲߢ఺∉ᛥ೙ᕈߦ௛ߊ⚦⢩ߩ⸃ᨆࠍㅴ߼, ᛥ೙ࠪࠣ࠽࡞ߩ⸃㒰ߣ఺∉੣ㅴࠪࠣ࠽࡞߳ߩᄌ឵ࠍታ⃻ߔࠆࠃ߁ߥಽሶ෻ᔕᯏᐨࠍ᣿ࠄ߆ߦߒߚ޿‫ޕ‬㧙㧙㧔3㧕⣲≌ᄖ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐศ↰๺ᒄ㧦
1㧕㘩㆏≸࡮⢗≸ߦ߅ߌࠆ⣻⣧㏜ᚻⴚߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
2㧕ಾ㒰ਇ⢻⢗≸ߦኻߔࠆ S-1+Docetaxel ≮ᴺߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
3㧕㘩㆏≸ߦ߅ߌࠆ Docetaxel+5-Fu+Radiation ߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
4㧕⢗≸ߦ߅ߌࠆ 5-FU ⠴ᕈߩࡔࠞ࠾࠭ࡓߩ⸃ᨆ
5㧕ᶖൻེ≸ߦ߅ߌࠆ Adjuvant Surgery ߩ᦭↪ᕈߦ㑐ߔࠆ⎇ⓥ
6㧕⢗≸ⴚᓟ⵬ഥ≮ᴺߦ㑐ߔࠆᄢⷙᮨ⥃ᐥ⹜㛎
7㧕ᶖൻེ≸ߦ߅ߌࠆಽሶᮡ⊛ᴦ≮ߣ᛫≸೷૬↪ߦࠃࠆലᨐჇᒝലᨐߦ㑐ߔࠆ⎇ⓥ㐳↰⌀ੑ㧦
1㧕ಾ㒰ਇ⢻⤟≸ߦኻߔࠆ Vitamin K3 ዪᚲᛩਈߩၮ␆⎇ⓥ‫ޕ‬2㧕ォ⒖ᕈ⢄߇ࠎߩᄖ⑼ಾ㒰ߩᴦ≮ㆡᔕ᜛ᄢ‫ޕ‬
3㧕㜞ᐲㅴⴕ⢄≸ߦኻߔࠆಓ⚿ᴦ≮ߩၮ␆⊛࡮⥃ᐥ⊛⎇ⓥ‫ޕ‬ጊญ๺਽㧦1㧕⢗≸ߦ߅ߌࠆ⣻⣧㏜ਅಾ㒰ⴚߩⴚᓟᶖൻ▤ᯏ⢻ߦ㑐ߔࠆ⎇ⓥ㜞ᯅቁᄦ㧦
1㧕ᄢ⣺≸ߦ߅ߌࠆ DNA ࡊࡠࡕ࡯࠲࡯㗔ၞ⇣Ᏹࡔ࠴࡞ൻࠍ↪޿ߚᣧᦼ⸻ᢿ߳ߩᔕ↪‫ޕ‬ဈਅᢥᄦ㧦
1㧕⢗≸ൻቇ≮ᴺߩၮ␆⊛⎇ⓥ‫ޕ‬ᓼጊᵏᴦ㧦
1㧕ᄢ⣺≸ߦ߅ߌࠆ߇ࠎᛥ೙ㆮવሶࡊࡠࡕ࡯࠲࡯㗔ၞߦ߅ߌࠆࡔ࠴࡞ൻߩᬌ⸛‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ศ↰๺ᒄ
ಎᢎ᝼㧦
㐳↰⌀ੑ
ಎᢎ᝼(૬છ)㧦 Ꮉญ㗅ᢘ
ጊญ๺਽
⻠Ꮷ㧦
㜞ᯅቁᄦ
⻠Ꮷ㧦
ဈਅᢥᄦ
⥃ᐥ⻠Ꮷ㧦
⚦㊁⧐᮸
⥃ᐥ⻠Ꮷ㧦
ᓼጊᵏᴦ
ഥᢎ㧦
ᅏ᧛⋥᮸
ഥᢎ㧦
↰ਛༀብ
කຬ㧦
ฬ๺ᱜੱ
කຬ㧦
੗Ꮉᗲሶ
කຬ㧦
⋿↰㓶Ꮢ
කຬ㧦
ጊ↰㗅ሶ
කຬ㧦

Kazuhiro Yoshida
Shinji Osada
Yoshihiro Kawaguchi
Kazuya Yamaguchi
Takao Takahashi
Fumio Sakashita
Yoshiki Hosono
Yasuharu Tokuyama
Naoki Okumura
Yoshihiro Tanaka
Masahito Nawa
Aiko Ikawa
Yuichi Sanada
Junko Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ቟㆐ᵗ␭✬⪺㧚කᏧߩ઀੐ߣ⸻≮⑼ࠟࠗ࠼㧘᧲੩㧦㊄ේ಴ 㧧2006 ᐕ㧚
2㧕 ቟㆐ᵗ␭㧚ᦨᣂࠛࡆ࠺ࡦࠬߦၮߠߊᄢ⣺߇ࠎ⸻≮ࠟࠗ࠼㧘᧲੩㧦㊄ේ಴ 㧧2006 ᐕ䋮
3㧕 ศ↰๺ᒄ㧚ᶖൻེ≸ߩൻቇ≮ᴺߩታ㓙,ࠝࡦࠦࡠࠫ࡯ࠢ࡝࠾ࠞ࡞ࠟࠗ࠼㧘ධጊၴ㧧2007 ᐕ㧦57㧙61.
⪺ᦠ㧔᰷ᢥ㧕ߥߒ㧙㧙✚⺑㧔๺ᢥ㧕1㧕 ቟㆐ᵗ␭㧘ጊญ๺਽㧘ጊ↰ ⺈㧘⒳᧛ᑝᏈ㧘࿡ᨑసⴕ㧚ᱷ⢗ߩ≸ߩᴦ≮ߣ੍㒐 ᱷ⢗≸ߩ੍㒐ߣᣧᦼ⊒⷗㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦280㧙285㧚
2㧕 ቟㆐ᵗ␭㧘᧻੗ᐽม㧘቟↰㚅❱㧘㋈ᧁ෹Ꮧ㧘㐷੗⛗⟤㧘੗ᷓᄼม㧚ᄢ⣺≸ߩ⣻⣧㏜ᚻⴚ ᦨᣂᢥ₂࡟ࡆࡘ࡯㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦751㧙753㧚
3㧕 ቟㆐ᵗ␭㧘ᴡว㓷ᒾ㧘⩲㊁ᤘብ㧘ᾢᴛદ๺↢㧘ጊญ๺਽㧚ࠢ࡝࠾ࠞ࡞ࡄࠬߦၮߠ޿ߚⴚᓟ▤ℂߩߔߴߡ ᐝ㐷஥⢗ಾ㒰㧘ᶖൻེᄖ⑼ 2006 ᐕ㧧29 Ꮞ㧦591㧙606㧚
4㧕 ᧖ጊ଻ᐘ㧚ᖚ⠪ℂ⸃ߩ∝⁁࡮ᬌᩏ୯ࡉ࠶ࠢ ࠤ࡯ࠬԘ ♧ዩ∛ࠍว૬ߒߡ޿ࠆ႐ว㧘ᄖ⑼ᷙว∛᫟ࠤࠕ
2006 ᐕ㧧1 Ꮞ(ഃೀ⸥ᔨภ)㧦4㧙11㧚
5㧕 ᧖ጊ଻ᐘ㧚ᖚ⠪ℂ⸃ߩ∝⁁࡮ᬌᩏ୯ࡉ࠶ࠢ ࠤ࡯ࠬԚ ᓴⅣེ∔ᖚ(ᔃ∔ᖚ‫ޔ‬㜞ⴊ࿶∝)ࠍว૬ߒߡ޿ࠆ႐
ว㧘ᄖ⑼ᷙว∛᫟ࠤࠕ 2006 ᐕ㧧1 Ꮞ(ഃೀ⸥ᔨภ)㧦24㧙33㧚
6㧕 ᧖ጊ଻ᐘ㧚ᖚ⠪ℂ⸃ߩ∝⁁࡮ᬌᩏ୯ࡉ࠶ࠢ ࠤ࡯ࠬԜ ⣢ᯏ⢻㓚ኂࠍว૬ߒߡ޿ࠆ႐ว㧘ᄖ⑼ᷙว∛᫟ࠤ
ࠕ 2006 ᐕ㧧1 Ꮞ(ഃೀ⸥ᔨภ)㧦48㧙55㧚
7㧕 ቟㆐ᵗ␭㧘Ꮉญ㗅ᢘ㧘⚦㊁⧐᮸㧘㐳የ⢒ሶ㧘ᮯႦ⊓⟤↵㧘ጊᧄ ᖗ㧚૶↪ߔࠆ┙႐߆ࠄߺߚ≸⸻≮ࠟࠗ࠼࡜ࠗࡦߩࡐࠗࡦ࠻ ੃≸⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦157㧙163㧚
8㧕 ቟㆐ᵗ␭㧘Ꮉญ㗅ᢘ㧘㐳የ⢒ሶ㧘ਛ↰℉Ꮘ㧘⚦㊁⧐᮸㧘੗Ꮉᗲሶ㧘᫪శ⪇Ẵ㧘ቝ૒⟤┨㕏㧚⤳ེ೎≸⸻≮ࠟࠗ࠼࡜ࠗࡦⷐ⚂㓸 ੃≸⸻≮ࠟࠗ࠼࡜ࠗࡦ㧘ᄖ⑼ 2006 ᐕ㧧68 Ꮞ㧦173㧙180㧚
9㧕 ศ↰๺ᒄ.ᶖൻེ≸ⴚᓟ⵬ഥൻቇ≮ᴺߩ⃻⁁ߣ໧㗴ὐ,ᣣᧄᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧108 Ꮞ㧦302㧙303.
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᧖ጊ଻ᐘ㧘㐳↰⌀ੑ㧘ጊญ๺਽㧘㐳የᚑᢅ㧘㜞ᯅቁᄦ㧘᧻੗ᐽม㧘↰ਛජᒄ㧘ဈਅᢥᄦ㧘ᅏ᧛⋥᮸㧘ᓼጊᵏᴦ㧚ಾ㒰ਇ⢻ㅴⴕᶖൻེ≸ߦኻߔࠆಓ⚿ᴦ≮ߩ᦭↪ᕈ㧘ᶖൻེ⑼ 2006 ᐕ㧧42 Ꮞ㧦178㧙185㧚
2㧕 ᧖ጊ଻ᐘ㧘㐳↰⌀ੑ㧘ጊญ๺਽㧘㐳የᚑᢅ㧘㜞ᯅቁᄦ㧘ဈਅᢥᄦ㧚ࠛࡆ࠺ࡦࠬߦၮߠ޿ߚࡃࠗࠝ࠮࡜ࡇࠖ
㧙ࠢ࡟ࠬ࠴ࡦߦ߅ߌࠆࠛࡆ࠺ࡦࠬ㧘Biotherapy 2006 ᐕ㧧20 Ꮞ㧦396㧙402㧚
3㧕 ᧖ጊ଻ᐘ㧘᧻ᯅᑧᄈ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧚ቢో IT ൻ∛㒮ߦ߅ߌࠆᖱႎࠪࠬ࠹ࡓߩ⣻ㇱᢇᕆ⸻≮߳ߩ⽸₂㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦637㧙641㧚
4㧕 ᧖ጊ଻ᐘ㧘᧻ᯅᑧᄈ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧚࡝ࠬࠢࡑࡀ࡯ࠫࡔࡦ࠻ߩⷰὐ߆ࠄߺߚ⣻ㇱᢇᕆක≮ߦ߅ߌࠆ㔚ሶࠞ࡞࠹⸻≮ߩഞ⟋㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦753㧙756㧚
5㧕 ဈਅᢥᄦ㧘᫜ᯅ೑ⴕ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⥄Ꮖ఺∉ᕈ⤟Ἳߦ૬⊒ߒߚ⤟የㇱ≸ߩ
1 ଀㧘ᣣᧄᶖൻེᄖ⑼ቇળ⹹ 2006 ᐕ㧧39 Ꮞ㧦78㧙83㧚
6㧕 ጊญ๺਽㧘ᅏ᧛⋥᮸㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⢗▤ౣᑪߦࠃࠆ⣻⣧㏜⵬ഥਅྃ㐷஥⢗ಾ㒰ⴚ㧘ᄖ⑼ᴦ≮ 2006 ᐕ㧧95 Ꮞ㧦449㧙453㧚
7㧕 ጊญ๺਽㧘ᅏ᧛⋥᮸㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⣻⣧㏜⵬ഥਅྃ㐷஥⢗ಾ㒰ⴚࠍߒߚ⢗ࠞ࡞࠴ࡁࠗ࠼⣲≌ߩ 1 ଀㧘ᄖ⑼ᴦ≮ 2007 ᐕ㧧96 Ꮞ㧦106㧙109㧚
8㧕 ጊญ๺਽㧘ዊ᫪ల༹㧘᧻੗ ⡡㧘૒‫⟵ᧁޘ‬ਯ㧘↰ਛ⑲ౖ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘቟㆐ᵗ␭㧘⨹ᧁኡม㧘ᑝἑༀା㧚B࡮⢗࡮චੑᜰ⣺ߩ⣲≌ᕈ∔ᖚ⒘ߥ⚵❱ဳߩ⢗ߩ⣲≌㧘ᄖ⑼ᴦ
≮ 2007 ᐕ㧧96 Ꮞ㧦467㧙472㧚
9㧕 ጊญ๺਽㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘Ꮉญ㗅ᢘ㧚⢗๟࿐ߩ␹⚻⸃೬ߣᯏ⢻ߩⷐὐ㧘ᚻⴚ
2007 ᐕ㧧61 Ꮞ㧦957㧙961㧚
10㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧘ᣣᧄᄢ⣺⢂㐷∛ળ⹹ 2007
ᐕ㧧60 Ꮞ㧦105㧙109㧚
11㧕 㜞ᯅቁᄦ㧘᧖ጊ଻ᐘ㧚ੱᎿ⢂㐷ߪᓟ⣻⤑⚻〝߇ᮡḰ߆㧘⥃ᐥᄖ⑼ 2007 ᐕ㧧62 Ꮞ㧦1578㧙1580㧚
12㧕 ဈਅᢥᄦ㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘᧻੗ ⡡㧘ᓼጊᵏᴦ㧘ᅏ᧛⋥᮸㧘↰ਛ⑲ౖ㧘⚦㊁⧐᮸㧘᧖ጊ଻ᐘ㧘቟㆐ᵗ␭㧚⤟ౝಽᴲ⣲≌ᩭ಴ᓟ 4 ᐕ⋡ߦ⊒∝ߒߚࠣ࡞ࠞࠧࡦ↥↢⣲≌૬ሽࠗࡦࠬ࡝ࡁ࡯ࡑߩ 1 ଀㧘ᣣᧄᶖൻེ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧40 Ꮞ㧦634㧙638㧚
13㧕 ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘↰ਛ⑲ౖ㧘ዊ᫪ల༹㧘᧻੗ ⡡㧘㐳↰⌀ੑ㧚ⴊᩖᕈⴊዊ᧼ᷫዋᕈ⚡᢬∛ߩᴦ≮ਛߦ૬⊒ߒߚ᳇⣲ᕈ⢙ྙἻߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧68 Ꮞ㧦1262㧙1265㧚
14㧕 ᓼጊᵏᴦ㧘㐳↰⌀ੑ㧘૒‫⟵ᧁޘ‬ਯ㧘੹੗ ኼ㧘᧻੗ ⡡㧘ዊ᫪ల༹㧘㜞੗శᴦ㧘ౝᧁ㓉ᢥ㧘੹੗ஜੑ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘౗᧻㓷ਯᑝἑༀା㧚ⴚ೨ߦ⢄⚦⢩≸ߣߩ㐓೎߇໧㗴ߣߥߞߚ⢄⚦⢩⣼⣲ߩ 1 ଀㧘⢄⢙⤟ᴦ⎇⹹ 2007 ᐕ㧧5 Ꮞ㧦35㧙40㧚
15㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘ᯫේ ᷕ㧘↰ㄝ๺ᾖ㧚⢗ో៰ߦ߅ߌࠆ቟ోߥེ᪾่วߩࡐࠗࡦ
࠻㧘⥃ᐥᄖ⑼ 2008 ᐕ㧧63 Ꮞ㧦203㧙207㧚
16㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘ᯫේ ᷕ㧘↰ㄝ๺ᾖ㧚ⴚ೨ൻቇ≮ᴺ㧘ᶖൻེᄖ⑼ 2008 ᐕ㧧31
Ꮞ㧦820㧙826㧚
17㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘ᯫේ ᷕ㧘↰ㄝ๺ᾖ㧚⢗≸-ၮ␆࡮⥃ᐥ⎇ⓥߩࠕ࠶ࡊ࠺࡯࠻-㧘ᣣᧄ⥃ῼ 2008 ᐕ㧧66 Ꮞ㧦409㧙413㧚
18㧕 ศ↰๺ᒄ㧘ጊญ๺਽㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘㜞ᯅቁᄦ㧘㐳↰⌀ੑ㧚DIF ߣ⢗≸㧚ࠦࡦ࠮ࡦࠨࠬ≸ᴦ≮ 2008
ᐕ㧧7 Ꮞ㧦220㧙223㧚
19㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑ㧙㧙ༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧘ᣣᧄᄢ⣺⢂㐷∛ቇળ㔀⹹
2008 ᐕ㧧61 Ꮞ㧦33㧙38㧚
20㧕 ᧻੗ ⡡㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘ጊญ๺਽㧘ศ↰๺ᒄ㧚⣲≜ᒻᚑᕈ⤟Ἳ
ߩ 2 ಾ㒰଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2008 ᐕ㧧33 Ꮞ㧦78㧙83㧚
21㧕 ጊญ๺਽㧘ศ↰๺ᒄ㧘㐳↰⌀ੑ㧘㜞ᯅቁᄦ㧘ဈਅᢥᄦ㧘↰ਛༀብ㧚⢗ྃ㐷ㇱ㧘ᚻⴚ 2008 ᐕ㧧62 Ꮞ㧦739
㧙743㧚
22㧕 ዊ᫪ల༹㧘㐳↰⌀ੑ㧘ᓼጊᵏᴦ㧘ศ↰๺ᒄ㧚⤟઒ᕈྙ⢩ౝ≪ⴚᓟߦ࡚ࠪ࠶ࠢࠍ઻߁ᄢ㊂ߩྙ⢩ౝ಴ⴊࠍ᧪
ߒߚ৻଀㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦51㧙54㧚
24㧕 㐳↰⌀ੑ㧘ศ↰๺ᒄ㧚ㅴⴕ⤟≸ᴦ≮ߦ߅ߌࠆ⚦⢩ౝࠪࠣ࠽࡞࿃ሶߩᔕ↪㧘Biotherapy 2008 ᐕ㧧22 Ꮞ㧦233
㧙240㧚
25㧕 ጊญ๺਽㧘ศ↰๺ᒄ㧘㐳↰⌀ੑ㧘㜞ᯅቁᄦ㧘ဈਅᢥᄦ㧘↰ਛༀብ㧘⨹ᧁኡม㧚⢗≸㧘ᄖ⑼ᴦ≮ 2008 ᐕ㧧
99 Ꮞ㧦120㧙126㧚
26㧕 㜞ᯅቁᄦ㧘ศ↰๺ᒄ㧚⢖≸-ၮ␆࡮⥃ᐥ⎇ⓥߩࠕ࠶ࡊ࠺࡯࠻- ᣣᧄ⥃ῼ 2008 ᐕ㧧66 Ꮞ㧦162㧙166㧚
27㧕 㜞ᯅቁᄦ㧘ጊ↰㗅ሶ㧘ฬ๺ᱜੱ㧘↰ਛༀብ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘ศ↰๺ᒄ㧚ㅴⴕౣ⊒ᄢ⣺≸ߦ߅ߌࠆᣂⷙ᛫≸೷ᴦ≮⚻㛎㧘≸ߩ⥃ᐥ 2008 ᐕ㧧54 Ꮞ㧦763㧙769㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Sakashita F, Osada S, Yawata K, Sugiyama Y. A case report of duodenal stenosis due to a ruptured
aneurysm of the pancreaticoduodenal artery. J Jpn Coll Surg. 2006;31:54-55.
2㧕 Amaoka N, Saio M, Nonaka K, Imai H, Tomita H, Sakashita F, Takahashi T, Sugiyama Y, Takami T,
Adachi Y. Expression of vascular endothelial growth factor receptors is closely related to thehistological grade of hepatocellular carcinoma. Oncol Rep. 2006;16:3-10.
IF3㧕 Osada S, Tomita H, Imai H, Okumura N, Tokuyama Y, Sakashita F, Nonaka K, Sugiyama Y. A
resected cace of icteric type hepatoma with tumor thrombi in common bile duct. J Jpn Coll Surg
2006;31:240-244.
4㧕 Osada S, Imai H, Okumura N, Tokuyama Y, Hosono Y, Sakashita F, Sugiyama Y. A modified
reconstruction method to prevent critical complications after pancreatoduodenectomy.
Hepato-Gastroenterol. 2006;53:296-300.
IF5㧕 Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, Sakashita F, Nonaka K, Sugiyama Y. Vascularendothelial growth factor protects hepatoma cells against oxidative stress-induced cell death. J
Gastroen Hepatol. 2006;21:988-993.
IF
6㧕 Takahashi T, Shigematsu H, Shivapurkar N, Reddy J, Zheng Y, Feng Z, Suzuki M, Nomura M,
Augustus M, Yin J, Meltzer SJ, Gazdar AF. Aberrant promoter methylation of multiple genrs duringmultistep pathogenesis of colorectal cancers. Int J Cancer. 2006;118:924-931.
IF
7㧕 Sanada Y, Yoshida K,Ohara M, Tsutani Y. Expression of orotate phosphorybosyltransferase (OPRT)in
hepatobiliary and pancreatic carcinoma. Pathology Oncology Research. 2007;13:105-113.
8㧕 Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, Matsuhashi N, Sakashita F, Nonaka K.Serumcytokine levels in response to hepatic cryoablation. J Surg Oncol. 2007;95:491-498.
IF9㧕 Osada S, Sakashita F, Hosono Y, Nonaka K, Tokuyama Y, Tanaka H, Sasaki Y, Tomita H, Komori S,
Matsui S, Takahashi T. Extracellular signal 㧙 regulated Kinase phosphorylation due tomenadione-inducd arylation mediates growth inhibition of pancreas cancer cells. Cancer ChemotherPharmacol. 2007;62:315-320.
IF
10㧕 Amaoka N, Osada S,Kanematsu M, Imai H, Tomita H, Tokuyama Y, Sakashita F, Nonaka K, Goshima
S, Kondoh H, Adachi Y. Clinicopathological features of hepatocellul ar carcinoma evaluated by
vascular endothelial growth factor expression. J Gastroenterol Hepatology. 2007;22:2202-2207.
IF
11㧕 Suzuki M, Shigematsu H, Shames DS, Sunaga N, Takahashi T, Shivapurkar N, Iizasa T, Minna JD,
Fujisawa T, Gazdar A.F, Frenkel EP. Methylation and Gene Silencing of the Ras㧙Related GTP ase
Gene in Lung and Breast Cancers. Ann Surg Oncol. 2007;14:1397-1404.
IF
12㧕 Nomura M, Shigematsu H, LiL, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H,
Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, Mutations, andAmplification of the EGFR Gene in Non㧙Small Cell Lung Cancers. PloS Med. 2007.
13㧕 Sakashita F, Osada S, Takemura M, Imai H, Tomita H, Nonaka K, Takahashi T, Seishima M. The
effect of p53gene expression on the inhibition of cell proliferation by paclitaxel. Cancer ChemotherPharmacol. 2007;62:379-385.
IF
14㧕 Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F, Tanaka Y.Challenge for abetter combination with basic evidence. Int J Clin Oncol. 2008;13:212-219.
15㧕 Nonaka K, Saio M, Suwa T, Alan B.Frey, Umemura N, Imai H, Guan-Feng Ouyang, Osada S, Margit
Balazs, Roza Adany, Kawaguchi Y, Yoshida K, Takami T. Skewing the Th cell phenotype Th1 alters thematuration of tumor-infiltrating mononuclear phagocytes. J Leukocyte Biol. 2008;84:679-688.
IF
16㧕 Osada S, Tomita H, Tanaka Y, Tokuyama Y, Tanaka H, Sakashita F, Takahashi T. The utility ofvitamin K3(menadione)against pancreatic cancer. Anti-Cancer Res. 2008;28:45-50.
IF
17㧕 Osada S, Sakashita F, Hosono Y, Nonaka K, Tokuyama Y, Tanaka H, Sasaki Y, Tomita H, Komori S,
Matsui S, Takahashi T. Extracellular signal-regulated kinase phosphorylation due to

㧙㧙

1.597

0.904

1.673

4.555

2.384

2.568

2.052

3.917

2.568

4.128
1.414

menadione-induced arylation mediates growth inhibition of pancreatic cancer cells. Cancer Chemoth
Pharm. 2008;62:315-320.
IF 2.56818㧕 Osada S, Imai H, Yawata K, Tanahashi T, Sakashita F, Tanaka C, Sugiyama Y. Growth inhibition ofunresectable tumors induced by hepatic cryoablation. Hepato-Gastroenterol. 2008;55:231-234.
IF 0.904
19㧕 Osada S, Kanematsu M, Imai H, Goshima S.Clinical significance of serum HGF and c-Met expression
in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma
Hepatogastroenterology. 2008;55:544-549.
IF 0.9044㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁᄦ㧘⎇ⓥಽᜂ⠪㧦ᓼጊᵏᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦≸ᛥ೙ㆮવሶߩࡊࡠࡕ࡯࠲࡯㗔ၞ⇣Ᏹࡔ࠴࡞ൻࠍ↪޿ߚ≸ߩᣧᦼ⸻ᢿ߳ߩ⥃ᐥᔕ↪㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
3,400 ජ౞(1,300㧦1,300㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ศ↰๺ᒄ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
≸ォ⒖㑐ㅪㆮવሶߩࠢࡠ࡯࠾ࡦࠣ(Molecular cloning of metastasis associated gene)㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦Ꮉญ㗅ᢘ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦੃≸⚦⢩ᩣߦ߅ߌࠆ Herceptin ߣ SERM(selective estrogen receptor modulator)ߩ૬↪ലᨐ㧧ᐔᚑ
19 ᐕᐲ㧧10 ਁ౞4㧕 ⎇ⓥઍ⴫⠪㧦㐳↰⌀ੑ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
Vitamin K3 ߦࠃࠆ⚦⢩ౝࠪࠣ࠽࡞વ㆐ᵴᕈߩㅴⴕ⤟≸ᴦ≮߳ߩᔕ↪㧧ᐔᚑ 19 ᐕᐲ㧧20 ਁ౞5㧕 ⎇ⓥઍ⴫⠪㧦㐳↰⌀ੑ㧧౏⋉ା⸤ᄖ⑼ቇ⎇ⓥഥᚑၮ㊄(૑෹ା⸤㌁ⴕᩣᑼળ␠)㧦ᄢ⣺≸ᄙ⊒⢄ォ⒖ߦ
ኻߔࠆᄖ⑼⊛ᷫ㊂ಾ㒰ⴚߩᗧ⟵㧧ᐔᚑ 19 ᐕᐲ㧧50 ਁ౞6㧕 ⎇ⓥઍ⴫⠪㧦ጊญ๺਽㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
⢗≸ߦ߅ߌࠆ mTOR ࠍ࠲࡯ࠥ࠶࠻ߣߒߚಽሶᮡ⊛ᴦ≮ߩᬌ⸛㧧ᐔᚑ 19 ᐕᐲ㧧10 ਁ౞7㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁᄦ, ⎇ⓥಽᜂ⠪㧦ᓼጊᵏᴦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦≸ᛥ೙ㆮવሶߩࡊࡠࡕ࡯࠲࡯㗔ၞ⇣Ᏹࡔ࠴࡞ൻࠍ↪޿ߚ≸ߩᣧᦼ⸻ᢿ߳ߩ⥃ᐥᔕ↪㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
3,400 ජ౞(1,300㧦1,300㧦800 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁᄦ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦ᶖൻེ≸ߦ߅ߌࠆ≸㑐ㅪㆮવሶߩ Aberrant promoter methylation ߩ㑐ਈ㧙ᣧᦼ⸻ᢿ߳ߩᔕ↪㧙㧧
ᐔᚑ 19 ᐕᐲ㧧50 ਁ౞9㧕 ⎇ⓥઍ⴫⠪㧦ဈਅᢥᄦ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇකቇㇱ ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌㧦
⢗≸⚦⢩ߦኻߔࠆ paclitaxel ߩലᨐ(the effect of paclitaxel for gastric cancer cells)㧧ᐔᚑ 19 ᐕᐲ㧧
20 ਁ౞
10㧕 ⎇ⓥ⠪㧧ဈਅᢥᄦ㧧ᐔᚑ 20 ᐕᐲᄢቇᵴᕈൻ⚻⾌㧦⢗≸⣻⤑᠞⣲ߦኻߔࠆ paclitaxel ߩലᨐ㧧ᐔᚑ
20 ᐕᐲ㧧1,060 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ศ↰๺ᒄ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦ᶖൻ▤ᄖ⑼ᚻⴚߦ߅ߌࠆวᚑๆ෼♻૶↪ߩᚻⴚㇱ૏ᗵᨴᛥ೙ലᨐߦ㑐ߔࠆᄙᣉ⸳౒หਗⴕ⟲㑆ή૞ὑൻᲧセ⹜㛎࡮⢄ಾ㒰߅ࠃ߮⤟㗡චੑᜰ⣺ಾ㒰ߦ߅ߌࠆวᚑๆ෼♻૶↪ߩᚻⴚㇱ૏ᗵᨴᛥ೙ലᨐߦ㑐ߔࠆᄙᣉ⸳౒หਗⴕ⟲㑆ή૞ὑൻᲧセ⹜㛎㧧ᐔᚑ 20㧙23 ᐕᐲ㧧100 ਁ౞
2㧕ฃ⸤⎇ⓥ1㧕 㜞ᯅቁᄦ㧦ⴚᓟ⵬ഥൻቇ≮ᴺߦ߅ߌࠆࡈ࠶ൻࡇ࡝ࡒࠫࡦ♽⮎೷ߩ᦭↪ᕈߦ㑐ߔࠆᲧセ⥃ᐥ⹜㛎(ᴦ≹ಾ㒰⋥⣺≸ߦኻߔࠆ UFT ≮ᴺߣ TS-1 ≮ᴺߣߩᲧセᬌ⸛)㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,457 ජ౞(819㧦819㧦
819 ජ౞)㧦߇ࠎ㓸ቇ⊛ᴦ≮⎇ⓥ⽷࿅2㧕 ศ↰๺ᒄ㧦StageΥ⚿⣺≸ᴦ≹ಾ㒰଀ߦኻߔࠆⴚᓟ⵬ഥൻቇ≮ᴺߣߒߡ UFT/Leucovorin ≮ᴺߣ TS-1
≮ᴺߩ╙Υ⋧Ყセ⥃ᐥ⹜㛎߅ࠃ߮ㆮવሶ⊒⃻ߦၮߠߊലᨐ੍᷹࿃ሶߩត⚝⊛⎇ⓥ㧧ᐔᚑ 20㧙24 ᐕᐲ㧧1,102 ජ౞㧦(⽷)వ┵ක≮ᝄ⥝⽷࿅
3㧕 ศ↰๺ᒄ㧦ೋ࿁ TS-1 ≮ᴺߦᴦ≮ᛶ᛫ᕈࠍ␜ߒߚㅴⴕ࡮ౣ⊒⢗≸ߦኻߔࠆੑᰴൻቇ≮ᴺ㧙CPT-11 න⁛≮ᴺ vsTS-1㧗CPT-11 ૬↪ൻቇ≮ᴺߩή૞ὑൻᲧセ╙Τ/Υ⋧⥃ᐥ⹜㛎㧙㧧ᐔᚑ 20㧙24 ᐕᐲ㧧1,160
ජ౞㧦NPO ᴺੱᣣᧄ߇ࠎ⥃ᐥ⹜㛎ផㅴᯏ᭴
3㧕౒ห⎇ⓥ1㧕 ศ↰๺ᒄ㧦ᄢ⣺≸ᖚ⠪ߦ߅ߌࠆ᛫≸೷ലᨐ੍᷹࿃ሶߩ mRNA ⊒⃻ಽᏓ⺞ᩏ㧧ᐔᚑ 20㧙23 ᐕᐲ㧧110㧙㧙ਁ౞㧦ᄢ㢈⮎ຠᎿᬺࢃ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 㐳↰⌀ੑ㧦‫ޟ‬㜞ᐲㅴⴕ⢄≸ߦኻߔࠆ᛫⣲≌఺∉⾮ᵴࠍ⋡⊛ߣߒߚಓ⚿ᴦ≮‫ޠ‬㜞ᐲක≮⹏ଔ೙ᐲ↳⺧ਛ
6㧚ቇળᵴേ
1㧕ቇળᓎຬศ↰๺ᒄ㧦
1㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᄖ⑼ቇળ⥃ᐥ⹜㛎ផㅴᆔຬ(㨪⃻࿷)4㧕 ᣣᧄ≸ᴦ≮ቇળᢎ⢒ᆔຬ(㨪⃻࿷)5㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ⢗≸ቇળ⽷ോᆔຬળ(ᐔᚑ 20 ᐕ 8 ᦬㨪⃻࿷)7㧕 ᣣᧄ㘩㆏ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄᶖൻེ≸⊒↢ቇળ⹏⼏ຬ(㨪⃻࿷)9㧕 ᣣᧄᶖൻེᄖ⑼ቇળ⹏⼏ຬㆬ಴ᆔຬ(㨪⃻࿷)10㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)11㧕 ᣣᧄ⥃ᐥᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)12㧕 ᣣᧄࡃࠗࠝ࠮࡜ࡇࠖቇળ⹏⼏ຬ(㨪⃻࿷)13㧕 ᣣᧄ≸∛૕ᴦ≮⎇ⓥળ਎⹤ੱ(㨪⃻࿷)14㧕 ᣣᧄ≸ዪᚲ≮ᴺ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)15㧕 ᣣᧄ≸఺∉ᄖ⑼⎇ⓥળ਎⹤ੱ(㨪⃻࿷)16㧕 ᣣᧄᄖ⑼ቇળ࿾ၞක≮቟ో▤ℂᆔຬળᆔຬ(㨪⃻࿷)17㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱᐙ੐(㨪⃻࿷)18㧕 ᣣᧄᄖ⑼ቇળኾ㐷ක⹺ቯᆔຬળ⹜㛎ᆔຬ(㨪⃻࿷)19㧕 ᣣᧄ⢈ḩ∝ᴦ≮ቇળℂ੐(㨪⃻࿷)Ꮉญ㗅ᢘ㧦1㧕 ᣣᧄ੃≸ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ≸ᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)㐳↰⌀ੑ㧦1㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪⃻࿷)
3㧕 ᣣᧄૐ᷷කቇቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᄖ⑼♽ㅪวቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(㨪⃻࿷)6㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 11 ᦬㨪⃻࿷)ጊญ๺਽㧦
1㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅㐳↰⌀ੑ㧦
1㧕 ╙ 2 ࿁ጘ㒂ᚻⴚᚻᛛ⎇ⓥળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂)2㧕 ╙ 3 ࿁ጘ㒂ᚻⴚᚻᛛ⎇ⓥળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ศ↰๺ᒄ㧦
1㧕 International Jouranl of Clinical Oncology 㧧Editorial board member(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)2㧕 ⢗≸ perspective㧧✬㓸ਥᐙ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)㧙㧙㐳↰⌀ੑ㧦
1㧕 Anti㧙Cancer Agents㧧Editorial Board Member(㨪⃻࿷)2㧕 Hepatogastroenterology㧧Co-Editor(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙṶ⠪㧘ᐳ㐳ศ↰๺ᒄ㧦
1㧕 ╙ 79 ࿁⢗≸ቇળ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘㨬ൻቇ≮ᴺ 2㨭ᐳ㐳)
2㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘㨬⢗≸(ಽሶ↢‛ቇ 2)㨭ᐳ㐳)
3㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળ⊛ቇⴚ㓸ળ࡮╙ 5 ࿁⥃ᐥ⎇ⓥ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘‫ޟ‬ᶖൻ▤ⴚᓟ⵬
ഥൻቇ≮ᴺߩ⃻⁁ߣ໧㗴ὐ‫ޠ‬Ṷ⠪)
4㧕 ╙ 62 ࿁ᶖൻེᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘㨬⢗≸࡮ಽሶ↢‛ቇ㨭ᐳ㐳)5㧕 45 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘੩ㇺ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬⢗≸ߦ߅ߌࠆᮡḰᴦ≮⏕┙߳ߩ㆏ߩࠅߣዷᦸ‫ޠ‬Ṷ⠪)
6㧕 ╙ 45 ࿁ᣣᧄ≸ᴦ≮ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ㧘੩ㇺ㧘㨬⢗ ㅴⴕ࡮ౣ⊒ ᴦ≮㨭ᐳ㐳)7㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱઍ 108 ࿁଀ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬㘩㆏≸‫ޔ‬⢗≸ᴦ≮ߩㅴᱠߣዷᦸ‫ޠ‬Ṷ⠪)8㧕 ╙ 63 ࿁ᣣᧄᶖൻེᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᧅᏻ‫ޔ‬㨬⢗≸‫ᦸⷐޔ‬Ṷ㗴‫ེޔ‬᪾่วࠍ↪޿ߚ⢗ಾ㒰ᓟౣᑪᴺߩഞ⟋ 1㨭ᐳ㐳)
9㧕 ╙ 46 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 17 ‫ޟ‬ㅴⴕ࡮ౣ⊒⢗≸ߦኻߔࠆᮡḰᴦ≮ߩࠦࡦ࠮ࡦࠨࠬߪᓧࠄࠇߚ߆‫ޠ‬ᐳ㐳)10㧕 ╙ 38 ࿁⢗ᄖ⑼࡮ⴚᓟ㓚ኂ⎇ⓥળ㧚(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘㨬ਥ㗴 II ⴚᓟൻ≮㨭ᐳ㐳)11㧕 ╙ 21 ࿁ᣣᧄࡃࠗࠝ࠮࡜ࡇ࡯ቇળቇⴚ㓸ળ✚ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ㨬᛫≸೷(2)㨭
ᐳ㐳)12㧕 The 6th International Symposium on Cancer Research and Therapy.(2008, Tokyo‫ޟ‬Molecular-Targeting
Therapy for Cancer and Cancer Stem Cell. Session 5. Basic Research and prognostic factor.‫ޠ‬ᐳ㐳)13㧕 ╙ 70 ࿁ᣣᧄ⥃ᐥᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 5㨬- ᣧᦼ⢗≸ߦኻߔࠆ⣻⣧㏜⵬ഥਅ⢗ಾ㒰ⴚ࡯ዉ౉ߦ߅ߌࠆࡐࠗࡦ࠻࡯㨭Ṷ⠪)
14㧕 ᣣᧄකᏧળ↢ᶦᢎ⢒⻠ᐳ‫ޔ‬ጘ㒂ᏒකᏧળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘㨬ᶖൻེ≸ߩಽሶᮡ⊛ᴦ≮ߩᦨ೨
✢㨭Ṷ⠪)
Ꮉญ㗅ᢘ㧦
1㧕 ╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Ἳ∝ᕈ੃߇ࠎߩ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)2㧕 ╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ᦨߩࠎ߇੃ޟ‬ᣂ࠻ࡇ࠶ࠢࠬ‫ޠ‬Ṷ⠪)3㧕 ߇ࠎߩ࡝ࡦࡄᶋ⣲⎇ⓥળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘‫ⴚ≸੃ޟ‬ᓟ਄⢇࡝ࡦࡄᶋ⣲ߦኻߔࠆᄖ᧪ᜰዉߩ
⃻⁁ߣ໧㗴ὐ‫ޠ‬Ṷ⠪)㐳↰⌀ੑ㧦
1㧕 ╙ 32 ࿁ᣣᧄᄖ⑼♽ㅪวળቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᄖ⑼㗔ၞߦ߅ߌࠆಽ
ሶ↢‛ቇߩᔕ↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 276 ࿁᧲ᶏᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ਃ㊀㧘‫ޟ‬⢄࡮⢙ 2‫ޠ‬ᐳ㐳)㜞ᯅቁᄦ㧦
1㧕 ╙ 32 ࿁ᣣᧄᄖ⑼♽ㅪวળቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེ≸ߦ߅ߌࠆⴚ
೨࡮ⴚᓟൻቇ≮ᴺߩㅴᱠ‫ޠ‬Ṷ⠪)⚦㊁⧐᮸㧦
1㧕 ╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫⥃ߩࠎ߇੃ޟ‬ᐥߦ߅ߌࠆ⃻⁁‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 㐳↰⌀ੑ㧦╙ 19 ࿁ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ࡮ળ㐳⾨(ᐔᚑ 19 ᐕᐲ)㧙㧙9㧚␠ળᵴേศ↰๺ᒄ㧦
1㧕 NOKIA ࠬࡁ࡯ࡏ࡯࠼ FIS ࡢ࡯࡞࠼ࠞ࠶ࡊ 2008GIFU/GUJO ᄢળ․೎㘈໧(ᐔᚑ 19 ᐕᐲ)
2㧕 ጘ㒂⋵≸ᬌ⸻♖ᐲ▤ℂᆔຬ(ᐔᚑ 20 ᐕᐲ)
3㧕 ੃≸Ꮢ᳃࠮ࡒ࠽࡯ߩ㐿௅(ᐔᚑ 20 ᐕ 5 ᦬ 24 ᣣ㧘ጘ㒂Ꮢ)4㧕 ጘ㒂⋵↢ᵴ⠌ᘠ∛ᬌ⸻▤ℂᜰዉද⼏ળ⢗߇ࠎㇱળᆔຬ5㧕 ጘ㒂⋵කᏧળᄖ⑼කㇱળ㘈໧
6㧕 (⽷)߇ࠎ㓸ቇ⊛ᴦ≮⎇ⓥ⽷࿅⹜㛎⺞ᢛᆔຬ࡮⹏⼏ຬ㐳↰⌀ੑ㧦
1㧕 Current Medicinal Chemistry Anti㧙Cancer Agents࡮Editorial Member(㨪ᐔᚑ 19 ᐕᐲ)
2㧕 International Surgical School࡮International Faculty Member(Professor Emeritus)(ᐔᚑ 19 ᐕᐲ)
3㧕 ጘ㒂⋵࿖᳃଻㒾ㅪวળክᩏᆔຬ(ᐔᚑ 19 ᐕᐲ)
4㧕 ࿖᳃ஜᐽ଻㒾ㅪวክᩏຬ(㨪⃻࿷)ဈਅᢥᄦ㧦1㧕 ࿖଻⸻≮ႎ㈽ክᩏᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 㐳↰⌀ੑ㧦≸ߩᨴ⦡૕ਇ቟ቯᕈߦ㑐ਈߔࠆ HsAIRK ߣ PLK ㆮવሶߩ⸃ᨆߣߘߩ⥃ᐥᔕ↪㧦ᐔᚑ 14ᐕᐲ㧙ᐔᚑ 17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙7(2006 ᐕ 3 ᦬)
2㧕 ᧖ጊ଻ᐘ㧦ᶖൻེ≸∝଀ߦ߅ߌࠆᧃ᪳ⴊ᮸⁁⚦⢩ߩ᛫ේ๒␜ᯏ⢻Ⴧᒝᴺߩ㐿⊒ߣߘߩ⥃ᐥᔕ↪㧦ᐔ
ᚑ 14 ᐕᐲ㧙ᐔᚑ 17 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙8(2006 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 㐳↰⌀ੑ㧦‫⦡ޟ‬ᄌൻߢ੍ళ⊒⷗㧙MRI ᣂࠪࠬ࠹ࡓ㐿⊒‫ޠ‬࡮౒ห⎇ⓥ㧦⺒ᄁᣂ⡞(2007 ᐕ 5 ᦬ 11 ᣣ)
2㧕 ศ↰๺ᒄ㧘Ꮉญ㗅ᢘ㧦‫∛ޟ‬㒮ߩታജ㨪ጘ㒂✬ 1 ੃߇ࠎ‫ޠ‬㧦⺒ᄁᣂ⡞(2008 ᐕ 1 ᦬ 6 ᣣ)
3㧕 ศ↰๺ᒄ㧦‫ޟ‬ᄢቇߪ޿߹ ⎇ⓥቶ߆ࠄ‫ ޠ‬ᣂߚߥ߇ࠎᴦ≮㐿⊒ㅴ߼ࠆ㧦ጘ㒂ᣂ⡞(2008 ᐕ 6 ᦬ 10 ᣣ)
4㧕 ศ↰๺ᒄ㧦‫ࠎ߇੃ޟ‬ᴦ≮⠨߃ࠆ‫ޠ‬㧦ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 7 ᣣ)
5㧕 ศ↰๺ᒄ㧘Ꮉญ㗅ᢘ㧘㐳↰⌀ੑ㧘ጊญ๺਽㧘㜞ᯅቁᄦ㧦‫ޟ‬ᖚ⠪ᧄ૏ߩ≸ᴦ≮ߦߟ޿ߡ⠨߃ࠆ‫ޠ‬㧦ᦺᣣᣂ⡞(2008 ᐕ 7 ᦬ 31 ᣣ)
6㧕 㐳↰⌀ੑ㧦‫ޟ‬㜞ᐲㅴⴕ⢄≸ߩಓ⚿ᴦ≮‫ޠ‬㧦ਛᣣᣂ⡞╬ో࿖࿾ᣇ⚕(2008 ᐕ 11 ᦬ 6 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᢎቶߣߒߡߩ⎇ⓥ࠹࡯ࡑࠍ⏕┙ߒߟߟ޽ࠅ㧘ㄭᐕߢߪቇળ⊒⴫ᢙߩჇട߇⹺߼ࠄࠇࠆ‫⺰޿઻ߦࠇߎޕ‬ᢥᢙߩჇട߇ᦼᓙߐࠇࠆ‫␠ߚߒߣࡑ࡯࠹ࠍ≸ޕ‬ળ⽸₂߿㧘ක≮ᓥ੐⠪߳ߩᢎ⢒ᵴേߐࠄߦߪߎࠇࠄߦ઻
߁␠ળႎ㆏ߥߤ߽ขࠅ਄ߍࠄࠇࠆߦ޿ߚߞߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ߅ࠃ߮ߘߩኻᔕ╷ᄖ⑼ቇᢎቶߣߒߡߐࠄߦ≸ኾ㐷ಽ㊁ߣߒߡ࿾ၞ߆ࠄߩା㗬ࠍᓧࠄࠇࠆߎߣߦࠃࠅᚻⴚ∝଀ᢙߩჇട߇
⹺߼ࠄࠇࠆ߽ߩߩ㧘ߘࠇߦ⷗ว߁ߛߌߩࠬ࠲࠶ࡈᢙ߇㒢ࠄࠇ㧘⎇ⓥߦኻߒߡߩᦝߥࠆ⊒ዷߦᡰ㓚߇ ᔨߐࠇࠆ‫ޕ‬ല₸ࠃߊ⸻≮㧘⎇ⓥࠍⴕ߁ኻ╷ࠍ⻠ߓߡ޿ࠆ‫ޕ‬੹ᓟߩዷᦸᢎቶߣߒߡߩ࠹࡯ࡑߣߒߡ㧘ᣧᦼ≸ߦኻߔࠆૐଚⷅᚻⴚߩ㐿⊒㧘㜞ᐲㅴⴕ߇ࠎߦኻߔࠆಽሶᮡ⊛ᴦ≮ߣߘߩჇᒝ૞↪ߩࡔࠞ࠾࠭ࡓߩ⸃ᨆߥߤࠍ㊀ὐ⊛ߦត⚝ߔࠆ‫ߦᦝޕ‬㧘ᢎቶ⁛⥄ߩᣂߚߥᴦ≮ᴺߥߤߩ㐿⊒ࠍ⹜ߺࠆ‫ޕ‬㧙㧙㧔4㧕ᶖൻེ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
⊒≸ߩᯏᐨߣߘߩ೙ᓮ㧘⢄ਇోߩ∛ᘒߣᴦ≮㧘ᶖൻེ∔ᖚߩ∛ᘒᩕ㙃ߣ੺౉㧘ᶖൻ▤∔ᖚߦኻߔࠆౝⷞ
㏜ᴦ≮ߩ㐿⊒߇ਥⷐ࠹࡯ࡑߢ޽ࠆ‫ޕ‬
1. ⊒≸ߩᯏᐨߣߘߩ೙ᓮߦߟ޿ߡߪ㧘ߣߊߦᩭౝฃኈ૕ࠍಽሶᮡ⊛ߣߒߚ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ޕ‬⢄≸ߦ߅ߌࠆᩭౝฃኈ૕ RXR ߦ㑐ߔࠆၮ␆⎇ⓥߪ߶߷⚳ੌߒ㧘ᄢ⣺≸㧘⤟≸ߥߤઁߩ≸⒳߳Ṷ➈ࠍ㐿ᆎߒߚ‫ޕ‬⢄≸ߦኻߒߡ RXR ࡝ࠟࡦ࠼ࠍ↪޿ߚ⊒≸೙ᓮ㧔੍㒐㧕ߩᄢⷙᮨ⥃ᐥ⹜㛎ࠍቢੌߢ߈ࠆ੍ቯߢ޽ࠆ‫ޕ‬
2. ⢄ਇోߩ߁ߜ㧘ᕆᕈ⢄ਇోߦߟ޿ߡ⢄⚦⢩ߩ↢ሽߣᱫ੢ࠍ᳿ቯߔࠆࡔࠞ࠾࠭ࡓߩ⸃᣿ࠍ⚦⢩ౝࠪࠣ࠽࡞㧘⚦⢩ᄖࡑ࠻࡝࠶ࠢࠬߩਔ㕙߆ࠄㅴ߼ߡ޿ࠆ‫ޕ‬ォ౮࿃ሶ HNF-4 ߇ࠠ࡯ߣߥࠆน⢻ᕈߦ೔㆐ߒ㧘࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞࡮࡝ࠨ࡯࠴㧔⢄ౣ↢ᴦ≮㧕߳ߩዷ㐿߇ⷞ㊁ߦ౉ߞߚ‫ޕ‬
3. ᘟᕈ⢄ਇోߢߪኋਥߩᩕ㙃⁁ᘒ߇⢄ਇోߩ∛ᘒㅴዷ࡮⊒≸ߦ᦭ᗧߥᗧ⟵ࠍ᦭ߔࠆߎߣࠍ⥃ᐥ⊛ߦ⸽᣿ߒ㧘ᣣ᰷ߩࠟࠗ࠼࡜ࠗࡦߦណ↪ߐࠇߚ‫੹ޕ‬ᓟ㧘ߘߩ᥉෸ࠍߐࠄߦ࿑ࠆ‫ޕ‬
4. ᶖൻ▤∔ᖚߩౝⷞ㏜ᴦ≮ߪ㧘ᦨᣂߩ࠺ࡃࠗࠬࠍ↪޿ߚ⸻≮ࠍㅴⴕߒߡ߅ࠅ㧘⥃ᐥ⎇ⓥ⺰ᢥߦߟߥߍߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ಎᢎ᝼㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

᫪⣁ਭ㓉
᳗ᧁᱜੳ
቟↰৻ᦶ
ౝᧁ㓉ᢥ
ᷡ᳓㓷ੳ
ศᎹᱞᔒ
౗᧛ାብ
੗ᷓ⾆჻
ጤਅᜏม
੹੗ஜੑ
ኹୖ㓁৻
ਭ଻↰ో຦
㜞↰ ᷕ
਄᧛⌀਽
ዊᧁᦥ⧷੺
㚍႐ ෘ

Hisataka Moriwaki
Masahito Nagaki
Ichiro Yasuda
Takafumi Naiki
Masahito Shimizu
Takeshi Yoshikawa
Nobuhiro Kanemura
Takashi Ibuka
Takuji Iwashita
Kenji Imai
Youichi Terakura
Masaya Kubota
Jun Takada
Shinya Uemura
Eisuke Ogiso
Atsushi Baba3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᫪⣁ਭ㓉㧚⢄ਇో࡮⢄ᕈ⣖∝ –Τ⸻ᢿߣ∝୥-㧦੗ᑫ㆏ᄦ㧘ᾢ↰ඳశ㧘ဝౝඳੳ㧘ᨋ ♿ᄦ✬㧚⢄⤳∛ቇ㧘᧲੩㧦ᦺୖᦠᐫ㧧2006 ᐕ㧦149㧙154.
2㧕 ᫪⣁ਭ㓉. 3.⢄ᕈ⣖∝㧦੗ᑫ㆏ᄦ㧘ᣣᲧ♿ᢥ✬㧚࿑⸃ ᶖൻེౝ⑼ቇ࠹ࠠࠬ࠻㧘᧲੩㧦ਛᄖකቇ␠㧧2006ᐕ㧦68㧙70.
3㧕 ᫪⣁ਭ㓉㧚∉ቇ⎇ⓥ߆ࠄߺߚ⢄߇ࠎߩൻቇ੍㒐ߣㅴዷᛥ೙㧦↰ፉ๺㓶㧘ฎ㊁♿ౖ✬㧚߇ࠎ⎇ⓥߩ޿߹г߇ࠎߩ∉ቇ-㧘᧲੩㧦᧲੩ᄢቇ಴ ળ㧧2006 ᐕ㧦174㧙182.
4㧕 ᫪⣁ਭ㓉㧚BCAA㧦ਛደ ⼾✬⪺㧚NST ↪⺆ࡂࡦ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2006 ᐕ㧦34
㧙35.5㧕 ട⮮ೣᑝ㧘⑔ንዄ㧚⣺▤಴ⴊᕈᄢ⣺⩶ᗵᨴ∝(O-157)㧦ᓟ⮮⑲ታ⋙ୃ. ਤ⠀ᐽᱜ✬㧚∝଀߆ࠄߺߚᶖൻེ∔ᖚߩ⸻ᢿߣᴦ≮㧘᧲੩㧦⸻ᢿߣᴦ≮␠㧧2006 ᐕ㧦109㧙112.
6㧕 ട⮮ೣᑝ㧘ጊ↰ථ਽㧚⸃㔌ᕈᄢേ⣂≜ߦࠃࠆ਄⣺▤⤑േ⣂㐽Ⴇ∝㧦ᓟ⮮⑲ታ⋙ୃ. ਤ⠀ᐽᱜ✬㧚∝଀߆ࠄߺߚᶖൻེ∔ᖚߩ⸻ᢿߣᴦ≮㧘᧲੩㧦⸻ᢿߣᴦ≮␠㧧2006 ᐕ㧦143㧙146.
7㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚⢄—⢄ᕈ⣖∝ߩ⸻ᢿၮḰߣ∛ဳಽ㘃—㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦227㧙
231㧚
8㧕 ᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄ౣ↢㧦ᚭ↰೰ᄥ㇢㧘⒢ᚲብశ㧘ኹ㊁ᓆ㧘᐀ౝ㓷ᢅ✬㧚Annual Review ᶖൻེ 2006㧘᧲੩㧦ਛᄖකቇ␠㧧2006 ᐕ㧦112㧙116㧚
9㧕 ᳗ᧁᱜੳ㧚⢄ᕈᤀ⌧㧦ጊญᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✬㧚੹ᣣߩᴦ≮ᜰ㊎ 2006 ᐕ 㧘᧲੩㧦කቇᦠ㒮㧧2006
ᐕ㧦384㧙385㧚
10㧕 ᳗ᧁᱜੳ㧚⢄Ἳ഍∝ൻߩࡔࠞ࠾࠭ࡓ㧦┻੗⻞ਯ㧘Ꮉፒ⺈ᴦ✬㧚೎ౠ࡮කቇߩ޽ࠁߺ㧙ᶖൻེ∔ᖚ-state of arts㧙㧙II. ⢄⢙⤟㧘᧲੩㧦කᱤ⮎಴ ᩣᑼળ␠㧧2006 ᐕ㧦112㧙116㧚
11㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚․ᱶ∛ᘒ(⁁ᘒ)ߦ߅ߌࠆᩕ㙃≮ᴺ㧙(ᚑੱ࡮ዊఽ)ⴊᶧ∔ᖚ㧙㧦ዊ⿧┨ᐔ⋙ୃ㧚ᩕ㙃≮ᴺ ࡒ࠾ࡑࡓࠛ࠶࠮ࡦࠪࡖ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦186㧙196㧚
12㧕 ቟↰৻ᦶ㧘ਛ੗ ታ㧘⊕ᧁ ੫㧘ᄢፉ㕏ᐢ㧘ጤਅᜏม㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧘᫪⣁ਭ㓉㧚⢙㆏∔ᖚ⸻≮ߩ࠻ࡇ࠶ࠢࠬ㧦ਛỈਃ㇢⋙ୃ㧚ੇ ๺㇢✬㧚⢄⢙⤟∔ᖚߩ⸻ᢿߣᴦ≮࠻ࡇ࠶ࠢࠬ 2006㧘᧲੩㧦ࠕ࡯ࠢࡔ࠺ࠖ
ࠕ㧧2006 ᐕ㧦45㧙52㧚
13㧕 ะ੗ ᒝ㧘቟↰৻ᦶ㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚⢙࡮⤟ ⤟⊒↢⇣Ᏹ(⤟≹วਇో)ߩ∛ဳಽ㘃㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ᣣᧄࡔ࠺ࠖࠞ࡞࠮ࡦ࠲࡯㧧2006 ᐕ㧦355㧙357㧚
14㧕 ౝᧁ㓉ᢥ㧘᫪⣁ਭ㓉㧚44㧚഍∝⢄Ἳ㧙Common Disease ࠗࡦࠬ࠻࡜࡚ࠢࠪࡦ࡮ࡑ࠾ࡘࠕ࡞-ᖚ⠪ߦ૗ࠍߤ߁⺑᣿ߔࠆ߆㧙㧦Medicina ✬㧚Medicina㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙171.
15㧕 ⑔ፉ⑲᮸㧚Ω. ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚ㧦ዊ⿧┨ᐔ⋙㧚᫪⣁ਭ㓉㧘ᄢ᧛ஜੑ㧘੗਄ༀᢥ✬㧚ᩕ㙃≮ᴺ ࡒ࠾ࡑࡓࠛ࠶࠮ࡦࠪࡖ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦119㧙125㧚
16㧕 ⑔ፉ⑲᮸㧚Ԙ∔ᖚ೎ߩ⸻ᢿ࡮ᴦ≮ᜰ㊎ B.∔ᖚ೎ߩᴦ≮ 6)㕖ઍఘᕈ⢄⎬ᄌ 1.⣻᳓ࠍว૬ߒߡ޿ࠆ႐ว㧦⢄ߣᩕ㙃ߩળ✬㧚ታ〣 ⢄∔ᖚߩᩕ㙃≮ᴺ㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦68㧙73㧚
17㧕 ⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘ᚭ↰ൎਭ㧘ਛ᧛ඳᑼ㧘⧯ේ೑㆐㧘੖๧㇚ሶ㧘ਃベ૫ⴕ㧘ᕺ⦟⡛৻㧘᫪⣁ਭ㓉㧚Τ ⢄ߩ✢⛽ൻ࡮Ἳ∝࡮ᴦ≮ 4㧚⢄⎬ᄌᖚ⠪ߦ߅ߌࠆ BCAA ⵾೷ᛩਈᤨߩ㉄ൻဳࠕ࡞ࡉࡒࡦߩᬌ⸛㧦⼱Ꮉਭ৻✬㧚╙ 2 ࿁‫㉄ޟ‬ൻࠬ࠻࡟ࠬߣ⢄‫⎇ޠ‬ⓥળ⸥㍳ 㧙㉄ൻࠬ࠻࡟ࠬߣ⢄∔ᖚ㧙 ╙ 2 Ꮞ㧘᧲੩㧦ᩣᑼળ␠ࠕ࡯
ࠢࡔ࠺ࠖࠕ㧧2006 ᐕ㧦79㧙84㧚
18㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚⢄㧙⢄ᕈ⣖∝ߩ⸻ᢿၮḰߣ∛ဳಽ㘃㧙㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ᣣᧄࡔ࠺ࠖࠞ࡞࠮ࡦ࠲࡯␠㧧2006 ᐕ㧦
227㧙231㧚
19㧕 ᳗ᧁᱜੳ㧚DNA ࡑࠗࠢࡠࠕ࡟ࠗࠍ↪޿ߚㆮવሶ⊒⃻⸃ᨆߦࠃࠆ⢄⚦⢩ᱫ࡮ಽൻᯏ᭴ߩ⸃᣿ߣォ౮⺞▵㧦
Liver Forum in Kyoto ╙ 8 ࿁ቇⴚ㓸ળ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࠻࡝ࡆࡘ࡯ࡦ㧧2006 ᐕ㧦29㧙34.
20㧕 ᫪⣁ਭ㓉㧚LC/HCC㧦ጟ↰ᱜ㧘㚍႐ᔘ㓶㧘ጊၔ㓶৻㇢✬㧚ᣂ⥃ᐥᩕ㙃ቇ㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦502
㧙506.
21㧕 ᫪⣁ਭ㓉㧚LC,HCC㧦ᱞ↰⧷ੑ㧘㐳⼱ㇱᱜ᥍✬㧚⥃ᐥᩕ㙃੍㒐࡮ᴦ≮ቇ㧘ᄢ㒋㧦᳗੗ᦠᐫ㧧2007 ᐕ㧦231
㧙233.
22㧕 ᫪⣁ਭ㓉㧚ᣣᧄᩕ㙃࡮㘩♳ቇળ✬㧚ᩕ㙃࡮㘩♳ቇ↪⺆ㄉౖ㧘᧲੩㧦ᑪᏡ␠㧧2007 ᐕ㧚
23㧕 ᫪⣁ਭ㓉㧚⢄ਇో࡮⢄ᕈ⣖∝㧦᧖ᧄᕡ᣿㧘⍫ፒ⟵㓶✬㧚ౝ⑼ቇ(╙ 9 )㧘᧲੩㧦ᦺୖᦠᐫ㧧2007 ᐕ㧦933
㧙936.
24㧕 ᫪⣁ਭ㓉㧚⢄⎬ᄌ㧙a.৻⥸⊛ᴦ≮㧘ᄖ᧪▤ℂ╬㧙㧦▤㊁ஜᄥ㇢㧘਄⷏♿ᄦ㧘੗ᑫ㆏ᄦ✬㧚ᶖൻེ∔ᖚᦨᣂߩᴦ≮㧘᧲੩㧦ධᳯၴ㧧2007 ᐕ㧦308㧙311.
25㧕 ᫪⣁ਭ㓉㧚↢ᵴᜰዉ㧦ጊญᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✬㧚੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦416.
26㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A㧦Medical Practice ✬㧚⥃ᐥᬌᩏࠟࠗ࠼ 2007㨪2008㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦265
㧙266.
27㧕 ᫪⣁ਭ㓉㧚⢄⎬ᄌ࡮⢄⤳≸㧦⍫ࡩፒ৻ਃ㧘㐷⣁ၮੑ㧘⥭㊀ᱜ৻㧘ᮮ⿧⑲ᒾ✬㧚ࠕࡒࡁ㉄ߩᯏ⢻․ᕈ㧘᧲੩㧦ஜᏡ␠㧧2007 ᐕ㧦261㧙722.
28㧕 ᫪⣁ਭ㓉㧚Pio̖NASH㧦Review Gastroenterol CGH㧘2007;1:62㧙64.
29㧕 ᫪⣁ਭ㓉㧚BCAA㧦〔⷗⵨㧘⊕㠽ᢘሶ㧘ᱜᧁዏᒾ㧘਄᧛⋥Ꮘ✬㧚⥃ᐥߦ⋥⚿ߔࠆ⢄࡮⢙࡮⤟∔ᖚᴦ≮ߩࠛࡆ࠺ࡦࠬ㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦67㧙68.
30㧕 ᳗ᧁᱜੳ㧚ᣣᧄᩕ㙃࡮㘩♳ቇળ✬㧚ᩕ㙃࡮㘩♳ቇ↪⺆ㄉౖ㧘᧲੩㧦ᑪᏡ␠㧧2007 ᐕ.
31㧕 ቟↰৻ᦶ㧘᫪⣁ਭ㓉㧚╙ 4 ┨㧚⢙㆏∔ᖚ㧦᧻የ ℂ⋙㧚᫪⣁ਭ㓉✬㧚ࠃߊࠊ߆ࠆ∛ᘒ↢ℂ 3 㧙ᶖൻེ∔ᖚ-㧘᧲੩㧦ᣣᧄක੐ᣂႎ␠㧧2007 ᐕ㧦113㧙136.
32㧕 ቟↰৻ᦶ㧚⿥㖸ᵄౝⷞ㏜ߦࠃࠆ❑㓒㗔ၞ߳ߩࠕࡊࡠ࡯࠴ 㧙EBUS-TBNA, EUS-FNA ߩታ㓙㧙㧦቟⑔๺ᒄ⋙㧚೙૞දജ ࠝ࡝ࡦࡄࠬࡔ࠺ࠖࠞ࡞ࠪࠬ࠹ࡓᩣᑼળ␠㧚33㧕 ⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚╙ 2 ┨ ⚻⣺ᩕ㙃೷ߩၮᧄߣᔕ↪ ․ᱶߥ∛ᘒߩ⚻⣺ᩕ㙃▤ℂ—⢄∔ᖚ—㧦૒‫ᧁޘ‬㓷਽✬㧚NST ߩߚ߼ߩ⚻⣺ᩕ㙃 ታ〣࠹ࠢ࠾࠶ࠢ㧘᧲੩㧦ᾖᨋ␠㧧2007 ᐕ㧦51㧙55.
34㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄⊒≸ߩ੍㒐㧦⷏ญୃᐔ✬㧚⢄⎬ᄌߩࡑࡀࠫࡔࡦ࠻㧚᧲੩㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2007 ᐕ㧦84㧙89㧚
35㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚Φ. ⢄⎬ᄌߩᴦ≮—ᩕ㙃ቇ⊛≮ᴺ—1. ಽጘ㎮ࠕࡒࡁ㉄(BCAA)—㧦⷏ญୃᐔ✬㧚ࡑࡀࠫࡔࡦ࠻ࠪ࡝࡯࠭ ⢄⎬ᄌߩࡑࡀࠫࡔࡦ࠻㧘᧲੩㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2007 ᐕ㧦66㧙72.
36㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚╙ 4 ┨▤ℂ࡮ᴦ≮ ↢ᵴ▤ℂ(ᩕ㙃▤ℂࠍ฽߻) 44 ⢄⎬ᄌ㧦ᴒ↰ ᭂ✬㧚ᦨᣂකቇ೎ౠ ᣂߒ޿⸻ᢿߣᴦ≮ߩ ABC㧘ᄢ㒋㧦ᦨᣂකቇ␠㧧2007 ᐕ㧦72㧙78.
37㧕 ⊕ᧁ ੫㧘⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚ࠕࡒࡁ㉄ߣߘߩಽ↹㧦Medical Practice ✬㧚⥃ᐥᬌᩏࠟࠗ࠼ 2007㨪2008㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦203㧙208.
38㧕 ᫪⣁ਭ㓉㧚∛ᘒ೎ߩᩕ㙃▤ℂ ⢄Ἳ㧘⢄⎬ᄌ㧘⢄ਇో㧦ጊ᧲ൕᒎ㧘ᐊᙗ৻㇢㧘଻ᧁ᣽ᓼ✬㧚࡟ࠫ࠺ࡦ࠻ߩߚ
߼ߩᩕ㙃▤ℂࡑ࠾ࡘࠕ࡞㧘᧲੩㧦ᢥశၴ㧧2008 ᐕ㧦201㧙206.
39㧕 ᫪⣁ਭ㓉㧚D.⢄∔ᖚߦኻߔࠆᩕ㙃≮ᴺ(⢄⎬ᄌ߽฽߻)㧦JASPEN ✬㧚ࠦࡔ࠺ࠖࠞ࡞ߩߚ߼ߩ㕒⣂⚻⣺ᩕ㙃࠮ࡒ࠽࡯㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦299㧙304.
40㧕 ᫪⣁ਭ㓉㧚╙ 5 ┨ ∛ᘒᩕ㙃ߣᩕ㙃≮ᴺ㧘7 ߘߩઁߩ∔ᖚ㧘Ԝ߇ࠎ㧦ᣣᧄ∛ᘒᩕ㙃ቇળ✬㧚ᡷ⸓╙ 2 
⹺ቯ ∛ᘒᩕ㙃ኾ㐷Ꮷߩߚ߼ߩ∛ᘒᩕ㙃ࠟࠗ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2008 ᐕ㧦248㧙249.
41㧕 ⊕ᧁ ੫㧘ኹୖ㓁৻㧘ጤ⍾ᷕᐔ㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄⎬ᄌᖚ⠪ߦ߅ߌࠆᚑ࿃೎ᬌ⸛㧦㕍ᩉ㧙㧙⼾㧘⷏ญୃᐔ㧘㆏ႌᶈੑ㇢✬㧚⢄⎬ᄌߩᚑ࿃೎ታᘒ㧘᧲੩㧦ਛᄖකቇ␠㧧2008 ᐕ㧦174㧙177㧚
42㧕 ቟↰৻ᦶ㧚II. ᔕ↪✬ B. ERCP 㑐ㅪᚻᛛ ฦ⺰ d. ERCP 㑐ㅪᚻᛛߦᔅⷐߥಣ⟎ౕߣᚻᛛߩታ㓙(⢙㆏
✬)2. EPBD(ౝⷞ㏜⊛੃㗡ࡃ࡞࡯ࡦ᜛ᒛⴚ)㧦♻੗㓉ᄦ✬㧚⢙⤟ౝⷞ㏜ߩ⸻ᢿ࡮ᴦ≮ߩၮᧄᚻᛛ㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦150㧙153㧚
43㧕 ቟↰৻ᦶ㧚Part1 h3. ⢙⤟∔ᖚߦኻߔࠆࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ A. ERCP ߣ㑐ㅪᬌᩏᚻᛛ(ࡉ࡜࠶ࠪࡦࠣ⚦⢩⸻㧘⚻੃㗡⊛↢ᬌ㧘POCS/POPS㧘IDUS)㧦ዊୀ᡽↵⋙㧚દ૒ጊᶈㅢ㧘ศ↰᥍ᒾ㧘ᬁฬ⑲৻ᦶ✬㧚⢄⢙⤟⸻≮ࠛࠠࠬࡄ࡯࠻ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦98㧙103㧚
44㧕 ቟↰৻ᦶ㧚Part3 h2. ⢙㆏࡮⤟⤳∔ᖚ 2) ✚⢙▤⚿⍹㧦ዊୀ᡽↵⋙㧚દ૒ጊᶈㅢ㧘ศ↰᥍ᒾ㧘ᬁฬ⑲৻ᦶ✬㧚⢄⢙⤟⸻≮ࠛࠠࠬࡄ࡯࠻ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦291㧙294㧚
45㧕 ะ੗ ᒝ㧘቟↰৻ᦶ㧚Part3 h2. ⢙㆏࡮⤟⤳∔ᖚ 10) ERCP ߣ㑐ㅪᬌᩏᚻᛛ(ࡉ࡜࠶ࠪࡦࠣ⚦⢩⸻㧘⚻੃㗡⊛↢ᬌ㧘POCS/POPS㧘IDUS)㧦ዊୀ᡽↵⋙㧚દ૒ጊᶈㅢ㧘ศ↰᥍ᒾ㧘ᬁฬ⑲৻ᦶ✬㧚⢄⢙⤟⸻≮ࠛࠠࠬࡄ࡯࠻ࡑ࠾ࡘࠕ࡞㧘᧲੩㧦⟠࿯␠㧧2008 ᐕ㧦338㧙343㧚
46㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧘↰᧛ቁᔒ㧚⢄Ἳ㧦ᷰㄝ᣿ᴦ㧘⑔੗ንⓄ✬㧚੹ᣣߩ∛ᘒᩕ㙃≮ᴺ(ᡷ⸓╙ 2 )㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦166㧙170㧚
47㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚⢄࡮⢙㆏∔ᖚߦኻߔࠆᩕ㙃▤ℂ㧦ᣣᧄ∛ᘒᩕ㙃ቇળ✬㧚⹺ቯ NST ࠟࠗ࠼ࡉ࠶ࠢ 2008ᡷ⸓ 㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2008 ᐕ㧦119㧙126㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu M, Weinstein IB, Moriwaki H. Targeting receptor tyrosine kinases and multiple downstream
signaling pathways by green tea catechin EGCG. In:Pandalai SG, ed. Cancer -Disease Progression andChemoprevention, India:Research Signpost;2006:203-206.
2㧕 Yasuda I, Iwashita T, Moriwaki H. Strategy for the endoscopic treatment of common bile duct stones-Should we cut or dilate the papilla?. In:Tajiri H, Nakajima M, Yasuda K. eds. New Challenges in
Gastrointestinal Endoscopy, Tokyo: Springer; 2008:379-384.
✚⺑㧔๺ᢥ㧕
1㧕 ᫪⣁ਭ㓉㧚⢄⤳ᩕ㙃ᴦ≮ߦ㑐ߔࠆᗧ⼂⺞ᩏ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦79㧙81.
2㧕 ᫪⣁ਭ㓉㧚⢄⎬ᄌᖚ⠪ߩᩕ㙃≮ᴺߩㅴ߼߆ߚ -ฦ⒳ࠕࡒࡁ㉄⵾೷ߩ૶޿ಽߌߩࠦ࠷㧘Medical Practice2006 ᐕ㧧23 Ꮞ㧦133㧙135.
3㧕 ᫪⣁ਭ㓉㧚․㓸 ᶖൻེ≸ߩ੍㒐කቇ 㧙⢄⤳≸ߩൻቇ੍㒐㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦695㧙698.
4㧕 ᫪⣁ਭ㓉㧚⢄⊒≸ -ൻቇ੍㒐㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦1090㧙1095.
5㧕 ᫪⣁ਭ㓉㧘ጊ↰ବ᮸㧚․㓸/⢄ᯏ⢻ᬌᩏ୯ -ߘߩ਄ᚻߥ⺒ߺᣇ ⴊᷡⰮ⊕࡮⤔⾰෻ᔕߩᬌᩏ୯ߩ⺒ߺᣇ㧘⥃ᐥߣ⎇ⓥ 2006 ᐕ㧧83 Ꮞ㧦180㧙182.
6㧕 ᫪⣁ਭ㓉㧚⢄⚦⢩≸ߩ੍㒐ᴦ≮(ᐳ⺣ળ)㧘⢄⢙⤟ 2006 ᐕ㧧52 Ꮞ㧦457㧙474.
7㧕 ᅏ㊁ᱜ㓉㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊒≸੍㒐ߣߘߩℂ⺰⊛⢛᥊㧘⢄⢙⤟ 2006 ᐕ㧧52 Ꮞ㧦393㧙402.
8㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘㢬⷗ ኼ㧘᧻ᶆసᒾ㧘ᷓየ੝↱⟤㧘ᧁਅᐘሶ㧘᧛ἑ૫ઍሶ㧘㋈ᧁ㤗Ꮧሶ㧘᫪⣁ਭ㓉㧚ቇળ࡟ࡐ࡯࠻ ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦174㧙176㧚
9㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚৻⥸⥃ᐥක߇ࠃߊㆣㆄߔࠆ⽺ⴊߩ⸻߆ߚ㧙ᶖൻེ∔ᖚߣ⽺ⴊ㧘⸻ᢿߣᴦ≮ 2006 ᐕ㧧
94 Ꮞ㧦2050㧙2053.
10㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊕ⴊ∛ߩಽൻ⺃ዉ≮ᴺ㧘Biotherapy 2006 ᐕ㧧20 Ꮞ㧦150㧙157.
11㧕 ቟↰৻ᦶ㧘᫪⣁ਭ㓉㧚ᢎ⢒࠮ࡒ࠽࡯‫ޟ‬⢙㆏ౝⷞ㏜ᴦ≮ߩࠦ࠷ߣ pitfall‫✚ޠ‬⢙▤⚿⍹ߩౝⷞ㏜ᴦ≮㧙ౝⷞ㏜⊛੃㗡ಾ㐿ⴚ(EST)ߣౝⷞ㏜⊛੃㗡ࡃ࡞࡯ࡦ᜛ᒛⴚ(EPBD)㧘⢙㆏ 2006 ᐕ㧧20 Ꮞ㧦159㧙164㧚
12㧕 ቟↰৻ᦶ㧘ะ੗ ᒝ㧘ᄢ⷏㓉຦㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚࡟ࠫ࠺ࡦ࠻ߩߚ߼ߩౝⷞ㏜⸻≮ࡑ࠾ࡘࠕ࡞ 㧙ౝⷞ㏜⊛⢙㆏࠼࡟࠽࡯ࠫⴚ㧙EBD(ࡊ࡜ࠬ࠴࠶ࠢࠬ࠹ࡦ࠻㧘㊄ዻࠬ࠹ࡦ࠻)㧘ᶖൻེౝⷞ㏜ 2006 ᐕ㧧18 Ꮞ㧦
869㧙871㧚
13㧕 ቟↰৻ᦶ㧚ᣂ⷏ᵗౝⷞ㏜⸻≮੐ᖱ㧙Master of Endoscopy㧘ᶖൻེౝⷞ㏜ 2006 ᐕ㧧18 Ꮞ㧦1037㧙1039㧚
14㧕 ቟↰৻ᦶ㧚ERCP 㑐ㅪᚻᛛߩࠦ࠷㧙⑳ߪߎ߁ߒߡ޿ࠆгEST ߣ EPBD㧘ᶖൻེ↹௝ 2006 ᐕ㧧8 Ꮞ㧦641
㧙646㧚
15㧕 ᄢ⷏㓉຦㧘቟↰৻ᦶ㧘ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚․㓸㧦⤟≸ᣧᦼ⸻ᢿߩࠬ࠻࡜࠹ࠫ࡯г9㧚
EUS㧘EUS-FNA㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦13.
16㧕 ⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚੹᦬ߩਥ㗴 ⚻㕒⣂࡮⚻⣺ᩕ㙃 ࡊ࡜ࡦ࠾ࡦࠣߣߘߩታ〣гࠊ߇࿖ߩᩕ㙃≮ᴺߩ⃻⁁гᩕ㙃≮ᴺ⊒ዷߩᱧผ⊛⢛᥊㧘Medicina 2006 ᐕ㧧43 Ꮞ㧦718㧙721.
17㧕 ⑔ፉ⑲᮸㧘᫪⣁ਭ㓉㧚ᴦ≮ᛶ᛫ᕈ⢄∔ᖚ߳ߩࠕࡊࡠ࡯࠴г⢄⎬ᄌߩว૬∝ߩ∛ᘒߣᴦ≮г⢄ᕈ⣖∝ߩ∛ᘒߣᴦ≮㧘Modern Physician 2006 ᐕ㧧26 Ꮞ㧦1276㧙1280.
18㧕 ⑔ፉ⑲᮸, ᫪⣁ਭ㓉㧚Subjective global assessment(SGA)ߩታ㓙ߣߘߩᗧ⟵㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧218
Ꮞ㧦496㧙500.
19㧕 ะ੗ ᒝ㧘቟↰৻ᦶ㧘Ⴎደᱜ㆏㧘ᄢ⷏㓉຦㧘౷↰ᩕ৻㧚⤟≸࡮⢙㆏≸ߩ⸻ᢿߣᴦ≮гᦨᣂߩ⎇ⓥേะ B. ⢙㆏≸ IX. ⢙㆏≸ᴦ≮ߦ߅ߌࠆ QOL㧘⢙㆏≸ߩ㕖ᚻⴚ≮ᴺߣ QOL㧘ᣣᧄ⥃ᐥ 2006 ᐕ㧧64 Ꮞ㧦560㧙564㧚
20㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘౷↰ᩕ৻㧚㕖ಾ㒰⢄㐷ㇱᖡᕈ⢙▤㐽Ⴇߦ߅ߌࠆ⢙㆏࠼࡟࠽࡯ࠫ㧦
up-to-date—⢄㐷ㇱᖡᕈ⢙▤㐽Ⴇߦ߅ߌࠆ Matallic stent ߩഞ⟋—⢙ߣ⤟ 2006 ᐕ㧧27 Ꮞ㧦379㧙382㧚
21㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄⊒≸ൻቇ੍㒐㧘೎ౠ‫ޟ‬කቇߩ޽ࠁߺ‫ޠ‬ᶖൻེ∔ᖚ II.⢄࡮⢙࡮⤟ 2006 ᐕ㧧3 Ꮞ㧦481㧙484.
22㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄ౣ⊒≸ߩൻቇ੍㒐㧘⢄⢙⤟ 2006 ᐕ㧧53 Ꮞ㧦843㧙850.

㧙㧙

23㧕 ጊፒஜ〝㧘㐳✽ ⡡㧘┵ጊᥰ㇢㧘⑺↰࿡ᴦ㧘⨹ᧁኡม㧘ፉፒ ା㧘ട⮮ೣᑝ㧘᫪⣁ਭ㓉㧚ㄦㅦߥౝⷞ㏜⸻
ᢿ࡮ᴦ≮ߦㅘ᣿ࡈ࡯࠼߇᦭↪ߢ޽ߞߚචੑᜰ⣺ᙑቶ಴ⴊߩ 1 ଀㧘ᶖൻེౝⷞ㏜ 2006 ᐕ㧧18 Ꮞ㧦379㧙383㧚
24㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚․㓸 ᩕ㙃ᛩਈ࡞࡯࠻ߩᎿᄦߣㅴᱠгක≮቟ో▤ℂ߆ࠄߺߚᩕ
㙃ᛩਈ࡞࡯࠻ߩᄌ㕟ߣ᦭↪ᕈ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦426㧙431.
25㧕 ቟↰৻ᦶ㧘Ⴎደᱜ㆏㧘ะ੗ ᒝ㧘ᄢ⷏㓉຦㧘ጤਅᜏม㧘࿯੗᤯ᐔ㧘Ⴚ ᶈᐽ㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚⤟∔ᖚߩ↹௝⸻ᢿ㧦ᦨㄭߩ࠻࡟ࡦ࠼г⤟ߩౝⷞ㏜⊛ࠗࡦ࠲࡯ࡌࡦ࡚ࠪࡦ㧘⥃ᐥ↹௝ 2006 ᐕ㧧22 Ꮞ㧦1376㧙1383㧚
26㧕 ᄢ⷏㓉຦㧘቟↰৻ᦶ㧘ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚⤟≸ᣧᦼ⸻ᢿߩࠬ࠻࡜࠹ࠫ࡯гEUS㧘
EUS-FNA ߦࠃࠆ⤟≸ᣧᦼ⸻ᢿ㧘⥃ᐥᶖൻེౝ⑼ 2006 ᐕ㧧21 Ꮞ㧦1771㧙1778.
27㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄ౣ⊒≸ߩൻቇ੍㒐㧘⢄⢙⤟ 2006 ᐕ㧧53 Ꮞ㧦881㧙887.
28㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘౷↰ᩕ৻㧚ಾ㒰ਇ⢻⢄㐷ㇱ⢙▤≸ߦ߅ߌࠆ⢙㆏ࠬ࠹ࡦ࠻ߩ⹏ଔ-Metallic
stent ߣ Tube stent—⢙㆏≸ߦኻߔࠆ IVR ߣౝⷞ㏜ᴦ≮㧘ᶖൻེ⑼ 2006 ᐕ㧧43 Ꮞ㧦345㧙349.
29㧕 ⊕ᧁ ੫, ⑔ፉ⑲᮸, ᫪⣁ਭ㓉. ⢄ᕈᶋ⣲㧘✚ว⥃ᐥ 2006 ᐕ㧧55 Ꮞ㧦2631㧙2635.
30㧕 ᫪⣁ਭ㓉㧚Care and Care Seriesг⢄࡮⢙࡮⤟∔ᖚߩᴦ≮ߣ⋴⼔㧘ౝ⑼ 2007 ᐕ㧧99 Ꮞ㧦686.
31㧕 ᫪⣁ਭ㓉㧘⊕ᧁ ੫㧚ࠞ࡜࡯ࠕ࠻࡜ࠬгり૕ᓽ୥߆ࠄߺࠆᩕ㙃⹏ଔ㧘⥃ᐥᩕ㙃 2007 ᐕ㧧110 Ꮞ㧦798㧙801.
32㧕 ᫪⣁ਭ㓉㧚♧ዩ∛ߦ߅ߌࠆㆬᛯߣߘߩታ㓙㧘ᩕ㙃⹏ଔߣᴦ≮ 2007 ᐕ㧧24 Ꮞ㧦53㧙55.
33㧕 ᫪⣁ਭ㓉㧚⢄ਇోᴦ≮ߩ⃻⁁ߣዷᦸ(ᐳ⺣ળ)㧘ᴦ≮ቇ 2007 ᐕ㧧41 Ꮞ㧦393㧙400.
34㧕 ᫪⣁ਭ㓉㧚LES(Late evening snack)ߦࠃࠆ⢄⤳ᩕ㙃≮ᴺߩ⃻⁁ߣዷᦸ(ᐳ⺣ળ)㧘ᩕ㙃⹏ଔߣᴦ≮ 2007
ᐕ㧧24 Ꮞ㧦64㧙73.
35㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A ߩၮ␆㧘Modern Physician 2007 ᐕ㧧27 Ꮞ㧦1187㧙1188.
36㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A ߩ⥃ᐥ㧘Modern Physician 2007 ᐕ㧧27 Ꮞ㧦1189㧙1190.
37㧕 ᫪⣁ਭ㓉㧚⢄ᕈ⣖∝㧘ᴦ≮ ᣣᶖ⹹ 2007 ᐕ㧧104 Ꮞ㧦352㧙356.
38㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚․㓸 ⢄ਇో 2㧚ᘟᕈ⢄ਇో 1)⢄ᕈ⣖∝ߩ⊒∝ᯏᐨߣᴦ≮㧘ᴦ≮ቇ 2007 ᐕ㧧
41 Ꮞ㧦363㧙367.
39㧕 㢬⷗ ኼ㧚 ⥃ᐥ✬ II. ⸻ᢿᴺ ৻⥸ⴊᶧᬌᩏ࡮㛽㜑ᬌᩏ㧘ㅧⴊེ⣲≌—ၮ␆࡮⥃ᐥ㗔ၞߦ߅ߌࠆᦨᣂߩ⎇ⓥേะ㧘ᣣᧄ⥃ᐥ 2007 ᐕ㧧65 Ꮞ㧦288㧙292.
40㧕 ቟↰৻ᦶ㧘Ⴎደᱜ㆏㧘ะ੗ ᒝ㧘ᄢ⷏㓉຦㧘ᚭ↰ൎਭ㧘ጤ↰࿻੺㧘ጤਅᜏม㧘࿯੗᤯ᐔ㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚․㓸㧦૶޿ᾫߘ߁ EUS—⤟࡮⢙㆏㗔ၞߩᮡḰᢿጀᴺ—ࠦࡦࡌ࠶ࠢࠬᯏ⒳㧘ᶖൻེౝⷞ㏜ 2007 ᐕ㧧
19 Ꮞ㧦923㧙928.
41㧕 ቟↰৻ᦶ㧘ጤਅᜏม㧘࿯੗᤯ᐔ㧘᫪⣁ਭ㓉㧚ౝⷞ㏜ߩ቟ోቇ㧙⧯ᚻ߳ߩࡔ࠶࠮࡯ࠫ࡯቟ోߥ EUS㧘ᶖൻེౝⷞ㏜ 2007 ᐕ㧧19 Ꮞ㧦1340㧙1343.
42㧕 ቟↰৻ᦶ㧘࿯੗᤯ᐔ㧘ጤਅᜏม㧘ጤ↰࿻੺㧘ᚭ↰ൎਭ㧘ᄢ⷏㓉຦㧘ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚✚⢙▤⚿⍹ណ⍹ߦ߅ߌࠆᎿᄦߣࡔࡕ࡝࡯8г✢ࡃࠬࠤ࠶࠻ߩ․ᓽߣ૶޿ᣇ㧘HIRATA NEWSLETTERS 2007 ᐕ㧧7 Ꮞ㧦1㧙7.
43㧕 ቟↰৻ᦶ㧚⿥㖸ᵄౝⷞ㏜ࠟࠗ࠼ਅ⓫ೝⴚ(EUS-FNA)-⑳ߩࠦ࠷࡯㧘ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦615㧙620.
44㧕 ⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉. ․㓸 II ⢄⎬ᄌߩᩕ㙃≮ᴺгC ဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ BMI ߩᗧ⟵㧘ᶖൻེ⑼ 2007 ᐕ㧧44 Ꮞ㧦603㧙608.
45㧕 ⊕ᧁ ੫, ᫪⣁ਭ㓉. ⢄ᕈ⣖∝㧘⢄⢙⤟ 2007 ᐕ㧧54 Ꮞ㧦109㧙114.
46㧕 ⊕ᧁ ੫, ᫪⣁ਭ㓉. ⢄⎬ᄌ㧘✚ว⥃ᐥ 2007 ᐕ㧧56 Ꮞ㧦1173㧙1179.
47㧕 ᧃᰴ ᷕ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄ౣ↢ߦ߆߆ࠊࠆಽሶ̅HNF ߪߤߩࠃ߁ߦ߆߆ࠊࠆߩ߆㧫㧘ಽሶᶖൻེ
∛ 2007 ᐕ㧧4 Ꮞ㧦322㧙326.
✚⺑㧔᰷ᢥ㧕
1㧕 Moriwaki H. Nutritional assessment in liver cirrhosis. J Gastroenterol. 2006;41:511-512.
2㧕 Shimomura Y, Honda T, Shiraki M, Murakami T, Sato J, Kobayashi H, Mawatari K, Obayashi M,
Harris RA.Branched-chain amino acid catabolism in exercise and liver disease. J Nutr.
2006;136:250S-253S.
3㧕 Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver
carcinogenesis with retinoids -Basic and clinic aspects. Hepatol Res. 2007;37(Suppl.2):S299-S302.
ේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ศᎹᱞᔒ㧘ਅ᧛㗅ሶ㧘㢬⷗ ኼ㧘ጊ↰㋕਽㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚ᣧᦼߦࡃ࡯ࠠ࠶
࠻࡝ࡦࡄ⣲ဳᒻ⾰ォ឵ࠍ␜ߒ㜞ᖡᕈᐲൻߒߚࠈ⢩ᕈ࡝ࡦࡄ⣲㧘⥃ᐥⴊᶧ 2006 ᐕ㧧46 Ꮞ㧦1055㧙1059.
2㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘ᄢፉ㕏ᐢ㧘⊕ᧁ ੫㧘⑔ፉ⑲᮸㧘቟↰৻ᦶ㧘᳗ᧁᱜੳ㧘ട⮮ೣᑝ㧘᫪⣁ਭ㓉㧘ᑝἑༀା㧚චੑᜰ⣺㒱ಳဳ⣼⣲ߩ 1 ଀㧘Gastroenterological Endoscopy 2006 ᐕ㧧48 Ꮞ㧦1228㧙1230㧚
3㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘ਛ੗ ታ㧘ᄢፉ㕏ᐢ㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧘᧻የ ᶈ㧘㑐㊁ቁผ㧘ጊ↰ථ਽㧘ᑝἑༀା㧚ਥ⤟▤⁜⓰ࠍ߈ߚߒߚ⤟ౝಽᴲ⣲≌ߩ 1 ଀㧘⢄⢙⤟ᴦ≮⎇ⓥળ⹹ 2006 ᐕ㧧4 Ꮞ㧦63㧙68.
4㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ਅ᧛㗅ሶ㧘ศᎹᱞᔒ㧘౷↰ᩕ৻㧚ᕆㅦߦㅴⴕߔࠆᗧ⼂㓚ኂࠍ઻߁⥄Ꮖ఺∉ᕈṁⴊᕈ⽺ⴊߦኻߔࠆⴊẏ੤឵≮ᴺ㧘⥃ᐥⴊᶧ 2006 ᐕ㧧47 Ꮞ㧦787㧙789㧚
5㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘⊕਄ᵗᐔ㧘Ⴆ↰⦟ᒾ㧘᫪⣁ਭ㓉㧚ᐢ▸ߥ⎬ൻᕈ⢙▤Ἳ௝ࠍ๒ߒߚ⥄Ꮖ఺∉ᕈ⤟Ἳߩ
1 ଀㧘Gastroenterological Endoscopy 2007 ᐕ㧧49 Ꮞ㧦51㧙57㧚
6㧕 ⊕਄ᵗᐔ㧘ᓟ⮮ዏ⛗㧘⷏⣁િੑ㧘ਤ⠀ఝ૫㉿㧘ਭ଻↰ో຦㧘ጤਅ㓷⑲㧘ዊ㊁ᧁ໪ੱ㧘ᨋ 㓉ᄦ㧘೨↰ᤩ↵㧘㥲⮮౏ᔒ㇢㧚ஜᏱᚑੱߦ⊒∝ߒߚࠨࠗ࠻ࡔࠟࡠ࠙ࠗ࡞ࠬ⢗චੑᜰ⣺Ἳߩ 1 ଀㧘ᣣᧄᶖൻེ∛ቇળ㔀⹹ 2007
ᐕ㧧104 Ꮞ㧦1377㧙1382㧚

㧙㧙7㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘᫪⣁ਭ㓉㧚㝼㛽ߦࠃࠆ⋤⣺ᘟᕈἻ∝ᕈ⡺⧘⣲㧘Gastroenterological Endoscopy 2008
ᐕ㧧50 Ꮞ㧦66㧙67㧚
8㧕 ═ේජ༹㧘ේ ᱞᔒ㧘㢬⷗ ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅ ஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘The
Japanese Journal of Antibiotics 2008 ᐕ㧧61 Ꮞ㧦115㧙121㧚
9㧕 ዊ㊁ᧁ┨ੱ㧘⨹ᧁኡม㧘ᧁ᧛⵨ሶ㧘੹੗ஜੑ㧘੗ᷓ⾆ᔒ㧘㜞੗శᴦ㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚⢄⚦⢩≸ߦኻߔࠆ⢄േ⣂ൻቇႧᩖ≮ᴺ㧙࡜ࠫࠝᵄ὾ἳ≮ᴺᓟ㐷⣂ⴊᩖߦࠃࠅᕆㅦߦჇᖡߒߚ⢗㘩㆏㕒⣂≜ߩ
1 ଀㧘ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ㔀⹹ 2007 ᐕ㧧13 Ꮞ㧦222㧙227㧚
10㧕 ᫪⣁ਭ㓉㧚㐷੣∝ߣᩕ㙃▤ℂ̅㐷੣∝∝଀ߦኻߔࠆࠕࡒࡁ㉄≮ᴺ㧘ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ㔀⹹ 2007 ᐕ㧧
13 Ꮞ㧦117㧙121㧚
11㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘ጤ↰࿻੺㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚㕖ಾ㒰⢄㐷ㇱ⢙▤≸ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠹ࠖࡦࠣߩᬌ⸛㧘⢙㆏ 2008 ᐕ㧧22 Ꮞ㧦47㧙55㧚
12㧕 ⊕ᧁ ੫㧘⑔ፉ⑲᮸㧘⧯ේ೑㆐㧘ౝᧁ㓉ᢥ㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚C ဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ BMI ߅ࠃ߮ౝ⬿⢽⢌㕙Ⓧߩᬌ⸛㧘ᩕ㙃 ⹏ଔߣᴦ≮ 2007 ᐕ㧧24 Ꮞ㧦42㧙45㧚
13㧕 ⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚C ဳᘟᕈ⢄∔ᖚߦ߅ߌࠆ⢈ḩߩᬌ⸛㧘ᶖൻེ⑼ 2008 ᐕ㧧47 Ꮞ㧦363㧙368㧚
14㧕 ࿯੗᤯ᐔ㧘቟↰৻ᦶ㧘ጤਅᜏม㧘ጊ↰ᢕሶ㧘↰ਛ⑲ౖ㧘㐳↰⌀ੑ㧘ᑝἑༀା㧘᫪⣁ਭ㓉㧚㤛⦡⡺⧘⣲ᕈ⢙ྙἻߣߩ㐓೎߇໧㗴ߣߥߞߚ⢙ྙ≸ߩ 1 ଀㧘⢄⢙⤟ᴦ⎇⹹ 2008 ᐕ㧧6 Ꮞ㧦49㧙54㧚
15㧕 ᧁ᧛␭ሶ㧘⨹ᧁኡม㧘ᄢ㊁ᥓᒾ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘౗᧛ାብ㧘ᓟ⮮ዏ⛗㧘ᧃᰴ ᷕ㧘⊕ᧁ ੫㧘═ේජ༹㧘ᷡ᳓㓷ੳ㧘ጊ↰ବ᮸㧘㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚਄ⴕ⚿⣺㕒⣂≜ࠍᄾᯏߦ⸻ᢿߐࠇߚᖡᕈ࡝ࡦࡄ⣲ߩ
1 ଀㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦59㧙61㧚
16㧕 ᴡౝ㓉ብ㧘⨹ᧁኡม㧘੹੗ஜੑ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘㜞੗శᴦ㧘⊕ᧁ ੫㧘ౝᧁ㓉ᢥ㧘⑔ፉ⑲᮸㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧚ㇱಽ⊛⣛േ⣂Ⴇᩖⴚ(PSE)ߦࠃࠅ㗼ᕈ㔍ᴦᕈ⢄ᕈ⣖∝߇ᡷༀߒߚ PBC ߩ৻଀㧘ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ㔀⹹ 2006 ᐕ㧧12 Ꮞ㧦296㧙301㧚
17㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧘ᣣᧄᄢ⣺⢂㐷∛ቇળ㔀⹹
2008 ᐕ㧧61 Ꮞ㧦33㧙38㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K,
Nishiguchi S, Kumada H, Ohashi Y. Overweight and obesity increase the risk for liver cancer inpatients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid
granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res.
2006;35:204-214.
2㧕 Yasuda I, Iwashita T, Ohnishi T, Mukai T, Enya M, Tomita E, Moriwaki H. Endoscopic nasobiliary
drainage: current indications and evaluation of the products. Dig Endosc. 2006;18:S105-S108.
3㧕 Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H,
Soehendra N. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of
unknown origin. Endoscopy. 2006;38:919-924.
4㧕 Suzui M, Sunagawa N, Chiba I, Moriwaki H, Yoshimi N. Acyclic retinoid, a novel synthetic retinoid,
induces growth inhibition, apoptosis, and changes in mRNA expression of cell cycle-anddifferentiation-related molecules in human colon carcinoma cells. Int J Oncol. 2006;28:1193-1199.
5㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
6㧕 Kimura K, Nagaki M, Nishihira J, Kuwata K, Moriwaki H, Chisari FV. Role of macropharge migration
inhibitory factor in hepatitis B virus-specific cytotoxic-T-lymphocyte-induced liver injury. Clin Vaccine
Immunol. 2006;13:415-419.
7㧕 Ito H, Koide N, Hassan F, Islam S, Tumurkhuu G, Mori I, Yoshida T, Kakumu S, Moriwaki H, Yokochi
T. Lethal endotoxic shock using alpha-galactosylceramide sensitization as a new experimental modelof septic shock. Lab Invest. 2006;86:254-261.
8㧕 Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, Okamoto K, Moriwaki H.
Late-onset neutropenia in patients with rituximab for non-Hodgkin’s lymphoma. Int J Hematol.
2006;84:242-247.
9㧕 Mukai T, Nagaki M, Imose M, Kimura K, Satake S, Takai S, Moriwaki H. Prevention of hepatic
fibrosis in nonobese diabetic mice: a critical role for interferon-J. Liver Int. 2006;26:1006-1014.
10㧕 Imao M, Nagaki M, Moriwaki H. Dual effects of heat stress on tumor necrosis factor-D-induced
hepatocyte apoptosis in mice. Lab Invest. 2006;86:959-967.
11㧕 Imao M, Nagaki M, Imose M, Moriwaki H. Differential caspase-9-dependent signaling pathway
between tumor necrosis factor receptor- and Fas-mediated hepatocyte apoptosis in mice. Liver Int.
2006;26:137-146
12㧕 Kimata T, Nagaki M, Ogiso T, Naiki T, Kato T, Moriwaki H. Actin organization and hepatocyte
differentiation are regulated by extracellular matrix via PI 4,5-bisphosphate in the rat. Hepatology.
2006;44:140-151.
13㧕 Kimata T, Nagaki M, Tsukada Y, Ogiso T, Moriwaki H. Hepatocyte nuclear factor-4a and –1 small㧙㧙

IF 1.892

IF 4.166

IF 2.295
IF 5.487

IF 1.995

IF 4.479

IF 1.491
IF 2.559
IF 4.479

IF 2.559

IF 10.734

interfering RNA inhibits hepatocyte differentiation induced by extracellular matrix. Hepatol Res.
2006;35:3-9.
14㧕 Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M,
Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Fas and Fas ligand expression on
germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 2006;76:465-472.
15㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor
receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's
lymphoma. Eur J Haematol. 2006;77:217-225.
16㧕 Ando N, Yasuda I, Saito M, Moriwaki H. Hilar lymphadenopathy associated with autoimmune
Pancreatitis. Pancreas. 2006;33:101-102.
17㧕 Yamaguchi M, Gabazza EC, Taguchi O, Yano Y, Ikoma J, Kaito M, Kojima Y, Imoto I, Satomi A,
D’Alessandro-Gabazza CN, Hayashi T, Moriwaki H, Suzuki K, Adachi Y. Decreased protein C
activation in patients with fulminant hepatic failure. Scand J Gastroenterol. 2006;41:331-337.
18㧕 Fukuno K, Tsurumi H, Kanemura N, Tanabashi S, Okamoto K, Moriwaki H. Chronic neutrophilia
preceding overt aggressive light chain multiple myeloma. Leuk Lymphoma. 2006;47:762-764.
19㧕 Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Bioph Res Commun.
2006;351:820-824.
20㧕 Nakamura H, Fukushima H, Miwa Y, Shiraki M, Gomi I, Saito M, Mawatari K, Kobayashi H, Kato M,
Moriwaki H. A longitudinal study on the nutritional state of eldery women at a nursing home in japan.
Int Med. 2006;45:1113-1120.
21㧕 Tsurumi H, Kanemura N, Hara T, Kasahara S, Yamada T, Sawada M, Oyama M, Moriwaki H.
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy ofcontinuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol.
2007;133:547-553.
22㧕 Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M,
Takami T, Moriwaki H. A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-Cell lymphoma. Hematol Oncol. 2007;25:107-114.
23㧕 Fukushima H, Miwa Y, Shiraki M, Gomi I, Toda K, Kuriyama S, Nakamura H, Wakahara T, Era S,
Moriwaki H. Oral branched-chain amino acid supplementation improves the oxidized/reduced
albumin ratio in patients with liver cirrhosis. Hepatology Res. 2007;37:765-770.
24㧕 Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H,
Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXRD and PPARJ ligands to inhibit growthin human colon cancer cells-phosphorylated RXRD is a critical target for colon cancer management.
Gut. 2007;56:1557-1563.
25㧕 Takai S, Nagaki M, Imao M, Kimura K, Kozawa O, Moriwaki H. Intrinsic resistance to TNF-D-induced
hepatocyte apoptosis in ICR mice correlates with expression of a short form of c-FLIP. Lab Invest.
2007;87:572-581.
26㧕 Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H.
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma
cells. Cancer Sci. 2007;98:431-437.
27㧕 Kuriyama S, Miwa Y, Fukushima H, Nakamura H, Toda K, Shiraki M, Nagaki M, Yamamoto M,
Tomita E, Moriwaki H. Prevalence of diabetes and incidence of angiopathy in patients with chronicviral liver disease. J Clin Biochem Nutr. 2007;40:116-122.
28㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor D loses its heterodimeric activity withretinoic acid receptor Ǫ. Cancer Sci. 2007;98:1868-1874.
29㧕 Satake S, Nagaki M, Kimura K, Moriwaki H. Inhibition of nuclear factor-kappa B induces
inflammatory cell migration and exacerbates severe liver injury in hepatitis B virus transgenic mice.
Hepatol Res. 2007;37:524-530.
30㧕 Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T, Moriwaki H.
Expression of retinoid X receptor D is decreased in 3'-methyl-4-dimethylaminoazobenzene-induced
hepatocellular carcinoma in rats. Oncol Rep. 2007;18:879-884.
31㧕 Wakahara T, Shiraki M, Murase K, Fukushima H, Matsuura K, Fukao A, Kinoshita S, Kaifuku N,
Arakawa N, Tamura T, Iwasa J, Murakami N, Deguchi T, Moriwaki H. Nutritional screening withsubjective global assessment predicts hospital stay in patients with digestive diseases. Nutrition.
2007;23:634-639.
32㧕 Gomi I, Fukushima H, Shiraki M, Miwa Y, Ando T, Takai K, Moriwaki H. Relationship between serum
albumin level and aging in community-dwelling self-supported elderly population. J Nutr Sci
Vitaminol. 2007;53:37-42.
33㧕 Nakaya Y, Okita K, Suzuki K, Moriwaki H, Kato A, Miwa Y, Shiraishi K, Okuda H, Onji M, Kanazawa㧙㧙

IF 1.892

IF 2.163

IF 2.163
IF 2.300

IF 2.052
IF 1.512

IF 2.749

IF

2.366

IF 2.180

IF 1.892

IF 10.015

IF 4.479

IF 3.165

IF 0.824

IF 3.165

IF 1.892

IF 1.597

IF 2.104

IF 0.784

H, Tsubouchi H, Kato S, Kaito M, Watanabe A, Habu D, Ito S, Ishikawa T, Kawamura N, Arakawa Y.
Hepatic Nutritional Therapy(HNT)Study Group -BCAA-enriched snack improves nutritional state of
cirrhosis. Nutrition. 2007;23:113-120.
34㧕 Ogiso T, Nagaki M, Takai S, Tsukada Y, Mukai T, Kimura K, Moriwaki H. Granulocytecolony-stimulating factor impairs liver regeneration in mice through the up-regulation of interleukin-1
beta. J Hepatol. 2007;47:816-825.
35㧕 Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role ofCD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952-961.
36㧕 Ohnishi T, Yasuda I, Nishigaki Y, Hayashi H, Otsuji K, Mukai T, Enya M, Salem Omar, Nib Soehendra,
Tomita E, Moriwaki H. Intraductal chilled saline perfusion to prevent bile duct injury duringpercutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol Hepatol.
2008;23:e410-e415.
37㧕 Ito H, Ando K, Ishikawa T, Nakayama T, Taniguchi M, Saito K, Imawari M, Moriwaki H, Yokochi T,
Kakumu S, Seishima M. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific
CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Int Immunol.
2008;20:869-879.
38㧕 Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG
inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular
carcinoma cells. Cancer Lett. 2008;262:10-18.
39㧕 Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
(-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/KsJ-db/db mice. Cancer Prev Res. 2008;1:298-304.
40㧕 Shimizu M, Shirakami Y, Moriwaki H. Targeting Receptor Tyrosine kinases for chemoprevention bygreen tea catechin, EGCG. Int J Mol Sci. 2008;9:1034-1049.
41㧕 Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008;2008:181047.
42㧕 Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki
H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer
Epidemiol Biomarkers Prev. 2008;17:3020-3025.
43㧕 Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H,
Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth
factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986-1993.
44㧕 Satake S, Nagaki M, Kimura K, Naiki T, Hayashi H, Sugihara J, Tomita E, Moriwaki H. Significant
effect of hepatitis C virus on viral clearance in patients with type C chronic hepatitis treated withantiviral agents. Hepatol Res. 2008;38:491-500.
45㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa JI, Shimizu
M, Oyama M, Moriwaki H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.
46㧕 Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H. Retinoid X
receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of
9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leuk Res. 2008;32:884-892.
47㧕 Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by
9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res.
2008;14:2806-2812.
48㧕 Iwashita T, Yasuda I, Doi S, Kato T, Sano K, Yasuda Y, Nakashima M, Hirose Y, Takami T, Moriwaki H.
The yield of endoscopic ultrasound-guided fine needle aspiration for histological diagnosis in patientssuspected of stage I sarcoidosis. Endoscopy. 2008;40:400-405.
49㧕 Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E
attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep.
2008;1:355-361.
50㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami
T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicated withduodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.
51㧕 Doi S, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract
implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal
lymphadenopathy. Gastrointest Endoscopy. 2008;67:988-990.

IF 2.104

IF 6.642
IF 6.642

IF 1.673

IF 3.290

IF 3.398

IF 0.750

IF 5.406

IF 1.892

IF 2.180

IF 2.561

IF 6.250

IF 4.166

IF 5.8884㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧘↰ਛථੑ㧘ዊ᎑⡡৻㧘⷏ญୃᐔ㧘ᷡ᳓㓷ੳ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ᩭౝฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇㧙㧙ⓥ㧦ᐔᚑ 17㧙21 ᐕᐲ㧧66,000 ජ౞(16,300㧦16,300㧦16,300㧦17,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᅏ㊁ᱜ㓉㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ࠨࠗ࠻ࠞࠗࡦㅪ㎮ߦࠃࠆ⢄ౣ↢ਇో⊒∝ᯏᐨߩ⸃᣿ߣߘߩ೙ᓮߦࠃࠆᴦ≮ᴺߩ㐿⊒㧦ᐔᚑ 16㧙18 ᐕᐲ㧧
3,400 ජ౞(1,300㧦1,100㧦1,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧘♿ࡁቯ଻⤿㧘ඨ↰ ብ㧘྾┬ሶᅢᐢ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦≸⚦⢩ߦ߅ߌࠆᩭౝฃኈ૕ߥࠄ߮ߦ⤑ฃኈ૕ߩ⇣Ᏹߣߘߩ೙ᓮߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 16㧙18 ᐕᐲ㧧3,400 ජ౞(1,700㧦1,100㧦600 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᧁ᧛౏ೣ㧘⎇ⓥಽᜂ⠪㧦ችጯ ⌀㧘᳗ᧁᱜੳ㧘᫪⣁ਭ㓉㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦B ဳ⢄Ἳ࠙ࠗ࡞ࠬߦኻߔࠆ RNA Ꮏቇࠍ↪޿ߚ᛫࠙ࠗ࡞ࠬ⮎ߩ㐿⊒;ᐔᚑ 17㧙19 ᐕᐲ㧧3,400 ජ౞(1,700㧦1,100㧦600 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ
⊛ߣߒߚ EGCG ᄢ⣺⊒≸ᛥ೙ߩ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,300 ජ౞(1,500㧦1,000㧦800 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ᄢ⷏ਃᦶ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ)㧦
㔍ᴦᕈߩ⢄࡮⢙㆏∔ᖚߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18㧙20 ᐕᐲ㧧1,200 ජ౞(400㧦400㧦400 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦⮮ේ⎇ม㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄߇ࠎᖚ⠪ߩ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,000 ජ౞(2,000㧦1,300㧦1,250 ජ౞)8㧕 ⎇ⓥઍ⴫⠪㧦቟↰৻ᦶ㧘⎇ⓥಽᜂ⠪㧦ጤਅᜏม㧦ᐔᚑ 18 ᐕᐲౝⷞ㏜කቇ⎇ⓥᝄ⥝⽷࿅⎇ⓥഥᚑ(B)㧦
EUS-FNA ᬌ ૕ ߦ ߅ ߌ ࠆ nucleoside transporter proteins ⊒ ⃻ ࠍ ᜰ ᮡ ߣ ߒ ߚ ⤟ ≸ ൻ ቇ ≮ ᴺ(Gemcitabine)ലᨐ੍᷹ߩ⹜ߺ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 18 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌ߦࠃࠆ⎇ⓥ⾌(╙ 2 ࿁ NaSNeL⎇ⓥળ)㧦ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ߣߘߩਅᵹࠪࠣ࠽࡞ࠍಽሶᮡ⊛ߣߒߚ✛⨥ࠞ࠹ࠠࡦ EGCG ߦࠃࠆᶖൻེ≸⚦⢩Ⴧᱺᛥ೙ߩ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 18 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨㧦ᩭౝฃኈ૕ RXR ࠍಽሶᮡ⊛ߣߒߚ⢄⊒≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ጘ㒂කቇᅑബ⾨㧦✛⨥ࡐ࡝ࡈࠚࡁ࡯࡞ EGCG ߦࠃࠆᄢ⣺≸⚦⢩Ⴧᱺᛥ೙ല
ᨐߩᬌ⸛࡯ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ߦᵈ⋡ߒߡ࡯; ᐔᚑ 18 ᐕᐲ㧧200 ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓㓷ੳ㧘ጊ↰ᵏᐢ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19㧙
20 ᐕ㧧3,400 ජ౞(1,800㧦1,600 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦ᄢỈ㓁੺㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ᘟᕈ⢄㓚ኂߦ߅ߌࠆࠬࡈࠖࡦࠧ
⢽⾰ࠪࠣ࠽࡞ߩ⢄⚦⢩ߩ↢ᱫ᳿ቯᯏᐨߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(1,800㧦1,500ජ౞)14㧕 ⎇ⓥઍ⴫⠪㧦ᾢ↰ඳశ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄⎬ᄌࠍ฽߼ߚ࠙ࠗ࡞ࠬᕈ⢄∔ᖚߩᴦ≮ߩᮡḰൻߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧4,000 ජ౞(2,000㧦2,000 ජ౞)
15㧕 ⎇ⓥઍ⴫⠪㧦᳗ᧁᱜੳ㧦ᐔᚑ 19 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌ߦࠃࠆ⎇ⓥ⾌㧧1,000 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 19 ᐕᐲ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌ߦࠃࠆ⎇ⓥ⾌㧧200 ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦቟↰৻ᦶ㧦╙ 19 ࿁ጘ㒂කቇᅑബ⾨㧦⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ(EUS-FNA)ߦࠃࠆ❑㓒࡮⣻⣧ౝ⣲ᄢ࡝ࡦࡄ▵ߩ⸻ᢿ㧧300 ජ౞
18㧕 ⎇ⓥઍ⴫⠪㧦቟↰৻ᦶ㧦Asian Pacific Digestive Week 2006 (APDW2006), Young InvestigatorAward 㧦Clinical impact of EUS-guided fine-needle aspiration biopsy for making diagnosis oflymphoma㧧US$1,000
19㧕 ⎇ⓥઍ⴫⠪㧦᳗ᧁᱜੳ㧘⎇ⓥಽᜂ⠪㧦ᄢỈ㓁੺㧘ᧃᰴ ᷕ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 20㧙
22 ᐕᐲ㧧3,500 ජ౞(1,100㧦1,000㧦1,400 ජ౞)
20㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 20㧙22 ᐕᐲ㧧3,500 ජ౞(1,500㧦1,100㧦900 ජ౞)
21㧕 ⎇ⓥઍ⴫⠪㧦⿷┙᡽ᴦ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦⢽⾰࡜ࡈ࠻ࠍᮡ⊛ߣߒߚ EGCG
ߦࠃࠆᄢ⣺≸੍㒐ߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,100 ජ౞(1,600㧦1,500 ජ౞)
22㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁ৻ᐘ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄⎬ᄌࠍ฽߼ߚ࠙ࠗ࡞ࠬᕈ⢄∔ᖚߩᴦ≮ߩᮡḰൻߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧙㧙23㧕 ⎇ⓥઍ⴫⠪㧦ᷡ᳓㓷ੳ㧦ᐔᚑ 20 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨㧦ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯
࠯ࠍᮡ⊛ߣߒߚ EGCG ߦࠃࠆ⢄✢⛽ൻ࡮⊒≸੍㒐ߩ⎇ⓥ㧧1,000 ජ౞
24㧕 ⎇ⓥઍ⴫⠪㧦⿷┙᡽ᴦ㧦ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇකቇㇱ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌㧧1,000 ජ౞
25㧕 ⎇ⓥઍ⴫⠪㧦ᧃᰴ ᷕ㧦ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇකቇㇱ⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⎇ⓥ⾌㧧500 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦วᚑ࡟࠴ࡁࠗ࠼ߣಽሶᮡ⊛ᴦ≮⮎ߣߩ૬↪ߦ㑐ߔࠆ⎇ⓥ(2)㧧ᐔᚑ 18㧙19 ᐕᐲ㧧6,000 ජ౞(3,000㧦3,000 ජ౞)㧦⥝๺ഃ⮎2㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦♧ዩ∛ࡕ࠺࡞ࡑ࠙ࠬߦ߅ߌࠆ EGCG ߩ Azoxymethane ⺃⊒ᄢ⣺೨≸∛ᄌᒻᚑᛥ೙ലᨐߩᬌ⸛гEffects of EGCG on Inhibition of Development of AOM-Induced ACF in db/db
Miceг㧧ᐔᚑ 18 ᐕᐲ㧧1,500 ජ౞㧦ਃ੗ㄘᨋ3㧕 ᫪⣁ਭ㓉㧘᧛਄໪㓶㧘㢬⷗ ኼ㧦HIV ᗵᨴ⠪╬଻ஜ⑔␩⋧⺣ផㅴ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧1,950 ජ౞(650㧦650㧦650㧦325 ජ౞)㧦ࠛࠗ࠭⽷࿅ฃ⸤⎇ⓥ⾌
4㧕 ᫪⣁ਭ㓉㧦ᩭ࡟࠴ࡁࠗ࠼ฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ߇ࠎൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕ
ᐲ㧧450 ජ౞㧧(150㧦150㧦150 ජ౞)㧦⢽ṁᕈࡆ࠲ࡒࡦ
5㧕 ᫪⣁ਭ㓉㧘⊕ᧁ ੫㧦ੱⴊᷡࠕ࡞ࡉࡒࡦᴦ≮ߦ㑐ߔࠆ⥃ᐥ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,300 ජ౞㧦ൻቇ෸
ⴊᷡ≮ᴺ⎇ⓥᚲ6㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦⢈ḩ㑐ㅪ⢄⊒≸ߦ߅ߌࠆวᚑ࡟࠴ࡁࠗ࠼ߩ੍㒐ലᨐ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦⥝๺ഃ⮎
7㧕 ᫪⣁ਭ㓉㧘ዊ᎑⡡৻㧦⢄∔ᖚߩಽሶ∛ᘒ⸃᣿ߦၮߠߊᣂⷙᴦ≮࡮੍㒐ᴺߩ⏕┙㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
300 ජ౞(100㧦100㧦100 ජ౞)㧦ℂൻቇ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄࡆ࠲ࡒࡦቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ≸ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᩕ㙃㘩♳ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળℂ੐(㨪⃻࿷)᳗ᧁᱜੳ㧦1㧕 ᣣᧄౝ⑼ቇળᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄੱᎿ⤳ེቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥಽሶකቇળ⹏⼏ຬ(㨪⃻࿷)቟↰৻ᦶ㧦1㧕 ᣣᧄᶖൻེౝⷞ㏜ቇળቇⴚ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᣣᧄ⢙㆏ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)2㧕ቇળ㐿௅᫪⣁ਭ㓉㧦
1㧕 ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 29 ࿁ᣣᧄᩕ㙃ࠕ࠮ࠬࡔࡦ࠻⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂)㧙㧙3㧕 ᫪⣁ਭ㓉㧦╙ 8 ࿁ᣣ㖧߇ࠎ⠧ൻࠪࡦࡐࠫ࠙ࡓ(The 8th Japan-Korea Joint Symposium on Cancer andAgeing Research)(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 8 ࿁ᣣᧄஜᐽᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)᳗ᧁᱜੳ㧦1㧕 ᣣᧄ⢄⤳ቇળ⧷ᢥ⹹㧦✬㓸ᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ㧦⧷ᢥ⹹ᩏ⺒ᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᰷Ꮊ⢄⤳ቇળ⹹㧦ᩏ⺒ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)
4㧕 ᣣᧄੱᎿ⤳ེቇળ㧦⺰ᢥ⾨ㆬ಴ᆔຬ(㨪ᐔᚑ 18 ᐕᐲ)቟↰৻ᦶ㧦1㧕 ⢄⢙⤟ᴦ≮⎇ⓥળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᫪⣁ਭ㓉㧦
1㧕 ╙ 103 ࿁ᣣᧄౝ⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘ᐳ㐳)2㧕 ╙ 92 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ዊୖ㧘ࠪࡦࡐ‫ޟ‬S7.ᶖൻེ∔ᖚߩ∛ᘒᩕ㙃ߣᴦ≮‫ޠ‬มળ)3㧕 HCMC’S Association Study of Liver Diseases(ᐔᚑ 18 ᐕ 5 ᦬㧘ࡎ࡯࠴ࡒࡦ㧘ࠪࡦࡐࠫ࠙ࡓ
‫ޟ‬Therapeutic Implication of Branch-Chain Amino Acid in Protein Energy Malnutrition in
Patients with Liver Cirrhosis‫ޠ‬Ṷ⠪)
4㧕 ╙ 42 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 4‫ޟ‬⢄ౣ↢ක≮‫ޠ‬มળ)
5㧕 ᐔᚑ 18 ᐕᐲᣣᧄ≸ቇળࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫⸻ޟ‬ᢿߣᴦ≮ߦߟ޿ߡ‫ޠ‬Ṷ⠪)
6㧕 ╙ 13 ࿁ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ✚ળࡕ࡯࠾ࡦࠣ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘᧲੩㧘⻠Ṷ‫ޟ‬⢄߇ࠎ೙࿶ࠍ
⋡ᜰߒߚ C ဳ⢄⎬ᄌߩᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)7㧕 ╙ 10 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘⻠Ṷ‫ޟ‬⢄⎬ᄌߣᩕ㙃≮ᴺ‫ޠ‬Ṷ⠪)8㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ ╙ 16 ࿁ᢎ⢒⻠Ṷળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ฬฎደ㧘ᢎ⢒⻠Ṷ มળ)
9㧕 ╙ 36 ࿁ᣣᧄ⢄⤳ቇળ᧲ㇱળ(ᐔᚑ 18 ᐕ 12 ᦬㧘᧲੩㧘ᢎ⢒⻠Ṷ㧘Ṷ⠪)10㧕 ╙ 36 ࿁ᣣᧄ⢄⤳ቇળ᧲ㇱળ(ᐔᚑ 18 ᐕ 12 ᦬㧘᧲੩㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ มળ)
11㧕 ╙ 10 ࿁ᣣᧄ∛ᘒᩕ㙃ቇળᐕᰴቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ᮮᵿ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ มળ)
12㧕 ╙ 22 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧻ጊ㧘วหࠪࡦࡐࠫ࠙ࡓ มળ)
13㧕 ╙ 5 ࿁ᣣᧄ⥃ᐥ⣲≌ቇળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ㧘Ṷ⠪)
14㧕 ╙ 17 ࿁ࠕࠫࠕ࡮ᄥᐔᵗ⢄⤳ળ⼏(ᐔᚑ 19 ᐕ 3 ᦬㧘੩ㇺ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬Long-team outcomeof BCAA treatment in liver cirrhosis‫ޠ‬Ṷ⠪)
15㧕 ╙ 93 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘㕍᫪㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)16㧕 ᣣᧄࡆ࠲ࡒࡦቇળ╙ 59 ࿁ᄢળ(ᐔᚑ 19 ᐕ 5 ᦬㧘㐳ፒ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)17㧕 ╙ 33 ࿁ᣣᧄᕆᕈ⢄ਇో⎇ⓥળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ Ṷ⠪)
18㧕 ╙ 43 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘࠮࠶࡚ࠪࡦ 22‫ޟ‬⢄⎬ᄌ࡮⢄ᕈ⣖∝‫ޠ‬มળ)
19㧕 The 6th JHS Single Topic Conference(ᐔᚑ 19 ᐕ 9 ᦬㧘቟Ყ㜞ේ㧘Symposium‫ޟ‬Long-Term Outcomeof BCAA treatment in patients with liver cirrhosis‫ޠ‬Ṷ⠪)20㧕 ╙ 14 ࿁ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ✚ળ࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢಽ㧘⻠Ṷ‫ޟ‬⢄ਇోߣ㐷⣂࿶੣ㅴ∝‫ޠ‬Ṷ⠪)
21㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ ╙ 66 ࿁Ꮢ᳃౏㐿⻠ᐳ⋵᳃ஜᐽ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘ၮ⺞⻠Ṷ㧘Ṷ⠪)
22㧕 APDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)23㧕 DDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ มળ)㧙㧙24㧕 DDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ มળ)
25㧕 DDW(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࠪࡦࡐࠫ࠙ࡓ ᐳ㐳)26㧕 ╙ 107 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 19 ᐕ 11 ᦬ 17 ᣣ㧘ฬฎደ㧘ᢎ⢒⻠Ṷ มળ)
27㧕 ╙ 37 ࿁ᣣᧄ⢄⤳ቇળ⷏ㇱળ(ᐔᚑ 19 ᐕ 12 ᦬㧘㐳ፒ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ มળ)28㧕 ╙ 11 ࿁ᣣᧄ∛ᘒᩕ㙃ቇળᐕᰴቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 1 ᦬㧘੩ㇺ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯13 ᐳ㐳)29㧕 ╙ 23 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 20 ᐕ 2 ᦬㧘੩ㇺ㧘วหࠪࡦࡐࠫ࠙ࡓ มળ)30㧕 ߇ࠎౣ↢ක≮ቇળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬⢄⤳ߩౣ↢‫ޠ‬ᐳ㐳)31㧕 ╙ 1 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ᧲ᶏᡰㇱቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 3 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ ᐳ㐳)32㧕 ╙ 31 ࿁ᣣᧄᩕ㙃ࠕ࠮ࠬࡔࡦ࠻⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᣂẟ㧘․೎⻠Ṷ‫ޟ‬⢄∔ᖚߣᩕ㙃ࠕ࠮ࠬࡔࡦ࠻‫ޠ‬Ṷ⠪)33㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 3‫ޟ‬⢄ߩ⊒≸ߣㅴዷߦ߅ߌࠆಽሶ
ઍ⻢ቇ⊛⎇ⓥ‫ޠ‬มળ)34㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 108 ࿁଀ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯ ᐳ㐳)35㧕 ╙ 2 ࿁ᩕ㙃᧚ᒻ⁁ᯏ⢻⎇ⓥળ(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘․೎⻠Ṷ ᐳ㐳)36㧕 International Clinical Exchange in Hepatic Clinical Nutrition(ᐔᚑ 20 ᐕ 9 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬Update New Approach in Prevention of Liver Impairment by BCAA Therapy‫ޠ‬Ṷ⠪)37㧕 ╙ 11 ࿁⢄ਇోᴦ≮▤ℂ⎇ⓥળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ජ⪲㧘․೎⻠Ṷ‫ޟ‬⢄⎬ᄌߩᩕ㙃≮ᴺ㧙ࠛࡆ࠺ࡦࠬ
ߣࠟࠗ࠼࡜ࠗࡦ㧙‫ޠ‬Ṷ⠪)38㧕 ╙ 67 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢄߇ࠎ੍㒐ߩ✚วᚢ⇛ߣൻቇ੍㒐‫ޠ‬Ṷ⠪)᳗ᧁᱜੳ㧦
1㧕 Asian Pasific Association for the Study of the Liver 2007(ᐔᚑ 19 ᐕ 3 ᦬㧘੩ㇺ㧘Oral Session‫ޟ‬Liver: Biology 2‫ޠ‬มળ)2㧕 Asian Pasific Association for the Study of the Liver 2007(ᐔᚑ 19 ᐕ 3 ᦬㧘੩ㇺ㧘Oral Session‫ޟ‬Portal Hypertension and Other Complication of Cirrhosis 1‫ޠ‬มળ)
3㧕 ╙ 43 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬B ဳ⢄Ἳ㧦B ဳ⢄Ἳߩ⥄ὼ఺∉ߣ࠙ࠗ࡞ࠬឃ㒰‫ޠ‬Ṷ⠪)
4㧕 ╙ 14 ࿁⢄⚦⢩⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘㣮ఽፉ㧘ࠪࡦࡐࠫ࠙ࡓ‫⚦ޟ‬⢩ᄖࡑ࠻࡝࠶ࠢࠬߦࠃࠆ⢄⚦⢩ಽൻߣ⚦⢩㛽ᩰ㑐ㅪࠪࠣ࠽࡞‫ޠ‬Ṷ⠪)5㧕 The 6th JHS Single Topic Conference(ᐔᚑ 19 ᐕ 9 ᦬㧘቟Ყ㜞ේ㧘Symposium‫ޟ‬P Implication ofcytokine: role of tumor necrosis factor in liver injury‫ޠ‬Ṷ⠪)
6㧕 ╙ 37 ࿁ᣣᧄ⢄⤳ቇળ⷏ㇱળ(ᐔᚑ 19 ᐕ 12 ᦬㧘㐳ፒ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬ᕆᕈ⢄ਇోߩ∛ᘒ⸃᣿ߣ⢄ౣ↢≮ᴺ‫ޠ‬Ṷ⠪)቟↰৻ᦶ㧦
1㧕 ╙ 16 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢙⤟ EUS ⷰኤߩታ㓙ߣ
EUS-FNA‫ޠ‬Ṷ⠪)
2㧕 ╙ 15 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ྾࿖࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ᓼፉ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫ޟ‬EUS-FNAߣߘߩᔕ↪ᚻᛛ‫ޠ‬Ṷ⠪)
3㧕 ╙ 18 ࿁ᣣᧄᶖൻེ⚿⍹⸻≮⎇ⓥળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ᾢᧄ㧘ࠪࡦࡐࠫ࠙ࡓ II‫ޟ‬⢙ྙ⚿⍹ว૬✚⢙▤⚿⍹ߦኻߔࠆౝⷞ㏜ᴦ≮(EST ߣ EPBD)ᓟߩ⢙ྙ៰಴ⴚߪᔅⷐ߆㧫‫ޠ‬Ṷ⠪)
4㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 7 ‫ޟ‬⢙ྙ࡮⢙▤⚿⍹∝ߦኻߔࠆౝⷞ㏜⊛ᴦ≮(EST ߣ EPBD)‫ޠ‬Ṷ⠪)
5㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 1-4‫ޟ‬⢙࡮⤟‫ޠ‬Ṷ⠪)
6㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘㒝⟎⎇ⓥળ㧦╙ 2 ࿁⿥㖸ᵄౝⷞ㏜ਅ↢ᬌᴺߩ⸻ᢿ♖ᐲะ਄ߩߚ߼ߩ⎇ⓥળ‫ ╙ޟ‬3 ㇱ EUS-FNA ߦࠃࠆᴦ≮ߣᣂߚߥ⹜ߺ‫ޠ‬ᐳ㐳)7㧕 Endoscopy Forum Japan 2006(ᐔᚑ 18 ᐕ 7 ᦬㧘Hakone㧘‫ޟ‬Risk management of Endoscopic
treatment for CBD stones -EST and EPBD-‫ޠ‬มળ)8㧕 ╙ 33 ࿁⢄⢙⤟ᴦ≮⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ฬฎደ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫☼ޟ‬ᶧ↥↢⢙▤≸̆⢙▤ߩ IPMN ߣ MCN‫ޠ‬มળ)㧙㧙9㧕 DDW-Japan 2006(╙ 48 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ
10 ᦬㧘ᧅᏻ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 9‫ޟ‬⢖≸ⴚ೨∛ᦼ⸻ᢿߦ߅ߌࠆ EUS-FNA ߩ૏⟎ߠߌߣᚻᛛ
ߩᮡḰൻ‫ޠ‬Ṷ⠪)10㧕 DDW-Japan 2006(╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠨ࠹࡜ࠗ࠻ࠪࡦࡐ
ࠫ࠙ࡓ 8‫ޟ‬ᕆᕈ⢙㆏Ἳ̆ౝ⑼࡮ᄖ⑼ߩᨒࠍ⿥߃ߚᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)11㧕 DDW-Japan 2006(╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࡒ࠾࡟ࠢ࠴ࡖ࡯
‫ޟ‬EUS-FNA ᣉⴕᤨߩࠦ࠷㨪ᬌ૕ណข߆ࠄ∛ℂ⸻ᢿ߹ߢ㨪‫ޠ‬Ṷ⠪)12㧕 DDW-Japan 2006(╙ 72 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽
࡯50‫ޟ‬⢄㐷ㇱᖡᕈ⢙㆏⁜⓰ߩኻߔࠆ JOSTENT SelfX ࠍ↪޿ߚ⚻ౝⷞ㏜⊛ࡑ࡞࠴ࠬ࠹ࡦ࠹ࠖࡦࠣ㧙ᝌ౉ߩታ㓙ߣ㐽Ⴇᤨߩኻᔕ㧙‫ޠ‬ᐳ㐳)13㧕 Asia Endoscopy Future Forum 2007(ᐔᚑ 19 ᐕ 1 ᦬㧘Jeju (Korea)㧘Session I‫ޟ‬Pancreato-biliary
stenting‫ޠ‬มળ)  
14㧕 Asia Endoscopy Future Forum 2007(ᐔᚑ 19 ᐕ 1 ᦬㧘Jeju (Korea)㧘Session IV‫ޟ‬Brainstorming for
co-operative study and friendship with the three countries‫ޠ‬มળ)  
15㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫⿥ޟ‬㖸ᵄౝⷞ㏜
ਅ↢ᬌᴺ(EUS-FNA)㧙਎⇇ߣᣣᧄ㧙‫ޠ‬Ṷ⠪)
16㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 8‫ޟ‬EUS-FNA ߩ⃻⁁ߣ዁᧪‫ޠ‬มળ)17㧕 ╙ 106 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᵿ᧻㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེ≸ߦኻߔࠆ㕖ⷰⴊ⊛ᴦ≮ߩ⃻ᴫߣዷᦸ‫ޠ‬มળ)18㧕 ╙ 7 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏᡰㇱࠟࠗ࠼࡜ࠗࡦ⎇ୃળ(ᐔᚑ 19 ᐕ 7 ᦬㧘࿯ጘ㧘‫⿥ޟ‬㖸ᵄౝⷞ㏜ⷰ
ኤ(⢙⤟)ߩታ㓙ߣ EUS-FNA‫ޠ‬Ṷ⠪)
19㧕 Endoscopy Forum Japan 2007(ᐔᚑ 19 ᐕ 8 ᦬㧘ዊᮻ㧘Special session‫ޟ‬Next-generation endoscopic
technology doctors expect from engineers‫ޠ‬Ṷ⠪)
20㧕 Asian Pacific Digestive Week 2007 (APDW2007) (ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘Symposium‫ޟ‬Strategy
of biliary stenting for non-resectable malignant biliary strictures‫ޠ‬Ṷ⠪)
21㧕 ╙ 48 ࿁ᣣᧄ⢖≸ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘࡜ࡦ࠴࡚ࡦ࠮ࡒ࠽࡯‫⚻ޟ‬㘩㆏⊛ࠕࡊࡠ࡯࠴
(EUS-FNA)‫ޠ‬Ṷ⠪)
22㧕 Asia Endoscopy Future Forum 2008(ᐔᚑ 20 ᐕ 1 ᦬㧘ᶏධ(ਛ࿖)㧘Symposium Υ ‫ޟ‬Extracorporeal
shock wave lithotripsy for clearance of bile duct stones resistant to endoscopic extraction‫ޠ‬Ṷ⠪)23㧕 ╙ 18 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬⢙⤟㗔ၞߩ⿥㖸ᵄౝⷞ㏜⸻ᢿ‫ޠ‬Ṷ⠪)24㧕 Asia Endoscopy Future Forum 2008(ᐔᚑ 20 ᐕ 1 ᦬㧘ᶏධ(ਛ࿖)㧘Symposium I: ‫ޟ‬Endoscopic
management of CBD stone‫ޠ‬Ṷ⠪)25㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫✚ޟ‬⢙▤⚿⍹
ߦኻߔࠆ EST ߣ EPBD ߩ㐳ᦼ੍ᓟߩᲧセ́Multi-center randomized controlled trial (JESED
study)‫ޠ‬Ṷ⠪)26㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠨ࠹࡜ࠗ࠻ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬EST࡮EPBD(੃㗡ಣ⟎)ߩࠦ࠷ߣ࠻࡜ࡉ࡞ࠪࡘ࡯࠹ࠖࡦࠣ‫ޠ‬Ṷ⠪)27㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫ޟ‬⢙▤⚿⍹ߦኻߔࠆ EST࡮EPBD ߩ㐳ᦼ੍ᓟ‫ޠ‬มળ)28㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 19 ࿁ᢎ⢒⻠Ṷળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ᢎ⢒⻠Ṷ‫ޟ‬EUS-FNA ߦࠃࠆ⸻ᢿ࡮ᴦ≮ߩ⃻⁁‫ޠ‬Ṷ⠪)29㧕 GIHep Singapore 2008(6th National Endoscopy Workshop)(ᐔᚑ 20 ᐕ 7 ᦬㧘ࠪࡦࠟࡐ࡯࡞㧘
Endoscopy Live Demonstration ‫ޟ‬EUS&EUS-FNA‫ޠ‬Ṷ⠪)30㧕 GIHep Singapore 2008 (Combined GESS & SCRS Annual Scientific Meeting) (ᐔᚑ 20 ᐕ 7 ᦬㧘ࠪࡦࠟࡐ࡯࡞㧘⻠Ṷ‫ޟ‬Clinical Symposium on Endoscopy㧙The roles of SEMS in biliary strictures‫ޠ‬Ṷ⠪)31㧕 ╙ 8 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏᡰㇱࠟࠗ࠼࡜ࠗࡦ⎇ୃળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬⢙⤟ EUS
ߩ࡞࡯࠴ࡦⷰኤߣ EUS-FNA‫ޠ‬Ṷ⠪)32㧕 Endoscopy Forum Japan 2008(ᐔᚑ 20 ᐕ 8 ᦬㧘ዊᮻ㧘Clinical symposium session‫ޟ‬Current status
and future perspective of interventional EUS‫ޠ‬Ṷ⠪)33㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘㧙㧙᧲੩㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 4‫ޟ‬EUS ⸻ᢿ࡮ᴦ≮ߩᣂߒ޿ዷ㐿‫ޠ‬ᐳ㐳)ౝᧁ㓉ᢥ㧦
1㧕 ╙ 10 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㊀∝ B ဳ⢄Ἳߦ߅ߌࠆ᛫࠙ࠗ࡞
ࠬ≮ᴺߩ⹏ଔ‫ޠ‬Ṷ⠪)ᷡ᳓㓷ੳ㧦
1㧕 ╙ 67 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 22‫ޟ‬Green Tea Catechins for
the Prevention of Metachronous Colorectal Adenomas‫ޠ‬Ṷ⠪)
2㧕 ╙ 94 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔ጟ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 8‫࠼ࠗࡁ࠴࡟ޟ‬ᩭౝฃኈ૕ RXRǩࠍᮡ⊛ಽሶߣߒߚ⢄⚦⢩≸ൻቇ੍㒐—㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߣ clonal deletion—‫ޠ‬Ṷ⠪)3㧕 JDDW2008(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 6‫ޟ‬Retinoid ᩭౝฃኈ૕ RXRǩࠍᮡ⊛ಽሶߣߒߚ Acyclic retinoid ߦࠃࠆ⢄≸ൻቇ੍㒐‫ޠ‬Ṷ⠪)4㧕 JDDW2008(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 18‫ޟ‬IGF/IGF-1R ࠍᮡ⊛ߣߒߚ✛⨥ࠞ࠹ࠠࡦ
EGCG ߦࠃࠆ⢈ḩ㑐ㅪᄢ⣺⊒≸ߩᛥ೙‫ޠ‬Ṷ⠪)ጤਅᜏม㧦
1㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 8‫❑ޟ‬㓒∛ᄌߦኻߔࠆ
EUS-FNA ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)2㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 22‫⦟ޟ‬ᕈ⢄ᄖ⢙▤⁜⓰ߦኻߔࠆࠬ࠹ࡦ࠻ᴦ≮‫ޠ‬Ṷ⠪)
3㧕 ╙ 50 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ 2‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯᣇ㊎‫ޠ‬Ṷ⠪)
4㧕 ╙ 19 ࿁ᣣᧄᶖൻེ⚿⍹⸻≮⎇ⓥળ(ᐔᚑ 20 ᐕ 3 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ౝⷞ㏜⊛ᴦ≮࿎㔍ߥ✚⢙▤⚿⍹ߦኻߔࠆ ESWL ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)
5㧕 ╙ 75 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 5‫⤟ޟ‬઒ᕈྙ⢩㧘⤟⤥≌㧘ᗵᨴᕈ⤟უᱫߦኻߔࠆᴦ≮ᚢ⇛ߩਛߢߩ EUS ਅ࠼࡟࠽࡯ࠫߩ૏⟎ߠߌ‫ޠ‬Ṷ⠪)
6㧕 ╙ 44 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 2‫⦟ޟ‬ᕈ⢄ᄖ⢙▤⁜⓰ߦኻߔࠆࠬ࠹ࡦ࠻ᴦ≮‫ޠ‬Ṷ⠪)7㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 17‫⥄ޟ‬Ꮖ఺∉ᕈ⤟Ἳ⸻ᢿߦ߅ߌࠆ 19G ㊎ࠍ↪޿ߚ EUS-FNA ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)⨹ᧁኡม㧦
1㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 3‫ޟ‬ᒰ⑼ߦ߅ߌ
ࠆ㘩㆏㕒⣂≜ EVL ߩᬌ⸛(EVL න⁛ߣ࿾࿕߼૬↪ᴺߩᲧセ⹜㛎ࠍ฽߼ߡ)‫ޠ‬Ṷ⠪)
2㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ᧲ᶏ࡮ർ㒽࿾඙ᐔᚑ 18 ᐕᐲᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ࠬࠬ࡯ࠤޟ‬࠲࠺ࠖ࡯࡮⢄∔ᖚ‫ޠ‬Ṷ⠪)
3㧕 ╙ 49 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬ᒰ⑼ߦ߅ߌ
ࠆ਄ਅㇱᶖൻ▤ ESD ߩᬌ⸛‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ⣻ㇱᢇᕆකቇળ✚ળ(ᐔᚑ 19 ᐕ 3 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 2‫ޟ‬ᒰ⑼ߦ߅ߌࠆ
㕒⣂≜ᴦ≮ߩᬌ⸛(㘩㆏⢗㕒⣂≜ߣ⇣ᚲᕈ㕒⣂≜)‫ޠ‬Ṷ⠪)
5㧕 ╙ 61 ࿁ᣣᧄ㘩㆏ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 1‫ޟ‬ᒰ⑼ߦ߅ߌࠆ⢗㕒⣂≜ᴦ≮ߩᬌ⸛‫ޠ‬Ṷ⠪)
6㧕 ╙ 7 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏᡰㇱࠟࠗ࠼࡜ࠗࡦ⎇ୃળ(ᐔᚑ 19 ᐕ 7 ᦬㧘࿯ጘ㧘⻠Ṷ‫ޟ‬ౝⷞ㏜⊛
ᱛⴊᴺ‫ޠ‬Ṷ⠪)7㧕 ╙ 14 ࿁ᣣᧄ㐷⣂࿶੣ㅴ∝ቇળ✚ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢಽ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬㘩㆏㕒⣂≜ߦኻߔࠆ
EVL ߢߩᴦ≮ᚑ❣ߣ EUS ߢߩ㘩㆏๟࿐ⴊ▤⟲ߩⷰኤ(EVL න⁛ߣ࿾࿕߼૬↪ᴺߣߩᲧセ)‫ޠ‬Ṷ⠪)8㧕 JDDW2007(╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 17‫ޟ‬⢗ྃ㐷ㇱ㕒⣂≜ว૬㘩㆏㕒⣂≜ߦኻߔࠆ EVL ߢߩᴦ≮ᚑ❣ߣ APC ࿾࿕߼≮ᴺߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)9㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 66 ࿁Ꮢ᳃౏㐿⻠ᐳ ⋵᳃ஜᐽ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 10 ᦬㧘⠀ፉ㧘⻠Ṷ‫ߣ⩶࡝ࡠࡇޟ‬⢗≸‫ޠ‬Ṷ⠪)10㧕 ╙ 50 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬ᒰ⑼ߦ߅ߌࠆ

㧙㧙਄ਅㇱᶖൻ▤ ESD ߩᴦ≮ᚑ❣‫ޠ‬Ṷ⠪)11㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 7 ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ⢄≸ว૬㘩㆏㕒⣂≜ߦኻߔࠆ EVL ߩᴦ≮ᚑ❣‫ޠ‬Ṷ⠪)12㧕 ╙ 3 ࿁㕒⣂≜ᴦ≮ᮡḰൻ⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ㘩㆏࡮⢗ྃ㐷ㇱ㕒⣂≜∝଀ߦኻߔࠆ EVL+APC ૬↪≮ᴺߩታ㓙‫ޠ‬Ṷ⠪)13㧕 GI Forum in Kanazawa(ᐔᚑ 20 ᐕ 6 ᦬㧘㊄ᴛ㧘⻠Ṷ‫ޟ‬ᒰ⑼ߦ߅ߌࠆ਄ਅㇱᶖൻ▤ ESD ߩ⚻㛎‫ޠ‬Ṷ
⠪)
14㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 68 ࿁Ꮢ᳃౏㐿⻠ᐳ ጘ㒂⋵කᏧળ⋵᳃ஜᐽ࠮ࡒ࠽࡯‫ޟ‬ᶖൻེߩ߇ࠎࠍ
ᱜߒߊ⍮ࠈ߁‫(ޠ‬ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᄢ⣺߇ࠎ‫ޠ‬Ṷ⠪)⊕ᧁ ੫㧦
1㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 3‫ޟ‬Cဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ⢈ḩߩᬌ⸛‫ޠ‬Ṷ⠪)
2㧕 ╙ 29 ࿁ᣣᧄ⥃ᐥᩕ㙃ቇળ✚ળ࡮╙Χ࿁ᄢㅪวᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘੩ㇺ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪ
ࡦ‫ޟ‬⢄⎬ᄌߦ߅ߌࠆಽጘ㎮ࠕࡒࡁ㉄(branched chain amino acids: BCAA)≮ᴺ‫ޠ‬Ṷ⠪)
3㧕 ╙ 94 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔ጟ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེౝ⑼౉㒮ᖚ⠪ߦ߅ߌࠆ
SGA ߣ࿷㒮ᦼ㑆ߩᬌ⸛‫ޠ‬Ṷ⠪)
4㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ ∛ᘒᩕ㙃ኾ㐷Ꮷᦝᣂ⠪ᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ࠤ࡯ࠬࠬ࠲࠺ࠖ 2‫ޟ‬⢄∔ᖚ‫ޠ‬Ṷ⠪)
5㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ਥ㗴ࡐࠬ࠲࡯1‫ޟ‬⢄⎬ᄌᖚ⠪ߩᚑ࿃೎ߦࠃࠆᬌ⸛‫ޠ‬Ṷ⠪)
6㧕 ╙ 8 ࿁ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེౝ⑼౉㒮ᖚ⠪ߦ߅ߌࠆ SGA ߣ࿷㒮ᦼ㑆ߩᬌ⸛‫ޠ‬Ṷ⠪)7㧕 ╙ 8 ࿁ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫▤ޟ‬ℂᩕ㙃჻ߦ᳞߼ࠄࠇࠆ⍮⼂ߣᛛ⢻-NCM ផㅴߩߚ߼ߦ-‫ޠ‬ᐳ㐳)
8㧕 ╙ 8 ࿁ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ߥ࡞ࡊࡦࠪࠅࠃޟ‬ᩕ㙃⹏ଔࠍ⋡ᜰߒߡ-ਥⷰ⊛൮᜝⊛⹏ଔ-‫ޠ‬ᐳ㐳)
9㧕 ╙ 16 ࿁ᣣᧄᶖൻེ㑐ㅪቇળㅳ㑆 JDDW 2008(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 9‫ޟ‬Tumor Necrosis Factor Dߣ Leptin ߇⢄⎬ᄌᖚ⠪ߩࠛࡀ࡞ࠡ࡯ઍ⻢ߦ෸߷ߔᓇ㗀‫ޠ‬Ṷ⠪)═ේජ༹㧦
1㧕 ╙ 68 ࿁ᣣᧄⴊᶧቇળ࡮╙ 48 ࿁ᣣᧄ⥃ᐥⴊᶧቇળ࡮วห✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶
ࡊ‫ޟ‬ㅧⴊེᖡᕈ∔ᖚߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ⥃ᐥ⊛ᬌ⸛‫ޠ‬Ṷ⠪)⿷┙᡽ᴦ㧦
1㧕 ╙ 94 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 4‫ߩࡦࠠ࠹ࠞ⨥✛ޟ‬ᄢ⣺≸⚦⢩Ⴧᱺᛥ೙ߩᣂⷙࡔࠞ࠾࠭ࡓ㨪⢽⾰࡜ࡈ࠻ߢߩ EGFR pathway ߩ㒖ኂ㨪‫ޠ‬Ṷ⠪)㜞੗శᴦ㧦
1㧕 ╙ 108 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㅴⴕ⢄⚦⢩≸ߦኻߔࠆࠕࠗࠛ࡯ࠦ࡯࡞෻ᓳേᵈߩലᨐߦ㑐ߔࠆᬌ⸛‫ޠ‬Ṷ⠪)ᄢỈ㓁੺㧦
1㧕 The 16th International Symposium on Regulatory Peptides (REGPEP’06)(ᐔᚑ 18 ᐕ 9 ᦬㧘▫ᩮ㧘‫ޟ‬Roles of AKT and sphingosine kinase in the anti-apoptotic effects of bile duct ligation in mouse
liver‫ޠ‬Ṷ⠪)
2㧕 ╙ 43 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬⢙▤⚿⚤ߦࠃࠅ⺃ዉߐࠇߚᘟᕈ
⢄㓚ኂࡑ࠙ࠬࡕ࠺࡞ߦ߅ߌࠆ᛫ࠕࡐ࠻࡯ࠪࠬ₪ᓧᯏᐨߩᬌ⸛‫ޠ‬Ṷ⠪)ਛፉ⾫ᙗ㧦
1㧕 JDDW2008(╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 29‫❑ޟ‬㓒࡮⣻⣧ౝᖡᕈ࡝ࡦࡄ⣲ߦኻߔࠆൻቇ≮ᴺᓟ⹏ଔߩߚ߼ߩ EUS-FNA ߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)2㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘㧙㧙᧲੩㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 4‫❑ޟ‬㓒∛ᄌߦኻߔࠆ EUS-FNA ߩታ㓙ߣ⸻ᢿ⢻‫ޠ‬Ṷ⠪)ട⮮ೣᑝ㧦
1㧕 ╙ 16 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ᧲ᶏ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㘩㆏ߩἻ∝ᕈ∔ᖚ‫ޠ‬Ṷ⠪)⷏⣁િੑ㧦
1㧕 JDDW2008(ᶖൻེౝⷞ㏜ቇળ࡮ᶖൻེ߇ࠎᬌ⸻ቇળวห)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ
࠶࡚ࠪࡦ 20‫⚦ޟ‬ᓘౝⷞ㏜ࠍ↪޿ߚ⚻⢗≪⊛ౝⷞ㏜ߦࠃࠆᴦ≮ᚻᛛߩ⚻㛎‫ޠ‬Ṷ⠪)᧖ጊᤘᒾ㧦
1㧕 ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ╙ 105 ࿁଀ળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓΣ‫ޟ‬㘩㆏ࠕ࡜ࠞࠪ
ࠕߣ㘩㆏≸ߦ㑐ߔࠆᬌ⸛‫ޠ‬Ṷ⠪)ጊ↰ବ᮸㧦
1㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ᱶ⁁ᴫਅߢߩⴊᶧ⵾೷ߩ૶↪-ⴊᶧ∔ᖚ-‫ޠ‬Ṷ⠪)Ⴎደᱜ㆏㧦
1㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 6‫⿥ޟ‬㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ⃻ᤨὐߦ߅ߌࠆ⹏ଔߣ੹ᓟߩዷᦸ‫ޠ‬Ṷ⠪)2㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 4‫⿥ޟ‬㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ᦭↪ᕈߦ㑐ߔࠆᬌ⸛ߣᚻᛛߩᎿᄦ‫ޠ‬Ṷ⠪)
3㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 1‫✭≸ޟ‬๺ක≮ߦ߅ߌࠆ⿥㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ᦭↪ᕈߦ㑐ߔࠆᬌ⸛‫ޠ‬Ṷ⠪)ᧁ᧛౏ೣ㧦
1㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬B ဳ⢄Ἳ࠻࡜ࡦࠬࠫࠚ࠾࠶ࠢࡑ
࠙ࠬࠍ↪޿ߚᕆᕈ⢄Ἳࡕ࠺࡞ߦ߅ߌࠆ CTL ߣ CD44 ߩ⋧੕૞↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 12 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬B ဳ⢄Ἳᴦ≮ߦ߅ߌࠆ⥄ὼ఺∉೙ᓮߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)ะ੗ ᒝ㧦
1㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 3‫ޟ‬ౝⷞ㏜⊛⤟▤ࠬ࠹ࡦ࠹ࠖࡦࠣߩ᦭↪ᕈ‫ޠ‬Ṷ⠪)
2㧕 ╙ 73 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 10‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯ‫ޠ‬Ṷ⠪)
3㧕 ╙ 106 ࿁ᣣᧄᶖൻེ∛ቇળ᧲ᶏᡰㇱ଀ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᵿ᧻㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯ‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 2‫ޟ‬㕖ಾ㒰⢄㐷ㇱ⢙▤≸ߦ߅ߌࠆ Metallic stent ߦࠃࠆ⢙㆏ౝ≪ⴚ‫ޠ‬Ṷ⠪)5㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 3‫ޟ‬ᖡᕈ⢄ᄖ⢙㆏㐽Ⴇߦኻߔࠆ Covered Metallic Stent ߩౣ㐽Ⴇᤨᴦ≮
㧙ᛮ෰ᴺߩታ㓙㧙‫ޠ‬Ṷ⠪)
6㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 2‫ޟ‬㕖ಾ㒰ᖡᕈ⢄㐷ㇱ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ౝ≪ⴚߩᬌ⸛́ౝⷞ㏜⊛ࠕࡊࡠ࡯࠴ߩ೑ὐߦߟ޿ߡ́‫ޠ‬Ṷ⠪)7㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 5‫ޟ‬㐽Ⴇᕈ㤛∏ࠍ઻߁ಾ㒰ਇ⢻⤟≸ߦኻߔࠆൻቇ≮ᴺߣ⢙㆏ࠬ࠹ࡦ࠻ߩᬌ⸛‫ޠ‬Ṷ⠪)8㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 18‫ޟ‬㕖ಾ㒰ᖡᕈ⢙㆏⁜⓰ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠻ߩㆬᛯ‫ޠ‬Ṷ⠪)
⑔ፉ⑲᮸㧦
1㧕 ╙ 92 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ዊୖ㧘ࠪࡦࡐࠫ࠙ࡓ 6‫ޟ‬ᶖൻེౝ⑼ߦ߅ߌࠆ SGA㧙㧙ࠍ↪޿ߚᩕ㙃ࠬࠢ࡝࡯࠾ࡦࠣߣ࿷㒮ᦼ㑆‫ޠ‬Ṷ⠪)
2㧕 ╙ 29 ࿁ ᣣ ᧄ ᩕ 㙃 ࠕ ࠮ ࠬ ࡔ ࡦ ࠻ ⎇ ⓥ ળ ( ᐔ ᚑ 18 ᐕ 5 ᦬ 㧘 ጘ 㒂 㧘 ᢎ ⢒ ࠮ ࡒ ࠽ ࡯ 5 ‫ ޟ‬Albumin
microheterogeneity ߣ∔ᖚ‫ޠ‬Ṷ⠪)
3㧕 ╙ 10 ࿁ᣣᧄ⢄⤳ቇળᄢળ⻠Ṷ࡮ᶖൻེ∛ቇળวห(ᐔᚑ 18 ᐕ 10 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ 14‫ޟ‬C ဳᘟᕈ⢄∔ᖚᖚ⠪ߦ߅ߌࠆ⢈ḩߩ㗫ᐲߣ⢽⢌⢄ߩว૬‫ޠ‬Ṷ⠪)ጊፒஜ〝㧦
1㧕 ╙ 71 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘᧲੩㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬75 ᚽએ਄ߩ㜞㦂⠪ߢߩ਄ㇱᶖൻ▤ ESD ߩᬌ⸛(APC ᴦ≮ߣߩᲧセࠍ฽߼ߡ)‫ޠ‬Ṷ⠪)ᧃᰴ ᷕ㧦
1㧕 ╙ 42 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 4‫ޟ‬ォ౮࿃ሶ HNF-4 ㆮવሶዉ౉
⢝ఽ⢄೨㚟⚦⢩ߩಽൻ⺃ዉߣ⚦⢩⒖ᬀ≮ᴺ‫ޠ‬Ṷ⠪)
2㧕 ╙ 44 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘᧻ጊ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬HNF-4 ㆮવሶዉ౉ߦࠃࠆ⢄೨㚟⚦⢩ߩಽൻ⺃ዉߣ⚦⢩≮ᴺ߳ߩᔕ↪‫ޠ‬Ṷ⠪)
3㧕 ╙ 12 ࿁ᣣᧄ⢄⤳ቇળᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢄ᐙ⚦⢩ߦ߅ߌࠆ HNF-4 ߩᓎഀߣ≸ᐙ⚦⢩ߦ߅ߌࠆ CD133 㓁ᕈ⚦⢩ߩ․ᓽ‫ޠ‬Ṷ⠪)ᧁోፏਯ㧦
1㧕 ╙ 42 ࿁ᣣᧄ⢄⤳ቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫⚦ޟ‬⢩ᄖࡑ࠻࡝࠶ࠢࠬߦࠃࠅ⺃ዉߐࠇࠆ⢄⚦⢩ಽൻᯏ᭴ߣォ౮࿃ሶ HNF-4 ߩᓎഀ‫ޠ‬Ṷ⠪)ጤ↰࿻੺㧦
1㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 2‫࡮⤟ޟ‬⢙㆏≸ߩ≸ᕈ−∩ߦኻߔࠆ⿥㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ(EUS-CPN)ߩ᦭↪ᕈߣᚻᛛߩᎿᄦ‫ޠ‬Ṷ⠪)2㧕 JDDW2008(╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ㧘╙ 39 ࿁ᣣᧄᶖൻๆ෼ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 15‫⤟ޟ‬઒ᕈྙ⢩ߦኻߔࠆౝⷞ㏜⊛ᴦ≮‫ޠ‬Ṷ⠪)3㧕 JDDW2008(╙ 50 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࡆ࠺ࠝࠪࡦࡐࠫ࠙ࡓ 1‫࡮⤟ޟ‬⢙㆏≸ߦࠃࠆ≸ᕈ−∩ߦኻߔࠆ⿥㖸ᵄౝⷞ㏜ਅ⣻⣧␹⚻ฌࡉࡠ࠶ࠢ‫ޠ‬Ṷ⠪)
ᄢ⷏㓉຦㧦1㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 21‫ޟ‬80 ᱦએ਄ߩ㜞㦂⠪✚⢙▤⚿⍹∝ߦኻߔࠆౝⷞ㏜ᴦ≮‫ޠ‬Ṷ⠪)
2㧕 ╙ 44 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ 1‫ޟ‬80 ᱦએ਄ߩ㜞㦂⠪✚⢙▤⚿⍹∝ߦኻߔࠆౝⷞ㏜ᴦ≮‫ޠ‬Ṷ⠪)࿯੗᤯ᐔ㧦
1㧕 ╙ 43 ࿁ᣣᧄ⢙㆏ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 1‫✚ޟ‬⢙▤⚿⍹ߦኻߔࠆౝⷞ㏜
ᴦ≮㧙㐳ᦼ੍ᓟߩᬌ⸛㧙‫ޠ‬Ṷ⠪)2㧕 JDDW2007(╙ 49 ࿁ᣣᧄᶖൻེ∛ቇળᄢળ㧘╙ 74 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 19 ᐕ 10 ᦬㧘␹ᚭ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫✚ޟ‬⢙▤⚿⍹ౝⷞ㏜ᴦ≮ᓟߩ੃㗡ᯏ⢻㓚ኂ߇㐳ᦼ੍ᓟߦਈ߃ࠆᓇ㗀‫ޠ‬Ṷ⠪)
3㧕 ╙ 75 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᮮᵿ㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ 6‫ޟ‬EST࡮EPBD
ߩ㐳ᦼ੍ᓟ‫ޠ‬Ṷ⠪)4㧕 DDW2008(╙ 76 ࿁ᣣᧄᶖൻེౝⷞ㏜ቇળ✚ળ)(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ 24‫ޟ‬EST࡮EPBD ߩ㐳ᦼ੍ᓟ߆ࠄߺߚ✚⢙▤⚿⍹ߩᴦ≮ᚢ⇛‫ޠ‬Ṷ⠪)㊄᫪ ၴ㧦
1㧕 ╙ 93 ࿁ᣣᧄᶖൻེ∛ቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘㕍᫪㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ 5‫ޟ‬㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߣࡆ࠲
ࡒࡦ K2 ߩ૬↪ಣℂߦࠃࠆ⋧ਸ਼⊛ߥ⢄≸⚦⢩Ⴧᱺᛥ೙ലᨐߩᬌ⸛‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᷡ᳓㓷ੳ㧦ᐔᚑ 18 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ᷡ᳓㓷ੳ㧦ጘ㒂කቇ⎇ⓥᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
3㧕 ቟↰৻ᦶ㧦ጘ㒂කቇ⎇ⓥᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
4㧕 ᷡ᳓㓷ੳ㧦ᐔᚑ 20 ᐕᐲ Liver Forum in Kyoto ⎇ⓥᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ᫪⣁ਭ㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪⑔␩ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળᐳ㐳(㨪⃻࿷)3㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)4㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂⋵ක≮ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂⋵ੱᮭᙣ⹤ળᆔຬ(㨪⃻࿷)᳗ᧁᱜੳ㧦1㧕 ጘ㒂⋵⢄Ἳᴦ≮ክᩏᆔຬળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)2㧕 ㇺ㆏ᐭ⋵⢄∔ᖚ⸻≮ㅪ៤᜚ὐ∛㒮㑆ㅪ⛊ද⼏ળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᫪⣁ਭ㓉㧘ᧃᰴ ᷕ㧘᳗ᧁᱜੳ㧦ォ౮࿃ሶ HNF-4 ㆮવሶዉ౉ߦࠃࠆ⢄೨㚟⚦⢩ߩಽൻ⺃ዉߣ⚦⢩≮ᴺߩ⏕┙㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 17 ᐕᐲ⎇ⓥႎ๔ᦠ㧦98㧙
100(2006 ᐕ)
2㧕 ⊕ᧁ ੫㧘⧯ේ೑㆐㧘᫪⣁ਭ㓉㧦SF-36 ࠍ↪޿ߚ⢄⎬ᄌ࡮⢄߇ࠎว૬⢄⎬ᄌᖚ⠪ߦ߅ߌࠆ QOL ⹏ଔߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ‫ޟ‬⢄߇ࠎᖚ⠪ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ‫ޠ‬ᐔᚑ 18 ᐕᐲ✚᜝⎇ⓥႎ๔ᦠ(2007 ᐕ)
3㧕 ᫪⣁ਭ㓉㧘᳗ᧁᱜੳ㧘ᧁోፏਯ㧦⚦⢩ᄖࡑ࠻࡝࠶ࠢࠬߦࠃࠅ⺃ዉߐࠇࠆ⚦⢩㛽ᩰߩᄌൻߣ⢄⚦⢩ಽൻᯏ⢻೙ᓮ㧦ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 18 ᐕᐲ⎇ⓥႎ๔ᦠ㧦98㧙100(2007 ᐕ)
4㧕 ᫪⣁ਭ㓉㧘᳗ᧁᱜੳ㧘ዊᧁᦥን↢㧦G-CSF ߩ⢄ౣ↢ᛥ೙ലᨐ㧦IL-1Eߩᓎഀ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦117㧙119(2008 ᐕ)
11㧚ႎ㆏
1㧕 ᫪⣁ਭ㓉㧦⢈ḩ㨯㨯㨯⢄≸㧦ਛᣣᣂ⡞(2006 ᐕ 12 ᦬ 17 ᣣ)‫ޟ‬ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮㧦ᬌᩏߩຠ⾰଻⸽ࠍ߼ߑߒߚ GPILS ߩ᭴▽‫ޠ‬ቢో㔚ሶൻ㧦A&T
2㧕 ⊕㠽⟵ቬ㧦ᬌᩏቶ⷗ቇ࠷ࠕ࡯(2006 ᐕ 12 ᦬)
3㧕 ᫪⣁ਭ㓉㧦ൕോක㧦ᾢකળႎ(2007 ᐕ)
4㧕 ᫪⣁ਭ㓉㧦⃻⁁㧦ห⓹ળႎ(2007 ᐕ 1 ᦬ 1 ᣣ)
5㧕 ᫪⣁ਭ㓉㧦․ቯᯏ⢻∛㒮㧦⋵∛㒮ᤨႎ 41 ภ(2007 ᐕ 3 ᦬ 31 ᣣ)
6㧕 ᫪⣁ਭ㓉㧦ൕോක㧦⋵කᏧળႎ(2007 ᐕ 4 ᦬ 1 ᣣ)
7㧕 ᫪⣁ਭ㓉㧦BCAA ᐳ⺣ળ㧦ࡔ࠺ࠖࠞ࡞ᦺᣣ(2007 ᐕ 5 ᦬ 1 ᣣ)
8㧕 ᫪⣁ਭ㓉㧦࠽࡯ࠬࠝࡉࠩࠗࡗ࡯㧦ਛᣣᣂ⡞࡮ጘ㒂ᣂ⡞(2007 ᐕ 5 ᦬ 8 ᣣ)
9㧕 ᧃᰴ ᷕ㧦ᴉ㤩ߩ⤳ེ⢄⤳㧦ᐢႎߺߩ(2007 ᐕ 8 ᦬ 1 ᣣภ)
10㧕 ᫪⣁ਭ㓉㧦∛㒮ߩ⃻⁁㧦⸥ᔨળ㙚ߛࠃࠅ(2007 ᐕ 9 ᦬ 1 ᣣ)
11㧕 ᫪⣁ਭ㓉㧦C ဳ⢄Ἳ/Ꮢ᳃౏㐿⻠ᐳ㧦ਛᣣᣂ⡞(2007 ᐕ 8 ᦬ 9 ᣣ)
12㧕 ᫪⣁ਭ㓉㧦ᄢቇකᏧળ㧦⋵කᏧળႎ(2007 ᐕ 9 ᦬ 1 ᣣ)
13㧕 ᫪⣁ਭ㓉㧦⢄⤳∛ߩᩕ㙃≮ᴺ㧦CN Hotline(2007 ᐕ 9 ᦬)
14㧕 ᫪⣁ਭ㓉㧦ᶖൻེ ౏㐿⻠ᐳ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 14 ᣣ)
15㧕 ⨹ᧁኡม㧦ᐳ⺣ળ‫ޟ‬ᄢ⣺≸ൻቇ≮ᴺߩ⃻⁁ߣ੹ᓟ‫ޠ‬㧦MEDICAMENT NEWS(2007 ᐕ 9 ᦬ 15 ᣣภ)16㧕 ቟↰৻ᦶ㧦⿥㖸ᵄౝⷞ㏜ਅ⓫ೝๆᒁᴺ㧙ࠊ߇࿖ߢ߽⌕ታߦ᥉෸ߩళߒࠍ␜ߔ㧦Medical Tribune vol.
40, No.27(2007 ᐕ 7 ᦬ 5 ᣣ)
17㧕 ቟↰৻ᦶ㧦⿥㖸ᵄౝⷞ㏜ਅๆᒁ㊎↢ᬌ(EUS-FNA)ߦࠃࠆ❑㓒࡮⣻⣧ౝ⣲ᄢ࡝ࡦࡄ▵ߩ⸻ᢿ㧦ጘ㒂ᄢቇකቇㇱ⸥ᔨળ㙚ߛࠃࠅ(2007 ᐕ㧧╙ 84 ภ㧦11㧙12)㧙㧙18㧕 ⊕㠽⟵ቬ㧦ක≮ᖱႎ IT ߢ౒᦭㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
19㧕 ⊕㠽⟵ቬ㧦ጘ㒂⋵ౝోၞߢ⸻≮ᖱႎࠍ౒᦭㧦ᣣᧄ⚻ᷣᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
20㧕 ⊕㠽⟵ቬ㧦∛㒮ߣㅪ៤ਃ੐ᬺ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
21㧕 ⊕㠽⟵ቬ㧦㔚ሶࠞ࡞࠹ߢᖚ⠪⚫੺㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
22㧕 ⊕㠽⟵ቬ㧦IT ᵴ↪㧘ක≮ㅪ៤㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
23㧕 ⊕㠽⟵ቬ㧦∛㒮ቢ⚿ဳ߆ࠄ࿾ၞቢ⚿ဳක≮߳ ࿾ၞㅪ៤ࡄࠬг㒮ౝ࠴࡯ࡓࠍ࿾ၞߦᐢߍࠆ㧦ㅳ㑆 කቇ⇇ᣂ⡞(2007 ᐕ 10 ᦬ 29 ᣣ)
24㧕 ᫪⣁ਭ㓉㧦ቯ଀ળ⷗㧦ਛᣣ࡮ጘ㒂࡮⺒ᄁ࡮ᦺᣣᣂ⡞(2007 ᐕ 11 ᦬ 27 ᣣ)
25㧕 ᫪⣁ਭ㓉㧦∛㒮ߩ⃻⁁㧦⸥ᔨળ㙚ߛࠃࠅ(2008 ᐕ 1 ᦬ 1 ᣣ)
26㧕 ᫪⣁ਭ㓉㧦∛ᘒᩕ㙃ቇળࠪࡦࡐࠫ࠙ࡓ㧦ࡔ࠺ࠖࠞ࡞࡮࠻࡝ࡆࡘ࡯ࡦ(2008 ᐕ 2 ᦬ 21 ᣣ)
27㧕 ᫪⣁ਭ㓉㧦⢄⎬ᄌߩࠢ࡝࠾ࠞ࡞ࡄࠬ㧦ጟፒකႎ(2008 ᐕ 7 ᦬ 15 ᣣ 300 ภ)
28㧕 ᫪⣁ਭ㓉㧦ቯ଀ળ⷗㧦ਛᣣ࡮ᦺᣣ࡮Ფᣣ࡮ᣣ⚻࡮⺒ᄁ࡮ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 24 ᣣ)
29㧕 ᫪⣁ਭ㓉㧦∛㒮ߩ⃻⁁ߣ዁᧪㧦⸥ᔨળ㙚ߛࠃࠅ(2008 ᐕ 9 ᦬ 1 ᣣ)
30㧕 ᷡ᳓㓷ੳ㧦✛⨥ࠞ࠹ࠠࡦߢࡐ࡝࡯ࡊౣ⊒੍㒐 ߇ࠎ੍㒐ߦน⢻ᕈ㧦ਛᣣ࡮ᣣ⚻ᣂ⡞(2008 ᐕ 10 ᦬ 12
ᣣ)31㧕 ቟↰৻ᦶ㧦⢙㆏߇ࠎ࡮⤟⤳߇ࠎ࡮ߘߩઁ⢙⤟∔ᖚ㧦ㅅߞߚߣ߈ߩක⠪ㆬ߮㧙᧲ᶏ㧙 ⷺᎹ SS ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࠭㧘p53(2008 ᐕ 4 ᦬)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
1. ⎇ⓥߩ᭎ⷐ㧦ᶖൻེ∛ᘒቇߩ 1㧙4 ߪ޿ߕࠇ߽㧘߶߷㗅⺞ߦㅴⴕߒߡ޿ࠆ‫ߦߊߣޕ‬ਅ⸥ߩὐࠍ㜞ߊ⹏ଔߔࠆ㧔1㧕RXR ࡝ࠟࡦ࠼ߦࠃࠆ⢄⊒≸ᛥ೙ߩᄢⷙᮨ⥃ᐥ⹜㛎ࠍㅴⴕߒߡ޿ࠆ㧔2009 ᐕ㧘ࠠ࡯࡮ࠝ࡯ࡊࡦߩ
੍ቯ㧕
㧔2㧕ᘟᕈ⢄∔ᖚߦኻߔࠆಽጘ㎮ࠕࡒࡁ㉄ࠍ↪޿ߚᩕ㙃ࠨࡐ࡯࠻߇㧘⢈ḩ⠪ߦ߅ߌࠆ⢄≸ࠍ੍㒐ߔࠆߣߩ⚿ᨐࠍᓧ㧘࿖㓙⊛ߦ౏⴫ߒߚ㧔ේ⪺㧙⧷ᢥ㧘No.5㧕‫⚿ߩߎޕ‬ᨐߪ 2006 ᐕ᰷Ꮊ㕒⣂⚻⣺ᩕ㙃ቇળࠟࠗ࠼࡜ࠗࡦߦ㧘2008 ᐕᧄ㇌ෘ↢ഭ௛⋭ࠟࠗ࠼࡜ࠗࡦߦขࠅ౉ࠇࠄࠇߚ‫ޕ‬
3. ⎇ⓥᚑᨐߩ⊒⴫㧦਄⸥㧔1㧕㧘㧔2㧕ߩ⽸₂߇ᄢ߈޿‫ߨ߻߅߅ઁߩߘޕ‬㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬
4. ⎇ⓥ⾌₪ᓧ⁁ᴫ㧦߅߅߻ߨ㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬
5. ⊒᣿࡮․⸵಴㗿⁁ᴫ㧦good ߢߥߊ fair ߣ⹏ଔߔࠆ‫ޕ‬
6㧘7. ቇળᵴേ㧦߅߅߻ߨ㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬
11. ႎ㆏㧦߅߅߻ߨ㗅⺞ߦᖱႎࠍ౏⴫ߢ߈ߡ޿ࠆߣ⹏ଔߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⥃ᐥߩᣰ⋓ߥ㔛ⷐߦኻᔕߔߴߊ㧘ੱຬࠍᝄࠅะߌߑࠆࠍᓧߥ޿⁁ᴫߦ޽ࠆ‫ߒߛߚޕ‬㧘⎇ⓥࠬ࠲࠶ࡈߣ
ߊߦᄢቇ㒮↢ߦߟ޿ߡߪჇ൓ߦォߓߚ‫ޕ‬੹ᓟߩዷᦸ
1㧙1㧚ᶖൻེ∛ᘒቇ㧦㧔1㧕RXR ࡝ࠟࡦ࠼ߦࠃࠆ⢄⊒≸ᛥ೙ߩ⥃ᐥ⹜㛎߇⚳ੌߒ㧘⚿ᨐ߇್᣿ߔࠆ੍ቯߢ޽ࠆ‫ޕ‬ᚑഞߩᥙߦߪઁ
೷૬↪ᴦ≮߳ዷ㐿ߔࠆ‫ޕ‬
㧔3㧕ᘟᕈ⢄∔ᖚߦኻߔࠆࠕࡒࡁ㉄ᩕ㙃ࠨࡐ࡯࠻ߪ㧘⊒≸߿㕖ࠕ࡞ࠦ࡯࡞ᕈ⢽⢌ᕈ⢄㓚ኂߥߤߦߟ޿ߡ㧘ࠗࡦࠬ࡝ࡦᛶ᛫ᕈࠍᮡ⊛ߣߒߚᰴߩᲑ㓏ߦㅴ߻⷗ㄟߺߢ޽ࠆ‫ޕ‬㧙㧙㧔5㧕ⴊᶧ∛ᘒቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
ᖡᕈ࡝ࡦࡄ⣲ߩᴦ≮ᚢ⇛㧘㜞㦂⠪⊕ⴊ∛ߩᴦ≮ߥࠄ߮ߦ⊕ⴊ∛ߩಽൻ⺃ዉ≮ᴺ㧘㛽㜑⇣ᒻᚑ∝୥⟲ߩᴦ≮߇ਥⷐ࠹࡯ࡑߢ޽ࠆ‫ޕ‬1㧕ᖡᕈ࡝ࡦࡄ⣲ߩᴦ≮ᚢ⇛㧘․ߦ߮߹ࠎᕈᄢ⚦⢩㧮⚦⢩ᕈ࡝ࡦࡄ⣲ߩጀ೎ൻᴦ≮ࠍ⋡ᮡߦ㧘⥃ᐥ⊛߹ߚߪ∛ℂቇ⊛ߦ੍ᓟ࿃ሶ⸃ᨆࠍⴕߞߡ޿ࠆ‫੍ߦ․ޕ‬ᓟ࿃ሶ⸃ᨆߪ㧘ฦ⒳ TNF superfamily ߦዻߔࠆⴊᷡࠨ
ࠗ࠻ࠞࠗࡦ߿ࠠ࠿࡟࠾ࡦ⊒⃻ߥߤࠍᬌ⚝ߔࠆߎߣߦࠃࠅ੍ᓟਇ⦟⟲ߩㆡᩰߥ᛽಴ࠍ⋡⊛ߣߒ㧘ߎߩ⟲ߦኻߒߡߪ㧘Ⓧᭂ⊛ߦㅧⴊᐙ⚦⢩⒖ᬀⴚࠍขࠅ౉ࠇࠆߥߤߩጀ೎ൻᴦ≮ࠍⴕߞߡ޿ࠆ‫ ߚ߹ޕ‬B ⚦⢩࡝ࡦࡄ⣲ߩߺߥࠄߕ㨀⚦⢩࡝ࡦࡄ⣲ߦ߅޿ߡ߽㧘ฦ⒳ᴦ≮ࠍ⥃ᐥ⹜㛎ߣߒߡⴕߞߡ޿ࠆ‫ޕ‬
2㧕⊕ⴊ∛ߩਛߢ߽ᕆᕈ೨㛽㜑⃿ᕈ⊕ⴊ∛ߦኻߔࠆಽൻ⺃ዉ≮ᴺߣߒߡߩ࡟࠴ࡁࠗ࠼≮ᴺߩᯏᐨߣ⠴ᕈ⊒⃻ߩ⸃᣿ࠍⴕ޿㧘⠴ᕈస᦯ᴺࠍ㐿⊒ߔࠆ⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ᦨޕ‬ㄭߪ㧘࡟࠴ࡁࠗ࠼ߩߺߥࠄߕ㧘ࡆ࠲ࡒࡦ
K2 ߥߤߦ߽ᵈ⋡ߒߡ޿ࠆ‫ޕ‬
3㧕㛽㜑⇣ᒻᚑ∝୥⟲ߩ఺∉∉ቇ⊛∛ᘒࠍ⸃᣿ߒ㧘ฦ⒳఺∉ᛥ೙೷ߦࠃࠆᴦ≮ᴺߩ㐿⊒ࠍⴕߞߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦
ಎᢎ᝼㧦

᫪⣁ਭ㓉
㢬⷗ ኼ

Hisataka Moriwaki
Hisashi Tsurumi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚․ᱶ∛ᘒ(⁁ᘒ)ߦ߅ߌࠆᩕ㙃≮ᴺ(ᚑੱ࡮ዊఽ)ⴊᶧ∔ᖚ㧦ዊ⿧┨ᐔ⋙㧚ᩕ㙃≮ᴺ ࡒ࠾ࡑࡓࠛ࠶࠮ࡦࠪࡖ࡞㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦186㧙196㧚
2㧕 ᫪⣁ਭ㓉㧚ࡆ࠲ࡒࡦ A㧦Medical Practice ✬㧚⥃ᐥᬌᩏࠟࠗ࠼ 2007㨪2008㧘᧲੩㧦ᢥశၴ㧧2007 ᐕ㧦265
㧙266㧚
⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu M, Weinstein IB, Moriwaki H. Targeting receptor tyrosine kinases and multiple downstream
signaling pathways by green tea catechin EGCG. In:Pandalai SG, ed. Cancer -Disease Progression andChemoprevention, India:Research Signpost;2006:203-206.
✚⺑㧔๺ᢥ㧕
1㧕 ᅏ㊁ᱜ㓉㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊒≸੍㒐ߣߘߩℂ⺰⊛⢛᥊㧘⢄⢙⤟ 2006 ᐕ㧧52 Ꮞ㧦393㧙402㧚
2㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚৻⥸⥃ᐥක߇ࠃߊㆣㆄߔࠆ⽺ⴊߩ⸻߆ߚ-ᶖൻེ∔ᖚߣ⽺ⴊ-㧘⸻ᢿߣᴦ≮ 2006 ᐕ㧧
94 Ꮞ㧦2050㧙2053㧚
3㧕 㢬⷗ ኼ㧘᫪⣁ਭ㓉㧚࡟࠴ࡁࠗ࠼ߦࠃࠆ⊕ⴊ∛ߩಽൻ⺃ዉ≮ᴺ㧘Biotherapy 2006 ᐕ㧧20 Ꮞ㧦150㧙157㧚
4㧕 㢬⷗ ኼ㧚 ⥃ᐥ✬ II. ⸻ᢿᴺ ৻⥸ⴊᶧᬌᩏ࡮㛽㜑ᬌᩏ—ㅧⴊེ⣲≌—ၮ␆࡮⥃ᐥ㗔ၞߦ߅ߌࠆᦨᣂߩ⎇ⓥേะ—㧘ᣣᧄ⥃ᐥ 2007 ᐕ㧧65 Ꮞ㧦288㧙292㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Moriwaki H, Shimizu M, Okuno M, Nishiwaki-Matsushima R. Chemoprevention of liver
carcinogenesis with retinoids -Basic and clinic aspects. Hepatol Res. 2007;37(Suppl.2):S299-S302.
ේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ศᎹᱞᔒ㧘ਅ᧛㗅ሶ㧘㢬⷗ ኼ㧘ጊ↰㋕਽㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚ᣧᦼߦࡃ࡯ࠠ࠶
࠻࡝ࡦࡄ⣲ဳᒻ⾰ォ឵ࠍ␜ߒ㜞ᖡᕈᐲൻߒߚࠈ⢩ᕈ࡝ࡦࡄ⣲㧘⥃ᐥⴊᶧ 2006 ᐕ㧧46 Ꮞ㧦1055㧙1059㧚
2㧕 㜞ᯅ ஜ㧘ේ ᱞᔒ㧘ਅ᧛㗅ሶ㧘ศᎹᱞᔒ㧘౷↰ᩕ৻㧚ᕆㅦߦㅴⴕߔࠆᗧ⼂㓚ኂࠍ઻߁⥄Ꮖ఺∉ᕈṁⴊᕈ⽺ⴊߦኻߔࠆⴊẏ੤឵≮ᴺ㧘⥃ᐥⴊᶧ 2006 ᐕ㧧47 Ꮞ㧦787㧙789㧚
3㧕 ═ේජ༹㧘ේ ᱞᔒ㧘㢬⷗ ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅ ஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘JapanJ Antibiot 2008 ᐕ㧧61 Ꮞ㧦115㧙121㧚
4㧕 ᧁ᧛␭ሶ㧘⨹ᧁኡม㧘ᄢ㊁ᥓᒾ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘౗᧛ାብ㧘ᓟ⮮ዏ⛗㧘ᧃᰴ ᷕ㧘⊕ᧁ ੫㧘═ේජ༹㧘ᷡ᳓㓷ੳ㧘ጊ↰ବ᮸㧘㢬⷗ኼ㧘᫪⣁ਭ㓉㧚਄ⴕ⚿⣺㕒⣂≜ࠍᄾᯏߦ⸻ᢿߐࠇߚᖡᕈ࡝ࡦࡄ⣲ߩ 1଀㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦59㧙61㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Yasuda I, Tsurumi H, Omar S, Iwashita T, Kojima Y, Yamada T, Sawada M, Takami T, Moriwaki H,
Soehendra N. Endoscopic ultrasound-guided fine-needle aspiration biopsy for lymphadenopathy of
unknown origin. Endoscopy. 2006;38:919-924.
IF 4.166㧙㧙2㧕 Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S, Okamoto K, Moriwaki H.
Late-onset neutropenia in patients with rituximab for non-Hodgkin’s lymphoma. Int J Hematol.
2006;84:242-247.
3㧕 Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T, Kanemura N, Hara T, Sawada M,
Saio M, Yamada T, Takahashi T, Tomita E, Takami T, Moriwaki H. Fas and Fas ligand expression on
germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J
Haematol. 2006;76:465-472.
4㧕 Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu
M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H. Serum-soluble tumor necrosis factor
receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's
lymphoma. Eur J Haematol. 2006;77:217-225.
5㧕 Fukuno K, Tsurumi H, Kanemura N, Tanabashi S, Okamoto K, Moriwaki H. Chronic neutrophilia
preceding overt aggressive light chain multiple myeloma. Leuk Lymphoma. 2006;47:762-764.
6㧕 Tsurumi H, Kanemura N, Hara T, Kasahara S, Yamada T, Sawada M, Oyama M, Moriwaki H.
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly -the efficacy ofcontinuous drip infusion with low dose cytarabine and etoposide. J Cancer Res Clin Oncol.
2007;133:547-553.
7㧕 Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M,
Takami T, Moriwaki H. A phase II study of a THP-COP regimen for the treatment of elderly patients
aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol. 2007;25:107-114.
8㧕 Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H,
Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXRD and PPARJ ligands to inhibit growthin human colon cancer cells-phosphorylated RXRD is a critical target for colon cancer management.
Gut. 2007;56:1557-1563.
9㧕 Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H.
Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma
cells. Cancer Sci. 2007;98:431-437.
10㧕 Yoshimura K, Muto Y, Shimizu M, Matsushima-Nishiwaki R, Okuno M, Takano Y, Tsurumi H, Kojima
S, Okano Y, Moriwaki H. Phosphorylated retinoid X receptor D loses its heterodimeric activity withretinoic acid receptor E. Cancer Sci. 2007;98:1868-1874.
11㧕 Ando N, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Tanaka T, Moriwaki H.
Expression of retinoid X receptor D is decreased in 3'-methyl-4-dimethylaminoazobenzene-induced
hepatocellular carcinoma in rats. Oncol Rep. 2007;18:879-884.
12㧕 Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG
inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular
carcinoma cells. Cancer Lett. 2008;262:10-18.
13㧕 Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
()-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/KsJ-db/db mice. Cancer Prev Res. 2008;1:298-304.
14㧕 Shimizu M, Shirakami Y, Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention bygreen tea catechin, EGCG. Int J Mol Sci. 2008;9:1034-1049.
15㧕 Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008;2008:181047.
16㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa JI, Shimizu
M, Oyama M, Moriwaki H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.
17㧕 Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H. Retinoid X
receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of
9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leukemia Res. 2008;32:884-892.
18㧕 Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by
9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res.
2008;14:2806-2812.
19㧕 Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E
attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep.
2008;1:355-361.
20㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H, Takami
T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicated withduodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.

㧙㧙

IF 1.491

IF 2.163

IF 2.163
IF 1.512

IF 2.366

IF 2.180

IF 10.015

IF 3.165

IF 3.165

IF 1.597

IF 3.398

IF 0.750

IF 2.180

IF 2.561

IF 6.2504㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘᧛਄໪㓶㧘㢬⷗ ኼ㧦 HIV ᗵᨴ⠪╬଻ஜ⑔␩⋧⺣ផㅴ⎇ⓥ㧧ᐔᚑ 15㧙18 ᐕᐲ㧧1,950
ජ౞(650㧦650㧦650㧦325 ජ౞)㧦ࠛࠗ࠭⽷࿅ฃ⸤⎇ⓥ⾌
2㧕 ᫪⣁ਭ㓉㧦ᩭ࡟࠴ࡁࠗ࠼ฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ߇ࠎൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕ
ᐲ㧧450 ජ౞(150㧦150㧦150 ජ౞)㧦⢽ṁᕈࡆ࠲ࡒࡦ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄࡆ࠲ࡒࡦቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ≸ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᩕ㙃㘩♳ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળℂ੐(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ᣣᧄ⥃ᐥⴊᶧቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⴊᶧቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄャⴊቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅᫪⣁ਭ㓉㧦
1㧕 ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 29 ࿁ᣣᧄᩕ㙃ࠕ࠮ࠬࡔࡦ࠻⎇ⓥળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂)
3㧕 ╙ 8 ࿁ᣣ㖧߇ࠎ⠧ൻࠪࡦࡐࠫ࠙ࡓ(The 8th Japan-Korea Joint Symposium on Cancer and Ageing
Research)(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 8 ࿁ᣣᧄஜᐽᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳㢬⷗ ኼ㧦
1㧕 ╙ 68 ࿁ᣣᧄⴊᶧቇળ࡮╙ 48 ࿁ᣣᧄ⥃ᐥⴊᶧቇળ࡮วห✚ળ(2006 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ
‫ᧂޟ‬ᴦ≮ CD20 㓁ᕈૐᖡᕈᐲ࡝ࡦࡄ⣲ߦኻߔࠆ Rituximab ૬↪ THP-COP ≮ᴺ‫ޠ‬Ṷ⠪)㧙㧙ጊ↰ବ᮸㧦
1㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(2007 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ᱶ⁁ᴫਅߢߩⴊᶧ⵾೷ߩ૶↪ -ⴊᶧ∔ᖚ-‫ޠ‬Ṷ⠪)═ේජ༹㧦
1㧕 ╙ 68 ࿁ᣣᧄⴊᶧቇળ࡮╙ 48 ࿁ᣣᧄ⥃ᐥⴊᶧቇળ࡮วห✚ળ(2006 ᐕ 10 ᦬㧘⑔ጟ㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ
‫ޟ‬ㅧⴊེᖡᕈ∔ᖚߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ⥃ᐥ⊛ᬌ⸛‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᫪⣁ਭ㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪⑔␩ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળᐳ㐳(㨪⃻࿷)3㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕ㨪⃻࿷)4㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕ㨪⃻࿷)5㧕 ጘ㒂⋵ක≮ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕ㨪⃻࿷)6㧕 ጘ㒂⋵ੱᮭᙣ⹤ળᆔຬ(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)2㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ1㧚 ⎇ⓥߩ᭎ⷐ㧦ⴊᶧ∛ᘒቇ 1㧙3 ߩ޿ߕࠇ߽㧘߶߷㗅⺞ߦㅴⴕߒߡ޿ࠆ‫ߦߊߣޕ‬ਅ⸥ߩὐࠍ㜞ߊ⹏ଔߔࠆ
㧔1㧕ᖡᕈ࡝ࡦࡄ⣲ߩ੍ᓟ࿃ሶ⸃ᨆߣߒߡ㧘ᣂߒ޿޿ߊߟ߆ߩ੍ᓟ࿃ሶࠍ᛽಴ߢ߈ߚ‫◲߽ࠇߕ޿ޕ‬ଢߥᬌᩏߢ޽ࠅ㧘ౣ⃻ᕈ߇㜞ߊ㧘⥃ᐥ⊛᦭↪ᕈ߇ᭂ߼ߡ㜞޿ߣᕁࠊࠇࠆ‫ޕ‬
㧔2㧕ᖡᕈ࡝ࡦࡄ⣲ߦኻߔࠆᣣᧄ⊒ߩ THP-COP ≮ᴺߦ㑐ߔࠆᚑ❣ࠍ࿖㓙⊛ߦ౏⴫ߒߚ㧔ේ⪺㧙⧷ᢥ㧘
No.10㧕‫ޕ‬
㧔3㧕㜞㦂⠪ᕆᕈ㛽㜑ᕈ⊕ⴊ∛߿ㅢᏱߩᮡḰ⊛ᒝജൻቇ≮ᴺߩㆀⴕ߇࿎㔍ߥ∝଀ࠍኻ⽎ߦ㧘ᣂⷙᴦ≮࡟ࠫࡔࡦࠍ┙᩺㧘ႎ๔ߒߚ㧔ේ⪺㧙⧷ᢥ㧘No.9࡮19㧕‫ ߦ․ޕ‬G-CSF ࠍ૬↪ߔࠆߣ޿߁࡙࠾࡯ࠢߥ࠺ࠩࠗ
ࡦ߽฽߹ࠇࠆ‫ߪࠄࠇߎޕ‬㧘ోり⁁ᘒਇ⦟ߩᖚ⠪ߦ߅޿ߡ߽቟ో߆ߟ᦭ലߥᴦ≮ߣ⸒߃ࠆ‫ޕ‬3㧚 ⎇ⓥᚑᨐߩ⊒⴫㧦਄⸥㧔2㧕㧘㧔3㧕ߩ⽸₂߇ᄢ߈޿‫ߨ߻߅߅ઁߩߘޕ‬㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬4㧚 ⎇ⓥ⾌₪ᓧ⁁ᴫ㧦੹ᓟ㧘ࠃࠅ৻ጀߩขᓧߦะߌߡദജߔࠆ‫ޕ‬5㧚 ⊒᣿࡮․⸵಴㗿⁁ᴫ㧦਄⸥ᴦ≮ᴺߩ㐿⊒ߣ޿߁ὐߢ㧘fair ߣ⹏ଔߔࠆ‫ޕ‬
6㧘7㧚ቇળᵴേ㧦߅߅߻ߨ㗅⺞ߣ⹏ଔߔࠆ‫ޕ‬11㧚 ႎ㆏㧦߅߅߻ߨ㗅⺞ߦᖱႎࠍ౏⴫ߢ߈ߡ޿ࠆߣ⹏ଔߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⥃ᐥߩᣰ⋓ߥ㔛ⷐߦኻᔕߔߴߊ㧘ੱຬࠍᝄࠅะߌߑࠆࠍᓧߥ޿⁁ᴫߦ޽ࠆ‫⎇ޕ‬ⓥࠬ࠲࠶ࡈߣߊߦᄢቇ
㒮↢ߩలታࠍ࿑ࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘ⴊᶧᖡᕈ⣲≌ࠍ฽߻ Clinical Oncology ߪ㧘․ߦలታߒߚࠛࡆ࠺ࡦ
ࠬ߇ᦸ߹ࠇࠆಽ㊁ߢ޽ࠅ㧘ᣂⷙᴦ≮ߥߤߪනᣉ⸳ߢߪ㒢⇇߇޽ࠅ㧘ᴦ≮ߩ㐿⊒ࠍ⋡⊛ߣߒߚ⥃ᐥ⹜㛎ߩ┙᩺ߦߪ㧘ઁᣉ⸳ߣߩදജࠍኒߦߒߚᄙᣉ⸳౒ห⹜㛎߇ᔅⷐߢ޽ࠆ‫ޕ‬㧙㧙੹ᓟߩዷᦸ
1㧚ⴊᶧ∛ᘒቇ㧦ᴦ≮ᛶ᛫ᕈ⊕ⴊ∛ߩᯏᐨ⸃᣿ߣ㧘ᣂߒ޿ᴦ≮ᴺ㐿⊒ߩዷ㐿ࠍᦼߒߡ޿ࠆ‫ߚ߹ޕ‬㧘࡟ࡌ࡞ߩ㜞޿⥃ᐥ⹜㛎ࠍ┙᩺ߒ㧘ᄙᣉ⸳౒ห⹜㛎ߣߒߡⓍᭂ⊛ߦㅴ߼ࠆ‫ޕ‬
3㧚⎇ⓥᚑᨐߩ⊒⴫㧦IF5 ߥࠄ߮ߦ 10 એ਄ࠍ⋡቟ߣߒ㧘ߘࠇߙࠇࠍ਄࿁ࠆᬺ❣ߩჇടࠍ⋡ᜰߔ‫ޕ‬
4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ㧦චಽߥ⎇ⓥ⾌₪ᓧߦะߌߡദജߔࠆ‫ޕ‬
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ㧦ᰴߩዷᦸߪⷞ㊁ߦ౉ߞߡ޿ߥ޿‫ޕ‬
6㧘7㧚ቇળᵴേ㧦ฦ⒳࿖㓙ቇળ㧘․ߦ☨࿖ⴊᶧળ⼏ߢߩ⛮⛯⊛ណᛯࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔6㧕↥⑼ᇚੱ⑼ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
‫⎇߇ޠ≸ߣࡦࡕ࡞ࡎޟ‬ⓥ⺖㗴ߢ޽ࠆ㨫ߘߩ৻ߟߣߒߡ㧘ᅚᕈ↢ᱺ↢ℂਗ߮ߦᕈࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦߦ೙
ᓮߐࠇࠆᅚᕈ↢ᱺེ߿ߘࠇ↱᧪ߩ⣲≌ߩ⊒⢒Ⴧᱺߣ⊒⢒ᛥ೙ࠍ᣿ࠄ߆ߦߔࠆߎߣࠍ⋡ᜰߔ㨫߹ߚ㧘ࡎ࡞ࡕࡦਇᔕ∝߿ฃኈ૕∔ᖚߦߟ޿ߡ߽㧘∛ᘒߩℂ⸃߿ಽሶ࡟ࡌ࡞ߢߩㅊ᳞ࠍߒ㧘዁᧪⊛ߥㆮવሶᴦ≮ߩၮ␆ࠍ࿕߼ߟߟ޽ࠆ‫ޕ‬ᅧᆼߩᚑ┙߿⢝ఽ⇣Ᏹࠍߪߓ߼ߣߔࠆ๟↥ᦼߦߟ޿ߡ߽㧘ᣢ⍮ߩ⍮⷗ߩߺߥࠄߕᧂ⍮ߩ੐㗄ߩ⸃᣿ࠍ⋡ᜰߔ㨫․ߦ㧘ߎߩಽ㊁ߢߪታ㛎ቶ࡟ࡌ࡞ߢߪߥߊ㧘⚦߆ߥ⥃ᐥᚲ⷗ߩ㓸Ⓧࠍ㊀ߨ⥃ᐥߩ႐߳ߩㆶరࠍ⋡ᜰߒߡ޿ࠆ㨫2㧚ฬ★
ᢎ᝼(૬છ)㧦
⻠Ꮷ㧦
⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
⥃ᐥ⻠Ꮷ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦
කຬ㧦

੹੗◊ᔒ
⮮ᧄᰴ⦟
દ⮮⋥᮸
ਤ⠀ᙗม
ฎ੗ㄖ㇢
Ꮢฎ ື
⼾ᧁ ᑝ
ੑችᦸ␽
᧖ጊਃ⍮ઍ
૒⮮⧷ℂሶ
᳓㊁ᥓሶ
ᠲᦇሶ
㋈ᧁ⌀ℂሶ

Atsushi ImaiJiro Fujimoto
Naoki Ito
Kenji Niwa
Tatsuro Furui
Satoshi Ichigo
Hiroshi Toyoki
Mochiyoshi Ninomiya
Michiyo Sugiyama
Eriko Sato
Tomoko Mizuno
Asako Misao
Mariko Suzuki

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⮮ᧄᰴ⦟㧚ᇚੱ⑼≸ߩᶐẢ࡮ォ⒖ߦ߅ߌࠆⴊ▤ᣂ↢㧦ᱞ⼱㓶ੑઁ✬㧚↥⑼ᇚੱ⑼ߩᦨᣂක≮㧘᧲੩㧦వ┵ක≮ᛛⴚ⎇ⓥᚲ㧧2006 ᐕ㧦153㧙156㧚
2㧕 ₹⥢ノᒾ㧚ᣂߒ޿↥ᇚੱ⑼↪⮎೷㧦ᱞ⼱㓶ੑઁ✬㧚↥⑼ᇚੱ⑼ߩᦨᣂක≮㧘᧲੩㧦వ┵ක≮ᛛⴚ⎇ⓥᚲ㧧
2006 ᐕ㧦318㧙322㧚
3㧕 ₹⥢ノᒾ㧚ᇚੱ⑼߇ࠎ㧘੃߇ࠎ㧦ᄤ㊁ᕺሶઁ✬㧚ṽᣇߪᅚᕈߩஜᐽࠍߚߔߌࠆ㧘᧲੩㧦ጤᵄᦠᐫ㧧2006 ᐕ㧦
135㧙146㧚
4㧕 ₹⥢ノᒾ㧚ᅚᕈࡎ࡞ࡕࡦߩ૞↪ߣᕈᏅߩ಴⃻㧘੩ㇺ㧦㊄⧐ၴ㧧2006 ᐕ㧦3㧙261㧚
5㧕 ₹⥢ノᒾ㧚ౝᕈེᗵᨴ∝㧔ౝ⤑Ἳ࡮㒝ዻེἻ࡮PID㧕㧦⍹Ⴆᢥᐔઁ✬㧚↥ᇚੱ⑼⸻≮㧘᧲੩㧦᳗੗ᦠᐫ㧧2006
ᐕ㧦362㧙365㧚
6㧕 ⮮ᧄᰴ⦟㧚ᄙྱ⢩ᕈෆᎽ∝୥⟲㧦ᄢ㑐ᱞᒾઁ✬㧚੹ᣣߩዊఽᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦200㧙
201㧚
7㧕 ₹⥢ノᒾ㧚↥ᇚੱ⑼㧦ᓟ⮮ర✬㧚ᦨᣂ࡮ᗵᨴ∝ᴦ≮ᜰ㊎㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2006 ᐕ㧦187㧙197㧚
8㧕 ਃ㡞ᑝ❥㧚Q27 ᄖ⑼㗔ၞߢᵈᗧߔߴ߈⌀⩶∝ߣ࡝ࠬࠢߪ㧫㧦ᷓ࿷ᕈ⌀⩶∝ Q&A㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞
␠㧧2006 ᐕ㧦84㧙86㧚
9㧕 ਃ㡞ᑝ❥㧚╙Υ┨ Ꮢਛᗵᨴ∝ߦኻߔࠆᚻⴚᤨߩ᛫⩶⮎ߩ૶޿ᣇ㧙D㧚↥ᇚੱ⑼∔ᖚ㧚๟ⴚᦼᗵᨴኻ╷ࡑ࠾ࡘࠕ࡞㧦᛫⩶⮎૶↪ᴺ߆ࠄ๟ⴚᦼ▤ℂ߹ߢ㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦62㧙67㧚
10㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᴡ㊁⨃㧘ᐔẟᵗ৻✬㧚7 ↥ᇚੱ⑼㗔ၞߩᗵᨴ∝߇⇼ࠊࠇߚߣ߈㧘ࡌ࠶࠼ࠨࠗ࠼ߢᓎ┙ߟᓸ↢‛ᬌᩏࠟࠗ࠼㧙╙ 1 ┨ ∝⁁࡮∝୥߆ࠄߤࠎߥᬌ૕ࠍណขߒߤߩࠃ߁ߦ⸻ᢿࠍㅴ߼ࠆ߆ ૗ߩᬌᩏࠍߔࠆ߆࡮⚿ᨐࠍߤ߁⹏ଔߔࠆ߆㧙㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦50㧙57㧚
11㧕 ਃ㡞ᑝ❥㧚ࡏ࠷࡝࠿ࠬਛᲥߩ․ᓽߣኻᔕ㧦ᷰㄝᴦ㓶✬㧚㘩ਛᲥᬌᩏ࡮⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦20㧙21㧚
12㧕 ੹੗◊ᔒ㧚ᇚੱ⑼∔ᖚ㧦ሶች૕≸㧦␹ፒ⑲㓁✬㧚⋴⼔ߩߚ߼ߩᦨᣂකቇ⻠ᐳ㧔╙ 2 㧕16 Ꮞ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦253㧙261㧚
13㧕 ੹੗◊ᔒ㧚ᇚੱ⑼∔ᖚ㧦ሶች⡺⣲㧦␹ፒ⑲㓁✬㧚⋴⼔ߩߚ߼ߩᦨᣂකቇ⻠ᐳ㧔╙ 2 㧕16 Ꮞ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦261㧙269㧚
14㧕 ੹੗◊ᔒ㧚ࠣ࡞ࠦࠦ࡞࠴ࠦࠗ࠼ᛩਈᴺ㧦ᣣᧄ↢ᱺකቇળ✬㧚ᣂߒ޿↢ᱺක≮ᛛⴚߩࠟࠗ࠼࡜ࠗࡦ ╙ 3 㧘᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦184㧙187㧚
15㧕 ₹⥢ノᒾ㧘⮮ᧄᰴ⦟㧚ᦨᣂ࡮ᗵᨴ∝ᴦ≮ᜰ㊎㧙6㧚↥ᇚੱ⑼㧙2008 ᐕᡷ⸓ 㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧
2008 ᐕ㧦178㧙188.
16㧕 ੹੗◊ᔒ㧚ක⠪߇ߔߔ߼ࠆኾ㐷∛㒮㧙᧲ᶏ (ᗲ⍮࡮ጘ㒂࡮ਃ㊀࡮㕒ጟ)㧙㧘␹ᄹᎹ㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦
324㧙324㧚㧙㧙⪺ᦠ㧔᰷ᢥ㧕1㧕 Fujimoto J, Alam SM, Jahan I, Sun W, Sakaguchi H, Toyoki H, Sato E, Tamaya T. Role ofimmunohistochemical Expression of ETS-1 Factor in Ovarian Carcinoma. In: Hayat MA, ed.
Immunohistochemistry of in situ Hybridization of Human Carcinomas. St. Louis: Academic Press;
2006:473-477.
2㧕 Imai A, Sugiyama M, Takahashi S, Furui T, Tamaya T. Role of membrane-associated serine/threonine
phosphatase in ovarian cancer cell survival: evidence for minor role of apoptosis in
gonadotropin-releasing hormone’s antiproliferative signaling. In: Bardos A P, ed. Ovarian Cancer: New
Research (E). New York: Nova Science Publishers; 2006:213-228.
3㧕 Furui T, Imai A. Testosterone level in pregnancy and gestational hyperandrogenemia-induced preterm
labor. Current Trends in Endocrinology, pt 2. India: Research Trends; 2006:15-18.
4㧕 Fujimoto J, Sakaguchi H, Toyoki H, Sato E, Jahan I, Alam SM, Tamaya T. Complicated angiogenesis
in uterine endometrial cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research Signpost;
2007:193-203.
5㧕 Fujimoto J, Alam SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Estrogen-related receptor ingynecological cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research Signpost;
2007:205-209.
6㧕 Sakaguchi H, Fujimoto J, Tamaya T. Expression of estrogen receptor  in estrogen-related
gynecological cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research Signpost;
2007:211-221.
7㧕 Sakaguchi H, Fujimoto J, Sun W, Tamaya T. Clinical Implications of Steroid Receptor Coactivators in
Estrogen-Related Gynecological Cancers. In: Fujimoto J, ed. Reproductive Oncology. Kerala: Research
Signpost; 2007:223-233.
8㧕 Fujimoto J, Sakaguchi H, Toyoki H, Jahan I, Alam SM, Sato E, Tamaya T. Novel gentle therapeutic
trends for patients of uterine cervical cancer. In: Hector T, ed. Trends in Cervical Cancer. New York:
Nova Science; 2007:89-96.
✚⺑㧔๺ᢥ㧕
1㧕 ⮮ᧄᰴ⦟㧚ࠛࠬ࠻ࡠࠥࡦ㧘ࡊࡠࠥࠬ࠴ࡦߣ߇ࠎ㧘ᕈᏅߣක≮ 2006 ᐕ㧧3 Ꮞ㧧65㧙70㧚
2㧕 ₹⥢ノᒾ㧚ᅚᕈߩ⣶∩ߣߘߩኻ╷㧙↥ᇚੱ⑼ߣ⣶∩㧙㧘↥ᇚᴦ≮ 2006 ᐕ㧧92 Ꮞ㧦103㧙108㧚
3㧕 ₹⥢ノᒾ㧚ಽሶ⢄⤳∛ቇ㧙ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߣಽሶ∛ᘒ↢ℂቇ㧙㧘ᣣᧄ⥃ῼ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦
271㧙275㧚
4㧕 ₹⥢ノᒾ㧚ᇚੱ⑼ࠟࡦߣṽᣇ㧘ṽᣇߣᦨᣂᴦ≮ 2006 ᐕ㧧15 Ꮞ㧦33㧙39㧚
5㧕 ₹⥢ノᒾ㧚ᕈᏅߦ߅ߌࠆࠛࠬ࠻ࡠࠥࡦ૞↪ᯏᐨࠃࠅߺࠆᶖൻེ∔ᖚ㧘↥ᇚᴦ≮ 2006 ᐕ㧧92 Ꮞ㧦437㧙444.
6㧕 ₹⥢ノᒾ㧚ࠛࠬ࠻ࡠࠥࡦߣ↢ᱺ↢ℂ㧘⥃ᐥಽሶౝಽᴲቇ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦355㧙360㧚
7㧕 ₹⥢ノᒾ㧚ࡊࡠࠥࠬ࠹ࡠࡦߣ↢ᱺ↢ℂ㧘⥃ᐥಽሶౝಽᴲቇ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦434㧙439㧚
8㧕 ⮮ᧄᰴ⦟㧚᛫ࡊࡠࠥࠬ࠹ࡠࡦ೷ߩ⥃ᐥᔕ↪㧘⥃ᐥಽሶౝಽᴲቇ 2006 ᐕ㧧64 Ꮞ(Ⴧೀ)㧦447㧙451㧚
9㧕 ₹⥢ノᒾ㧚࡜ࠗࡈࠨࠗࠢ࡞ߦ߅ߌࠆᅚᕈߩᔃり∝㧙ᕈࠬ࠹ࡠࠗ࠼ߣߩ㑐ଥߦ߅޿ߡ㧙㧘ᅚᕈᔃり⹹ 2006
ᐕ㧧11 Ꮞ㧦20㧙23㧚
10㧕 ₹⥢ノᒾ㧚ᯏ⢻ᕈෆᎽ⣲≌㧘ᣣᧄ⥃ῼ ᣂ㗔ၞ೎∝୥⟲ࠪ࡝࡯࠭ 2006 ᐕ㧧2 Ꮞ(Ⴧೀ)㧦361㧙365㧚
11㧕 ₹⥢ノᒾ㧚ࡎ࡞ࡕࡦߣᇚੱ⑼⣲≌㧙੍㒐කቇ߅ࠃ߮ᴦ≮කቇߩ஥㕙ࠃࠅ㧙㧘ᣣᧄ↥⑼ᇚੱ⑼ቇળ㔀⹹
2006 ᐕ㧧58 Ꮞ㧦1279㧙1287㧚
12㧕 ₹⥢ノᒾ㧚ࠞࡦࠫ࠳∝ߩ⸻ᢿߣᴦ≮㧘ⴊᶧ࡮⣲≌⑼ 2006 ᐕ㧧53 Ꮞ㧦295㧙301㧚
13㧕 ₹⥢ノᒾ㧚ࡎ࡞ࡕࡦߣᇚੱ⑼⣲≌㧘↥ᇚੱ⑼ᴦ≮ 2006 ᐕ㧧10 Ꮞ㧦386㧙391㧚
14㧕 ₹⥢ノᒾ㧚↵ᅚߦ߅ߌࠆࠕࡦ࠼ࡠࠥࡦਇో∝୥⟲㧙ࠕࡦ࠼ࡠࠥࡦ⵬లߣ໧㗴ὐ㧙㧘↥ᇚੱ⑼ᴦ≮ 2006
ᐕ㧧11 Ꮞ㧦598㧙605㧚
15㧕 ₹⥢ノᒾ㧚࡜ࠗࡈࠬ࠹࡯ࠫߣᅚᕈࡎ࡞ࡕࡦ㧙ᅚᕈߩ࡜ࠗࡈࠬ࠹࡯ࠫߦ߅ߌࠆᕈᏅߩ಴⃻ߣࠛࠬ࠻ࡠࠥࡦ㧙㧘කቇߩ޽ࠁߺ 2006 ᐕ㧧5 Ꮞ㧦321㧙326㧚
16㧕 ⮮ᧄᰴ⦟㧚ሶችౝ⤑≸ߣࠛࠬ࠻ࡠࠥࡦฃኈ૕㧘Hormone Frontier in Gynecology ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧘
2006 ᐕ㧧13 Ꮞ㧦23㧙29㧚
17㧕 ₹⥢ノᒾ㧚ࡎ࡞ࡕࡦߣᇚੱ⑼⣲≌㧙੹㧘ᡷ߼ߡ“ሶች߇ࠎ”ࠍ⠨߃ࠆ㧙㧘↥ᇚੱ⑼ᴦ≮ 2006 ᐕ㧧12 Ꮞ㧦617
㧙621㧚
18㧕 ₹⥢ノᒾ㧚ࠛࡦ࠼ࠢ࡝ࡁࡄ࠴࡯ߣߒߡߩሶችౝ⤑≸㧘ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠ 2006 ᐕ㧧13 Ꮞ㧦11㧙16㧚
19㧕 ₹⥢ノᒾ㧚ࡇ࡞ߣ߇ࠎ㧘⥃ᐥᇚੱ⑼↥⑼ 2006 ᐕ㧧12 Ꮞ㧦1501㧙1505㧚
20㧕 ↰ਛ㚅߅㉿㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧚ࡃࠢ࠹ࡠࠗ࠺ࠬዻ㧘ᗵᨴߣ᛫⩶⮎ 2006 ᐕ㧧9 Ꮞ㧦 2㧙4㧚
21㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᓸ↢‛ቇ⷗࿾߆ࠄߺߚ᛫⩶⮎ߩㆡᱜ૶↪ᴺߣ⮎೷⠴ᕈ⩶೙ᓮߩߚ߼ߩ
ᚢ⇛㧘࡝࠙ࡑ࠴⑼ 2006 ᐕ㧧35 Ꮞ㧦63㧙68㧚
22㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚MRSA ᗵᨴ∝ߦ߅ߌࠆ࡝ࡀ࠱࡝࠼ߩ᦭ലᕈ㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦
83㧙84㧚
23㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᵈᗧߔߴ߈ᗵᨴ∝ߣኻ╷ 5㧚↥ᇚੱ⑼㗔ၞߩᗵᨴ∝ߣኻ╷㧘ᢇᕆකቇ
2006 ᐕ㧧30 Ꮞ㧦216㧙220㧚
24㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ህ᳇ᕈ⩶ߦࠃࠆ࠮ࡊࠪࠬߪሽ࿷ߔࠆ߆㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦521
㧙524㧚

㧙㧙

25㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚๟↥ᦼߦ߅ߌࠆ B ⟲ㅪ㎮⃿⩶ᗵᨴ∝ߩ੍㒐ߦ㑐ߔࠆ CDC ߩᡷ⸓ࠟࠗ
࠼࡜ࠗࡦ㧘ᣂߒߊ⊒⴫޽ࠆ޿ߪᡷ⸓ߐࠇߚᗵᨴ∝ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗࡦ㧘ൻ≮ߩ㗔ၞ 2006 ᐕ㧧22 Ꮞ(Ⴧೀ)㧦134㧙137㧚
26㧕 ਃ㡞ᑝ❥㧚↥ᇚੱ⑼㗔ၞߦ߅ߌࠆ๟ⴚᦼߩᗵᨴ೙ᓮ㧘PHYSICIAN’S THERAPY MANUAL 2006 ᐕ㧧5Ꮞ㧦1㧙2㧚
27㧕 ਃ㡞ᑝ❥㧚ࠃߊㆣㆄߔࠆᗵᨴ∝㧘⃟ߒ޿߇⍮ߞߡ߅߈ߚ޿ᗵᨴ∝㧘ᇚੱ⑼ INFECTION FRONT 2006
ᐕ㧧7 Ꮞ㧦12㧙13㧚
28㧕 ਃ㡞ᑝ❥㧚․ᱶ∛ᘒߦ߅ߌࠆ᛫⩶ൻቇ≮ᴺ ᅧᇚ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦2208㧙2213㧚
29㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᣂߒ޿⥃ᐥᬌᩏ࡮ᧂ᧪ߩ⥃ᐥᬌᩏ ฦ⺰ 5㧚ᗵᨴ∝ᬌᩏ ࠢ࡜ࡒࠫࠕ࡮
࠻࡜ࠦࡑ࠴ࠬ/ᶷ⩶ᩭ㉄หᤨჇ᏷หቯᬌᩏ㧘ᬌᩏߣᛛⴚ 2006 ᐕ㧧34 Ꮞ㧦1293㧙1294㧚
30㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧘₹⥢ノᒾ㧚↢ᱺකቇߦ߅ߌࠆ࡝࠱ࡎࠬࡈࠔ࠴ࠫࡦ㉄(LPA)ߩᓎഀ㧘᧲ᶏ↥⑼ᇚੱ⑼ቇ
ળ㔀⹹ 2007 ᐕ㧧43 Ꮞ㧦1㧙7㧚
31㧕 ਤ⠀ᙗม㧘ዊ㊁ᧁ੩ሶ㧘ὖ㔕㧘໊ᩉᨋ㧘ㅪჇᨋ㧘₹⥢ノᒾ㧚ሶችౝ⤑≸⚦⢩ߦኻߔࠆචోᄢ⵬ḡ㧘྾‛ḡߩ૞↪ߣ ER ⊒⃻ߣߩ㑐ㅪ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2007 ᐕ㧧24 Ꮞ㧦39㧙42㧚
32㧕 ᑝἑ⃍ሶ㧘㐳የ⢒ሶ㧘ᷡ᳓ൎ㧘₹⥢ノᒾ㧚ᅚᕈᄖ᧪ㅢ㒮ਛߦᅧᆼߦ⥋ߞߚ 10 ∝଀ߦ߅ߌࠆṽᣇߩലᨐ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2007 ᐕ㧧24 Ꮞ㧦55㧙58㧚
33㧕 ૒⮮ᵏ᣽㧘ᚑᎹᏗ㧘↰਄ᘮሶ㧘ᮮጊᐽብ㧘ጊ↰ᣂዏ㧚㗡∩ࠍਥ⸷ߣߔࠆᅚᕈᖚ⠪ߦኻߔࠆᒰᏫ ྾ㅒട๓⨠⪪↢ᆗḡߩ QOL ᡷༀലᨐ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2007 ᐕ㧧24 Ꮞ㧦102㧙104㧚
34㧕 ⮮ᧄᰴ⦟㧚≸ᴦ≮ᓟߩࡎ࡞ࡕࡦ⵬ల≮ᴺ(HRT)㧘↥⑼ߣᇚੱ⑼ 2007 ᐕ㧧74 Ꮞ㧦1486㧙1490㧚
35㧕 ੹੗◊ᔒ㧚ጘ㒂࿾඙ߦ߅ߌࠆ๟↥ᦼක≮ࠍ⠨߃ࠆ(Უ૕៝ㅍߣ㓸⚂ൻ)㧘޿ߜ޿ 2007 ᐕ㧧49 Ꮞ㧦18㧙21㧚
36㧕 ੹੗◊ᔒ㧚ጘ㒂⋵↥⑼ᇚੱ⑼ක≮ߩ໧㗴ὐ(1)㧘޿ߜ޿ 2007 ᐕ㧧50 Ꮞ㧦23㧙26㧚
37㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧚↥ᇚੱ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧨ή᦬⚻㧪㧦⥃ᐥᇚੱ⑼↥⑼ 2007 ᐕ㧧61 Ꮞ
4 ภ(೎ౠ)㧦403㧙413㧚
38㧕 ੹੗◊ᔒ㧚Უ૕៝ㅍᢇᕆࡑ࠾ࡘࠕ࡞㧙↥⑼ක߆ࠄߩⷞὐ㧙㧘ጘ㒂⋵කᏧળႎ 2008 ᐕ㧧676 ภ㧦18㧙20㧚
39㧕 ⮮ᧄᰴ⦟㧚ሶችౝ⤑∝ߩჇᱺㅴዷߦ㑐ࠊࠆⴊ▤ᣂ↢ߣᕈࠬ࠹ࡠࠗ࠼㧘↥ᇚੱ⑼ߩታ㓙 2008 ᐕ㧧57 Ꮞ 2
ภ㧦227㧙232㧚✚⺑㧔᰷ᢥ㧕
1㧕 Furui T, Imai A . Testosterone level in pregnancy and gestational hyperandogenemia-induced preterm
labor. Curr Trends Endocrinol. 2006;2:15-18.
2㧕 Imai A, Furui T. Chemotherapy-induced female infertility and protective action of
gonadotropin-releasing hormone analogues. J Obstet Gynaecol. 2007;27:20-24.
3㧕 Imai A, Furui T, Yamamoto A. Preservation of female fertility during cancer treatment. Reprod Med
Biol. 2008;7:17-27.
4㧕 Fujimoto J. Novel therapeutic strategy for uterine endometrial cancers. Int J Clin Oncol.
2008;5:411-415.
5㧕 Imai A, Furui T, Hatano Y, Suzuki M, Suzuki N, Goshima S. Leiomyoma and rhabdomyoma of thevagina Vaginal myoma. J Obstet Gynaecol. 2008;28:563-566.
ේ⪺㧔๺ᢥ㧕
1㧕 ਃ㡞ᑝ❥㧘₹⥢ノᒾ㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ࠢ࡜ࡒࠫࠕຜ㗡ᗵᨴߩ⃻⁁ߣᴦ≮ᣇᴺߦ㑐ߔࠆᬌ⸛㧘Jpn J
Antibiot 2006 ᐕ㧧59 Ꮞ㧦35㧙40㧚
2㧕 㜞ᯅ㓶৻㇢㧘ੑችᦸ␽㧘Ꮉ㠈Ꮢ㇢㧘ጤ၂㊀♿㧘₹⥢ノᒾ㧚ጘ㒂⋵ߩ↥ᇚੱ⑼ߦ߅ߌࠆⴊᩖ∝⊒∝ߩ∉ቇ⊛⺞ᩏ㨪੍㒐ߩὑߩᣂࠟࠗ࠼࡜ࠗࡦዉ౉એ೨ߩ⊒∝₸㨪㧘᧲ᶏ↥⑼ᇚੱ⑼ቇળ⹹ 2006 ᐕ㧧42 Ꮞ(Ⴧೀ)㧦61
㧙65㧚
3㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚⠴ᕈൻ㒐ᱛߩߚ߼ߩ᛫⩶⮎૶↪ ᛫⩶⮎ࠨࠗࠢ࡝ࡦࠣ≮ᴺ㧘᦬ೀ⮎੐
2006 ᐕ㧧48 Ꮞ㧦1521㧙1527㧚
4㧕 ਃ㡞ᑝ❥㧚PK/PD ߦၮߠ޿ߚ᛫⩶⮎ߩㆡᱜߥᛩਈ⸳⸘㧘PHYSICIAN’S THERAPY MANUAL 2006 ᐕ㧧
5 Ꮞ㧦9㧙10㧚
5㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘ጊጟ৻ᷡ㧘ਃベ߹ࠁߺ㧘Ỉ᧛ᴦ᮸㧘᧻Ꮉᵗሶ㧘૒ષᶈ๺㧘ᵻ㊁⵨ሶ㧘⍹ㇹầ⟤㧘ᧃ᧻ኡਯ㧘᧻ේ⨃ⷙ㧘ᯅᷰᒾౖ㧘ኹ࿾⌀ᑿ㧘ች㉿ᱜ༹㧘ᏒᎹᖝม㧚ጘ㒂⋵ਅߦ߅޿ߡಽ㔌ߐࠇߚ✛⤥⩶ߦ㑐ߔࠆ∉ቇ⊛ᬌ⸛ 㨪2004 ᐕ㨪㧘Jpn J Antibiot 2006 ᐕ㧧59 Ꮞ㧦355㧙363㧚
6㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘₹⥢ノᒾ㧘๺ᴰቁᴦ㧚PK/PD ℂ⺰ߦၮߠ޿ߚࠟ࠴ࡈࡠࠠࠨࠪࡦߩᛩਈ
ᣇᴺߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘Jpn J Antibiot 2006 ᐕ㧧59 Ꮞ㧦364㧙372㧚
7㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ጘ㒂⋵ਅߢ⥃ᐥಽ㔌ߐࠇߚ✛⤥⩶ 250 ᩣߦኻߔࠆࠞ࡞ࡃࡍࡀࡓ♽(ࡔࡠࡍࡀࡓ㧘࠼࡝ࡍࡀࡓ)ߩ᛫⩶ᵴᕈߣ Monte Carlo Simulation ࠍ↪޿ߚࡔࡠࡍࡀࡓ߅ࠃ߮࠼࡝ࡍࡀࡓߩ᦭ല
ᕈ⹏ଔ㧘╙ 40 ࿁✛⤥⩶ᗵᨴ∝⎇ⓥળ⻠Ṷ⸥㍳ 2006 ᐕ㧧40 Ꮞ㧦88㧙91㧚
8㧕 ਤ⠀ᙗม㧘໊ᩉᨋ㧘ὖ㔕㧘ዊ㊁ᧁ੩ሶ㧘₹⥢ノᒾ㧚ሶችౝ⤑⊒≸ߦኻߔࠆ⵬ਛḷ᳇ḡߩᛥ೙૞↪㧘↥ᇚṽᣇ⎇ⓥ 2006 ᐕ㧧23 Ꮞ㧦54㧙57㧚
9㧕 ਤ⠀ᙗม㧘ዊ㊁ᧁ੩ሶ㧘ὖ㔕㧘₹⥢ノᒾ㧚਄⊹ᕈෆᎽ≸ᴦ≮ߦ߅ߌࠆචోᄢ⵬ḡߩ㐳ᦼ੍ᓟߦኻߔࠆᓇ㗀ߣ CD34 ⊒⃻ߣߩ㑐ㅪ㧘ṽᣇ⎇ⓥߩ޽ࠁߺ 2008 ᐕ㧧25 Ꮞ㧦35㧙37㧚
10㧕 ጊ↰ᣂዏ㧘ዊဈ੗ᕺሶ㧘ᣣᳯ੗㚅ઍሶ㧘᳓㊁ᥓሶ㧘ዊ㊁ᧁ੩ሶ㧘↰਄ᘮሶ㧘૒⮮ᵏ᣽㧘ᮮጊᐽብ㧘੹੗◊ᔒ㧚ᅧᆼ 27 ㅳߢሶች⎕ⵚߦ⥋ߞߚ೨⟎≹⌕⢝⋚ߩ 1 ଀㧘⥃ᐥᇚੱ⑼↥⑼ 2008 ᐕ㧧62 Ꮞ㧦875㧙878㧚㧙㧙ේ⪺㧔᰷ᢥ㧕1㧕 Fujimoto J, Toyoki H, Sakaguchi H, Jahan I, Alam SM, Tamaya T. Clinical implications of expressionof cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol Rep. 2006;15:21-25.
2㧕 Imai A, Sugiyama M, Furui T, Tamaya T. Gi protein-mediated translocation of serine/threonine
phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response togonadotropin-releasing hormone antagonist cetrorelix. J Obstet Gynaecol. 2006;26:37-41.
3㧕 Tang LL, Yokoyama Y, Wan X, Iwagaki S, Niwa K, Tamaya T. PTEN sensitizes epidermal growth
factor-mediated proliferation in endometrial carcinoma cells. Oncol Rep. 2006;15:855-859.
4㧕 Lian Z, Niwa K, Onogi K, Mori H, Harrigan RC, Tamaya T. Anti-tumor effects of herbal medicines on
endometrial carcinomas via estrogen receptor-alpha-related mechanism. Oncol Rep.
2006;15:1133-1136.
5㧕 Imai A, Onogi K, Sugiyama Y. Omental liposarcoma; a rare complication in neurofibromatosis type 1. J
Obstet Gynaecol. 2006;26:381-382.
6㧕 Imai A, Shinohara A, Narikawa N. Successful perinatal outcome following maternal comatose state. J
Obstet Gynaecol. 2006;26:469-470.
7㧕 Fujimoto J, Alam SM, Jahan I, Sato E, Toyoki H, Bao LH, Sakaguchi H, Tamaya T. Plausible linkage
of hypoxia inducible factor-1alpha in uterine cervical cancers. Cancer Sci. 2006;97:861-867.
8㧕 Matsubara K, Mikamo H, Numa M, Yamamoto G, Kusano H, Takamine Y. Three fatal cases of invasive
serotype VI group B streptococcal infection. J Infect. 2006;53:139-142.
9㧕 Nonaka M, Toyoki H, Imai A. Cesarean section scar pregnancy may be the cause of serious
hemorrhage after first-trimester abortion by dilatation and curettage. Int J Gynaecol Obstet.
2006;95:50-51.
10㧕 Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Jahan I, Alam SM, TamayaT. Expression of
cyclooxygenase-2 related to angiogenesis in uterine cervical cancers. J Biomed Sci. 2006;13:825-832.
11㧕 Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct Protection by a Gonadotropin-Releasing
Hormone Analog from Doxorubicin-Induced Granulosa Cell Damage. Gynecol Obstet Invest.
2006;63:102-106.
12㧕 Tanaka K, Mikamo H, Nakao K, Watanabe K. In vitro antianaerobic activity of X-619, a new des-fluoro(6) quinolone. Antimicrob. Agents Chemother. 2006;50:3908-3913.
13㧕 Onogi K, Niwa K, Tang L, Yun W, Mori H, Tamaya T. Inhibitory effects of Hochu-ekki-to on
endometrial carcinogenesis induced by N-methyl-N-nitrosourea and 17beta-estradiol in mice. Oncol
Rep. 2006;16:1343-1348.
14㧕 Sakaguchi H, Fujiomto J, Hong BL, Tamaya T. Clinical implications of osteopontin in metastatic
lesions of uterine cervical cancers. Cancer Lett. 2007;247:98-102.
15㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynaecol Obstet. 2007;96:49-50.
16㧕 Furui T, Imai A, Ohno T : Pre-term labour in cases with high maternal testosterone levels. J Obstet
Gynaecol. 2007;27:155-156.
17㧕 Imai A, Itoh N, Matsushi K. Direct extension of a sigmoid colon cancer to a uterine leiomyoma andadherent small intestine. Oncologie. 2007;9:252-253.
18㧕 Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing
hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest.
2007;63:102-106.
19㧕 Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Overexpression of ephrinB2 and EphB4 in tumor
advancement of uterine endometrial cancers. Ann Oncol. 2007;18:485-490.
20㧕 Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Expression of protease activatedreceptor-2 related to angiogenesis in tumor advancement of uterine endometrial cancers. Oncol Rep.
2007;17:345-350.
21㧕 Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic
marker in ovarian cancers. J Biomed Sci. 2007:14;373-381.
22㧕 Niwa K, Lian Z, Onogi K, Yun W, Tang L, Mori H, Tamaya T. Preventive effects of glycyrrhizin on
estrogen-related endometrial carcinogenesis in mice. Oncol Rep. 2007;17:617-622.
23㧕 Fujimoto J, Sato E, Alam SM, Jahan I, Toyoki H, Bao LH, Sakaguchi H, Tamaya T. Plausible linkage
of hypoxia inducible factor (HIF) in uterine endometrial cancers. Oncology-Basel. 2007;71:95-101.
24㧕 Wu Y, Niwa K, Onogi K, Tang L, Mori H, Tamaya T. Effects of selective estrogen receptor modulatorsand genistein on the expression of ERalpha/beta and COX-1/2 in ovarectomized mouse uteri. Eur J
Gynaecol Oncol. 2007;8:89-94.
25㧕 Niwa K, Hirose R, Mizuno T, Hirose Y, Tamaya T. Pseudomyxoma peritonei and mucinous pyometral
fluid arising from an ovarian borderline mucinous tumor (case report). Eur J Gynaecol Oncol.
2007;28:145-146.
26㧕 Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, Tamaya T. Expression of IP-10 related
to angiogenesis in uterine cervical cancers. Brit J Cancer. 2007;96:1735-1739.
27㧕 Sakaguchi H, Fujimoto J, Sun WS, Tamaya T. Clinical implications of steroid receptor coactivator㧙㧙

IF 1.597

IF 0.833
IF 1.597

IF 1.597
IF 0.833
IF 0.833
IF 3.165
IF 2.844

IF 1.144
IF 2.024

IF 1.157
IF 4.390

IF 1.597
IF 3.398
IF 1.144
IF 0.833
IF 1.724

IF 1.157
IF 4.875

IF 1.597
IF 2.024
IF 1.597
IF 2.444

IF 0.587

IF 0.587
IF 4.635

(SRC) -3 in uterine endometrial cancers. J Steroid Biochem Mol Biol. 2007;104:237-240.
28㧕 Fujimoto J, Alam SM, Jahan I, Sato E, Sakaguchi H, Tamaya T. Clinical implication of
estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol.
2007;104:301-304.
29㧕 Jahan I, Fujimoto J, Alam SM, Sato E, Sakaguchi H, Tamaya T. Role of protease activated receptor-2
in tumor advancement of ovarian cancers. Ann Oncol. 2007;18:1506-1512.
30㧕 Imai A, Toyoki H, Furui T. Electronic door interference mimicking distress in fetal monitoring. Int J
Gynaecol Obstet. 2007;99:60-61.
31㧕 Niwa K, Onogi K, Wu Y, Mori H, Tamaya T. Primary endodermal sinus tumor of the vulva in a 52-yearold woman with long-term survival: a cace report. Eur J Gynaec Oncol. 2007;28:506-508.
32㧕 Niwa K, Onogi K, Yun W, Hirose Y, Tamaya T. Primary lymphoma of the uterine corpus: An unusual
location for a common disease-case report. Eur J Gynaec Oncl. 2007;28:522-523.
33㧕 Imai A, Toyoki H, Furui T, Nagao N. Maternal small bowel volvulus hindered by prodromal labor.
Gynecol Surg. 2007;28:16-18.
34㧕 Imai A, Matsunami K, Takagi H. Preoperative value of CT angiography in the laparoscopic removal of
rudimentary uterine horn. Gynecol Surg. 2007;14:199-200.
35㧕 Furui T, Ohno T, Imai A. Preterm labor in cases with high testosterone condition. J Obstet Gynaecol.
2007;27:155-156.
36㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynecol Obstet. 2007;96:49-50.
37㧕 Niwa K, Onogi K, Wu Y, Mori H, Inoue Y, Tamaya T. Prognostic implications of cimetidine on advanced
serous ovarian carcinoma related to cyclooxygenase-2 expression. Mol Med Rep. 2008;1:119-122.
38㧕 Alam SM, Fujimoto J, Jahan I, Sato E, Tamaya T. Coexpression of EphB4 and ephrinB2 in tumour
advancement of ovarian cancers. Brit J Cancer. 2008;98:845-851.
39㧕 Sato E, Fujimoto J, Tamaya T. Expression of IP-10 related to angiogenesis in uterine endometrial
cancers. Oncology-Basel. 2008;73:246-251.
40㧕 Niwa K, Onogi K, Wu Y, Mori H, Harrigan R C, Tamaya T. Clinical implication of
medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study. Eur J Gynaecol
Oncol. 2008;29:252-255.
41㧕 Jahan I, Fujimoto J, Mahfuzul Alam S, Sato E, Tamaya T. Role of protease activated receptor-2 inlymph node metastasis of uterine cervical cancers. BMC Cancer. 2008;8:301-307.
42㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y. Carcinosarcoma of
the uterus. radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Reson Imaging. 2008;26:1446-1450.
43㧕 Maw MK, Fujimoto J, Tamaya T: Expression of inhibitor of DNA binding (ID)-1 protein as anangiogenic mediator in tumor advancement of uterine cervical cancers. Brit J Cancer.
2008;99:1557-1563.

IF 2.799

IF 2.799
IF 4.875
IF 1.144
IF 0.587
IF 0.587

IF 0.883
IF 1.144

IF 4.635
IF 2.444

IF 0.587
IF 2.709

IF 1.486

IF 4.6354㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀ᙗม㧘⎇ⓥಽᜂ⠪㧦₹⥢ノᒾ㧧ᐔᚑ 18 ᐕᐲ⽷࿅ᴺੱᣣᧄṽᣇකቇ⎇ⓥഥᚑ㊄㧦ṽᣇ⵾೷ߦࠃࠆォ⒖ᛥ೙૞↪ߣ㐳ᦼ੍ᓟ㧘ⴊ▤ᣂ↢࿃ሶ CD105㧘COX㧙2 ⊒⃻ߣߩ㑐ㅪ㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦ဈญ⧷᮸㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࠛࠬ࠻ࡠࠥࡦଐሽᕈᇚੱ⑼⣲≌ߦ߅ߌࠆォ౮࿃ሶߩ⊒⃻ߣߘߩ⥃ᐥ⊛ᗧ⟵㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,860 ජ౞(1,000㧦2,860 ජ౞)
3㧕 ੹੗◊ᔒ㧦⤑ฃኈ૕࡝ࠟࡦ࠼ߩ⚦⢩Ქᕈࠕ࠽ࡠࠣࠍ↪޿ߚ᛫≸ൻቇ≮ᴺߣࡔࠞ࠾࠭ࡓ㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ੹੗◊ᔒ㧦㇭਄Ꮢߦ߅ߌࠆ↥⑼ක≮ߩ⃻⁁ߣᡷༀ㧧ᐔᚑ 20 ᐕᐲ㧧2,000 ජ౞㧦㇭਄Ꮢ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ੹੗◊ᔒ㧦
1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↢ᱺකቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↢ᱺౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᇚੱ⑼⣲≮ቇળ⹏⼏ຬ(㨪⃻࿷)⮮ᧄᰴ⦟㧦1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᇚੱ⑼ᖡᕈ⣲≌⑼ቇ≮ᴺ⎇ⓥᯏ᭴ળᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬ 31 ᣣ㨪⃻࿷)
4㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄࠬ࠹ࡠࠗ࠼ࡎ࡞ࡕࡦቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)દ⮮⋥᮸㧦1㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᲣᕈⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)ਤ⠀ᙗม㧦1㧕 ᣣᧄᇚੱ⑼⣲≌ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)ฎ੗ㄖ㇢㧦1㧕 ᣣᧄ↢ᱺකቇળਛㇱᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↥ᇚੱ⑼੃≸ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
⮮ᧄᰴ⦟㧦
1㧕 International Journal of Clinical Oncology: Editorial Board(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳₹⥢ノᒾ㧦
1㧕 ╙ 58 ࿁ᣣᧄ↥⑼ᇚੱ⑼ቇળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ߣࡦࡕ࡞ࡎޟ‬ᇚੱ⑼⣲≌㧙੍㒐කቇ෸߮ᴦ≮කቇߩ஥㕙ࠃࠅ㧙‫ޠ‬Ṷ⠪)
2㧕 ╙ 6 ࿁ਛㇱ᳇ಽ࡮ਇ቟㓚ኂ(ᐔᚑ 18 ᐕ 6 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ᕈࠬ࠹ࡠࠗ࠼ߣᅚᕈᔃり∝‫ޠ‬Ṷ⠪)
3㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘ળ㐳⻠Ṷ‫ޟ‬ሶች㗖≸ᚻⴚߩ▤ℂߦ߅ߌࠆឭ⸒ߣ
ߘߩᩮ᜚‫ޠ‬Ṷ⠪)ਃ㡞ᑝ❥㧦
1㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ህ᳇ᕈ⩶ᗵᨴ∝ᴦ≮ߩࠟࠗ࠼࡜ࠗࡦ‫ޠ‬Ṷ⠪)2㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘⑔ጟ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬᛫⩶⮎㑐ㅪਅ∯∝㧛⣺Ἳߩ⃻⁁ߣ⺖㗴㧙ᗵᨴ೙ᓮቇ߆ࠄߺߚൻቇ≮ᴺߩ޽ࠅᣇ㧙‫ޠ‬Ṷ⠪)3㧕 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (2006.04,
Nice, Symposium: The penetration of telithromycin in gynaecological tissues and activity in㧙㧙cervicitis patients; Ṷ⠪)4㧕 44th Annual Meeting Infectious Diseases Society of America (2006.10, Toronto, Symposium:
Mycoplasma genitalium in Japanese patients with uterine cervicitis; Ṷ⠪)੹੗◊ᔒ㧦1㧕 ╙ 1 ࿁᧲੩੃߇ࠎࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᅚᕈࡎ࡞ࡕࡦߣ੃߇ࠎ Q&A‫ޠ‬Ṷ⠪)
2㧕 ╙ 59 ࿁ᣣᧄ↥⑼ᇚੱ⑼ቇળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 4 ᦬㧘੩ㇺ㧘ᢎ⢒⻠Ṷ‫ޟ‬ෆᎽ⣲≌‫ޠ‬ᐳ㐳)
3㧕 ╙ 8 ࿁↢ᱺකቇ࡮↢‛ቇ⎇ⓥળࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ൻቇ≮ᴺਛߩᕈ⣼଻⼔‫ޠ‬Ṷ⠪)⮮ᧄᰴ⦟㧦
1㧕 17th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology(2006.05, Seefeld, Symposium: Estrogen-related receptor (ERR) expression in ovarian cancers;Ṷ⠪)2㧕 The 5th International Symposium on Cancer Research and Therapy (2006.02, Tokyo,Symposium: Novel therapeutic strategy for hormone-dependent endometrial cancers; Ṷ⠪)3㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶች૕≸ߦ߅ߌࠆⴊ▤ᣂ↢߆ࠄߺߚ੍ᓟ࿃ሶ‫ޠ‬Ṷ⠪)
4㧕 ╙ 80 ࿁ᣣᧄౝಽᴲቇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶችౝ⤑ߦ߅ߌࠆⴊ▤ᣂ↢ߣෆᎽࡎ࡞ࡕࡦ‫ޠ‬Ṷ⠪)
5㧕 ╙ 9 ࿁ࡎ࡞ࡕࡦߣ≸⎇ⓥળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶችౝ⤑≸ߦ߅ߌࠆࡎ࡞ࡕࡦଐ
ሽᕈ༚ᄬߣⴊ▤ᣂ↢‫ޠ‬Ṷ⠪)6㧕 18th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology(2008.09, Seefeld, Clinical implication of estrogen-related receptor (ERR) expression in uterine
endometrial cancers; Ṷ⠪)7㧕 8th International Conference of Anticancer Research (2008.10, Kos, Special lecture, Novel
strategy of anti-angiogenic therapy for uterine cervical cancers; Ṷ⠪)8㧕 The 6th International Symposium on Cancer Research and Therapy (2008.11, Tokyo,
Symposium, Anti-vasculr endothelial growth factor (VEGF) therapeutic strategy for
gynecological cancers; Ṷ⠪)ਤ⠀ᙗม㧦1㧕 ╙ 7 ࿁ࡎ࡞ࡕࡦߣ≸⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘⟲㚍㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᬀ‛ࠛࠬ࠻ࡠࠥࡦߣሶች૕≸‫ޠ‬Ṷ⠪)
2㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫⧯ޟ‬ᐕᕈሶችౝ⤑≸ߦኻߔࠆᅧሺ
᷷ሽᴦ≮ߣߘߩ outcome‫ޠ‬Ṷ⠪)
3㧕 ╙ 44 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶች૕≸ߦኻߔࠆㆬᛯ⊛ COX
㧙2 ೙ᓮ೷ߣ MEKinhibitor ߦࠃࠆ೙ᓮ૞↪ߣൻቇ੍㒐‫ޠ‬Ṷ⠪)ฎ੗ㄖ㇢㧦
1㧕 ╙ 16 ࿁⥃ᐥౝಽᴲઍ⻢ Update(ᐔᚑ 18 ᐕ 3 ᦬㧘㊄ᴛ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᅧᆼਛߩࠕࡦ࠼ࡠࠥࡦㆊ೾
∝‫ޠ‬Ṷ⠪)
૒⮮⧷ℂሶ㧦
1㧕 ╙ 28 ࿁ࠛࡦ࠼ࡔ࠻࡝ࠝ࡯ࠪࠬ⎇ⓥળ(ᐔᚑ 19 ᐕ 1 ᦬㧘๺᱌ጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ሶችౝ⤑∝ߦ߅ߌࠆⴊ▤ᣂ↢‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ੹੗◊ᔒ㧦
1㧕 ጘ㒂࿾ᣇⵙ್ᚲኾ㐷ᆔຬ(㨪ᐔᚑ 20 ᐕ 6 ᦬)
2㧕 ጘ㒂⋵․ቯਇᅧᴦ≮ഥᚑ੐ᬺᜰቯක≮ᯏ㑐ክᩏᆔຬ(ᐔᚑ 19 ᐕ 12 ᦬㨪⃻࿷)3㧕 ጘ㒂⋵๟↥ᦼක≮ද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵ᅧ↥ᇚ✕ᕆ៝ㅍㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵කᏧળᲣ૕଻⼔ᴺᜰቯකክᩏᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)ฎ੗ㄖ㇢㧦1㧕 ጘ㒂⋵․ቯਇᅧᴦ≮ഥᚑ੐ᬺᣉ⸳ክᩏຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)2㧕 ጘ㒂⋵ᅧ↥ᇚ✕ᕆ៝ㅍㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ਤ⠀ᙗม㧦㓸࿅ᬌ⸻ߦ߅ߌࠆሶችౝ⤑⚦⢩⸻ߦࠃࠆሶችౝ⤑∛ᄌߩᣧᦼ⊒⷗ߣ COX㧙2 ⊒⃻㧦╙ 33࿁ฬฎደ౏ⴐකቇ⎇ⓥᚲ 㓸࿅ᬌ⸻⎇ⓥ㐿⊒ഥᚑ㊄੤ઃႎ๔ᦠ(2006 ᐕ 3 ᦬)
2㧕 ਤ⠀ᙗม㧦ෆᎽ≸㧘ሶችౝ⤑⊒≸ߦኻߔࠆṽᣇ⵾೷ߩ૞↪ߣࠪࠣ࠽࡞વ㆐ߦ㑐ߔࠆ⎇ⓥ㧦ᣣᧄṽᣇකቇ⎇ⓥᚲ ᐔᚑ 17 ᐕᐲ⎇ⓥഥᚑߦ㑐ߔࠆႎ๔ᦠ(2007 ᐕ 1 ᦬)
11㧚ႎ㆏
1㧕 ੹੗◊ᔒ㧘₹⥢ノᒾ㧦ᚻⴚᢙߢࠊ߆ࠆ‫∛޿޿ޟ‬㒮‫ޠ‬㧙ᅚᕈߩ߇ࠎ㧙㧦ㅳ㑆ᦺᣣ(2006 ᐕ 12 ᦬ 15 ᣣ)
2㧕 ਤ⠀ᙗม㧦╙ 33 ࿁ฬฎደ౏ⴐකቇ⎇ⓥᚲ 㓸࿅ᬌ⸻⎇ⓥ㐿⊒ഥᚑ㊄⿅๒ᑼ㧦Ფᣣᣂ⡞(2006 ᐕ 3 ᦬
2 ᣣ)
3㧕 ੹੗◊ᔒ㧦ᚻⴚᢙߢࠊ߆ࠆ޿޿∛㒮(ో࿖㧒࿾ᣇ೎࡜ࡦࠠࡦࠣ)㧦ㅳೀᦺᣣ⥃ᤨჇೀภ(2007 ᐕ 3 ᦬ 5
ᣣ)4㧕 ੹੗◊ᔒ㧦⋵ౝ 6 ∛㒮 ↥⑼ 3 ∛㒮ߦ㓸⚂㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 4 ᣣ)㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
5㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮↥⑼㧘ᐕౝߢભᱛ‫ޟ‬ㄭ㓞ߦ∛㒮లታ‫ޠ‬
6㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮಴↥ኻᔕ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
7㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮޽ࠅᣇᆔຬળ㧦↥⑼ભᱛ㧘㓸⚂㧦Ფᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
8㧕 ੹੗◊ᔒ㧦3 ∛㒮߇↥⑼ભᱛ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
9㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ කᏧ߇್ᢿ ߚࠄ޿࿁ߒ㒐ᱛ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 19 ᣣ)
10㧕 ੹੗◊ᔒ㧦ක≮ߪ੹‫ޟ‬ᅧᇚฃߌ౉ࠇ࿎㔍 ᰴߩ៝ㅍవ‫ޠ‬㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 23 ᣣ)
11㧕 ੹੗◊ᔒ㧦߅↥ߩ቟ోߪ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 26 ᣣ)
12㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ㧘↥⑼ක߇್ᢿ㧦⋵ౝోၞߦ᜛ᄢ߳㧦ᦺᣣᣂ⡞(2007 ᐕ 11 ᦬ 23 ᣣ)
13㧕 ੹੗◊ᔒ㧦∛㒮ߩታജ(ᇚੱ⑼≸)㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬ 23 ᣣ)
14㧕 ੹੗◊ᔒ㧦⋵ౝᅧᇚ៝ㅍࠪࠬ࠹ࡓ㧦ጘ㒂ᣂ⡞(2007 ᐕ 12 ᦬ 25 ᣣ)
15㧕 ੹੗◊ᔒ㧦[07 ߉߰ࠍᝄࠅ㄰ࠆ]㧨11㧪ᅧᇚߩߚࠄ޿࿁ߒ໧㗴㧦ᦺᣣᣂ⡞(2007 ᐕ 12 ᦬ 28 ᣣ)
16㧕 ੹੗◊ᔒ㧦޿޿∛㒮 2008㧦ㅳೀᦺᣣ MOOK(2008 ᐕ 1 ᦬ 30 ᣣ)
17㧕 ੹੗◊ᔒ㧦ኾ㐷ක߇ផ⮈‫᧲ޟ‬ᶏ࡮↲ା⿧ߩኅᐸක‫ޠ‬25 ੱ㧦AERA2008 ᐕ 2 ᦬ 18 ᣣภ(2008 ᐕ 2 ᦬
18 ᣣ)㧦ጘ㒂࡜ࠫࠝ(2008 ᐕ 4 ᦬ 2 ᣣ)
18㧕 ੹੗◊ᔒ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯‫ޟ‬ೋ⚻(ೋầ)ߩㆃࠇ‫ޠ‬
19㧕 ੹੗◊ᔒ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯‫ޟ‬ዊఽᦼߩᕈེ಴ⴊ‫ޠ‬㧦ጘ㒂࡜ࠫࠝ(2008 ᐕ 4 ᦬ 25
ᣣ)20㧕 ੹੗◊ᔒ㧦๮ࠍߟߥߋ㧨ਇᅧᴦ≮ߩⓨ⊕࿾Ꮺ㧪㧦ጘ㒂ᣂ⡞(2008 ᐕ 5 ᦬ 9 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᒰೋߩ⋡ᮡߦㄭߠ߈ߟߟ޽ࠆ߇㧘ࡍ࡯ࠬ࠳࠙ࡦߩᗵ߇ߧߋ߃ߥ޿‫ޕ‬ᬺ❣ߢߪ‫ޟ‬ᢙ‫⋡ࠍޠ⾰ޟࠅࠃޠ‬ᜰߒߡ޿ࠆ߇㧘↥⑼ක≮ߩෂᯏ߇ต߫ࠇߡ޿ࠆᤨὐߢߪ‫ޟ‬น‫⹏ߣ߁ࠈ޽ߢޠ‬ଔߒߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡑࡦࡄࡢ࡯ߩਇ⿷߇ᦨᄢߩ໧㗴ὐߢ޽ࠆ‫ୃ⎇ޕ‬ක೙ᐲ߇ࠬ࠲࡯࠻ߒߡ 5 ᐕ⋡ࠍㄫ߃㧘ᐕ‫ޘ‬ᄢቇ㒮↢ߩ⏕଻߇㔍ߒߊߥߞߡ߈ߡ޿ࠆ‫ޕ‬Ⓧᭂ⊛ߥ␠ળੱᨒߩዉ౉߿ᄖ࿖ੱ⇐ቇ↢ߩฃߌ౉ࠇߦࠃߞߡ㧘⎇ୃකᄢቇ㒮↢ߩ࡞࡯࠻߇⏕┙ߢ߈ࠆ߹ߢਸ਼ࠅಾࠅߚ޿‫ޕ‬㧙㧙⢻₸⊛ߥ⎇ⓥᤨ㑆ߩ⏕଻߇಴᧪ࠆࠃ߁੹߹ߢએ਄ߦദജߒߚ޿‫ޕ‬੹ᓟߩዷᦸ⥃ᐥ⑼ߦ߅ߌࠆ⎇ⓥߪ㧘⥃ᐥߩ႐ߦㆶరߔࠆߎߣ߇೨ឭߢ޽ࠆ‫ߪߦ߼ߚߩߘޕ‬㧘⥃ᐥኅߣߒߡߩ⍮⼂࡮
ᛛ㊂ߦട߃ߡ㧘৻ቯߩ࡟ࡌ࡞ߩၮ␆⊛ߥ⍮⼂࡮ᚻᴺ߇ᔅⷐߢ޽ࠆ‫߽߆ߒޕ‬㧘ࠃࠅ㜞޿࡟ࡌ࡞ߩၮ⋚ߪ㧘ᔕ↪ߩ▸࿐ࠍࠃࠅ৻ጀᐢߍࠆߎߣ߇಴᧪ࠆ‫ޕ‬ᓥߞߡ㧘ᄢቇ㒮ᢎ⢒ߢߪ㧘࿖㓙⊛ߥ┹੎ജߩ޽ࠆ⎇ⓥ⠪ߩ㙃ᚑࠍ⋡ᜰߒߚ޿‫ޕ‬⎇ⓥ⚻㛎ߪ໧㗴⸃᳿ဳᕁ⠨ߩṑ㙃ߣߥࠅ㧘߭޿ߡߪ㜞ᐲኾ㐷⡯ᬺੱߣߒߡߩఝࠇߚ⥃ᐥකࠍ㙃ᚑߔࠆߎߣߦ❬߇ࠈ߁‫↢ޕ‬๮⃻⽎ߩᩮరߦㄼࠆၮ␆⊛࡮⁛ഃ⊛ߥ⎇ⓥࠍ⋡ᜰߒߚ޿‫ޕ‬ᓧࠄࠇߚᚑᨐ߿ၭࠊࠇߚ
ᕁ⠨ㆊ⒟࡮⍮⼂࡮ᚻᴺߪ㧘ක♽ᄢቇߩ૶๮ߢ޽ࠆ㔍ᴦᕈ∔ᖚߩ∛࿃⸃᣿߿ᣂߒ޿⸻ᢿ࡮ᴦ≮ᣇᴺߩ㐿⊒ߦ⋥⚿ߒ㧘⥃ᐥߩ⃻႐߳ߩㆶర߇ᦼᓙߢ߈ࠆ‫ޕ‬⹜㛎▤⊛ߥၮ␆⎇ⓥߩ⥃ᐥᔕ↪ߩߺߥࠄߕ㧘㓸Ⓧߒߚ∝଀ߩౣ⠨߿ઁಽ㊁ߣߩ౒ห⎇ⓥߦ߽Ⓧᭂ⊛ߦෳടߒߚ޿‫⎇ޕ‬ⓥߪᧂ⍮߳ߩ࠴ࡖ࡟ࡦࠫߢ޽ࠆߚ߼㧘ၮ␆⎇ⓥ࡮⥃ᐥ⎇ⓥࠍㅢߓߡᓥ᧪ߩᚻᛛ࡮ᚻᴺࠍ
ౣ⠨ߢ߈㧘ࠃࠅ቟ోߢ⏕ታߥ⸻ᢿ࡮ᴦ≮ࠍᏱߦㅊ᳞ߔࠆࠪࠬ࠹ࡓ૞ࠅࠍߒߚ޿‫ޕ‬㧙㧙㧔7㧕᡼኿✢කቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
1㧕 ⣻ㇱ⤳ེ㑐ㅪ㧦⣻ㇱ⤳ེᖡᕈ⣲≌ߩ CT㧘MRI ⸻ᢿࠍਥߥ⎇ⓥ⺖㗴ߣߒߡ޿ࠆ‫▤ⴊߦ․ޕ‬ㅧᓇਅ CT㧘
࠳ࠗ࠽ࡒ࠶ࠢㅧᓇ MRI㧘⿥Ᏹ⏛ᕈ㉄ൻ㋕ㅧᓇ MRI ࠍ↪޿ߚ⢄߇ࠎ㧘⤟߇ࠎߩᣧᦼ⸻ᢿ㧘ⴚ೨⸻ᢿߦ
㑐ߔࠆ⎇ⓥߥࠄ߮ߦ✕ᕆႧᩖⴚ㧘ⴚ೨Ⴇᩖⴚߥߤߩࠗࡦ࠲࡯ࡌࡦ࡚ࠪ࠽࡞࡜ࠫࠝࡠࠫ࡯㧔IVR㧕ߪ㧘․╩ߒߚᬺ❣ࠍ޽ߍߡ߈ߚ‫ߚ߹ޕ‬㧘ᶖൻ▤㑐ㅪߦ㑐ߒߡ߽ MDCT ࠍ㚟૶ߒߚ઒ᗐౝⷞ㏜ߦ㑐ߔࠆ⎇ⓥ߽㗅⺞ߦㆀⴕߒߡ޿ࠆ‫ޕ‬
2㧕 ਛᨔ␹⚻࡮ᩭකቇ㑐ㅪ㧦ోಽ㊁㧘⸻≮⑼ߣߩ౒หߩర㧘⣖ MRI㧘⣖ⴊᵹ SPECT ߥߤਛᨔ␹⚻ߩ↹௝⸻ᢿ࡮ᩭකቇߩᬌ⸛ߥߤࠍਥ૕ߣߒߡ߈ߚ‫ߡߞ߇ߚߒޕ‬㧘functional MRI ߦࠃࠆ⣖ᯏ⢻⹏ଔ㧘⣖ⴊᵹߩ SPECT ߩቯ㊂ൻߥߤ㑐ߔࠆ⎇ⓥߦ߽ขࠅ⚵ࠎߢ߈ߚ‫ޕ‬
3㧕 ᡼኿✢ᴦ≮㑐ㅪ㧦3 ᰴరᾖ኿ߩ૕ᐙㇱ⣲≌߳ߩᔕ↪㧘ቯ૏ᚻⴚ⊛᡼኿✢ᴦ≮ߩ⣖⣲≌߳ߩᔕ↪㧘᦭∩ᕈ㛽ォ⒖ߦኻߔࠆ⥋ㆡᾖ኿ᴺߩᬌ⸛߿๟ⴚᦼ⚵❱ౝᾖ኿ߩᬌ⸛ߥߤࠍⴕߞߡ߈ߚ‫ߚ߹ޕ‬㧘೨┙⣼≸ߦኻߔࠆዊ✢Ḯᴦ≮ߪ 2004 ᐕߦ᧲ᶏ࿾඙ߢೋ߼ߡᣉⴕߐࠇ㧘ߘߩᓟ⦟ᅢߥᚑ❣ࠍ෼߼ߡ޿ࠆ߇㧘CT㧘
MRI ࠍ↪޿⥋ㆡ✢㊂⹏ଔᴺࠍ㐿⊒ߒߡ߈ߚߎߣ߽㜞޿⹏ଔࠍฃߌߡ޿ࠆ‫ޕ‬4㧕 CAD 㑐ㅪ㧦ࠦࡦࡇࡘ࡯࠲ߦࠃࠆ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߢ޽ࠆࠦࡦࡇࡘ࡯࠲⸻ᢿᡰេࠪࠬ࠹ࡓ㧔CAD㧕ߪ㧘ౣ↢ಽሶ⛔ᓮቇ⻠ᐳ㧘⍮⢻ᖱႎࠗࡔ࡯ࠫಽ㊁ߩᓧᗧߣߔࠆ⎇ⓥಽ㊁ߢ޽ࠅ㧘ᘟᕈ⢄∔ᖚߩ⸻ᢿ㧘੃≸ߩ⸻ᢿ㧘⥃ᐥᔕ↪ߦ౒ห⎇ⓥࠍⴕ޿㧘㜞ᐲߥᚑᨐࠍ᜼ߍߡ߈ߚ‫੹ޕ‬ᓟ㧘ߐࠄߦઁࡕ࠳࡝࠹ࠖ㧘ઁ⤳ེ߳ߩᔕ↪ࠍᬌ⸛ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᤊ ඳᤘ
ಎᢎ᝼㧦
ᨋ ⌀਽
ಎᢎ᝼(૬છ)㧦 ౗᧻㓷ਯ
ㄭ⮮ᶈผ
⻠Ꮷ㧦
ᵻ㊁㓉ᒾ
⻠Ꮷ㧦
ട⮮ඳၮ
⥃ᐥ⻠Ꮷ㧦
੖ፉ ⡡
⥃ᐥ⻠Ꮷ㧦
ᄢቲ๺ඳ
⥃ᐥ⻠Ꮷ㧦
㥱⮮⡡ሶ
⥃ᐥ⻠Ꮷ㧦
ዊፉኼਭ
⥃ᐥ⻠Ꮷ㧦
ᵻ↰ୃᏒ
ഥᢎ㧦
᧖ፒ࿻ሶ
කຬ㧦
ᨷᬀ⵨੺
කຬ㧦
ᷰㆻᤐᄦ
කຬ㧦
’↰ᥓ⹷ሶ
කຬ㧦
↰ਛ⑲๺
කຬ㧦

Hiroaki Hoshi
Shinya Hayashi
Masayuki Kanematsu
Hiroshi Kondo
Takahiko Asano
Hiroki Kato
Satoshi Goshima
Kazuhiro Ohtakara
Akiko Saitoh
Toshihisa Kojima
Syuichi Asada
Keiko Sugisaki
Yusuke Tuge
Haruo Watanabe
Chiyoko Makita
Hidekazu Tanaka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧚౗᧻㓷ਯ✬㧘㜞ᯅ㓷჻⋙㧚MRI㧙᠟௝ߩ⠨߃ᣇߣ⸻ᢿቇ࡟ࡆࡘ࡯㧙 ╙ 3 Ꮞ ߎࠇߛߌ߅ߐ߃ࠇ߫ᄢਂᄦ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦50㧙68㧚
2㧕 ౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ⵨੺㧘㋈ᧁ↱㉿㧚⷏᧛ᕡᒾ㧘ጊ↰ ᗆ㧚દ⮮ඳᢅ✬㧚⢄⤳ߩἠᵹ㧔࠳ࠗ࠽ࡒ࠶ࠢ㧕MRI㧦Diffusion࡮perfusion MRI ৻ᦸජ㉿ 3 Ꮞ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦
144㧙153㧚3㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧚᪀㢬⦟ᐔ✬㧘࿯ደ৻ᵗ⋙㧚ߢ߈ࠆ㧍↹௝⸻ᢿ౉㐷ࠪ࡝࡯࠭⣻ㇱ࡮㛽⋚ ↹௝⸻ᢿߩߎߎ߇㐓೎ࡐࠗࡦ࠻ 3 Ꮞ㧘᧲੩㧦⟠࿯␠㧧2006 ᐕ㧦36㧙53㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Leonardou P, Pappas P, Kanematsu M. The role of US in the diagnosis of obstructive jaundice. Current
advances and perspectives. In: McMahon MJ, Filippou D, Skandalakis P, eds. Advances in obstructive
jaundice. Diagnosis and treatment. Athens: Paschalidis Medical Publications, Ltd; 2007:285-304.
2㧕 Onozuka M, Hirono Y, Tachibana A, Kim W, Ono Y, Sasaguri K, Kubo K, Niwa M, Kanematsu M,
Watanabe H. Interactions between chewing and brain activity in humans. In: Onozuka M, Yen CT, eds.
Novel trends in brain science. Brain imaging, learning and memery, stress and fear, and pain. Tokyo:
Springer; 2008:99-113.

㧙㧙✚⺑㧔๺ᢥ㧕1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘ᨷᬀ␭੺㧘ਃᅢ೑ᴦ㧘੗਄ᐽᒄ㧘⴩᢫⾫ม㧚਄⣻ㇱㅧᓇ MDCT ߩᦨㆡㅧᓇᴺ㧘INNERVISION 2006 ᐕ㧧21 Ꮞ㧦69㧙75㧚
2㧕 ᨷᬀ␭੺㧘౗᧻㓷ਯ㧘੖ፉ ⡡㧘ㄭ⮮ᶈผ㧘ട⮮ඳၮ㧘ᮮጊ㦖ੑ㇢㧘ਃᅢ೑ᴦ㧘᫃↰౏ඳ㧘੗਄ᐽᒄ㧘㜞੗శᴦ㧘⷏၂ᵗ৻㧘౷↰ᩕ৻㧘ᷡ᳓㆐ᴦ㧚⦟ᕈ⢄⣲≜߅ࠃ߮⣲≜᭽∛ᄌ㧘⥃ᐥ↹௝ 2006 ᐕ㧧22 Ꮞ㧦974
㧙984㧚
3㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘੖ፉ ⡡㧘ട⮮ඳၮ㧘ᨷᬀ⵨੺㧚⢄ᖡᕈ⣲≌ߩⴊᵹേᘒ⸻ᢿ̆േᵈ CT ࠍਛᔃߦ㧘Radiology Frontier 2006 ᐕ㧧9 Ꮞ㧦25㧙30㧚
4㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧚චੑᜰ⣺⣲≌ߩ 1 ଀㧘CLINICIAN 2007 ᐕ㧧55 Ꮞ㧦71㧙72㧘133㧙135㧚
5㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧚㜞⏛႐ MRI ᤨઍߦ߅ߌࠆ㗡㗖ㇱ㗔ၞߩ↹௝⸻ᢿ㧘ᣣᧄ⏛᳇౒㡆ቇળ⹹ 2007 ᐕ㧧
27 Ꮞ㧦166㧙176㧚
6㧕 ዊፉኼਭ㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧚੤ㅢᄖ்ᓟ㧘⁛ᱠߦߡ᧪㒮ߒߚ 60 ઍᅚᕈ㧘࡟ࠫ࠺ࡦ࠻ࡁ࡯࠻ 2007 ᐕ㧧
9 Ꮞ㧦1253㧙1254㧚
7㧕 ౗᧻㓷ਯ㧚ⓥᭂߩ਄⣻ㇱㅧᓇ CT ࠍ⋡ᜰߒߡ㧙ᵈ౉ᤨ㑆࿕ቯߣ Lean Body Weight ߢᦨㆡൻߒࠃ߁㧍㧘
Innervision 2007 ᐕ㧧22 Ꮞ㧦76㧙79㧚
8㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᨷᬀ␭੺㧘੖ፉ ⡡㧚⢄㗔ၞߩ↹௝⸻ᢿ㧙MDCT ߦࠃࠆ⢄ߩᦨᣂ⸻ᢿ㧙㧘⥃ᐥ↹௝
2007 ᐕ㧧23 Ꮞ㧦850㧙858㧚
9㧕 ౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ␭੺㧘ᷰㄝᤐᄦ㧘ਃᅢ೑ᴦ㧘੗਄ᐽᒄ㧘⴩᢫⾫ม㧘౷↰㓶ᐔ㧘੗ᚭ㕏ม㧚․㓸 ㅧᓇ CT ߦ߅ߌࠆ⥋ㆡㅧᓇ೷ᛩਈᴺࠍតࠆ㧙⢄Ớᨴᒝᐲߣ࡛࡯࠼㊂ߩ㑐ଥ Lean Body
Weight㧔㒰⢽⢌૕㊀㧕ߢ⠨߃ࠃ߁㧍㧘ᤋ௝ᖱႎࡔ࠺ࠖࠞ࡞ 2007 ᐕ㧧39 Ꮞ㧦684㧙688㧚
10㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘੖ፉ ⡡㧘ᨷᬀ␭੺㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘ᑝἑༀା㧚Misdiagnosis ߦቇ߱ⴚ೨⸻
ᢿ㧙☼ᶧ↥↢⢙▤⚦⢩≸㧙㧘ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦91㧙94㧚
11㧕 ᪀ේᅢㅧ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ␭੺㧘౗᧻㓷ਯ㧚․㓸 ⢄඙ၞᕈ 㗔ၞᕈ⇣Ᏹߩ↹௝ߣ∛ᘒ 㕒⣂ⴊㆶᵹ⎕ᩰߩ↹௝ߣ∛ᘒ㧘ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦167㧙172㧚
12㧕 ዊፉኼਭ㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧚ᄙᓀߥᚲ⷗ࠍ๒ߔࠆ Common disease ߩ↹௝ᚲ⷗⢄㧙⚦⢩≸㧘ᶏ✎⁁ⴊ▤⣲㧘ォ⒖ᕈ⢄≸㧘⤟≸㧘ᘟᕈ⤟Ἳ㧘⥃ᐥ↹௝ 2008 ᐕ㧧24㧦1226㧙1235㧚
13㧕 ട⮮ඳၮ㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ᨷᬀ⵨੺㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧚CAD ࠍ↪޿ߚ⢄⎬ᄌ∝ߩ MRI ⸻ᢿ㧘ᤋ௝ᖱႎ Medical 2008 ᐕ㧧40㧦470㧙473㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y, Kim MJ, Moriyama N. Imaging liver
metastases: Review and update. Eur J Radiol. 2006;58:217-228.
2㧕 Kanematsu M, Osada S, Amaoka N, Goshima S, Kondo H, Moriyama N. Expression of vascularendothelial growth factor in hepatocellular carcinoma and the surrounding liver: correlation with MR
imaging and angiographically assisted CT. Abdom Imaging. 2006;31:78-89.
ේ⪺㧔๺ᢥ㧕
1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧘ᬀ᧻ቁᐢ㧚Misdiagnosis ߦቇ߱㧘ⴚ೨⸻ᢿ㧙⢄⤥≌ࠍ⇼ߞߚ 1 ଀㧘ᶖൻེ↹௝ 2006
ᐕ㧧8 Ꮞ㧦5㧙8㧚
2㧕 Ꮉዥ வ㧘๟ ะᩕ㧘ᒛ ቇァ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚න
⚐ X ✢ CT ↹௝ߦ߅ߌࠆ⢄⤳ⴊ▤ߩ⥄௛᛽಴ᴺߩೋᦼᬌ⸛㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦141
㧙144㧚
3㧕 ᓼጊᵏᴦ㧘㐳↰⌀ੑ㧘૒‫⟵ᧁޘ‬ਯ㧘੹੗ ኼ㧘᧻੗ ⡡㧘ዊ᫪ల༹㧘㜞੗శᴦ㧘ౝᧁቁᢥ㧘੹੗ஜੑ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘౗᧻㓷ਯ㧘ᑝἑༀା㧚ⴚ೨ߦᐙ⚦⢩≸ߣߩ㐓೎߇໧㗴ߣߥߞߚ⢄⚦⢩⣼⣲ߩ 1 ଀㧘⢄⢙㆏ᴦ≮⎇ⓥળ⹹ 2007 ᐕ㧧5 Ꮞ㧦35㧙40㧚
4㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧚ࡌࠢ࠻࡞㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ㧘ක↪↹௝ᖱႎቇળ㔀⹹
2007 ᐕ㧧24 Ꮞ㧦84㧙89㧚
5㧕 ᩿↢ᜏม㧘Ꮉญ⌀ᐔ㧘ጤ↰ ዏ㧘ዊਭ଻శᒄ㧘ਅᎹ㇌ᵏ㧘᧻᳗⎇๋㧘᧻੗⧷੺㧘ᤊ ඳᤘ㧚ᧃ᪳⢖≸ߣߩ㐓೎߇࿎㔍ߢಾ㒰ߐࠇߚ⦟ᕈቅ┙⢖⚿▵∛ᄌߩ↹௝ᚲ⷗ߩᬌ⸛㧘⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦150㧙166㧚
6㧕 ട⮮ඳၮ㧘ᤊ ඳᤘ㧘ጊ↰ධᤊ㧘㕍ᧁ⻞ᄥ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧘᧻᳗⎇๋㧘ᑝἑༀା㧚৻஥⡊ਅ✢ߦ⊒↢ߒߚᄙ⊒⡊ਅ✢ౝ␹⚻㕽⣲ߩ 1 ଀㧘⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦312㧙317㧚
7㧕 ᨋ ⌀਽㧘೨↰ߔߥ߶㧘ᄢቲ๺ඳ㧘↰ਛ ୃ㧘᧻የ᡽ਯ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚ᚻⴚਇ⢻⢄⚦⢩≸ߩ᡼኿✢ᴦ≮㧘⢙ߣ⤟ 2007 ᐕ㧧28 Ꮞ㧦759㧙763㧚
8㧕 ౝጊ⦟৻㧘᧻੗ ◊㧘ᮮጊ㦖ੑ㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ᵻ㊁㓉ᒾ㧘ട⮮ඳၮ㧘ጤ㑆 ੧㧘ᤊඳᤘ㧘⮮↰ᑝᔒ㧚⣖ MR ↹௝ߦ߅ߌࠆ࡜ࠢ࠽᪪Ⴇߩᬌ಴ᴺ㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹ 2007 ᐕ㧧D㧘J90-D㧦
1820㧙1829㧚
9㧕 ጊౝ዁ผ㧘ౝጊ⦟৻㧘ዊ᫾ Ả㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘቟⮮ᒄ㆏㧘ጊᎹᒄ଻㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧚MRA ↹௝ߦ߅ߌࠆ⣖ⴊ▤ฬߩ⥄േኻᔕઃߌᚻᴺߩ㐿⊒㧘↢૕කᎿቇ 2007 ᐕ㧧45 Ꮞ㧦27㧙35㧚
10㧕 ᓟ⮮⵨ᄦ㧘᧖ፒ࿻ሶ㧘ᤊ ඳᤘ㧘ᑝἑༀା㧚ẩ≌≚∥㧫㧘ᣣᧄᶖൻེ߇ࠎᬌ⸻ቇળ㔀⹹ 2007 ᐕ㧧45 Ꮞ㧦
445㧙449㧚
11㧕 ർᎹノᒾ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚⢄⤳㔚ሶࠕ࠻࡜ࠬߣ✢ᒝ⺞ࡈࠖ࡞࠲ߦࠃࠆ૕ᐙㇱ㕖ㅧᓇ X ✢ CT ௝߆ࠄߩਛ⢄㕒⣂ߩ⥄േ᛽಴㧘ᣣᧄ᡼኿✢ᛛⴚቇળ㔀㧙㧙⹹ 2007 ᐕ㧧63 Ꮞ㧦1382㧙1387㧚
12㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ, ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ⣄ᬁᬁ૕ㇱߩ㛽ኒᐲߩ⺞ᩏ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦256㧙266㧚
13㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ, ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘ක↪↢૕Ꮏቇ 2007 ᐕ㧧45 Ꮞ㧦451
㧙457㧚
14㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧚ࡌࠢ࠻࡞㓸ਛᐲࡈࠖ࡞࠲ࠍ↪޿ߚ MRA ↹௝ߦ߅ߌࠆ⣖േ⣂≜ߩᬌ಴ᴺ㧘ක↪↹௝ᖱႎቇળ㔀⹹
2007 ᐕ㧧24 Ꮞ㧦84㧙89㧚
15㧕 ᨷᬀ⵨੺㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘ട⮮ඳၮ㧘ᷰㆻᤐᄦ㧘ᮮጊ㦖ੑ㇢㧘᫃↰౏ඳ㧘⴩᢫⾫ม㧚MRIߦࠃࠆ⢄ߩ⸻ᢿ㧘↹௝⸻ᢿ 2007 ᐕ㧧27 Ꮞ㧦1299㧙1306㧚
16㧕 ੑች໪ᓆ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝ߦ߅ߌࠆ⢷ㇳਅญߩ⥄േ᛽಴ߣᮮ㓒⤑ߩ⥄േផቯ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇળᛛⴚ⎇ⓥႎ๔ MI2007
2007 ᐕ㧧107 Ꮞ㧦107㧙110㧚
17㧕 ᨋ ⌀਽㧘ᄢቲ๺ඳ㧘↰ਛ ୃ㧘ᤊ ඳᤘ㧚ਃᰴర᡼኿✢ᴦ≮ߢߩ⢖⣲≌ዪᚲౣ⊒ߦኻߔࠆౣᾖ኿଀ߩᬌ
⸛㧘⥃ᐥ᡼኿✢ 2008 ᐕ㧧53 Ꮞ㧦449㧙445㧚
18㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ↹௝߆ࠄߩੱ૕ߩᬁ૕ᶏ✎㛽ㇱߦ߅ߌࠆૐ㛽ኒᐲ㗔ၞߩಽᏓߦ㑐ߔࠆ⎇ⓥ㧘↢૕කᎿቇ 2008 ᐕ㧧46 Ꮞ㧦451
㧙457㧚
19㧕 ᄹ⦟᧛੖චᔒ㧘ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘㒸 ⪇ጪ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ X ✢ CT ↹௝ߦ߅ߌࠆ૕⣧᭴ㅧߩ⥄േ⹺⼂㧘Medical Imaging Technology 2008 ᐕ㧧26 Ꮞ㧦261
㧙271㧚
20㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚X ✢ CT ௝ߦ߅ߌࠆ᳇▤࡮᳇▤ᡰߩᒻ⁁ᖱႎߩ⸘᷹㧘ක↪↹௝ᖱႎቇળ㔀⹹ 2008 ᐕ㧧25 Ꮞ㧦18㧙21㧚
21㧕 ␹⼱⋥Ꮧ㧘๟ ะᩕ㧘㒸 ⪇ጪ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚㛽ᩰߣ㛽ᩰ╭ߩ⸃೬ቇ⊛૏⟎㑐ଥߦၮߠߊ૕ᐙㇱ X ✢ CT ↹௝߆ࠄߩ㛽ᩰ╭ߩ⥄േឬ಴㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹
2008 ᐕ㧧J01-D㧦1918㧙1022㧚
22㧕 ർᎹノᒾ㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘ᤊ ඳᤘ㧚૕ᐙㇱ㕖ㅧᓇ
X ✢ CT ↹௝ߦ߅ߌࠆ⢄⤳ࠕ࠻࡜ࠬߩ᭴▽ߣߘߩ⢄⤳⥄േ᛽಴ᴺ߳ߩᔕ↪㧘㔚ሶᖱႎㅢାቇળ⺰ᢥ⹹
2008 ᐕ㧧J91-D㧦1837㧙1850㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Zhang X, Tajima T, Kitagawa T, Kanematsu M, Zhou X, Hara T, Fujita H, Yokoyama R, Kondo H,
Hoshi H. An automatic method for extracting the liver region with hepatic lesions on multi-phase CT
images. Skeletal Radiology. 2006;1:MI2005-87(2006-01):85-88.
2㧕 Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi
H. Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy. 2006;5:
127-130.
3㧕 Kanematsu M, Goshima S, Kondo H, Yokoyama R, Kajita K, Hoshi H, Onozuka M, Nozaki A, Hirano
M, Shiratori Y, Moriyama N. Double hepatic arterial phase MRI of the liver with switching of reversed
centric and centric K-space reordering. AJR Am Roentgenol. 2006;187:464-472.
4㧕 Tanaka O, Kiryu T, Hirose Y, Fujikake R, Sakurai K, Hoshi H. Chest wall Castleman’s disease: CT and
MRI findings. Radiat Med. 2006;24:529-533.
5㧕 Tanaka O, Hayashi S, Matsuo M, Sakurai K, Nakano M, Maeda S, Kajita K, Deguchi T, Hoshi H.
Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostatebrachytherapy. Int Radiat Oncol Biol Phys. 2006;66:597-602.
6㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Kato H, Tsuge Y, Shiratori Y, Hoshi H,
Onozuka M, Moriyama N, Bae KT. Pancreas: Optimal scan delay for contrast-enhanced multi-detector
row CT. Radiology. 2006;241:167-174.
7㧕 Matsuo M, Hayashi S, Maeda S, Tanaka O, Mizuta K, Shibata T, Itou Y, Hoshi H. 4 Gy single fraction
palliative radiotherapy for the treatment of painful recurrent soft plate carcinoma by high-dose-ratemold brachytherapy: A case report. Oral Oncology Extra. 2006;42:305-307.
8㧕 Tanaka O, Hayashi S, Sakurai K, Matsuo M, Nakano M, Maeda S, Hoshi H, Deguchi T. Importance of
the CT/MRI fusion method as a learning tool for CT-based postimplant dosimetry in prostatebrachytherapy. Radiotherapy and Oncology. 2006;81:303-308.
9㧕 Tanaka O, Hayashi S, Kanematsu M, Matsuo M, Nakano M, Maeda S, Deguchi T, Hoshi H. CT-based
postimplant dosimetry of prostate brachytherapy: comparison of 1-mm and 5-mm section CT. Radiat
Med. 2007;25:22-26.
10㧕 Zhou X, Kitagawa T, Hara T, Fujita H, Zhang X, Yokoyama R, Kondo H, Kanematsu M, Hoshi H.
Constructing a probabilistic model for automated liver region segmentation using non-contrast X-ray
torso CT images. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput
Assist Interv. 2006;9:856-863.
11㧕 Matsuhashi N, Satake S, Yawata K, Asakawa E, Mizoguchi T, Kanematsu M, Kondo H, Yasuda I,㧙㧙

IF 0.980

IF 7.535

IF 0.253
IF 0.951

IF 0.800

IF 5.377

IF 3.304

IF 4.074

IF 0.951

IF 2.196

Nonaka K, Tanaka C, Misao A, Ogura S. Volvulus of the gall bladder diagnosed by ultrasonography,
computed tomography, coronal magnetic resonance imaging and magnetic resonancecholangio-pancreatography. World J Gastroenterol. 2006;28:4599-4601.
IF
12㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Miyoshi T, Nishibori H, Kato H, Hoshi H, Onozuka
M, Moriyama N. MDCT of the liver and hypervascular hepatocellular carcinomas: optimizing scandelays for bolus-tracking techniques of hepatic arterial and portal venous phases. Am J Roentgenol.
2006;187:W25-32.
IF
13㧕 Matsuhashi N, Mizoguchi T, Kanematsu M, Kondo H, Goshima S, Mitsuishi N, Yoshimura K, Ogiso T,
Tawada M, Kuwabara S, Ikegame Y, Kato M, Shirai K, Yamaguchi H, Toyoda I, Ogura S. A case ofdelayed rectal stenosis from severe pelvic fracture with massive bleeding successfully treated bybilateral internal iliac TAE: report on a patient survival. Int J Colorectal Dis. 2007;22:853-854.
IF
14㧕 Hirano Y, Fujita M, Watanabe K, Niwa M, Takahashi T, Kanematsu M, Ido Y, Tomida M, Onozuka M.
Effect of unpleasant loud noise on hippocampal activities during picture encoding: An fMRI study.
Brain Cogn. 2006;61:280-285.
IF
15㧕 Kato H, Kanematsu M, Ando K, Mizuta K, Ito Y, Hirose Y, Hoshi H. Ossifying pleomorphic adenoma of
the parotid gland: A case report and review. Australas Radiol. 2007;51:B173-175.
16㧕 Amaoka N, Osada S, Kanematsu M, Imai H, Tomita H, Tokuyama Y, Sakashita F, Nonaka K, Goshima
S, Kondo H, Adachi Y. Clinicopathological features of hepatocellular carcinoma evaluated by vascularendothelial growth factor expression. J Gastroenterol Hepatol. 2007;22:2202-2207.
IF
17㧕 Kato H, Kanematsu M, Zhang X, Saio M, Kondo H, Goshima S, Fujita H. Computer-aided diagnosis ofhepatic fibrosis: preliminary evaluation of MRI texture analysis using the finite difference method andan artificial neural network. Am J Roentgenol. 2007;189:117-122.
IF
18㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clin Imaging. 2007;31:206-209.
IF
19㧕 Kanematsu M, Goshima S, Kondo H, Tsuge Y, Yokoyama R, Kajita K, Onozuka M, Suzuki Y, Van
Cauteren M, Moriyama N. Gadolinium-enhanced multiphasic 3D MRI of the liver with prospective
adaptive navigator correction: phantom study and preliminary clinical evaluation. Am J Roentgenol.
2007;188:309-316.
IF
20㧕 Goshima S, Kanematsu M, Nishibori H, Kondo H, Tsuge Y, Yokoyama R, Miyoshi T, Onozuka M,
Shiratori Y, Moriyama N, Bae KT. Multi-detector row CT of the kidney: Optimizing scan delays forbolus tracking techniques of arterial, corticomedullary, and nephrographic phases. Eur J Radiol.
2007;63:420-426.
21㧕 Tajima T, Zhang X, Kitagawa T, Kanematsu M, Zhou X, Hara T, Fujita H, Yokoyama R, Kondo H,
Hoshi H. Computer-aided detection (CAD) of hepatocellular carcinoma on multiphase CT images, Proc.
of SPIE Medical Imaging. 2007: Computer-Aided Diagnosis, 6514, 65142Q-1-65142Q-10.
22㧕 Kondo H, Yamada T, Kanematsu M, Kako N, Goshima S, Yamamoto N. Related Articles, Embolization
for massive urethral hemorrhage. Abdom Imaging. 2007;32:262-263.
IF
23㧕 Kondo H, Kanematsu M, Goshima S, Miyoshi T, Shiratori Y, Onozuka M, Moriyama N, Bae KT. MDCTof the pancreas: optimizing scanning delay with a bolus-tracking technique for pancreatic,
peripancreatic vascular, and hepatic contrast enhancement. Am J Roentgenol. 2007;188:751-756.
IF
24㧕 Yokoyama R, Zhang X, Uchiyama Y, Fujita H, Hara T, Zhou X, Kanematsu M, Asano T, Kondo H,
Goshima S, Hoshi H, Iwata T. Develoment of an automated method for detection of chronic lacunar
infarct regions in brain MR images. IEICE T Inf Syst. 2007;E90-D:943-954.
IF
25㧕 Uchiyama Y, Yokoyama R, Ando H, Asano T, Kato H, Yamakawa H, Hara T, Iwama T, Hoshi H, Fujita
H. Computer-aided diagnosis scheme for detection of lacunar infarcts on MR images. Acad Radiol.
2007;1554-1561.
IF
26㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
Comparison of urethral diameters for calculating the urethral dose after permanent prostatebrachytherapy. Radiat Med. 2007;329-334.
27㧕 Zhou X, Kamiya N, Hara T, Fujita H, Chen H, Yokoyama R, Hoshi H. Automated segmentation andrecognition of abdominal wall muscles in X-ray torso CT images and its application in abdominal CAD.
Int J Computer Assisted Radiol and Surg. 2007;2:Supplement1: S388-S390.
28㧕 Uchiyama Y, Yokoyama R, Asano T, Kato H, Yamakawa H, Ando H, Yamakawa H, Hara T, Iwama T,
Hoshi H, Fujita H. Performance of computer-aided diagnosis for detection of lacunar infarcts on brain
MR images: ROC analysis of radiologists' detection. Int J Computer Assist Radiol and Surg.
2007;2:Supplement 1:S395-S397.
29㧕 Manabe T, Hirose Y, Kiryuu T, Kondo H, Hoshi H. Magnetic resonance imaging of endmetrial cancer
and clear cell cancer. J Comput Assist Tomogr. 2007;31:229-235.
IF
30㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Uno H, Ohtakara K, Miyoshi T, Deguchi T, Hoshi H.
Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion. Int J
Radiat Oncol Biol Phys. 2007;69:614-618.
IF
31㧕 Matsuo M, Shinoda J, Miwa K, Yano H, Iwama T, Hayashi S, Okada S, Tanaka O, Hoshi H.
Stereotactic radiosurgery for patients with newly diagnosed glioblastoma multiforme (GBM):

㧙㧙

0.634

2.209

1.749

1.845

1.785

2.117
0.742

2.117

1.213

2.117

0.280

1.781

1.530

4.463

comparison with intra-operative radiotherapy and evaluation of prognostic factors. J Radiotherapy inPractice. 2007;143-152.
32㧕 Matsuo M, Nakano M, Hayashi S, Ishihara S, Maeda S, Uno H, Tanaka O, Kanematsu M, Deguchi T,
Hoshi H, Aoyama T, Fujiwara H. Prostate brachytherapy seed migration to the right ventricle: Chest
radiographs and CT appearances. Eur J Radiol Extra. 2007;61:91-93.
33㧕 Shibamoto Y, Baba F, Oda K, Hayashi S, Kokubo M, Ishihara S, Itoh Y, Ogino H, Koizumi M. Incidenceof brain atrophy and decline in mini-mental state examination score after whole-brain radiotherpy inpatients with brain metastases: aprospective study. Int J Radiat Oncol Biol Phys. 2008;72:1168-1173.
34㧕 Tanaka O, Hayashi S, Matsuo M, Nakano M, Kubota Y, Maeda S, Ohtakara K, Deguchi T, Hoshi H.
MRI-based preplanning in low-dose-rate prostate brachytherapy. Radiotherapy Oncology.
2008;72:1168-1173.
35㧕 Kato H, Kanematsu M, Mizuta K, Ito Y, Hirose Y. Carcinoma Ex pleomorphic adenoma of the parotid
gland: Radiologic-pathologic correlation with MR imaging including diffusion-weighted imaging. Am J
Neuroradiol. 2008;29:865-867.
36㧕 Kato H, Kanematsu M, Kiryu T, Iwata H, Shirahashi K, Matsumoto S, Hirose Y, Matsutomo H,
Sasaoka I. Nonfunctional mediastinal parathyroid cyst: imaging findings in two cases. Clin Imaging.
2008;32:310-313.
37㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y. Carcinosarcoma of
the uterus: radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Reson Imaging. 2008;26:1446-1450.
38㧕 Bae KT, Shah AJ, Shang SS, Wang JH, Chang S, Kanematsu M, Hildebolt CF. Aortic and hepatic
contrast enhancement with abdominal 64-MDCT in pediatric patients: effect of body weight and iodine
dose. Am J Roentgenol. 2008;191:1589-1594.
39㧕 Zhou X, Han M, Hara T, Fujita H, Sugisaki K, Chen H, Lee G, Yokoyama R, Kanematsu M, Hoshi H.
Automated segmentation of mammary gland regions in non-contrast X-ray CT images. Comput Med
Imaging Graph. 2008;32:699-709.
40㧕 Miyoshi T, Kanematsu M, Kondo H, Goshima S, Tsuge Y, Hatcho A, Shiratori Y, Onozuka M,
Moriyama N, Bae KT. Abdomen: angiography with 16-detector CT- -comparison of image quality andradiation dose between studies with 0.625-mm and those with 1.25-mm collimation. Radiolgy.
2008;249:142-150.
41㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Kajita K, Tsuge Y, Watanabe H, Shiratori Y,
Onozuka M, Moriyama N. Diffusion-weighted imaging of the liver: optimizing b value for the detection
and characterization of benign and malignant hepatic lesions. J Magn Reson Imaging. 2008;28:691-697.
42㧕 Hong HS, Kim HS, Kim MJ, De Becker J, Mitchell DG, Kanematsu M. Single breath-holdmultiarterial dynamic MRI of the liver at 3T using a 3D fat-suppressed keyhole technique. J Magn
Reson Imaging. 2008;28:396-402.
43㧕 Osada S, Kanematsu M, Imai H, Goshima S. Clinical significance of serum HGF and c-Met expression
in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.
Hepatogastroenterology. 2008;55:544-549.
44㧕 Kawajiri S, Zhou X, Zhang X, Hara T, Fujita H, Yokoyama R, Kondo H, Kanematsu M, Hoshi H.
Automated segmentation of hepatic vessels in non-contrast X-ray CT images. Radiol Phys Technol
2008;1:214-222.
45㧕 Kudo M, Zheng RQ, Kim SR, Okabe Y, Osaki Y, Iijima H, Itani T, Kasugai H, Kanematsu M, Ito K,
Usuki N, Shimamatsu K, Kage M, Kojiro M. Diagnostic accuracy of imaging for liver cirrhosis
compared to histologically proven liver cirrhosis. A multicenter collaborative study. Intervirology.
2008;51 Suppl 1:17-26.
46㧕 Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J.
Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels oftumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract.
2008;82:58-65.
47㧕 Goshima S, Kanematsu M, Kondo H, Yokoyama R, Tsuge Y, Shiratori Y, Onozuka M, Moriyama N.
Evaluating local hepatocellular carcinoma recurrence post-transcatheter arterial chemoembolization:is diffusion-weighted MRI reliable as an indicator? J Magn Reson Imaging. 2008;27:834-839.
48㧕 Bae KT, Seeck BA, Hildebolt CF, Tao C, Zhu F, Kanematsu M, Woodard PK. Contrast enhancement in
cardiovascular MDCT: effect of body weight, height, body surface area, body mass index, and obesity.
Am J Roentgenol. 2008;190:777-784.
49㧕 Kanematsu M, Goshima S, Kondo H, Bae KT. How should we optimize bolus tracking withmultidetector CT of the abdomen? Radiology. 2008;246:643; author reply 643-644.
50㧕 Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Hepatic fibrosis influences the growth ofhepatocellular carcinoma. Hepatogastroenterology. 2008;55:184-187.
51㧕 Kubota Y, Kamei S, Nakano M, Ehara H, Deguchi T, Tanaka O. The potential role of prebiopsy
magnetic resonance imaging combined with prostate-specific antigen density in the detection of
prostate cancer. Int J Urol. 2008;15:322-327.

㧙㧙

IF 3.970

IF 1.330

IF 4.290

IF 4.074

IF 2.338

IF 0.742

IF 1.486

IF 2.470

IF 0.848

IF 5.661

IF 2.209

IF 2.209

IF 0.904

IF 1.827

IF 1.823

IF 2.209

IF 2.470
IF 0.904
IF 0.904

IF 0.769

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦౗᧻㓷ਯ㧘⎇ⓥಽᜂ⠪㧦ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘㜞੗శᴦ㧧ᢥㇱ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ
⋚⎇ⓥ(C)㧦㜞⸃௝⢄ㅧᓇ MRI ߳ߩࡄ࡯ࡈࡘ࡯࡚ࠫࡦ⸃ᨆ⚵ㄟߺߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
160 ජ౞(120㧦40 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ዊ㊁Ⴆታ㧘⎇ⓥಽᜂ⠪㧦૒⮮⽵㓶㧘ᬀ᧻ ብ㧘ട⮮ೣᑝ㧘౗᧻㓷ਯ㧧ᢥㇱ⋭⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦࠴ࡘ࡯ࠗࡦࠣߦࠃࠆ⣖ᯏ⢻࿁〝ߩ⾮ᵴൻߣౣ↢㧧ᐔᚑ 18㧙19 ᐕᐲ㧧40,43 0ජ౞(33,150㧦7,280 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⮮↰㓷ᢥ㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘ട⮮ೣᑝ㧘⮮ේ ๟㧘ਭ଻㊄ᒎ㧧ᢥㇱ⋭⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦㜞㦂␠ળߦ߅޿ߡ⠧ᐕᱤ⑼කቇ߇ᜂ߁␠ળ⊛㊀ⷐᕈࠍ⣖⑼ቇ⊛ߦታ⸽ߔࠆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧20,410 ජ౞(16,900㧦3,510 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦♿ࡁቯ଻⤿㧘⎇ⓥಽᜂ⠪㧦ᤊ ඳᤘ㧘ᗆ⦟⡛৻㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕
㧦MRI/RI
ࡑ࡞࠴ࠗࡔ࡯ࠫࡦࠣᴺߦࠃࠆࡅ࠻↢ℂᯏ⢻ߩቯ㊂⹏ଔ(Evaluation of tissue/cell functions using
MRI/RI multi-modality imaging technique)㧧ᐔᚑ 19 ᐕᐲ㧧60 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ㄭ⮮ᶈผ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦⣻ㇱㅧᓇ MDCT ߦ߅ߌࠆ⥋ㆡㅧᓇ೷㊂㧘᠟௝ࡊࡠ࠻ࠦ࡯࡞ߩ⥄േ⸳ቯߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧900 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦੖ፉ ⡡㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘ᨷᬀ⵨੺㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᄙ೉ᬌ಴ེဳ CT ↹௝ߦ߅ߌࠆ㊄ዻࠕ࡯࠴ࡈࠔࠢ࠻シᷫࠕ࡞ࠧ࡝࠭ࡓߩ㐿⊒㧧ᐔᚑ 19㧙20 ᐕᐲ㧧
2,250 ජ౞(1,600㧦650 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ᷰㆻᤐᄦ㧘⎇ⓥಽᜂ⠪㧦౗᧻㓷ਯ㧘੖ፉ ⡡㧘ㄭ⮮ᶈผ㧘ᨷᬀ⵨੺㧘⮮↰ᑝᔒ㧧⑼ቇ
⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦Cinetagging ↹௝ࠍ↪޿ߚ⢄✢⛽ൻ⹏ଔ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧2,200 ජ౞(1,400㧦500㧦300 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ౗᧻㓷ਯ㧦ᰴᦼࡑࠗࠢࡠࠞ࠹࡯࠹࡞㐿⊒ߩὑߩ⃻ⴕࡑࠗࠢࡠࠞ࠹࡯࠹࡞㧔ࡊࡠࠣ࡟࡯࠻㧕ߩᕈ⢻⹏ଔ㧧ᐔᚑ 18 ᐕᐲ㧧130 ජ౞㧦࠹࡞ࡕᩣᑼળ␠ࠞ࠹࡯࠹࡞ࠞࡦࡄ࠾࡯
3㧕౒ห⎇ⓥ1㧕 ౗᧻㓷ਯ㧦Multi Detector row CT ߦ߅ߌࠆ⣻ㇱ᠟ᓇߩ↹⾰ᡷༀߦ㑐ߔࠆၮ␆ᬌ⸛㧧ᐔᚑ 18㧙19 ᐕᐲ㧧38.8 ජ౞(20㧦18.8 ජ౞)㧦ࠫ࡯ࠗ࡯ᮮᴡࡔ࠺ࠖࠞ࡞ࠪࠬ࠹ࡓᩣᑼળ␠
2㧕 ౗᧻㓷ਯ㧦ㅧᓇ೷⥄േᵈ౉ེࠍ↪޿ߚ࡛࡯࠼ㅧᓇ೷ߩ᦭ല೑↪ߦ㑐ߔࠆၮ␆⎇ⓥ㧘෸߮ߘߩᵈ౉ᴺߩ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧42 ජ౞(22㧦20 ජ౞)㧦ᩮᧄ᧙ᨋၴ㧔ᩣ㧕
3㧕 ౗᧻㓷ਯ㧦Multi Detector row CT ߦ߅ߌࠆㅧᓇࡊࡠ࠻ࠦ࡞ᦨㆡൻߩၮ␆ᬌ⸛㧧ᐔᚑ 20 ᐕᐲ㧧182
ජ౞㧦ࠫ࡯ࠗ࡯ᮮᴡࡔ࠺ࠖࠞ࡞ࠪࠬ࠹ࡓᩣᑼળ␠
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᤊ ඳᤘ㧦
1㧕 ᣣᧄකቇ᡼኿✢ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄᩭකቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᔃ⤳ᩭකቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↹௝කቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ർ㑐᧲කቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄකቇ᡼኿✢ቇળஜ଻ᆔຬ(㨪⃻࿷)౗᧻㓷ਯ㧦1㧕 ᣣᧄࠗࡦ࠲࡯ࡌࡦ࡚ࠪ࠽࡞࡜ࠫࠝࡠࠫ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⏛᳇౒㡆කቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄᩭකቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙ᨋ ⌀਽㧦1㧕 ᣣᧄ᡼኿✢⣲≌ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 10 ᦬㨪⃻࿷)2㧕ቇળ㐿௅ᤊ ඳᤘ㧦
1㧕 ᣣᧄකቇ᡼኿✢ቇળ╙ 140 ࿁ਛㇱ࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂)2㧕 ᣣᧄᩭකቇળ╙ 65 ࿁ਛㇱ࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂)౗᧻㓷ਯ㧦
1㧕 ᣣᧄ IVR ቇળ╙ 21 ࿁ਛㇱ࿾ᣇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹ᤊ ඳᤘ㧦
1㧕 ᢿጀᤋ௝⎇ⓥળ㔀⹹㧘✬㓸ᆔຬ(㨪⃻࿷)2㧕 ක↪↹௝ᖱႎቇળ㔀⹹㧘✬㓸 Advisory board (㨪⃻࿷)
3㧕 Acta Oto-Laryngologica㧘Reviewer (ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)౗᧻㓷ਯ㧦
1㧕 ⥃ᐥ↹௝㧘✬㓸දജᆔຬ(㨪⃻࿷)2㧕 ᶖൻེ↹௝㧘✬㓸ᆔຬ(㨪⃻࿷)3㧕 Radiology, JCAT, JMRI, CVIR㧘⹹⊓㍳ᩏ⺒ຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᤊ ඳᤘ㧦
1㧕 ╙ 60 ࿁᧲ᶏ✚ว↹௝කቇ⎇ⓥળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬஥㗡㛽ߩ↹௝⸻ᢿ㧙߅ߐ߃ߡ߅߈ߚ޿ࡐࠗࡦ࠻‫ޠ‬ᐳ㐳)2㧕 ╙ 43 ࿁ᣣᧄකቇ᡼኿✢ቇળ⑺ቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬ‫ޟ‬ᩭකቇࠍ↪޿ߚ⸻ᢿߣᴦ≮‫ޠ‬ᐳ㐳)
3㧕 ╙ 74 ࿁᧲ᶏᩭකቇ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ࠆࠃߦࡦ࡝ࠔࡧ࠯ޟ‬᡼኿఺∉≮ᴺ㧙
․ᓽߣḰ஻߆ࠄታ㓙߹ߢ㧙‫ޠ‬ᐳ㐳)౗᧻㓷ਯ㧦
1㧕 MDCT symposium “MDCT Made Easy”, (2006.02, Seoul, Invited lecture: Contrast-enhanced
MDCT of the liver and pancreas –Focusing on fixed duration injection–; symposist)2㧕 ╙ 42 ࿁ ᣣᧄකቇ᡼኿✢ቇળ⑺ᦼ⥃ᐥᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘⑔ጟ㧘࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬ‫ޟ‬⢄⦟ᕈ⣲≜ߩ↹௝⸻ᢿ‫ޠ‬㧘‫ޟ‬⢄ⴊ▤⣲ߩ↹௝⸻ᢿ㧙MRI ࠍਛᔃߦ㧙‫ޠ‬Ṷ⠪)
3㧕 ╙ 44 ࿁ᣣᧄ≸ᴦ≮ቇળ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᶖൻེ≸ߦ߅ߌࠆ↹௝⸻ᢿߩㅴᱠߣᴦ≮߳ߩዷ㐿㧘MRI ߦࠃࠆ⢄∔ᖚ⸻ᢿᚢ⇛‫ޠ‬Ṷ⠪)
4㧕 ╙ 12 ࿁ Hepatologyfest in N43(ᐔᚑ 18 ᐕ 11 ᦬㧘ᧅᏻ㧘․೎⻠Ṷ‫ޟ‬⢄ߩ MRI 㧙ᦨㄭߩ⹤㗴ࠍ੤߃ߡ㧙‫ޠ‬Ṷ⠪)
5㧕 ╙ 67 ࿁ᣣᧄකቇ᡼኿✢ቇળ✚ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬਄⣻ㇱߩㅧᓇ MDCT㧙㒰⢽⢌
૕㊀ߦࠃࠆ࡛࡯࠼⽶⩄ᦨㆡൻ㧙‫ޠ‬Ṷ⠪)
6㧕 ╙ 36 ࿁ᣣᧄ⏛᳇౒㡆කቇᄢળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ᮮᵿ㧘․೎⻠Ṷ‫ޟ‬EOB࡮ࡊ࡝ࡕࡆࠬ࠻ㅧᓇ MRI-᠟௝ߩᦨㆡൻࠍਛᔃߦ‫ޠ‬Ṷ⠪)7㧕 The 5th. Japan-Korea Liver Symosium (2008.08, Osaka, Invited Lecture: Diagnostic strategy for
HCC-focused on MRI; symposist)8㧕 The 12th. Asian Oceanian Congress of Radiology (2008.10, Seoul, Symosium㧘Moderators ofdebate session: Optimization of contrast-enhanced liver CT which is best?; symposist)9㧕 The 12th. Asian Oceanian Congress of Radiology (2008.10, Seoul, Invited Lecture: Optimizationof iodine load by other than total body weight; symposist)10㧕 The 12th. Asian Oceanian Congress of Radiology (2008.10, Seoul, Invited Lecture: MR imaging
of hepatocellular carcinoma; speaker)
11㧕 The 2nd. International Forum for Liver MRI (2008.10, Kyoto, Invited Lecture: Optimization㧙㧙hepatic arterial-dominant phase imaging for the diagnosis of hepatocellular carcinomas;
speaker)ᨋ ⌀਽㧦
1㧕 ╙ 43 ࿁ᣣᧄකቇ᡼኿✢ቇળ⑺ቄ⥃ᐥᄢળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ฬฎደ㧘࡝ࡈ࡟࠶ࠪࡖ࡯ࠦ࡯ࠬ‫ޟ‬㗡㗪ㇱ⣲≌ߩᴦ≮ᴺߩㆬᛯ‫ޠ‬ᐳ㐳)ㄭ⮮ᶈผ㧦
1㧕 ╙ 36 ࿁ᣣᧄ⏛᳇౒㡆ቇળ (ᐔᚑ 20 ᐕ 9 ᦬㧘ᣩᎹ㧘ᢎ⢒⻠Ṷ‫ࠎ߹߮ޟ‬ᕈ⢄∔ᖚ‫ޠ‬Ṷ⠪)੖ፉ ⡡㧦
1㧕 ╙ 35 ࿁ᣣᧄ⏛᳇౒㡆ቇળ (ᐔᚑ 19 ᐕ 9 ᦬㧘␹ᚭ㧘ᢎ⢒⻠Ṷ‫ޟ‬⢄㧙MRI‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ੖ፉ ⡡㧘౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘ᨷᬀ␭੺㧦╙ 34 ࿁ᣣᧄ⏛᳇౒㡆කቇળᄢળࡐࠬ࠲࡯ㇱ㐷 ቇⴚᅑ
ബ⾨(ᐔᚑ 18 ᐕᐲ)
2㧕 ੖ፉ ⡡㧦ጘ㒂කቇ⎇ⓥද⼏ળᐔᚑ 18 ᐕᐲጘ㒂කቇᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
3㧕 ੖ፉ ⡡㧦ᣣᧄකቇ᡼኿✢ቇળ᧼੗⎇ⓥᅑബ⾨(ᐔᚑ 18 ᐕᐲ)
4㧕 ౝጊ⦟৻㧘᧻੗ ◊㧘ᮮጊ㦖ੑ㇢㧘⮮↰ᑝᔒ㧘ේ ᱞผ㧘๟ ะᩕ㧘ᵻ㊁㓉ᒾ㧘ട⮮ඳၮ㧘ᤊ ඳᤘ㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧦ᣣᧄ᡼኿✢ᛛⴚቇળ㌃⾨(ᐔᚑ 18 ᐕᐲ)
5㧕 Tanaka O㧦International Health Professional of the year 2006(ᐔᚑ 18 ᐕᐲ)
6㧕 ౗᧻㓷ਯ㧦Radiology Editor’s Recognition Award for Reviewing with Distinction(ᐔᚑ 18 ᐕᐲ)
7㧕 ౗᧻㓷ਯ㧦Radiology Editor’s Recognition Award for Reviewing with Distinction(ᐔᚑ 19 ᐕᐲ)
8㧕 Yamauchi M, Uchiyama Y, Yokoyama R, Hara T, Fujita H, Ando H, Yamakawa H, Iwama T,
Hoshi H㧦Cum Laude Poster Award, Computer Aided Diagnosis 6514, SPIE Medical Imaging
2007 Symposium(ᐔᚑ 19 ᐕᐲ)
9㧕 ↰ਛ ୃ㧦ᣣᧄ᡼኿✢⣲≌ቇળ᪢၂⾨(ᐔᚑ 19 ᐕᐲ)
10㧕 ↰ਛ ୃ㧦JASTRO Silver Prize(ᐔᚑ 19 ᐕᐲ)
11㧕 ᨋ ㆐㇢㧘๟ ะᩕ㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ᮮጊ㦖ੑ㇢㧘᩿↢ᜏม㧘㒸 ⪇ጪ㧘ᤊ ඳᤘ㧦㔚ሶᖱႎㅢାቇળቇⴚᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
12㧕 ౝጊ⦟৻㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘⮮↰ᑝᔒ㧘ട⮮ඳၮ㧘ᵻ㊁㓉ᒾ㧘ᤊ ඳᤘ㧦CyPos ㌃⾨(ᐔᚑ 20ᐕᐲ)13㧕 ዊ᫾ Ả㧘ౝጊ⦟৻㧘ጊౝ዁ผ㧘ᮮጊ㦖ੑ㇢㧘ේ ᱞผ㧘ጊᎹᒄ଻㧘቟⮮ᒄ㆏㧘ጤ㑆 ੧㧘ᤊ ඳᤘ㧘⮮↰ᑝᔒ㧦㊄᫪ᅑബ⾨(ᐔᚑ 20 ᐕᐲ)
14㧕 ౗᧻㓷ਯ㧦Radiology Editor’s Recognition Award for Reviewing with Distinction(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ౗᧻㓷ਯ㧘㐳↰⌀ੑ㧘ᄤጟ ᦸ㧘᧻የ᡽ਯ㧘ട⮮ඳၮ㧦᡼኿✢↹௝කቇߦࠃࠆ⢄≸ߩⴊ▤ᣂ↢∛ᘒ߳ߩࠕࡊࡠ࡯࠴ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 16 ᐕᐲ㧙17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙64 (2006 ᐕ 6 ᦬)
2㧕 ౗᧻㓷ਯ㧘ㄭ⮮ᶈผ㧘੖ፉ ⡡㧘㜞੗శᴦ㧦㜞⸃௝⢄ㅧᓇ MRI ߳ߩࡄ࡯ࡈࡘ࡯࡚ࠫࡦ⸃ᨆ⚵ㄟߺߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18㧙19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ㧦1㧙35(2008 ᐕ 3 ᦬)
3㧕 ዊ㊁Ⴆታ㧘૒⮮⽵㓶㧘ᬀ᧻ ብ㧘ട⮮ೣᑝ㧘౗᧻㓷ਯ㧦࠴ࡘ࡯ࠗࡦࠣߦࠃࠆ⣖ᯏ⢻࿁〝ߩ⾮ᵴൻߣౣ↢㧦ᐔᚑ 18㧙19 ᐕᐲᢥㇱ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 6 ᦬)
11㧚ႎ㆏
1㧕 ᤊ ඳᤘ㧦૕ౝ⚦⢩ߩ௛߈೑↪ߒ⸻ᢿ㧦ጘ㒂ᣂ⡞(2007 ᐕ 9 ᦬ 18 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔ↹௝⸻ᢿߩ⎇ⓥߪ㧘↹௝⸻ᢿߩߺߥࠄߕᯏེࠍ㚟૶ߒߚ᠟ᓇᛛⴚ㧘↹௝⸃ᨆ߽✂⟜ߐࠇࠆ߇㧘ㄭᐕߩᯏེ߿ࡀ࠶࠻ࡢ࡯ࠢߩㅴᱠߦࠃࠅ㧘⸻ᢿ⢻߇ᩰᲑߦะ਄ߒ㧘ᦨᣂߩ⥃ᐥ⊛⹏ଔࠍᄙߊⴕߞߡ߈ߚ‫ޕ‬⣻ㇱ⤳ེᖡᕈ⣲≌ߩ⎇ⓥߢߪ㧘CT㧘MRI ߩ⥋ㆡ᠟௝ᴺߩ㐿⊒㧘ⴊ▤ㅧᓇਅ CT㧘࠳ࠗ࠽ࡒ࠶ࠢㅧᓇ MRI㧘᜛ᢔᒝ⺞↹௝ߦࠃࠆ MRI ߥߤࠍ↪޿ߚ㧘⢄߇ࠎ㧘⤟߇ࠎࠍᆎ߼ߣߔࠆᣧᦼᖡᕈ⣲≌↹௝⸻ᢿߦ㑐ߔࠆ⎇ⓥᚑᨐࠍ᜼ߍߡ߈ߚߎߣߪ․╩ߦ୯ߔࠆߣ⠨߃ߡ޿ࠆ‫ߚ߹ޕ‬㧘ᩭකቇߦࠃࠆ⣖ⴊ⛔ SPECT ߽ eZIS ࠍᆎ߼ߣߔࠆᣂߒ޿ቯ㊂ൻߦ㑐ߔࠆ⎇ⓥߦขࠅ⚵ࠎߢ߅ࠅ㧘⥃ᐥ⊛ߦᔕ↪ߐࠇߡ޿ࠆ‫ޕ‬᡼኿✢ᴦ≮㑐ㅪߢߪ㧘3ᰴరᾖ኿ߩ૕ᐙㇱ⣲≌߳ߩᔕ↪㧔․ߦ IMRT ߩၮ␆⊛ᬌ⸛㧕㧘ቯ૏ᚻⴚ⊛᡼኿✢ᴦ≮ߩ⣖⣲≌߳ߩᔕ↪㧘᦭∩ᕈ㛽ォ⒖ߦኻߔࠆ⥋ㆡᾖ኿ᴺߩᬌ⸛ࠍⴕߞߡ߈ߚ‫ޕ‬ዊ✢Ḯᴦ≮ߦߟ޿ߡߪ᧲ᶏ࿾඙ߢೋ߼ߡ೨┙⣼߇ࠎߦ⥃ᐥᔕ↪ߐࠇ㧘⦟ᅢߥᚑᨐࠍ᜼ߍߡ߈ߚ‫⥋ߩߎޕ‬ㆡ✢㊂ࠍᓧࠆߚ߼ᣂߒ޿ CT㧘MRI ߩ࠰ࡈ࠻ߩ
㐿⊒߽ⴕߞߡ߈ߚ‫ߚ߹ޕ‬㧘↹௝⸻ᢿ↪ߩᣂߒ޿࠰ࡈ࠻ߣߒߡ⥃ᐥᔕ↪ߦะߌߡᕆㅦߦㅴᱠߒߡ߈ߚ CAD
ߦߟ޿ߡߪ㧘ౣ↢ಽሶ⛔ᓮቇ⻠ᐳ㧘⍮⢻ࠗࡔ࡯ࠫᖱႎಽ㊁ߣ౒ห⎇ⓥⴕ޿ߥ߇ࠄ㧘․ߦ੃≸㧘ᘟᕈ⢄∔ᖚߦߟ޿ߡ⎇ⓥᚑᨐࠍ᜼ߍߡ߈ߡ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻࿷ߩ⎇ⓥߪ⥃ᐥ⎇ⓥ߇ਥߥ߽ߩߢ޽ࠆ‫ᤨ⃻ޕ‬ὐߢߪၮ␆⎇ⓥ߇චಽⴕ߃ࠆⅣႺ߇ᢛߞߡ޿ߥ޿ߚ߼㧘੹ᓟ㧘዁᧪ߩ⥃ᐥᔕ↪ߦߟߥ߇ࠆࠃ߁ߥၮ␆⊛ᬌ⸛ࠍⴕ߁ߚ߼ߩᣉ⸳㧘ⵝ⟎ߩᢛ஻ࠍ࿑ߞߡ޿ߊᔅⷐ߇
޽ࠆ‫ߚ߹ޕ‬㧘ᘟᕈ⊛ߥࡑࡦࡄࡢ࡯ਇ⿷߇⛯޿ߡ޿ࠆߚ߼㧘዁᧪ߦะߌߡ⥃ᐥ㧘ᢎ⢒㧘⎇ⓥ߇චಽⴕ߃ࠆ
ੱ⊛లታ߇ᔅⷐߢ޽ࠆ‫߼ߚߩߎޕ‬㧘ౝᄖࠍ฽߼ߚฦ⸻≮⑼㧘ฦಽ㊁㧘ઁᣉ⸳ߣߩ౒ห⎇ⓥࠍᦝߦలታߐ
ߖࠆᔅⷐ߇޽ࠆ‫ߚ߹ޕ‬㧘ౕ૕⊛ࡊࡠࠫࠚࠢ࠻߅ࠃ߮ࠬ࠻࡜࠹ࠫ࡯ࠍᦝߦផᢚߒ㧘step by step ߢ⃻ታน⢻ߥ߽ߩߣߒߡ޿߆ߥߌࠇ߫ߥࠄߥ޿‫ޕ‬
੹ᓟߩዷᦸ
2004 ᐕ 6 ᦬ߦᣂ∛㒮߇Ⓙ௛ߒ㧘ቢో㔚ሶࠞ࡞࠹ൻߐࠇߚߚ߼㧘↹௝ᖱႎ࠺ࠫ࠲࡞ൻߦࠃࠅ㧘↹௝⸃ᨆߩᐢ▸࿐ߥᔕ↪߇น⢻ߣߥࠅ㧘∝଀Ფߩ↹௝Ყセ߿ห৻∝଀ߩ⚻ᤨ⊛ߥᄌൻߥߤ߽ኈᤃߦ್೎น⢻ߦߥߞߚ‫ߚ߹ޕ‬㧘ක≮ᯏེߩᦝߥࠆㅴᱠߦࠃࠅ㧘ฦ⒳↹௝⸻ᢿߩ⎇ⓥߪߐࠄߦ㜞ᐲൻߒ㧘߹ߔ߹ߔ⋓ࠎߦߥࠆߣ੍ᗐߐࠇࠆ‫ޕ‬2007 ᐕߦߪ PET-CT ߇Ⓙ௛ࠍߪߓ߼㧘2009 ᐕ߆ࠄߪ 64 ೉ CT ߇ዉ౉ߐࠇࠆ੍ቯߢ޽
ࠆ‫ߡߒߘޕ‬㧘ࠦࡦࡇࡘ࡯࠲ߦࠃࠆ↹௝ಣℂߣੱᎿ⍮⢻ࠍ↪޿ߚ↹௝⸻ᢿᡰេࠪࠬ࠹ࡓߩ⊒ዷߣ߽⋧଼ߞߡ㧘઒ᗐౝⷞ㏜ߦࠃࠆᶖൻ▤ᬌ⸻㧘੃≸⸻ᢿ㧘⣻ㇱ↹௝⸻ᢿߥߤߩ♖ᐲ߇ࠃࠅ৻ጀ㜞߹ࠆߎߣ߇ᦼᓙߐ
ࠇࠆ‫ᦨޕ‬ᣂߩ Interventional Radiology ᛛⴚߦࠃࠆૐଚⷅᴦ≮ߦ㑐ߔࠆ⎇ⓥ߽⋓ࠎߣߥࠆߢ޽ࠈ߁‫߹ޕ‬ߚ㧘⚦⢩߿ಽሶ࡟ࡌ࡞ߢߩᩭකቇ⤳ེᯏ⢻⹏ଔ߇ߢ߈ࠆࠃ߁ߦߥࠆߣ㧘ࠕࡐ࡯࠻ࠪࠬߩ↹௝ൻ߿ฦ⒳ઍ
⻢ߩ↹௝⴫␜߇น⢻ߣߥࠅ㧘ㄭ޿዁᧪⥃ᐥ߳ᔕ↪ߢ߈ࠆน⢻ᕈࠍ߽⒁߼ߡ޿ࠆ‫ޕ‬᡼኿✢ᴦ≮㑐ㅪߢߪ㧘᡼኿✢ᴦ≮ⵝ⟎߇ᦨᣂߩⵝ⟎߳ᦝᣂߐࠇࠆ੍ቯߢ޽ࠅ㧘ࠃࠅലᨐ⊛ߢ೽૞↪ߩዋߥ޿᡼኿✢ᴦ≮߇น⢻ߣߥࠆߢ޽ࠈ߁‫޿઻ߦࠇߎޕ‬ᒝᐲᄌ⺞᡼኿✢ᴦ≮ᴺ㧔IMRT㧕ߪ੹ᓟᄢ߈ߊ⊒ዷߔࠆߣᕁࠊࠇࠆ‫ޕ‬᡼኿✢ᴦ≮ߪ㧘Radiation Oncology ߣߒߡ㓸ቇ⊛ᴦ≮ߣߒߡ߽⊒ዷߒߡ߅ࠅ㧘੹ᓟ߽ߘߩᣇะᕈߪᄌࠊࠄߥ޿ߣᕁࠊࠇࠆ‫ߚ߹ޕ‬㧘↲⁁⣼ᯏ⢻੣ㅴ∝߿↲⁁⣼߇ࠎߦኻߒߡⴕࠊࠇߡ߈ߚ㕖ኒኽ᡼኿✢ᴦ≮ߪ㧘੹ᓟᣂߚߥ᡼኿ᕈක⮎ຠ߇㐿⊒ߐࠇߡ߅ࠅ㧘ߘߩਛߢߪ㧘89Sr㧔ࡔ࠲ࠬ࠻ࡠࡦ㧕ࠍ↪ ޿ ߚ 㛽 ォ ⒖ ߩ ᴦ ≮ ߿ 㕖 ࡎ ࠫ ࠠ ࡦ ࡝ ࡦ ࡄ ⣲ ߦ ኻ ߔ ࠆ ᛫ ේ ᛫ ૕ ෻ ᔕ ࠍ ೑ ↪ ߒ ߚ 90Y-Ibritumomab
Tiuxetan㧔࠯ࡃ࡝ࡦ㧕ߪ੹߹ߢߦߥ޿ᣂߒ޿ In Vivo ߦࠃࠆ᡼኿✢ᴦ≮ᴺߣߒߡᦼᓙߐࠇߡ޿ࠆ‫ޕ‬㧙㧙㧔8㧕∉ቇ࡮੍㒐කቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
∉ቇࠍᣇᴺ⺰ߣߒߡ↪޿ߚ߇ࠎߘߩઁߩ↢ᵴ⠌ᘠ∛ߩ࡝ࠬࠢⷐ࿃ࠍ᣿ࠄ߆ߦߔࠆ⎇ⓥ㧘ⴕേ⑼ቇ෸߮⚻ᷣቇ╬␠ળ⑼ቇߩᚻᴺߦၮߠߊක≮⹏ଔ⎇ⓥ߿ᖚ⠪ⴕേ㧘කᏧ࡮ᖚ⠪㑐ଥߦ㑐ߔࠆ⎇ⓥࠍ߅ߎߥߞߡ޿ࠆ‫ޕ‬޿ߕࠇ߽ੱ㑆ߩ࡜ࠗࡈࠬ࠲ࠗ࡞࡮ⴕേߦ㊀ὐࠍ߅߈㧘ੱ㑆㓸࿅ࠍኻ⽎ߣߒߡ޿ࠆ‫ޕ‬1㧕߇ࠎߩ∉ቇ⎇ⓥ
߇ࠎߩ∉ቇ⎇ⓥߩਛᔃߪ㧘ᐔᚑ 4 ᐕߦ㐿ᆎߒߚ㜞ጊᏒ૑᳃⚂ 3 ਁੱࠍኻ⽎ߣߒߚࠦࡎ࡯࠻⎇ⓥ㧔㜞ጊࠬ࠲࠺ࠖ㧕ߢ޽ࠆ‫ߦᤨࡦࠗ࡜ࠬ࡯ࡌޕ‬㘩↢ᵴࠍਛᔃߣߒߚஜᐽߣ↢ᵴ⠌ᘠߦ㑐ߔࠆ⺞ᩏࠍ߅ߎߥߞߡ߅ࠅ㧘ߘߩᓟߩ߇ࠎ⊒↢ߦߤߩࠃ߁ߥ↢ᵴⅣႺⷐ࿃߇㑐ㅪߔࠆ߆ࠍ⹏ଔߔࠆ‫ޕ‬ᣢߦᄢ⣺߇ࠎ㧘⢗߇ࠎߩ࡝ࠬࠢⷐ
࿃ߦߟ޿ߡႎ๔ߒߡ޿ࠆ߇㧘⃻࿷㧘ㅴⴕਛߢ㧘ઁߩ⤳ེߩ߇ࠎߦߟ޿ߡ߽੹ᓟႎ๔ࠍട߃ࠆ੍ቯߢ޽ࠆ‫ޕ‬੃߇ࠎߦ㑐ߒߡߪ㧘࡝ࠬࠢⷐ࿃୥⵬ߣߒߡᄢ⼺៨ข߿ࠗ࠰ࡈ࡜ࡏࡦઍ⻢‛㧘ᄛ㑆ᾖ᣿㧘ࡔ࡜࠻࠾ࡦߦ⌕⋡ߒ㧘ࠤ࡯ࠬ࡮ࠦࡦ࠻ࡠ࡯࡞⎇ⓥ߿ᮮᢿ⎇ⓥߩ࠺ࠩࠗࡦߢ੃߇ࠎ࡝ࠬࠢ߿ࠛࠬ࠻ࡠࠥࡦ୯㧘IGF-1 ୯㧘੃⣼⚵❱ኒᐲߥߤ੃߇ࠎߩ࡝ࠬࠢࡑ࡯ࠞ࡯ߣߩ㑐ㅪࠍ⹏ଔߒߡ޿ࠆ‫ߚ߹ޕ‬㧘੃߇ࠎ࡝ࠬࠢߩ⇣ߥࠆᣣᧄੱ㧘ᣣ♽☨࿖ੱ㧘☨࿖⊕ੱᅚᕈߦ߅޿ߡ੃⣼⚵❱ኒᐲࠍ฽߻੃߇ࠎ࡝ࠬࠢߩࡑ࡯ࠞ࡯Ყセ⎇ⓥ߽ࡂࡢࠗ≸࠮ࡦ࠲࡯ߣߩ౒ห⎇ⓥߣߒߡ߅ߎߥߞߡ޿ࠆ‫ޕ‬ሶች㗪ㇱ߇ࠎߦ㑐ߔࠆ⎇ⓥߢߪ㧘ઁᄢቇߣߩ౒หߦࠃࠆሶች㗪ㇱ⇣ᒻᚑᖚ⠪ߩㅊ〔⎇ⓥߦෳടߒ㧘HPV ᗵᨴࠍਛᔃߦሶች㗪ㇱ߇ࠎߩෂ㒾࿃ሶߩหቯࠍ߅ߎߥߞߡ޿ࠆ‫ޕ‬
2㧕↢ᵴ⠌ᘠ∛╬ߩ∉ቇ⎇ⓥ߇ࠎએᄖߦ㧘ᔃⴊ▤㓚ኂ㧘⣖තਛ㧘♧ዩ∛㧘㜞⢽ⴊ∝㧘㜞ⴊ࿶∝ߥߤߩ↢ᵴ⠌ᘠ∛߿⊕ౝ㓚㧘⡊㡆㧘⧎☳∝ߥߤ↢ᵴ⠌ᘠ߇㑐ਈߔࠆߣ⠨߃ࠄࠇࠆ∔ᖚߦߟ޿ߡ߽㜞ጊࠬ࠲࠺ࠖ߿৻⥸ஜᐽᚑੱࠍኻ⽎ߣߒߚᮮᢿ⎇ⓥߢ㧘࡝ࠬࠢⷐ࿃ߩหቯߣ੍㒐ߩ޽ࠅᣇߦߟ޿ߡ⎇ⓥࠍ߅ߎߥߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ᐜఽࠍኻ⽎ߦᮮᢿ⎇ⓥ㧘ㅊ〔⎇ⓥߢࠕ࡟࡞ࠡ࡯ߩ࡝ࠬࠢⷐ࿃ߦߟ޿ߡߩ⎇ⓥ߽ⴕߞߡ޿ࠆ‫ޕ‬
3㧕ᩕ㙃∉ቇ⎇ⓥ㘩ຠ㧘ᩕ㙃⚛㧘․ߦࠗ࠰ࡈ࡜ࡏࡦ៨ขࠍਛᔃߦࡎ࡞ࡕࡦߦ㑐ㅪߔࠆ∔ᖚ߿∝⁁ߦߟ޿ߡ㑐ㅪᕈࠍ⎇ⓥߒߡ޿ࠆ‫ޕ‬㘩੐߆ࠄ៨ขߐࠇࠆࡔ࡜࠻࠾ࡦߦߟ޿ߡ߽⌕⋡ߒ㧘ߘߩஜᐽᓇ㗀ࠍ⹏ଔߔࠆ⎇ⓥࠍ㐿ᆎߒߡ޿ࠆ‫ޕ‬
4㧕ᖚ⠪ߩⴕേකቇ⎇ⓥ
߇ࠎᖚ⠪ߩ♖␹⊛ߥㆡᔕᐲߦ㑐ਈߔࠆᔃℂቇ⊛㧘ⴕേቇ⊛࿃ሶࠍ⷗಴ߘ߁ߣߒߡ޿ࠆ‫ߚ߹ޕ‬㧘ᴦ≮߿⮎೷ߦኻߔࠆᖚ⠪ߩᗧᕁ᳿ቯ߿ߘࠇߦ෸߷ߔⷐ࿃ߩಽᨆࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
᳗↰⍮㉿
ಎᢎ᝼(૬છ)㧦 㜞Ⴆ⋥⢻
ਛ᧛ߎߕᨑ
ഥᢎ㧦
๺↰ᕺሶ
ഥᢎ㧦

Chisato Nagata
Naoyoshi Takatsuka
Kozue Nakamura
Keiko Wada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᳗↰⍮㉿. ੃߇ࠎߩ∉ቇߣ੍㒐㧦↰ፉ๺㓶㧘ฎ㊁⚐ౖ ✬㧘߇ࠎ⎇ⓥߩ޿߹ ╙ 4 Ꮞ㧘߇ࠎߩ∉ቇ㧘᧲੩㧦᧲੩಴ ળ㧧2006 ᐕ㧦51㧙60㧚
2㧕 ᳗↰⍮㉿. ࠗ࠰ࡈ࡜ࡏࡦߩࡅ࠻ஜᐽߦ߅ߌࠆᓎഀ̆∉ቇ⎇ⓥ߆ࠄ㧦⷏Ꮉ⎇ᰴ㇢ ⋙ୃ㧘㘩ຠᯏ⢻ᕈߩ⑼ቇ㧘↥ᬺᛛⴚࠨ࡯ࡆࠬ࠮ࡦ࠲࡯㧘᧲੩㧧2008 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Nagata C. Soyfood consumption in Asian countries versus western countries and epidemiologicalevidence for soy health effects. In: Discover the World of Soy: Impact on Health. Belgium:Alpro
Soya;2008:22-25.
✚⺑㧔๺ᢥ㧕
1㧕 ᳗↰⍮㉿㧚ᣂⷙ࡝ࠬࠢࡈࠔࠢ࠲࡯ߣ੍㒐⎇ⓥ. ᣣᧄ⥃ᐥ 2006 ᐕ㧧64 Ꮞ㧦437㧙441.
2㧕 ᳗↰⍮㉿㧚㜞⢽ⴊ∝ ࠗ࠰ࡈ࡜ࡏࡦߣࠦ࡟ࠬ࠹ࡠ࡯࡞ߩ㑐ଥߪ㧫Q&A ߢࠊ߆ࠆ. ⢈ḩߣ♧ዩ∛㧚2006㧧5
Ꮞ㧦433㧙434㧚
✚⺑㧔᰷ᢥ㧕ߥߒ㧙㧙ේ⪺㧔๺ᢥ㧕ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Matsumoto K, Yasugi T, Oki A, Fujii T, Nagata C, Sekiya S, Hoshiai H, Taketani Y, Kanda T, Kawana
T, Yoshikawa H. IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of
cervical intraepithelial neoplasia. Cancer Lett. 2006;231:309-313.
2㧕 Mizoue T, Inoue M, Tanaka K, Tsuji I, Wakai K, Nagata C, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking andcolorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:25-39.
3㧕 Wakai K, Inoue M, Mizoue T, Tanaka K, Tsuji I, Nagata C, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Tobacco smoking and lungcancer risk: an evaluation based on a systematic review of epidemiological evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:309-324.
4㧕 Nagata C, Mizoue T, Tanaka K, Tsuji I, Wakai K, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan: Tobacco smoking and breast
cancer risk: an evaluation based on a systematic review of epidemiological evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:387-394.
5㧕 Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer.
2006;55:1-12.
6㧕 Tanaka K, Tsuji I, Wakai K, Mizoue T, Nagata C, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Cigarette smoking and livercancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese.
Jpn J Clin Oncol. 2006;36:445-456
7㧕 Mizoue T, Tanaka K, Tsuji I, Wakai K, Nagata C, Otani T, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking andcolorectal cancer risk: an evaluation based on a systematic review of epidemiologic evidence among theJapanese population. Jpn J Clin Oncol. 2006;36:582-597.
8㧕 Nagata C, Oba S, Shimizu H. Associations of menstrual cycle length with intake of soy, fat, and dietaryfiber in Japanese women. Nutr Cancer. 2006;54:166-170.
9㧕 Oba S, Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. The
relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: A
prospective study in Japan. Cancer Lett. 2006;244:260-267.
10㧕 Nagata, C, Iwasa S, Shiraki M, Shimizu H. estrogen and ǩ-fetoprotein levels in maternal andumbilical cord blood samples in relation to birth weight. Cancer Epidemiol Biomarkers Prev.
2006;15:1469-1472.
11㧕 Nagata, C, Iwasa S, Shiraki M, Ueno T, Uchiyama S, Urata K, Sahashi Y, Shimizu H. Associations
among maternal soy intake, isoflavone levels in urine and blood samples, and maternal and umbilicalhormone concentrations (Japan). Cancer Causes Control. 2006;17:1107-1113.
12㧕 Nishino Y, Inoue M, Tsuji I, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsugane S, Research Group forthe Development and Evaluation of Cancer Prevention Strategies in Japan. Alcohol Tobacco smoking
and gastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among
the Japanese population. Jpn J Clin Oncol. 2006;36:800-807.
13㧕 Maskarinec G, Paganol I, Chen Z, Nagata C, Gram IT. Ethnic and geographic differences inmammographic density and their association with breast cancer incidence.Breast Cancer Res Treat.
2007;104:47-56.
14㧕 Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I , Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and lungcancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2007;37:168-174.
15㧕 Nagata C, Iwasa S, Shiraki M, Sahashi Y, Shimizu H. Association of maternal fat and alcohol intake
with maternal and umbilical hormone levels and birth weight. Cancer Sci. 2007;98:869-873.
16㧕 Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, Kawashita Y, Yoshida N, Suetsugu
A, Kato T, Okuda J, Ida K. Nonalcoholic fatty liver disease is a novel predictor of cardiovasculardisease. World J Gastroenterol. 2007;13:1579-1584.
17㧕 Takata Y, Maskarinec G, Rinaldi S, Kaarks R, Nagata C. Serum insulin-like growth factor-I levels
among women in Hawaii and Japan with different levels of tofu intake. Nutr Cancer. 2006;56:136-142.
18㧕 Maskarinec G, Takata Y, Chen Z, Nagata C, Pagano I, Hayashi K, Arendell L, Skeir G, Rinaldi S,
Kaaks S. IGF-I and mammographic density in four geographic locations: A pooled analysis. Int J
Cancer. 2007;121:1786-1792.
19㧕 Oba S, Nagata C, Snimizu N, Shimizu H, Kametani M, Takayama N, Ohmura T, Matsushita S. Soy
product consumption and the risk of colon cancer: a prospective study in Takayama, Japan. Nutr㧙㧙

IF 3.398

IF 1.269

IF 1.269

IF 1.269
IF 2.361

IF 1.269

IF 1.269
IF 2.361

IF 3.398

IF 4.500

IF 2.847

IF 1.269

IF 4.671

IF 1.376
IF 3.869

IF 2.361

IF 4.693

Cancer. 2007;57:151-157.
20㧕 Nagata C, Mizoue T, Tanaka K, Tsuji I , Wakai K, Inoue M, Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and breast
cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2007;37:568-574.
21㧕 Inoue M, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsuji I , Tsugane S, Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and totalcancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2007;37:692-700.
22㧕 Tanaka T, Nagata C, Oba S, Takatsuka N, Shimizu H. Prospective cohort study of body mass index inadolescence and death from stomach cancer in Japan. Cancer Sci. 2007;98:1785-1789.
23㧕 Sawada A, Aoyama A, Yamamoto T, Takatsuka N. Long-term therapeutic outcome of acute primary
angle closure in Japanese. Jpn J Ophthalmol. 2007;51:353-359.
24㧕 Nagata C, Matsubara T, Hara T, Fujita H, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H.
Urinary 6-sulfatoxymelatonin and mammographic density in Japanese women. Cancer Epidemiol
Biomarkers Prev. 2007;16:2509-2512.
25㧕 Shimazu T, Tsuji I, Inoue M, Wakai K, Nagata C, Mizoue T, Tanaka K, Tsugane S; Research Group forthe Development and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking andgastric cancer risk: an evaluation based on a systematic review of epidemiologic evidence among theJapanese population. Jpn J Clin Oncol. 2008;38:8-25.
26㧕 Nagata C, Ueno T, Uchiyama S, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H. Dietary andlifestyle correlates of urinary excretion status of equol in Japanese women. Nutr Cancer.
2008;60:49-54.
27㧕 Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, Otani T, Tanaka K, Matsuo K, Tamakoshi
A, Sasazuki S, Tsugane S; Research Group for Development and Evaluation of Cancer Prevention
Strategies in Japan. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of resultsfrom five cohort studies. Am J Epidemiol. 2008;167:1397-1406.
28㧕 Oba S, Nakamura K, Sahashi Y, Hattori A, Nagata C. Consumption of vegetables alters morning
urinary 6-sulfatoxymelatonin concentration. Nutr Cancer. 2008;45:17-23.
29㧕 Nakamura K, Nagata C, Oba S, Takatsuka N, Shimizu H. Fruit and vegetable intake and mortality
from cardiovascular disease are inversely associated in Japanese women but not in men. J Nutr.
2008;138:1129-1134.
30㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Smoking and risk ofcedar pollinosis in Japanese men and women. Int Arch Allergy Immunol. 2008;147:117-124.
31㧕 Nagata C, Nagao Y, Yamamoto S, Shibuya C, Kashiki Y, Shimizu H. Light exposure at night, urinary
6-sulfatoxymelatonin, and serum estrogens and androgens in postmenopausal Japanese women.
Cancer Epidemiol Biomarkers Prev. 2008;17:1418-1423.
32㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Soy isoflavone intake is
not associated with the development of cedar pollinosis in adults. J Nutr. 2008;138:1372-1376.
33㧕 Hirokawa K, Nagata C, Takatsuka N, Shimizu N, Shimizu H. Rationality/anti-emotionality
personality and dietary habits in a community population in Japan. J Epidemiol. 2008;18:183-190.
34㧕 Oba S, Nagata C, Nakamura K, Takatsuka N, Shimizu H. Self-reported diabetes mellitus and risk ofmortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based
prospective cohort study in Japan. J Epidemiol. 2008;18:197-203.
35㧕 Tanaka K, Tsuji I, Wakai K, Nagata C, Mizoue T, Inoue M, Tsugane S; Research Group for theDevelopment and Evaluation of Cancer Prevention Strategies in Japan. Alcohol drinking and livercancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese
population. Jpn J Clin Oncol. 2008;38:816-838.

IF 2.361

IF 1.269

IF 1.269
IF 3.869
IF 0.770

IF 4.642

IF 1.269

IF 2.361

IF 5.285
IF 2.361

IF 3.771

IF 4.642
IF 3.771
IF 1.906

IF 1.906

IF 1.2694㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧘ᱞ↰ೣਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦
ᾖ᣿ⅣႺߣ੃߇ࠎ࡝ࠬࠢߩ㑐ଥߦ੺࿷ߔࠆࡔ࡜࠻࠾ࡦߩᓎഀ㧧ᐔᚑ 18 ᐕᐲ㧧4,500 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᳯፒቁⴕ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․ቯ⎇ⓥ㧦ࠛࠢࠝ࡯࡞
↥↢ߣ੃߇ࠎ࡝ࠬࠢߩ㑐ㅪ߅ࠃ߮ࠛࠢࠝ࡯࡞↥↢⢻ߩⷙቯ࿃ሶߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
9,900 ජ౞(4,800㧦5,100 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ᵤ㊄᣽৻㇢㧘⎇ⓥಽᜂ⠪㧦᳗↰⍮㉿ઁ㧘ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧘╙ 3 ᰴኻ߇ࠎ✚วᚢ⇛⎇ⓥ੐ᬺ㧧↢ᵴ⠌ᘠᡷༀߦࠃࠆ߇ࠎ੍㒐ᴺߩ㐿⊒ߣ⹏ଔ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧20,000 ජ౞(7,000㧧7,000㧧6,000 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ศᎹ⵨ਯ㧘⎇ⓥಽᜂ⠪㧦㜞Ⴆ⋥⢻ઁ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ሶ㧙㧙ች㗖ㇱ⊒߇ࠎߩኋਥⷐ࿃ߣߒߡߩ HLA ㆮવሶᄙဳߦ㑐ߔࠆ᳃ᣖ∉ቇ⊛⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧
1,600 ජ౞(800㧦800 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㜞Ⴆ⋥⢻㧘⎇ⓥಽᜂ⠪㧦⷏᧛๟ਃ㧧ක≮⚻ᷣ⎇ⓥᯏ᭴⎇ⓥഥᚑ㊄㧘ක≮ᖱႎࠪࠬ࠹ࡓ
߇∛㒮↢↥ᕈ㧘∛㒮ౝㇱⅣႺ෸߮ᄖㇱⅣႺߦ෸߷ߔᓇ㗀ߩ⹏ଔ㧧ᐔᚑ 18 ᐕᐲ㧧750 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ߎߕᨑ㧘⎇ⓥಽᜂ⠪㧦᳗↰⍮㉿㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦Უሶߦ߅ߌࠆ⢽⾰෸߮ࠗ࠰ࡈ࡜ࡏࡦࠍਛᔃߣߒߚᩕ㙃៨ขߣࠕ࡟࡞ࠡ࡯∔ᖚߣߩ㑐ㅪᕈߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧
1,130 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧘ᱞ↰ೣਯ, ⮮↰ᐢᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)㧦੃߇ࠎ࡝ࠬࠢߣߒߡߩࠛࠬ࠻ࡠࠥࡦ㧘ࡔ࡜࠻࠾ࡦߣࠨ࡯ࠞ࠺ࠖࠕࡦ࡝࠭ࡓߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧10,000 ජ౞(5,200㧧4,800 ජ౞)
8㧕 ⎇ⓥઍ⴫⠪㧦᳗↰⍮㉿, ⎇ⓥಽᜂ⠪㧦ᷡ᳓ᒄਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ฦ⒳ࠕࡒ
ࡁ㉄߅ࠃ߮ DNA ࡔ࠴࡞ൻߦ㑐ਈߔࠆ㘩੐࿃ሶߣ߇ࠎ⟕ᖚߦ㑐ߔࠆࠦࡎ࡯࠻⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧
4,400 ජ౞9㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛ߎߕᨑ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(࿾ၞㅪ៤㧦৻⥸)㧦౏⊛ᣉ⸳ߢߩ࡝࠭ࡓㆆ߮ߣኾ㐷⊛⋧⺣ࠍㅢߓߚ⢒ఽᡰេᵴേ㧧ᐔᚑ 20 ᐕᐲ㧧260 ජ౞2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ᄢႦ⵾⮎ᩣᑼળ␠ ዩਛࠗ࠰ࡈ࡜ࡏࡦઍ⻢‛᷹ቯߩߚ߼ߩ౒ห⎇ⓥ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᳗↰⍮㉿㧦
1㧕 ᧲ᶏ౏ⴐⴡ↢ቇℂ੐(㨪⃻࿷)2㧕 ᣣᧄ౏ⴐⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ∉ቇળ⹏⼏ຬ(㨪⃻࿷)ਛ᧛ߎߕᨑ㧦
1㧕 ᧲ᶏ౏ⴐⴡ↢ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙṶ⠪㧘ᐳ㐳᳗↰⍮㉿㧦
1㧕 The 73rd Annual Meeting of KoSFoST Korea-China-Japan International Symposium “Asian
Summit for World Foods” (2006.06, Jeju, Korea.:Soy intake and biomarkers of breast cancer risk
among Japanese women; symposist)2㧕 ╙ 8 ࿁ᣣᧄ≸ቇળᏒ᳃౏㐿⻠ᐳ(2006 ᐕ 9 ᦬㧘ᮮᵿ㧘߇ࠎߦߥࠄߥ޿ߚ߼ߦ㧘߇ࠎࠍᣧߊߺߟߌࠆ
ߚ߼ߦ‫ࠍࠎ߇ޟ‬㒐ߋ㘩੐‫ޠ‬Ṷ⠪)3㧕 The National Institute of Environmental Health Sciences (NIEHS) Workshop, "Circadian
Rhythms in Human Health and Disorders" (2006.09, Georgetown, Washington, DC.: Light
exposure at night, melatonin, and cancer; speaker)
4㧕 ╙ 44 ࿁ᣣᧄ≸ᴦ≮ቇળ(2006 ᐕ 10 ᦬㧘᧲੩㧘߇ࠎ੍㒐ߩᦨ೨✢‫ޠࡦࡏ࡜ࡈ࠰ࠗߣࠎ߇੃ޟ‬Ṷ⠪)‫∉ࠎ߇ޟ‬ቇߩ⚫੺‫ޠ‬Ṷ⠪)
5㧕 ‫․ࠎ߇ޟ‬ቯ‫ޠ‬㕍ዋᐕ࡮Ꮢ᳃౏㐿⻠ᐳ(2006 ᐕ 11 ᦬㧘ᓼፉ㧘㧙㧙6㧕 ╙ 4 ࿁ᣣᧄ੍㒐කቇળ(2006 ᐕ 12 ᦬㧘ߐ޿ߚ߹Ꮢ㧘‫ޟ‬ᄢ⼺࡮ࠗ࠰ࡈ࡜ࡏࡦߣᅚᕈߩஜᐽ‫ޠ‬Ṷ⠪)
7㧕 Soy Nutrition Institute Japan (2007 ᐕ 2 ᦬㧘᧲੩ ‫ᦝޟ‬ᐕᦼᅚᕈߣࠗ࠰ࡈ࡜ࡏࡦ‫ޠ‬Ṷ⠪)8㧕 7th International Symposium Role of Soy in health and disease prevention.(2007.05, Bangkok.
Studies on soy intake and risk of breast cancer in Japanese women; speaker)
9㧕 3rd International Conference on Polyphenols and Health (2007.11, Kyoto, Dietary soy and riskof breast cancer; symposist)10㧕 ␹ᄹᎹ⋵߇ࠎ࠮ࡦ࠲࡯߇ࠎࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᅚᕈߣ߇ࠎ‫(ޠ‬2007 ᐕ 12 ᦬㧘ᮮᵿ‫ޟ‬ᅚᕈߣ੃߇ࠎ‫ޠ‬Ṷ⠪)11㧕 ╙ 13 ࿁ᗲ⍮⋵߇ࠎ࠮ࡦ࠲࡯࿖㓙ࠪࡦࡐࠫ࠙ࡓ‫∉ࠎ߇੃ޟ‬ቇ੍㒐ߣ୘೎ൻ⸻ᢿ࡮ᴦ≮ߩዷᦸ‫(ޠ‬2008ᐕ 2 ᦬㧘ᐳ㐳)12㧕 JCA-AACR Cancer Research Conference. The Latest Advances in Breast Cancer Research:
From Basic Science to Therapeutics (2008.07, Hyogo, Japan :Hormone-related risk factors forbreast cancer in Japanese women; speaker)
13㧕 8th International Symposium Role of Soy in Health and Disease Prevention (2008.11, Tokyo,
Chairperson)㜞Ⴆ⋥⢻㧦
1㧕 ጘ㒂⋵࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(2006 ᐕ 1 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛੍㒐ߣ࿾ၞߩขࠅ⚵ߺ‫ޠ‬Ṷ⠪)
2㧕 ᴤൻቇ⻠Ṷળ‫ޟ‬ᯏ⢻ᕈ㘩ຠߩ⑼ቇߣዷᦸ‫(ޠ‬2006 ᐕ 11 ᦬㧘ጘ㒂㧘‫ⴊޟ‬ᷡ⢽⾰ߦኻߔࠆᄢ⼺ߩᓇ㗀‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᳗↰⍮㉿㧦For Outstanding Contribution to Increasing Scientific Understanding of the Health
Effects of Soyfoods and Soybean Constituents. 8th International Symposium Role of Soy in
Health and Disease Prevention (2008)9㧚␠ળᵴേ᳗↰⍮㉿㧦
1㧕 ᳗↰⍮㉿㧦ౝ㑑ᐭ㘩ຠ቟ోᆔຬળኾ㐷ຬ(㨪⃻࿷)2㧕 ᳗↰⍮㉿㧦ᣣᧄቇⴚળ⼏ㅪ៤ળຬ(㨪⃻࿷)3㧕 ᳗↰⍮㉿㧦ጘ㒂Ꮢ଻ஜක≮ክ⼏ળᆔຬ(㨪⃻࿷)4㧕 ᳗↰⍮㉿㧦ጘ㒂⋵ᑪ▽ክᩏᆔຬળᆔຬ(㨪⃻࿷)5㧕 ᳗↰⍮㉿㧦ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᆔຬ(㨪⃻࿷)6㧕 ᳗↰⍮㉿㧦ጘ㒂⋵ⅣႺᓇ㗀⹏ଔክᩏળᆔຬ(㨪⃻࿷)㜞Ⴆ⋥⢻㧦ක≮⚻ᷣቇಽ㊁ෳᾖਛ᧛ߎߕᨑ㧦
1㧕 Უሶ↢ᵴᡰេᣉ⸳‫⪇࡯ࡢ࡜ࡈ࡮ࡦࠨޟ‬㓁‫(ޠ‬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᳗↰⍮㉿㧦↢ᵴ⠌ᘠᡷༀߦࠃࠆ੃߇ࠎ੍㒐ᴺߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲ㧘ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ਥછ⎇ⓥ⠪ᵤ㊄᣽৻㇢)㧦53㧙60(2007 ᐕ 4 ᦬)㧘73
㧙80(2008 ᐕ 4 ᦬)
11㧚ႎ㆏1㧕 ᳗↰⍮㉿㧦߇ࠎߩේ࿃ 3 ഀ߇㘩੐㧦ᦺᣣᣂ⡞(2006 ᐕ 10 ᦬ 30 ᣣ)
2㧕 ᳗↰⍮㉿㧦ᄢ⼺ߣᦝᐕᦼ∝⁁㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 20 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᬺ❣Ⓧ਄ߍߣ⎇ⓥ⾌ߩ⏕଻ࠍ⋡ᜰߔᔅⷐ߇޽ࠆ‫ޕ‬㧙㧙⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࡔࠞ࠾࠭ࡓㅊ᳞ࠍ㊀ⷞߒ߇ߜߢ޽ࠆකቇ⎇ⓥಽ㊁ߦ߅޿ߡ㧘ᒰቇ໧ಽ㊁ߩࠃ߁ߦੱ㑆㓸࿅ࠍኻ⽎ߦ࿃ᨐ㑐ଥߩᛠីࠍਛᔃߣߔࠆ⎇ⓥߩ㊀ⷐᕈࠍᒝ⺞ߔࠆ‫⥃ޕ‬ᐥ∉ቇࠍ฽߼∉ቇ⊛ᣇᴺ⺰ߩ⚫੺߽᦭↪ߢ޽ࠈ
߁‫ޕ‬
੹ᓟߩዷᦸ
ࠛࡆ࠺ࡦࠬᕈߩ㜞޿∉ቇ⎇ⓥߣߒߡᄢⷙᮨࠦࡎ࡯࠻⎇ⓥߩᔅⷐᕈ߽⹺⼂ߐࠇߡ߈ߚ߇㧘⎇ⓥෳട⠪ߩ⏕଻㧘୘ੱᖱႎ଻⼔ߩ໧㗴ߪ㧘⎇ⓥ⠪୘ੱߩദജߦଐሽߔࠆߦߪ㒢ᐲ߇޽ࠅ㧘࿖ኅ⊛ࡊࡠࠫࠚࠢ࠻ߣߒ
ߡ૏⟎ߠߌ߇ᦸ߹ߒ޿‫ޕ‬ታ㓙㧘㖧࿖ߢߪ㧘ߘߩࠃ߁ߥᣇᴺߢ∉ቇ⎇ⓥ߇㘧べ⊛ߦ⊒ዷߒߟߟ޽ࠆ‫ޕ‬࿖ߩਥዉߦࠃࠆ⎇ⓥ߇ⴕࠊࠇࠆ႐ว㧘ᄢቇߪߘࠇߦᔅⷐߥኾ㐷ኅ㓸࿅ߩଏ⛎Ḯߣߒߡߩᓎഀࠍᜬߟߢ޽ࠈ߁‫ޕ‬ߘߩ৻ᣇ㧘ᄢቇߪዊⷙᮨߢ޽ࠆ߇઒⺑ᕈߩ㜞޿⎇ⓥ߿ᣇᴺ⺰ߦ㑐ࠊࠆ⎇ⓥߥߤ㧘⁛⥄⦡޽ࠆᚑᨐ߇ⷐ᳞
ߐࠇࠆߣ⠨߃ࠄࠇࠆ‫ߥ⊛ੱޕ‬ల⿷߽฽߼ᣇᴺ⺰ߦ♖ㅢߒߚ⎇ⓥ⠪ߩ⢒ᚑߦദ߼ࠆߣߣ߽ߦ㧘ࠝ࡝ࠫ࠽࡝
࠹ࠖߩ㜞޿⎇ⓥࠍ⋡ᜰߔ‫ޕ‬㧙㧙㧔9㧕⥃ᐥ⣲≌ቇಽ㊁1㧚⎇ⓥߩ᭎ⷐ
2008 ᐕ 11 ᦬ߩ┙ߜ਄ߍߚᣂߒ޿ಽ㊁ߢ޽ࠅ㧘ᦨㄭߣߺߦ㊀ⷐᕈࠍჇߒߡ޿ࠆ⥃ᐥ⣲≌ቇ ClinicalOncology ࠍขࠅᛒ߁‫ޕ‬
1. ࿕ᒻ⣲≌ߦߟ޿ߡᚻⴚ㧘ౝⷞ㏜ᴦ≮㧘ൻቇ≮ᴺ㧘᡼኿✢ᴦ≮ߥߤ㧘㓸ቇ⊛ᴦ≮ߩ᭴▽ߣᚑ❣ߩಽᨆࠍⴕߥ߁‫ޕ‬
2. ⴊᶧ⣲≌ߦߟ޿ߡᣂߒ޿࡟ࠫࡔߩ㐿⊒ࠍⴕߥ߁‫ޕ‬
3. 1㧘2 ࠍ㆐ᚑߔࠆ਄ߢᔅⷐߥ⥃ᐥ⹜㛎࠺ࠩࠗࡦߩ⎇ⓥࠍⴕߥ߁‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ᫪⣁ਭ㓉ᢎ᝼(૬છ)㧦 દ⮮ༀⷙಎᢎ᝼(૬છ)㧦 㢬⷗ ኼ
ේ ᱞᔒ
⥃ᐥ⻠Ꮷ㧦

Hisataka Moriwaki
Yoshinori Ito
Hisashi Tsurumi
Takeshi Hara3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᷡ᳓㓷ੳ㧘᫪⣁ਭ㓉㧚㕖Ⅳᑼ࡟࠴ࡁࠗ࠼ߦࠃࠆ⢄⊒≸ߩ੍㒐㧦⷏ญୃᐔ✬㧚⢄⎬ᄌߩࡑࡀࠫࡔࡦ࠻㧚᧲੩㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2007 ᐕ㧦84㧙89㧚
2㧕 ᫪⣁ਭ㓉㧚╙ 5 ┨ ∛ᘒᩕ㙃ߣᩕ㙃≮ᴺ㧘7 ߘߩઁߩ∔ᖚ㧘Ԝ߇ࠎ㧦ᣣᧄ∛ᘒᩕ㙃ቇળ✬㧚ᡷ⸓╙ 2 
⹺ቯ ∛ᘒᩕ㙃ኾ㐷Ꮷߩߚ߼ߩ∛ᘒᩕ㙃ࠟࠗ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࡟ࡆࡘ࡯␠㧧2008 ᐕ㧦248㧙249㧚
3㧕 ቟↰ᶈੑ㧘દ⮮ༀⷙ㧚ᐔ㊁๺ⴕ✬㧚2008 ᐕታ⠌ߦⴕߊ೨ߩⷡ߃ࠆක⮎ຠ㓸㧙᦯⮎ᜰዉߦᓎ┙ߟ㧙㧘᧲੩㧦ᑝᎹᦠᐫ㧧2008 ᐕ㧚
4㧕 ᄢ⍹ੌਃ㧘ᳰᧃ⵨᣿㧘દ⮮ༀⷙ✬⪺㧘߇ࠎൻቇ≮ᴺࡢ࡯ࠢࠪ࡯࠻╙ 3 㧘᧲੩㧦ߓ߶߁㧧2008 ᐕ㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘᫪⣁ਭ㓉㧚㝼㛽ߦࠃࠆ⋤⣺ᘟᕈἻ∝ᕈ⡺⧘⣲㧘Gastroenterological endoscopy 2008
ᐕ㧧50 Ꮞ㧦66㧙67㧚
2㧕 ═ේජ༹㧘ේ ᱞᔒ㧘㢬⷗ ኼ㧘ᓟ⮮ዏ⛗㧘౗᧛ାብ㧘ศᎹᱞᔒ㧘ጊ↰ବ᮸㧘Ỉ↰㆏ᄦ㧘㜞ᯅ ஜ㧘᫪⣁ਭ㓉㧚ㅧⴊེ⣲≌ߦว૬ߒߚ⊒ᾲᕈᅢਛ⃿ᷫዋ∝ߦኻߔࠆ Biapenem ߩ᦭↪ᕈߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘JapanJ Antibiotics 2008 ᐕ㧧61 Ꮞ㧦115㧙121㧚
3㧕 ะ੗ ᒝ㧘Ⴎደᱜ㆏㧘቟↰৻ᦶ㧘ጤ↰࿻੺㧘౷↰ᩕ৻㧘᫪⣁ਭ㓉㧚㕖ಾ㒰⢄㐷ㇱ⢙▤≸ߦኻߔࠆ⢙㆏ࠬ࠹ࡦ࠹ࠖࡦࠣߩᬌ⸛㧘⢙㆏ 2008 ᐕ㧧22 Ꮞ㧦47㧙55㧚
4㧕 ࿯੗᤯ᐔ㧘቟↰৻ᦶ㧘ጤਅᜏม㧘ጊ↰ᢕሶ㧘↰ਛ⑲ౖ㧘㐳↰⌀ੑ㧘ᑝἑༀା㧘᫪⣁ਭ㓉㧚㤛⦡⡺⧘⣲ᕈ⢙ྙἻߣߩ㐓೎߇໧㗴ߣߥߞߚ⢙ྙ≸ߩ 1 ଀㧘⢄⢙⤟ᴦ⎇⹹ 2008 ᐕ㧧6 Ꮞ㧦49㧙54㧚
5㧕 ᧁ᧛␭ሶ㧘⨹ᧁኡม㧘ᄢ㊁ᥓᒾ㧘ዊ㊁ᧁ┨ੱ㧘੗ᷓ⾆჻㧘౗᧛ାብ㧘ᓟ⮮ዏ⛗㧘ᧃᰴ ᷕ㧘⊕ᧁ ੫㧘═ේජ༹㧘ᷡ᳓㓷ੳ㧘ጊ↰ବ᮸㧘㢬⷗ኼ㧘᫪⣁ਭ㓉㧚਄ⴕ⚿⣺㕒⣂≜ࠍᄾᯏߦ⸻ᢿߐࠇߚᖡᕈ࡝ࡦࡄ⣲ߩ 1଀㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2008 ᐕ㧧22 Ꮞ㧦59㧙61㧚
6㧕 ਤ⠀㓉㧘᧖ጊᱜ㧘ጟ቟િੑ㧘ጊౝᳯ㉿ሶ㧘⷏၂⟤ᄹሶ㧘᧻ᶆసᒾ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚㔚ሶࠞ࡞࠹ࠪࠬ
࠹ࡓߩ৻Ⅳߣߒߡߩ⮎೷▤ℂᜰዉᡰេࠪࠬ࠹ࡓߩ᭴▽㧘ක≮⮎ቇ 2008 ᐕ㧧34 Ꮞ㧦103㧙111㧚
7㧕 㘵ේᄢ⒤㧘᧻ᶆసᒾ㧘ศ᧛⍮ື㧘ᐔ಴⠹⍹㧘⍹ේᱜᔒ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚⢖߇ࠎᖚ⠪ߦ߅ߌࠆ Carboplatinᛩਈ㊂ߩ᳿ቯᣇᴺߣ೽૞↪⊒⃻ߦ㑐ߔࠆ retrospective study㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦
428㧙431㧚
8㧕 ┄↰ᢅᄦ㧘㊁ਛᢅᴦ㧘⍫㊁⾆ਭ㧘૑᧛ᥓሶ㧘ᨋ ⚐㧘દ⮮ༀⷙ㧘ᄢ⍹ੌਃ㧚᛫ MRSA ⮎ߩㆡᱜ૶↪ࠍ⋡ᜰߒߚ⮎‛ⴊਛỚᐲࡕ࠾࠲࡝ࡦࠣታᣉ₸ะ਄߳ߩขࠅ⚵ߺ㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦277
㧙280㧚
9㧕 ਅ↰ᶈᰵ㧘ጟ቟િੑ㧘♿ࡁቯ଻⤿㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚㔚ሶࠞ࡞࠹ᖱႎ߆ࠄಽᨆߔࠆᄢቇ∛㒮ߩ♧ዩ∛∛᫟ᖚ⠪ߩ․ᓽಽᨆߩ⹜ⴕ㨪ᬺോࠍนⷞൻߔࠆ᦭↪ᕈߦߟ޿ߡ㨪㧘⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ(೎ౠ)㧦
89㧙93㧚
10㧕 ጟ቟િੑ㧘ਅ↰ᶈᰵ㧘♿ࡁቯ଻⤿㧘ᱞ↰ ⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂߦ㑐ߔࠆ㔚ሶࠞ࡞࠹ᯏ㧙㧙⢻ߩ᦭↪ᕈߣ໧㗴ὐ㧘⢈ḩߣ♧ዩ∛ 2008 ᐕ㧧7 Ꮞ(೎ౠ)㧦28㧙35㧚
11㧕 ਤ⠀ 㓉㧘ዊ᫪ༀᢥ㧘⍹ේᱜᔒ㧘㜞ᯅ㋈ઍ㧘᧻ᶆసᒾ㧘ᓟ⮮ජኼ㧘દ⮮ༀⷙ㧚࡝ࠬࠢ⹏ଔߦࠃࠆ⺞೷ㆊ⺋㒐ᱛኻ╷ߩ᦭ലᕈߩᬌ⸽㧘ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹ 2008 ᐕ㧧44 Ꮞ㧦1487㧙1490㧚
12㧕 ศ᧛⍮ື㧘ᐔ಴⠹⍹㧘㘵ේᄢ⒤㧘⍹ේᱜᔒ㧘ዊ᫪ༀᢥ㧘ጟ቟િੑ㧘᧻ᶆసᒾ㧘቟↰ᔘม㧘દ⮮ༀⷙ㧚Paclitaxelᛩਈᖚ⠪ߦ߅ߌࠆᛩਈ㊂࡮ᛩਈࠬࠤࠫࡘ࡯࡞ߦၮߠ޿ߚ೽૞↪⸃ᨆ㧘≸ߣൻቇ≮ᴺ 2008 ᐕ㧧35 Ꮞ㧦1721
㧙1726㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Ohnishi T, Yasuda I, Nishigaki Y, Hayashi H, Otsuji K, Mukai T, Enya M, Salem Omar, Nib Soehendra,
Tomita E, Moriwaki H. Intraductal chilled saline perfusion to prevent bile duct injury duringpercutaneous radiofrequency ablation for hepatocellular carcinoma. J Gastroen Hepatol.
2008;23:e410-415.
2㧕 Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG
inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular
carcinoma cells. Cancer Lett. 2008;262:10-18.
3㧕 Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H.
()-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male
C57BL/KsJ-db/db mice. Cancer Prev Res. 2008;1:298-304.
4㧕 Shimizu M, Shirakami Y, Moriwaki H. Targeting Receptor Tyrosine kinases for chemoprevention bygreen tea catechin, EGCG. Int J Mol Sci. 2008;9:1034-1049.
5㧕 Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008;2008:181047.
6㧕 Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki
H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer
Epidemiol Biomarkers Prev. 2008;17:3020-3025.
7㧕 Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H,
Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth
factor receptor in human colon cancer cells. Carcinogenesis. 2008;29:1986-1993.
8㧕 Kanemura N, Tsurumi H, Okuno M, Matsushima-Nishiwaki R, Shimizu M, Moriwaki H. Retinoid X
receptor alpha is highly phosphorylated in retinoic acid-resistant HL-60R cells and the combination of
9-cis retinoic acid plus MEK inhibitor induces apoptosis in the cells. Leukemia Res. 2008;32:884-892.
9㧕 Kanemura N, Tsurumi H, Kasahara S, Hara T, Yamada T, Sawada M, Goto N, Kitagawa JI, Shimizu
M, Oyama M, Moriwaki H. Continuous drip infusion of low dose cytarabine and etoposide with
granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible forintensive chemotherapy. Hematol Oncol. 2008;26:33-38.
10㧕 Tatebe H, Shimizu M, Shirakami Y, Tsurumi H, Moriwaki H. Synergistic growth inhibition by
9-cis-retinoic acid plus trastuzumab in human hepatocellular carcinoma cells. Clin Cancer Res.
2008;14:2806-2812.
11㧕 Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E
attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep.
2008;1:355-361.
12㧕 Hara T, Tsurumi H, Kato T, Imao Y, Kojima Y, Kojima K, Kitagawa J, Katsumura N, Araki H,
Takami T, Moriwaki H. Immunoproliferative small intestinal disease with protein loss complicatedwith duodenal T cell lymphoma during progression. Intern Med. 2008;47:299-303.
13㧕 Doi S, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract
implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal
lymphadenopathy. Gastrointest Endosc. 2008;67:988-990.
14㧕 Ohmori T, Nakamura M, Tada S, Sugiyama T, Itoh Y, Udagawa Y, Hirano K. A highly sensitive assay
for ritodrine in human serum by hydrophilic interaction chromatography-tandem mass spectrometry.
J Chromatogr. 2008;861:95-100.
15㧕 Sobue S, Nemoto S, Murakami M, Ito H, Kimura A, Gao S, Furuhata A, Takagi A, Kojima T,
Nakamura M, Itoh Y, Suzuki M, Banno Y, Nozawa Y, Murate T. Implications of sphingosine kinase 1
expression level for the cellular sphingolipid rheostat; relevance as a marker for daunorubicin
sensitivity of leukemia cell. Int J Hematol. 2008;87:266-275.
16㧕 Aki T, Egashira N, Hama M, Yamauchi Y, Yano T, Itoh Y, Oishi R. Characteristics of gabexate
mesilate-induced cell injury in porcine aorta endothelial cells. J Pharmacol Sci. 2008;106:415-422.
17㧕 Aki T, Egashira N, Yamauchi Y, Hama M, Yano T, Itoh Y, Yamada T, Oishi R. Protective effects ofamino acids against gabexate mesilate–induced cell injury in porcine aorta endothelial cells. J
Pharmacol Sci. 2008;107:238-245.
18㧕 Yano T, Itoh Y, Yamada M, Egashira N, Oishi R. Combined treatment with L-carnitine and apan-caspase inhibitor effectively reverses amiodarone-induced injury in cultured human lungepithelial cells. Apoptosis. 2008;13:543-552.
19㧕 Matsuura K, Ohmori T, Nakamura M, Itoh Y, Hirano K. A simple and rapid determination of valproic㧙㧙

IF 1.673

IF 3.398

IF 0.750

IF 5.406

IF 2.561

IF 2.180

IF 6.250

IF 5.888

IF 2.935

IF 1.491
IF 2.408

IF 2.408

IF 3.043

acid in human plasma using a non-porous silica column and liquid chromatography with tandem mass
spectrometric detection. Biomed Chromatogr. 2008;22:387-393.
IF 1.663

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ጟ㊁ᐘ㓶㧘↰ਛථੑ㧘ዊ᎑⡡৻㧘⷏ญୃᐔ㧘ᷡ᳓㓷ੳ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ᩭౝฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ⢄≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 17㧙21 ᐕᐲ㧧66,000 ජ౞(16,300㧦16,300㧦16,300㧦17,100 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⮮ේ⎇ม㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉㧦ෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄(⢄Ἳ╬స᦯✕ᕆኻ╷⎇ⓥ੐ᬺ)㧦⢄߇ࠎᖚ⠪ߩ QOL ะ਄ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,000 ජ౞(2,000㧦1,300㧦1,250 ජ౞)3㧕 ⎇ⓥઍ⴫⠪㧦᫪⣁ਭ㓉㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓㓷ੳ㧘ጊ↰ᵏᐢ㧦ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙
20 ᐕᐲ㧧3,400 ජ౞(1,800㧦1,600 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦⊕㠽⟵ቬ㧘⎇ⓥಽᜂ⠪㧦᫪⣁ਭ㓉:ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦ᩭౝฃኈ૕߅ࠃ߮ฃኈ૕ဳ࠴ࡠࠪࡦࠠ࠽࡯࠯ࠍᮡ⊛ಽሶߣߒߚ≸ൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧
3,500 ජ౞(1,500㧦1,100㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦วᚑ࡟࠴ࡁࠗ࠼ߣಽሶᮡ⊛ᴦ≮⮎ߣߩ૬↪ߦ㑐ߔࠆ⎇ⓥ(2)㧧ᐔᚑ 18㧙19 ᐕᐲ㧧6,000 ජ౞(3,000㧦3,000 ජ౞)㧦⥝๺ഃ⮎2㧕 ᫪⣁ਭ㓉㧦ᩭ࡟࠴ࡁࠗ࠼ฃኈ૕Ⱞ⊕ࠍಽሶᮡ⊛ߣߒߚ߇ࠎൻቇ੍㒐ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕ
ᐲ㧧450 ජ౞(150㧦150㧦150 ජ౞)㧦⢽ṁᕈࡆ࠲ࡒࡦ
3㧕 ᫪⣁ਭ㓉㧘ᷡ᳓㓷ੳ㧦⢈ḩ㑐ㅪ⢄⊒≸ߦ߅ߌࠆวᚑ࡟࠴ࡁࠗ࠼ߩ੍㒐ലᨐ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦⥝๺ഃ⮎
4㧕 ᫪⣁ਭ㓉㧘ዊ᎑⡡৻㧦⢄∔ᖚߩಽሶ∛ᘒ⸃᣿ߦၮߠߊᣂⷙᴦ≮࡮੍㒐ᴺߩ⏕┙㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
300 ජ౞(100㧦100㧦100 ජ౞)ℂൻቇ⎇ⓥᚲ
5㧕 દ⮮ༀⷙ㧦⮎೷฽᦭ࡈࠖ࡞ࡓ⵾೷ߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧800 ජ౞㧦࠷ࠠࠝࠞ (ᩣ)
3㧕౒ห⎇ⓥ1㧕 ੹੗◊ᔒ㧘ਤ⠀ᙗม㧘દ⮮ༀⷙ㧘ᶉ᧻ᤘᄦ(ᣣᧄ⤳ེ⵾⮎ᩣᑼળ␠)㧦ࡄࠢ࡝࠲ࠠ࠮࡞ࠍ฽߻ൻቇ≮ᴺ
ᣉⴕᤨߦ⊒⃻ߒߚᧃ᪳␹⚻㓚ኂߦኻߔࠆ−∩ᴦ≮೷ࡁࠗࡠ࠻ࡠࡇࡦ㍤ߩ⥃ᐥ⹏ଔ㧧ᐔᚑ 20 ᐕᐲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ᄢ⍹ੌਃ㧘દ⮮ༀⷙ㧘ᳯ㗡િᤘ㧘⮮੗㇚㇢㧦᛫߇ࠎ೷ߦࠃࠆᧃ᪳␹⚻㓚ኂߩ੍㒐෶ߪシᷫ೷(⊒᣿)㧧
ᐔᚑ 20 ᐕ(․㗿 2008-65399)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢄⤳ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄࡆ࠲ࡒࡦቇળℂ੐(㨪⃻࿷)5㧕 ᣣᧄ⥃ᐥઍ⻢ቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ≸ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄᩕ㙃㘩♳ቇળ⹏⼏ຬ(㨪⃻࿷)8㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળℂ੐(㨪⃻࿷)દ⮮ༀⷙ㧦1㧕 ᣣᧄක≮⮎ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ∛㒮⮎೷Ꮷળઍ⼏ຬ(㨪⃻࿷)㧙㧙4㧕 ᣣᧄ⮎ቇળ᧲ᶏᡰㇱળᐙ੐(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ᣣᧄ⥃ᐥⴊᶧቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⴊᶧቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄャⴊቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅᫪⣁ਭ㓉㧦
1㧕 ╙ 8 ࿁ᣣᧄஜᐽᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹᫪⣁ਭ㓉㧦
1㧕 ᣣᧄౝ⑼ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᶖൻེ∛ቇળ⹹(⧷ᢥ)㧧✬㓸ᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ⹹㧦✬㓸ᆔຬ(㨪⃻࿷)દ⮮ༀⷙ㧦1㧕 ᣣᧄ∛㒮⮎೷Ꮷળ㔀⹹࿾ၞ✬㓸ᆔຬ(㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᫪⣁ਭ㓉㧦
1㧕 ╙ 67 ࿁ᣣᧄ≸ቇળቇⴚ✚ળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⢄߇ࠎ੍㒐ߩ✚วᚢ⇛ߣൻቇ੍㒐‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ᫪⣁ਭ㓉㧦
1㧕 ጘ㒂⋵り૕㓚ኂ⠪⑔␩ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ጘ㒂⋵㔍∛ක≮ㅪ⛊ද⼏ળᐳ㐳(㨪⃻࿷)3㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)4㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᐳ㐳(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)5㧕 ጘ㒂⋵ක≮ክ⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂⋵ੱᮭᙣ⹤ળᆔຬ(㨪⃻࿷)દ⮮ༀⷙ㧦1㧕 ጘ㒂⋵∛㒮⮎೷Ꮷળ೽ળ㐳(㨪⃻࿷)2㧕 ጘ㒂⋵⮎೷Ꮷળℂ੐(㨪⃻࿷)㢬⷗ ኼ㧦
1㧕 ጘ㒂⋵߇ࠎኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)2㧕 ጘ㒂⋵ࠛࠗ࠭ኻ╷ផㅴද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 1 ᦬㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᫪⣁ਭ㓉㧘᳗ᧁᱜੳ㧘ዊᧁᦥን↢㧦G-CSF ߩ⢄ౣ↢ᛥ೙ലᨐ㧦IL-1 ߩᓎഀ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄‫ޟ‬㔍ᴦᕈߩ⢄∔ᖚ⺞ᩏ⎇ⓥ⃰‫ޠ‬ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦117㧙119(2008 ᐕ)
2㧕 દ⮮ༀⷙ㧦ࠪࠬࡊ࡜࠴ࡦ⣢㓚ኂߦኻߔࠆ⚦⢩ౝࠨࠗࠢ࡝࠶ࠢ AMP ࠍ੺ߔࠆ଻⼔૞↪ߦ㑐ߔࠆ⎇ⓥ㧦
ᐔᚑ 17㧙18 ᐕᐲ⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(⎇ⓥಽᜂ⠪㧦ᄢ⍹ੌਃ) (2007 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ᫪⣁ਭ㓉㧦⢈ḩ㨯㨯㨯⢄≸㧦ਛᣣᣂ⡞(2006 ᐕ 12 ᦬ 17 ᣣ)㧙㧙

12㧚⥄Ꮖ⹏ଔ
⹏ଔ┙ߜ਄ߍ߆ࠄ߹ߛ 3 ࡩ᦬ߢ޽ࠆ߇㧘ᓥ᧪ߩ㑐ㅪಽ㊁߆ࠄታ❣ࠍᒁ߈⛮ߋᒻߢ㧘ᣢߦᬺ❣ࠍ᜼ߍᆎ߼ߡ
߅ࠅ㧘⦟ᅢߣߩ⹏ଔߦ୯ߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱ⊛ߦ㑐ㅪಽ㊁߆ࠄߩࠨࡐ࡯࠻߇ᔅ㗇ߢ޽ࠆ‫ߩ⥄⁛ޕ‬ᄢቇ㒮↢⏕଻߇✕ᕆߩ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ
2009 ᐕᐲᣂⷙᄢቇ㒮౉ቇ↢ࠍ 2 ฬ⏕଻ߒߚ‫⎇ޕ‬ⓥߩ᭎ⷐ 1㧘2 ߦฦ 1 ฬࠍ޽ߡ㧘⎇ⓥࠍផㅴߔࠆ‫ޕ‬㧙㧙